"","nct_id","trial_title","Conditions","condition","Interventions","intervention_type","Sponsor_Collaborators","sponsor_class","fda.drug","fda.device","Gender","min.age","max.age","Enrollment","Start_Date","Completion_Date","title","p","p.desc","method","param.value","param.type","ci","ci.side","ci.l","ci.u"
"1","NCT00103506","Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma","Multiple Myeloma",0,"Bortezomib (VELCADE)","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","646","December 2004","May 2014","Time to Progression (TTP)","0","0","0","0","0","0","0","0","0"
"2","NCT00127881","Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome","Mycosis Fungoides",0,"HuMax-CD4 (zanolimumab)","Drug","Emergent Product Development Seattle LLC","Industry",0,0,"All","18 Years","N/A","76","July 2005","February 2014","PGA Score","0","0","0","0","0","0","0","0","0"
"3","NCT00129545","WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation","Atrial Fibrillation",0,"WATCHMAN Left Atrial Appendage Closure Technology","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","800","February 2005","August 2013","Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death","0","0","0","0.61","Risk Ratio (RR)","95","2-Sided","0.42","1.07"
"4","NCT00163189","Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm","Growth Hormone Deficiency",0,"Somatropin","Drug","Pfizer","Industry",0,0,"All","N/A","N/A","98","January 2005","December 2014","Change From Baseline in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36: Full Analysis Population","<0.001","0","Student’s paired t-test","0","0","0","0","0","0"
"5","NCT00202878","IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)","Hypercholesterolemia",0,"ezetimibe/simvastatin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","18144","October 17, 2005","September 18, 2014","Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)","0.016","0","Cox proportional hazard model","0.936","Hazard Ratio (HR)","95","2-Sided","0.887","0.988"
"6","NCT00271518","Treatment of Children With Insufficient Secretion of Growth Hormone","Growth Hormone Deficiency (GHD)",0,"growth hormone (somatropin)","Drug","LG Life Sciences","Industry",0,0,"All","3 Years","11 Years","144","September 2005","December 2013","Height velocity at the end of 12 months treatment","0","0","0","0","0","0","0","0","0"
"7","NCT00297232","Natalizumab (Tysabri) Re-Initiation of Dosing","Relapsing-Remitting Multiple Sclerosis",0,"Natalizumab","Drug","Biogen","Industry",0,0,"All","18 Years","N/A","1094","March 2006","April 2014","Time to 24-week Confirmed Expanded Disability Status Scale (EDSS) Progression","0","0","0","0","0","0","0","0","0"
"8","NCT00319501","Efficacy and Safety of Diazepam in the Management of Refractory Epilepsy in Selected Patients Who Require Intermittent Medical Intervention for Acute Repetitive Seizures.","Seizures",0,"Placebo","Drug","Pfizer","Industry",0,0,"All","2 Years","N/A","234","January 2006","July 2014","Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile)","0.012","p-value is adjusted. All statistical tests were 2-sided and employed a level of significance of alpha=0.05.","Cox Proportional Hazard","0.55","Hazard Ratio (HR)","95","2-Sided","0.34","0.88"
"9","NCT00320710","Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer","Breast Cancer",0,"Zoledronic acid","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","416","February 2006","July 2013","Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)","0","0","0","0","0","0","0","0","0"
"10","NCT00332202","PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin","Non Hodgkin Lymphoma",0,"enzastaurin","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","709","June 2006","April 2013","Overall disease free survival","0","0","0","0","0","0","0","0","0"
"11","NCT00338286","A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy","Breast Cancer",0,"Standard supportive care (packed RBC transfusion)","Other","Janssen Research & Development, LLC","Industry",0,0,"Female","18 Years","99 Years","2098","March 2, 2006","July 7, 2014","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"12","NCT00359632","Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater","Optic Nerve Diseases",0,"Zyvox - linezolid","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","34","November 2008","December 2013","Percentage of Participants With an Adverse Event","0","0","0","0","0","0","0","0","0"
"13","NCT00373425","A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors","Non-small Cell Lung Cancer",0,"Erlotinib","Drug","OSI Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","1252","September 2006","April 2013","Disease Free Survival (DFS)","0.3235","If the primary analysis of DFS was not statistically significant, the hierarchical testing procedure would stop and all key secondary efficacy analyses would be nonsignificant; any further analysis of these outcomes would be considered exploratory.","Log Rank","0.90","Hazard Ratio (HR)","95","2-Sided","0.741","1.104"
"14","NCT00378014","Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy","Liver Transplantation",0,"everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","276","August 2006","January 2013","Calculated Glomerular Filtration Rate (cGFR)","0","0","0","0","0","0","0","0","0"
"15","NCT00412893","Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis","Invasive Fungal Infection",0,"Isavuconazole","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","527","March 2007","March 2013","All-cause Mortality Through Day 42","0","0","0","-1.0","Adjusted Treatment Difference","95","2-Sided","-7.759","5.683"
"16","NCT00416208","Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma","Multiple Myeloma",0,"Bortezomib","Drug","Janssen-Cilag G.m.b.H","Industry",0,0,"All","61 Years","75 Years","154","October 2006","May 2013","The difference in event-free survival time will be compared between both arms","0","0","0","0","0","0","0","0","0"
"17","NCT00416273","A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma","Multiple Myeloma",0,"Bortezomib","Drug","Janssen-Cilag G.m.b.H","Industry",0,0,"All","18 Years","60 Years","217","December 2006","May 2013","Number of patients with event-free survival (PFS)","0","0","0","0","0","0","0","0","0"
"18","NCT00420888","ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma","Renal Cell Carcinoma",0,"ABR-217620/naptumomab estafenatox","Drug","Active Biotech AB","Industry",0,0,"All","18 Years","N/A","526","January 2007","January 2013","Time to death","0","0","0","0","0","0","0","0","0"
"19","NCT00436748","Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","Anemia",0,"Darbepoetin Alfa","Drug","Amgen","Industry",0,0,"All","1 Year","18 Years","116","September 2008","March 2014","Proportion of Participants Achieving Hemoglobin ≥ 10.0 g/dL","<0.001","0","Exact","0","0","0","0","0","0"
"20","NCT00448916","Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures","Epilepsies, Partial",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","1 Month","16 Years","54","May 2007","October 2013","Number of Participants With Adverse Events (AE).","0","0","0","0","0","0","0","0","0"
"21","NCT00477269","Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"Imatinib mesylate","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","59","April 2006","January 2014","Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core","0","0","0","0","0","0","0","0","0"
"22","NCT00477282","Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer","Ovarian Cancer",0,"Karenitecin","Drug","BioNumerik Pharmaceuticals, Inc.","Industry",0,0,"Female","18 Years","N/A","509","August 2007","June 2013","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"23","NCT00484458","Wallis Stabilization System for Low Back Pain","Low Back Pain",0,"Interspinous process and dynamic stabilization (Wallis System)","Device","Zimmer Spine","Industry",0,0,"All","18 Years","60 Years","340","January 2007","November 2013","Non-inferior to commercially available lumber TDR after 24 months.","0","0","0","0","0","0","0","0","0"
"24","NCT00490139","ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","Neoplasms, Breast",0,"Lapatinib","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","8381","May 2007","December 2013","Disease-free Survival (DFS)","0.048","0","Stratified log-rank test","0.84","Hazard Ratio (HR)","97.5","0","0.70","1.02"
"25","NCT00511147","IGIV Study for Chronic ITP Patients Ages 3-70","Idiopathic Thrombocytopenic Purpura",0,"IGIV3I Grifols 10%","Biological","Grifols Biologicals Inc.","Industry",1,0,"All","3 Years","70 Years","64","May 2008","April 2014","Response Rate","0","0","0","0","0","0","0","0","0"
"26","NCT00521586","Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine","Influenza",0,"13 valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","50 Years","59 Years","1116","September 2007","December 2013","Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1","0","0","0","2.8","percent difference","95","2-Sided","-1.8","7.4"
"27","NCT00543543","Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)","Cervical Cancer",0,"Comparator: GARDASIL","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","16 Years","26 Years","14840","September 24, 2007","April 10, 2013","Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis)","<0.0001","0","Exact test, 1-sided","96.7","Vaccine efficacy","95","2-Sided","80.9","99.8"
"28","NCT00552344","A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease","Crohn Disease",0,"Cimzia","Biological","UCB BIOSCIENCES GmbH","Industry",0,0,"All","18 Years","75 Years","403","May 2008","December 2014","Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks)","0","0","0","0","0","0","0","0","0"
"29","NCT00556374","Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy","Breast Cancer",0,"Placebo","Drug","Amgen","Industry",0,0,"Female","45 Years","100 Years","3420","December 2006","March 2014","Time to First Clinical Fracture","<0.0001","0","Cox Proportional Hazard Model","0.504","Hazard Ratio (HR)","95","2-Sided","0.39","0.65"
"30","NCT00561990","Nimotuzumab in Adults With Pancreatic Cancer","Pancreatic Cancer, Advanced or Metastatic",0,"Nimotuzumab","Drug","Oncoscience AG","Industry",0,0,"All","18 Years","100 Years","188","September 2007","January 2013","Time to tumor progression (TTP) and overall survival (OS) in chemotherapy-naive patients. To assess the efficacy of Nimotuzumab as add on therapy to Gemcitabine in comparison with Gemcitabine and placebo","0","0","0","0","0","0","0","0","0"
"31","NCT00567853","Safety and Efficacy Study of the Sorin 3D Annuloplasty Ring For Mitral Repair","Mitral Valve Regurgitation",0,"Implantation of the MEMO 3D Annuloplasty Ring","Device","Sorin Group USA, Inc.","Industry",0,0,"All","18 Years","N/A","278","August 2007","June 2013","The percentage of patients with successful repair at 6 months.","0","0","0","0","0","0","0","0","0"
"32","NCT00576225","CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL","NSCLC",0,"CT-2103/carboplatin","Drug","CTI BioPharma","Industry",0,0,"Female","18 Years","N/A","450","September 2007","January 2014","Survival","0","0","0","0","0","0","0","0","0"
"33","NCT00585312","Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)","Adenomatous Polyposis Coli",0,"Celecoxib","Drug","Pfizer","Industry",0,0,"All","10 Years","17 Years","106","September 2006","October 2013","Time to Disease Progression","0","0","0","0","0","0","0","0","0"
"34","NCT00609115","Sub-Acute Stroke Rehabilitation With AMES","Cerebrovascular Stroke",0,"AMES device","Device","AMES Technology","Industry",0,0,"All","18 Years","80 Years","132","September 2007","June 2014","Fugl-Meyer Assessment","0","0","0","0","0","0","0","0","0"
"35","NCT00615186","Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy","Glioblastoma Multiforme",0,"Neuradiab + Radiotherapy + Temozolomide","Drug","Bradmer Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","N/A","9","June 2008","August 2013","The primary measure of efficacy is overall survival (OS).","0","0","0","0","0","0","0","0","0"
"36","NCT00617981","Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)","Hepatocellular Carcinoma",0,"ThermoDox","Drug","Celsion","Industry",0,0,"All","18 Years","N/A","701","May 2008","January 2013","Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause","0","0","0","0","0","0","0","0","0"
"37","NCT00622336","A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma","Multiple Myeloma",0,"Lenalidomide","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","330","December 2003","November 2013","Number of Participants With Adverse Events (AE) During the Treatment Phase","0","0","0","0","0","0","0","0","0"
"38","NCT00627523","Genotropin Treatment In Very Young Children Born Small For Gestational Age","Infant, Small for Gestational Age",0,"Genotropin (PN-180,307) Somatropin","Drug","Pfizer","Industry",0,0,"All","19 Months","29 Months","43","February 2008","December 2013","Change From Baseline in Height Standard Deviation Score (SDS) at Month 24.","<0.001","ANCOVA model, fitting treatment as a factor, and the baseline parameter value as covariate was used. All hypotheses were tested at a 5% level of significance.","ANCOVA","1.20","Mean Difference (Final Values)","95","2-Sided","0.82","1.59"
"39","NCT00634049","Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi","Aspergillosis",0,"isavuconazole","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","149","April 2008","January 2014","Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT).","0","0","0","0","0","0","0","0","0"
"40","NCT00636168","Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma","High Risk Stage III Melanoma",0,"ipilimumab","Drug","Bristol-Myers Squibb","Industry",1,0,"All","18 Years","N/A","1211","June 2008","July 26, 2013","Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population","0.0013","0","Log Rank","0.75","Hazard Ratio (HR)","95","2-Sided","0.64","0.90"
"41","NCT00637494","A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features","Psychotic Depression",0,"mifepristone","Drug","Corcept Therapeutics","Industry",0,0,"All","22 Years","N/A","292","March 2008","June 2014","Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56","0","0","0","0","0","0","0","0","0"
"42","NCT00642616","Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease","Type 1 Diabetes Mellitus",0,"Technosphere® Insulin","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","N/A","34","March 2009","November 2014","Change in Post-bronchodilator FEV1 From Baseline to Week 52","0","0","0","0","0","0","0","0","0"
"43","NCT00643201","Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism","Venous Thrombosis",0,"Enoxaparin","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","5614","July 2008","March 2013","Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment","<0.0001","This is the first test in a sequential testing sequence. p-value calculated based on the Yanagawa-Tango-Hiejima test stratified by index event strata for non-inferiority. Tested at 1-sided α=0.025","Yanagawa-Tango-Hiejima","0.8390","Risk Ratio (RR)","95","2-Sided","0.5965","1.1802"
"44","NCT00644501","Long-Term Treatment Effect of DiaPep277 in Type 1 Diabetes","Type 1 Diabetes",0,"DiaPep277","Drug","Andromeda Biotech Ltd.","Industry",0,0,"All","18 Years","48 Years","43","September 2008","May 2013","Preservation of endogenous insulin secretion/beta-cell function, as measured by mixed-meal tolerance test stimulated C-peptide secretion.","0","0","0","0","0","0","0","0","0"
"45","NCT00657540","Black Widow Spider Antivenin for Patients With Systemic Latrodectism","Latrodectism",0,"Analatro","Drug","Instituto Bioclon S.A. de C.V.","Industry",0,0,"All","10 Years","N/A","60","August 2009","October 2014","Pain Control","0","0","0","0","0","0","0","0","0"
"46","NCT00661661","Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan","Rheumatoid Arthritis",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","487","April 2008","December 2013","Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"47","NCT00669331","Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis","Bronchiectasis",0,"Inhaled mannitol","Drug","Pharmaxis","Industry",0,0,"All","18 Years","85 Years","485","November 2009","January 2014","Rate of Graded Pulmonary Exacerbations","0.3115","0","Negative binomial regression model","0.92","Rate Ratio Mannitol:Control","95","2-Sided","0.78","1.08"
"48","NCT00676507","Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy","Lung Neoplasm",0,"Lucanix™","Biological","NovaRx Corporation","Industry",0,0,"All","18 Years","75 Years","532","July 2008","January 2013","Compare the overall survival of subjects with stage III or IV non-small cell lung cancer treated with belagenpumatucel-L (Lucanix™) vs placebo.","0","0","0","0","0","0","0","0","0"
"49","NCT00680446","Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency","Primary Immune Deficiency",0,"Immunoglobulin G (Ig NextGen 16%)","Drug","CSL Limited","Industry",0,0,"All","3 Years","N/A","41","April 2008","May 2013","Rate, Severity and Relatedness of reported Adverse Events","0","0","0","0","0","0","0","0","0"
"50","NCT00683696","Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)","Heart Failure",0,"Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)","Device","Biotronik, Inc.","Industry",0,0,"All","18 Years","N/A","1680","August 2008","March 2013","Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death","0","0","0","0","0","0","0","0","0"
"51","NCT00684047","Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis","Target Bleeding Site During Peripheral Vascular Surgery",0,"FS Grifols","Biological","Instituto Grifols, S.A.","Industry",0,0,"All","3 Years","N/A","239","February 2008","March 2014","The Primary Efficacy Endpoint is Time to Hemostasis.","0","0","0","0","0","0","0","0","0"
"52","NCT00686959","Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","Non Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","598","September 2008","October 2014","Overall Survival","0.831","0","Log Rank","0.98","Hazard Ratio (HR)","95","2-Sided","0.79","1.20"
"53","NCT00689390","Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)","Hepatitis C, Chronic",0,"Boceprevir","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1954","February 2007","October 2014","Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response)","0","0","0","0","0","0","0","0","0"
"54","NCT00692770","Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)","Carcinoma, Hepatocellular",0,"Nexavar (Sorafenib, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","1114","August 2008","November 2013","Recurrence Free Survival (RFS) by Independent Assessment","=0.258329","One sided P-value was stratified by region, risk of recurrence and previous curative treatment.","Log Rank","0.94","Hazard Ratio (HR)","95","2-Sided","0.78","1.134"
"55","NCT00694109","An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia","Lipid Metabolism, Inborn Errors",0,"Mipomersen Sodium","Drug","Kastle Therapeutics, LLC","Industry",0,0,"All","12 Years","N/A","144","April 2008","September 2014","Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)","0","0","0","0","0","0","0","0","0"
"56","NCT00699140","Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura","Immune (Idiopathic) Thrombocytopenic Purpura",0,"IGIV3I Grifols","Biological","Instituto Grifols, S.A.","Industry",0,0,"All","18 Years","82 Years","18","February 2008","December 2013","Responder Patients","0","0","0","0","0","0","0","0","0"
"57","NCT00699517","A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies","Sarcoma",0,"OMBRABULIN (AVE8062)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","355","June 2008","April 2013","Progression free survival","0","0","0","0","0","0","0","0","0"
"58","NCT00703326","Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer","Breast Cancer",0,"ramucirumab (IMC-1121B)","Biological","Eli Lilly and Company","Industry",0,0,"Female","18 Years","N/A","1144","August 2008","March 2013","Progression-Free Survival (PFS)","0.077","0","Stratified Log Rank (SLR)","0.88","Hazard Ratio (HR)","95","2-Sided","0.75","1.01"
"59","NCT00712348","Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase","Gaucher Disease",0,"Taliglucerase alfa","Drug","Protalix","Industry",0,0,"All","2 Years","N/A","31","December 2008","April 2013","Hemoglobin","0","0","0","0","0","0","0","0","0"
"60","NCT00718861","3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs","Post-menopausal Osteoporosis",0,"Placebo","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","65 Years","N/A","190","May 2008","April 2013","Percentage Change in Total Hip Bone Mineral Density BMD at Year 6 (Baseline) and Year 9","0","0","0","0","0","0","0","0","0"
"61","NCT00723450","Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients","Bipolar Disorder",0,"lamictal","Drug","GlaxoSmithKline","Industry",0,0,"All","10 Years","17 Years","301","July 2008","August 2013","Time From Randomization to the Occurrence of a Bipolar Event (TOBE)","0.0717","0","Log Rank","0","0","0","0","0","0"
"62","NCT00731549","Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole IM Depot","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","1081","December 2008","November 2013","Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).","0","0","0","0","0","0","0","0","0"
"63","NCT00735397","Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures","Epilepsy",0,"perampanel","Drug","Eisai Inc.","Industry",0,0,"All","12 Years","N/A","1218","October 2008","September 2014","Number of Participants With Treatment-emergent Non-Serious Adverse Events (AEs) and Treatment-emergent Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"64","NCT00740376","Uniglide™ Mobile Bearing Unicondylar Knee System vs the Uniglide™ Fixed Bearing Unicondylar Knee System","Osteoarthritis",0,"Uniglide Mobile Bearing Unicondylar Knee System","Device","Corin","Industry",0,0,"All","40 Years","80 Years","47","August 2008","May 2014","Composite Clinical Success (CCS): HSS success(Month 24):HSS greater than/equal to 70 (If preop HSS between 60 & 69, HSS greater than 70 plus a min 10 point improvement; No radiographic failure (Month 24): No radiolucent lines greater than 1mm in greater","0","0","0","0","0","0","0","0","0"
"65","NCT00748189","Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia","Leukaemia, Lymphocytic, Chronic",0,"chlorambucil, tablets","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","447","December 22, 2008","March 20, 2013","Progression-Free Survival (PFS), as Assessed by the Independent Review Committee (IRC)","<0.001","0","Log Rank","0.57","Hazard Ratio (HR)","95","2-Sided","0.45","0.72"
"66","NCT00761735","5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)","Hepatitis C, Chronic",0,"Peginterferon alfa-2b","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","3 Years","17 Years","94","July 2007","January 2013","Number of Participants Who Relapsed At End of LTFU Year 5","0","0","0","0","0","0","0","0","0"
"67","NCT00764478","Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691)","Bipolar 1 Disorder",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","367","April 2012","April 2014","Change From Baseline in Young Mania Rating Scale (Y-MRS) Total Score at Day 21","0.0136","Adjusted p-value from graphical approach to control Type 1 error rate among primary and secondary hypotheses","MMRM","-3.5","Least Square (LS) means difference","95","2-Sided","-6.3","-0.7"
"68","NCT00769704","Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma","Melanoma",0,"Talimogene laherparepvec","Biological","BioVex Limited","Industry",0,0,"All","18 Years","N/A","437","April 2009","February 2013","Durable Response Rate","<0.0001","0","Fisher Exact","14.1","Treatment Difference","95","2-Sided","9.3","19.0"
"69","NCT00774930","An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","Carcinoid Syndrome",0,"Lanreotide","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","115","May 2009","May 2013","Percentage of Days With Subcutaneous Octreotide as Rescue Medication","0.0165","0","ANCOVA","0","0","0","0","0","0"
"70","NCT00775437","Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use","Juvenile Idiopathic Arthritis",0,"Adalimumab","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","2 Years","4 Years","32","March 2009","March 2013","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"71","NCT00777907","Complete Occlusion of Coilable Aneurysms","Intracranial Aneurysm",0,"Pipeline Embolization Device (PED)","Device","Chestnut Medical Technologies","Industry",0,0,"All","21 Years","75 Years","13","October 2008","November 2014","Effectiveness: Proportion of subjects whose target aneurysm shows complete occlusion on angiogram with <=50% stenosis of the parent artery. Safety: Proportion of subjects with ipsilateral major stroke or neurologic death.","0","0","0","0","0","0","0","0","0"
"72","NCT00781118","AngelMed for Early Recognition and Treatment of STEMI","Acute Myocardial Infarction (AMI)",0,"Guardian System","Device","Angel Medical Systems","Industry",0,0,"All","21 Years","N/A","1020","December 2008","January 2014","The primary efficacy objective is to determine that the Guardian System reduces the composite of Cardiac or unexplained death, new Q-wave MI and time to door for a confirmed occlusive event at a medical facility >2 hours","0","0","0","0","0","0","0","0","0"
"73","NCT00781391","Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","Stroke",0,"warfarin tablets","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","21 Years","N/A","21105","November 2008","April 2013","Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","<.0001","Two stratification factor covariates: 1) CHADS2 score 2) dose-adjustment factor. If upper limit of CI of HR was below 1.38, then non-inferiority to warfarin was established for group.","Cox proportional hazards model","0.79","Hazard Ratio (HR)","97.5","2-Sided",".632",".985"
"74","NCT00788697","SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization","Liver Neoplasms",0,"SonoVue-enhanced ultrasound","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","18 Years","N/A","349","September 2009","July 2013","Sensitivity","0.0754","0","McNemar","11.3","Difference in Sensitivity (%)","95","2-Sided","-1.0","23.6"
"75","NCT00790920","Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke","Stroke",0,"Desmoteplase","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","85 Years","492","December 2008","July 2014","Modified Rankin Scale Score","0","0","0","0","0","0","0","0","0"
"76","NCT00794326","Clinical Evaluation of Low Sodium Peritoneal Dialysis (PD) Solution on Hypertensive Patients Treated With PD","Chronic Kidney Failure",0,"Solution for Peritoneal Dialysis","Drug","Fresenius Medical Care Deutschland GmbH","Industry",0,0,"All","18 Years","N/A","140","October 2008","December 2014","The primary criterion is the ambulatory 24 h mean systolic blood pressure measurement and drug doses management after 2 months of treatment compared to Baseline.","0","0","0","0","0","0","0","0","0"
"77","NCT00794456","Association of Passiflora Incarnata L; Crataegus Oxyacantha L and Salix Alba L. on Mild and Moderate Anxiety","Anxiety Disorder",0,"Passiflora ; Crataegus and Salix","Drug","Marjan Industria e Comercio ltda","Industry",0,0,"All","18 Years","65 Years","150","September 2009","October 2013","Hamilton anxiety scale","0","0","0","0","0","0","0","0","0"
"78","NCT00799903","The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial","Atherosclerosis",0,"Darapladib","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","15828","December 2008","October 2013","Time to the first occurrence of any component of the composite of Major Adverse Cardiovascular Events [MACE: CV death (death due to a cardiovasacular cause), non-fatal myocardial infarction, non-fatal stroke]","0","0","0","0","0","0","0","0","0"
"79","NCT00802841","Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib","Chronic Myelogenous Leukemia",0,"nilotinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","16 Years","N/A","191","May 2009","July 2014","Percentage of Participants With Complete Cytogenetic Response (CCyR)","0.3106","0","Fisher Exact","0","0","0","0","0","0"
"80","NCT00809757","A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma","Asthma",0,"Levalbuterol","Drug","Sunovion","Industry",0,0,"All","N/A","48 Months","197","December 2008","June 2013","Change From Baseline to Visit 4 in the Mean Daily Composite Score Based on the Pediatric Asthma Caregiver Assessments (PACA)","0","0","0","-0.54","Mean Difference (Final Values)","95","2-Sided","-1.412","0.342"
"81","NCT00812097","Mentor Siltex® Contour Profile Gel Mammary Prosthesis Clinical Trial","Breast Augmentation",0,"Mentor Siltex® Contour Profile Gel Mammary Prosthesis","Device","Mentor Worldwide, LLC","Industry",0,0,"Female","18 Years","N/A","955","February 2002","October 2014","10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation","0","0","0","0","0","0","0","0","0"
"82","NCT00812240","A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment","Gastrointestinal Stromal Tumors",0,"masitinib (AB1010)","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","222","January 2009","June 2013","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"83","NCT00813150","Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma","Multiple Myeloma",0,"Dexamethasone","Drug","Janssen-Cilag G.m.b.H","Industry",0,0,"All","18 Years","N/A","96","January 2009","January 2013","Time to Progression of Disease","0.196","0","Regression, Cox","0.71","Hazard Ratio (HR)","95","2-Sided","0.43","1.19"
"84","NCT00815516","Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis","Candidiasis",0,"micafungin","Drug","Astellas Pharma Global Development, Inc.","Industry",0,0,"All","N/A","120 Days","30","February 2013","December 2014","Fungal-free Survival","0","0","0","0","0","0","0","0","0"
"85","NCT00816166","VISSIT Intracranial Stent Study for Ischemic Therapy","Ischemic Stroke",0,"Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)","Device","Codman & Shurtleff","Industry",0,0,"All","18 Years","85 Years","125","October 2008","April 2013","Successful Outcome: No Stroke or Hard TIA in the Same Territory Within 12 Months","0","0","0","0","0","0","0","0","0"
"86","NCT00824265","Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia","Leukaemia, Lymphocytic, Chronic",0,"OFC Infusion","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","365","March 2009","December 2014","Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)","0.0032","0","Log Rank","0.67","Hazard Ratio (HR)","95","2-Sided","0.51","0.88"
"87","NCT00827606","Atorvastatin Three Year Pediatric Study","Familial Hypercholesterolemia",0,"atorvastatin","Drug","Pfizer","Industry",0,0,"All","6 Years","15 Years","272","March 2009","October 2013","Low Density Lipoprotein Cholesterol (LDL-C; Millimoles Per Liter [mMol/L]) During the Study","0","0","0","0","0","0","0","0","0"
"88","NCT00829413","SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization","Liver Neoplasms",0,"SonoVue®","Drug","Bracco Diagnostics, Inc","Industry",0,0,"All","18 Years","N/A","353","June 2010","July 2013","To demonstrate the Sensitivity and Specificity of SonoVue®-enhanced US to that of unenhanced US for the characterization of benign versus malignant FLLs using final diagnosis based on histology or combined imaging clinical data as truth standard.","0","0","0","0","0","0","0","0","0"
"89","NCT00831025","Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen","Rhinitis or Rhinoconjunctivitis (With or Without Asthma) Induced by Hypersensitivity to Olea Europea Pollen.",0,"Immunotherapy with modified extract of Olea europaea pollen","Biological","Laboratorios Leti, S.L.","Industry",0,0,"All","18 Years","55 Years","158","January 2008","January 2013","Symptoms and medication score","0","0","0","0","0","0","0","0","0"
"90","NCT00836875","A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children","Invasive Aspergillosis",0,"Voriconazole","Drug","Pfizer","Industry",0,0,"All","2 Years","17 Years","31","May 2009","May 2013","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"91","NCT00840749","Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer","Non-small Cell Lung Cancer",0,"CyberKnife Stereotactic Radiotherapy","Radiation","Accuray Incorporated","Industry",0,0,"All","18 Years","N/A","36","December 2008","March 2013","Overall survival","0","0","0","0","0","0","0","0","0"
"92","NCT00846976","Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer","Prostate Cancer",0,"Bicalutamide","Drug","AstraZeneca","Industry",0,0,"Male","18 Years","N/A","101","December 1994","June 2013","Safety profile of patients treated with a 200 mg daily dose of CASODEX","0","0","0","0","0","0","0","0","0"
"93","NCT00850343","Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients","Rheumatoid Arthritis",0,"Certolizumab pegol","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","74 Years","208","March 2009","May 2013","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"94","NCT00851318","Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients","Rheumatoid Arthritis",0,"Certolizumab pegol","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","74 Years","285","March 2009","June 2013","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"95","NCT00853827","Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients","Coronary Artery Disease (CAD)",0,"Placebo","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","35 Years","N/A","613","March 2009","January 2013","Change From Baseline in Percent Atheroma Volume(PAV) After 104 Weeks of Treatment","0","0","0","0","0","0","0","0","0"
"96","NCT00855712","Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation","Heart Failure",0,"Organ Care System","Device","TransMedics","Industry",0,0,"All","18 Years","N/A","128","March 2009","October 2013","30-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30","0","0","0","0","0","0","0","0","0"
"97","NCT00856661","Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)","Stroke",0,"Desmoteplase","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","85 Years","270","April 2009","October 2014","Modified Rankin Scale Score (mRS) (Percentage of Participants With mRS Scores 0-2)","0.2290","0","Regression, Logistic","1.45","Odds Ratio (OR)","95","2-Sided","0.79","2.64"
"98","NCT00863655","Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole","Breast Cancer",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","724","June 3, 2009","December 4, 2014","Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.","<0.0001","0","Log Rank","0.43","Hazard Ratio (HR)","95","2-Sided","0.35","0.54"
"99","NCT00866775","Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs","Epilepsy With Simple or Complex Partial Onset Seizures",0,"Eslicarbazepine acetate","Drug","Sunovion","Industry",0,0,"All","16 Years","70 Years","193","April 2009","May 2013","Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method","0","0","0","0","0","0","0","0","0"
"100","NCT00868634","Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer","Metastatic Breast Cancer",0,"capecitabine","Drug","iOMEDICO AG","Industry",0,0,"Female","18 Years","N/A","600","February 2009","March 2014","Progression free survival (PFS)","0","0","0","0","0","0","0","0","0"
"101","NCT00868959","Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression","Bipolar Depression",0,"lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","817","April 2009","February 2013","Number of Participants With Serious and Non-serious Treatment-emergent Adverse Events Who Have Completed 24 Weeks of Extension Study Treatment","0","0","0","0","0","0","0","0","0"
"102","NCT00876447","A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis","Overactive Bladder",0,"Botulinum Toxin Type A 300U","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","397","January 2009","June 2013","Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","0","0","0","0","0","0","0","0","0"
"103","NCT00876486","Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer","Breast Cancer",0,"Genexol-PM®","Drug","Samyang Biopharmaceuticals Corporation","Industry",0,0,"Female","18 Years","N/A","213","December 2008","February 2013","Objective Response Rate","0","0","0","0","0","0","0","0","0"
"104","NCT00878709","Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer","Breast Cancer",0,"neratinib","Drug","Puma Biotechnology, Inc.","Industry",0,0,"Female","18 Years","N/A","2840","July 2009","November 2013","disease free survival (DFS)","0","0","0","0","0","0","0","0","0"
"105","NCT00879333","Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)","Advanced Gastric Cancer",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","656","July 2009","January 2014","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"106","NCT00884260","GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China","Contraception",0,"Levonorgestrel IUS (LCS, BAY86-5028)","Drug","Bayer","Industry",0,0,"Female","18 Years","40 Years","918","April 2009","June 2013","Primary efficacy variable is the occurrence of pregnancy, the Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.","0","0","0","0","0","0","0","0","0"
"107","NCT00887198","Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","Prostate Cancer",0,"Abiraterone acetate","Drug","Janssen Research & Development, LLC","Industry",0,0,"Male","18 Years","N/A","1088","April 2009","March 2014","Overall Survival","0","0","0","0","0","0","0","0","0"
"108","NCT00906308","A Study of MF101 in Postmenopausal Women","Hot Flushes",0,"MF101 5 g/day","Drug","Bionovo","Industry",0,0,"Female","40 Years","65 Years","1200","October 2011","February 2013","Determine the safety and efficacy of two doses of MF101 (5 g/day and 10 g/day) compared to placebo.","0","0","0","0","0","0","0","0","0"
"109","NCT00907504","Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",0,"CP-751,871","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","0","July 2010","May 2014","Overall Survival","0","0","0","0","0","0","0","0","0"
"110","NCT00910065","BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)","Acute Coronary Syndrome",0,"D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","270","March 2011","April 2014","Concentration of Thromboxane B2 (TXB2) at 5 Minutes Post-dose","0","0","0","0","0","0","0","0","0"
"111","NCT00910910","Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)","B-Cell Chronic Lymphocytic Leukemia (B-CLL)",0,"Lenalidomide","Drug","Celgene","Industry",0,0,"All","65 Years","N/A","450","October 2009","March 2014","Kaplan-Meier Estimate of Progression Free Survival (PFS) With a Later Cut-off of 31 March 2014","0","0","0","0","0","0","0","0","0"
"112","NCT00911326","Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma (HNSCC)",0,"Lymphoseek","Drug","Navidea Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","101","May 2009","August 2013","False Negative Rate (FNR)","0","0","0","0","0","0","0","0","0"
"113","NCT00911573","Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin On Complicated Skin And Skin Structure Infections Including Those Due To Methicillin-Resistant Staphylococcus Aureus (MRSA) In Pediatric Subjects","Skin Diseases",0,"Tigecycline","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","8 Years","17 Years","0","August 2011","May 2014","Clinical response rate at the test-of-cure visit for the 2 co-primary populations: clinically evaluable and clinically modified intent to treat populations","0","0","0","0","0","0","0","0","0"
"114","NCT00914888","Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","Community Acquired Bacterial Pneumonia",0,"Tigecycline","Drug","Wyeth is now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","8 Years","17 Years","0","January 2011","May 2014","Clinical efficacy response (cure, failure, or indeterminate) at the test of cure (TOC) visit for 2 co-primary populations: the clinically evaluable (CE) and clinical modified Intent-to-Treat (c-mITT) populations","0","0","0","0","0","0","0","0","0"
"115","NCT00915525","Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","Overactive Bladder",0,"botulinum toxin Type A","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","829","February 2010","August 2014","Change From Study Baseline in the Daily Average Number of Urinary Incontinence Episodes","0","0","0","0","0","0","0","0","0"
"116","NCT00916422","Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Grass Pollen","Seasonal Allergic Rhinitis",0,"Allergen extract (Phleum pratense)","Biological","Laboratorios Leti, S.L.","Industry",0,0,"All","18 Years","55 Years","153","June 2008","January 2013","Symptoms and medication score recorded by subjects","0","0","0","0","0","0","0","0","0"
"117","NCT00916656","Fibrinogen Concentrate (Human) − Efficacy and Safety Study","Afibrinogenemia",0,"Fibrinogen Concentrate, Human (FCH)","Biological","CSL Behring","Industry",0,0,"All","N/A","N/A","0","October 2009","March 2014","Clinical assessment of hemostatic efficacy","0","0","0","0","0","0","0","0","0"
"118","NCT00916760","Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica","Allergic Rhinoconjunctivitis",0,"Depigoid Parietaria judaica 1000DPP/ml","Biological","Laboratorios Leti, S.L.","Industry",0,0,"All","18 Years","55 Years","153","February 2008","February 2013","Symptoms score","0","0","0","0","0","0","0","0","0"
"119","NCT00918580","Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease","Pneumococcal Conjugate Vaccine",0,"13-valent Pneumoccocal Conjugate Vaccine","Biological","Pfizer","Industry",0,0,"All","6 Years","17 Years","158","November 2009","March 2013","Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2","0","0","0","0","0","0","0","0","0"
"120","NCT00918983","Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Hyperplasia",0,"NX-1207","Drug","Nymox Corporation","Industry",0,0,"Male","45 Years","N/A","500","April 2009","November 2013","International Prostate Symptom Score (IPSS)","0","0","0","0","0","0","0","0","0"
"121","NCT00927238","XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)","Degenerative Disc Disease",0,"XL TDR","Device","NuVasive","Industry",0,0,"All","18 Years","70 Years","246","July 2009","July 2014","Improvement in ODI","0","0","0","0","0","0","0","0","0"
"122","NCT00930644","Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)","Short Bowel Syndrome",0,"teduglutide","Drug","Shire","Industry",0,0,"All","18 Years","N/A","88","September 2009","January 2013","Percent Change in PN/IV Volume by Visit","0","0","0","0","0","0","0","0","0"
"123","NCT00931632","Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants","Bronchopulmonary Dysplasia",0,"Inhaled Nitric Oxide","Drug","Mallinckrodt","Industry",0,0,"All","N/A","14 Days","451","November 2009","May 2013","Survival Without BPD at 36 Weeks","0.427","0","Mantel Haenszel","0","0","0","0","0","0"
"124","NCT00936884","Study Evaluating The Efficacy And Safety Of Subcutaneous MOA-728 For The Treatment Of Opioid-Induced-Constipation","Constipation",0,"MOA728","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","51","July 2009","November 2013","The proportion of subjects having a rescue-free bowel movement (RFBM) within 4 hours after the first injection, and after each dose during DB period.","0","0","0","0","0","0","0","0","0"
"125","NCT00940823","The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma","Glaucoma",0,"Ahmed FP7 Valve","Device","Credit Valley EyeCare","Industry",0,0,"All","18 Years","N/A","238","July 2005","April 2014","Surgical Failure (composite measure)","0","0","0","0","0","0","0","0","0"
"126","NCT00943306","Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia","Familial Hypercholesterolemia",0,"lomitapide","Drug","Aegerion Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","19","September 2009","December 2014","Percent change in LDL-C","0","0","0","0","0","0","0","0","0"
"127","NCT00945490","Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018","Benign Prostatic Hyperplasia (BPH)",0,"NX-1207","Drug","Nymox Corporation","Industry",0,0,"Male","45 Years","N/A","500","May 2009","May 2014","American Urological Association Symptom Index (AUASI)","0","0","0","0","0","0","0","0","0"
"128","NCT00948675","Study of Participants With Advanced Non-Small Cell Lung Cancer","Advanced Non-Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","361","September 2009","January 2013","Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0","0.176","0","Log Rank","0","0","0","0","0","0"
"129","NCT00962780","Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine","HIV Infections",0,"13-valent Pneumococcal Conjugate Vaccine (13vPnC)","Biological","Pfizer","Industry",0,0,"All","6 Years","N/A","303","March 2010","April 2013","Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All Participants","0","0","0","0","0","0","0","0","0"
"130","NCT00964795","Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)","Neovascular Age-related Macular Degeneration",0,"Intravitreal Aflibercept Injection 2mg","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","50 Years","N/A","323","December 2009","August 2013","Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD","0","0","0","0","0","0","0","0","0"
"131","NCT00966914","Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin","Non-small Cell Lung Cancer",0,"Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel","Drug","BioNumerik Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","540","April 2010","April 2013","Overall Survival","0","0","0","0","0","0","0","0","0"
"132","NCT00968708","Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome","Diabetes Mellitus, Type 2",0,"Alogliptin","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","5380","September 2009","April 2013","Percentage of Participants With Primary Major Adverse Cardiac Events (MACE)","0.315","0","Cox proportional hazards","0.962","Hazard Ratio (HR)","97.5","1-Sided","0","1.160"
"133","NCT00971152","Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle","Subfertility",0,"menotropins for injection","Drug","OVO R & D","Industry",0,0,"Female","18 Years","40 Years","366","September 2009","October 2013","Number of metaphase II oocytes retrieved during the course of one treatment cycle","0","0","0","0","0","0","0","0","0"
"134","NCT00971776","Voyager I: Patient Discharge Using the AB5000 Portable Driver System","Acute Cardiac Dysfunction",0,"AB Portable Driver System","Device","Abiomed Inc.","Industry",0,0,"All","18 Years","N/A","9","June 2008","April 2013","Adverse events, Quality of life assessment, NIH Stroke Scale Assessments, and patient outcome after readmission","0","0","0","0","0","0","0","0","0"
"135","NCT00973362","Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System","Human Papillomavirus Infection",0,"APTIMA HPV Assay","Device","Gen-Probe, Incorporated","Industry",0,0,"Female","21 Years","N/A","12896","March 2008","June 2013","Adjunct Study Arm: Compare Assay Performance for Aptima HPV Assay to a FDA-Approved HPV Assay for Detecting CIN2+","0","0","0","75.0","Sensitivity (%)","95","2-Sided","53.1","88.8"
"136","NCT00975000","Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients","Chronic Allograft Nephropathy",0,"Cinacalcet","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","114","December 2009","April 2013","Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP)","<0.001","0","Cochran-Mantel-Haenszel","66.437","Chi-Square test statistic","0","0","0","0"
"137","NCT00980655","Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","Vaccines, Pneumococcal Conjugate Vaccine",0,"13vPnC","Biological","Pfizer","Industry",0,0,"All","2 Years","N/A","251","January 2010","May 2013","Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants","0","0","0","0","0","0","0","0","0"
"138","NCT00981058","First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin","Non Small Cell Lung Cancer",0,"Necitumumab","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1093","January 2010","June 2013","Overall Survival Time (OS)","0.0120","0","Log Rank","0.842","Hazard Ratio (HR)","95","2-Sided","0.736","0.962"
"139","NCT00986154","Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).","Venous Thromboembolism",0,"edoxaban tosylate(DU-176b)","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","8292","October 2009","April 2013","Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE","<0.0001","0","Regression, Cox","0.89","Hazard Ratio (HR)","95","2-Sided",".703","1.128"
"140","NCT00989131","Study of Paclitaxel in Patients With Ovarian Cancer","Epithelial Ovarian Cancer",0,"Paclical®","Drug","Oasmia Pharmaceutical AB","Industry",0,0,"Female","18 Years","N/A","789","February 2009","October 2013","Progression free survival (PFS).","0","0","0","0","0","0","0","0","0"
"141","NCT00990951","Study of Efficacy of Association of Senna Alexandrina Mill and Associations on Functional Intestinal Constipation","Constipation",0,"Senna alexandrina and associations","Drug","Marjan Industria e Comercio ltda","Industry",0,0,"All","18 Years","65 Years","80","June 2010","July 2014","average frequency of bowel movements measured at baseline and at 2 weeks of treatment","0","0","0","0","0","0","0","0","0"
"142","NCT00994318","Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","Iron Deficiency Anaemia",0,"FCM (Ferric carboxymaltose) high ferritin target","Drug","Vifor Inc.","Industry",0,0,"All","18 Years","N/A","626","December 2009","February 2013","Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger","0.026","0","Log Rank","0.65","Hazard Ratio (HR)","95","2-Sided","0.44","0.95"
"143","NCT00996216","Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390","Hepatitis C",0,"Eltrombopag","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","27","September 2009","February 2013","Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE) in Part 1","0","0","0","0","0","0","0","0","0"
"144","NCT01000727","The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial","Acute Coronary Syndrome",0,"Darapladib 160 mg","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","13026","December 2009","April 2014","Time to the first occurrence of any component of the composite of major coronary events (i.e., Coronary Heart Disease (CHD) death, non-fatal myocardial infarction (MI), or urgent coronary revascularization for myocardial ischemia).","0","0","0","0","0","0","0","0","0"
"145","NCT01001377","ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer","Metastatic Colorectal Cancer",0,"Cetuximab","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","1010","February 2, 2010","February 5, 2013","Overall Survival","0","0","0","0.966","Stratified Cox proportional hazard ratio","95","2-Sided","0.839","1.113"
"146","NCT01001988","Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers","Encephalitis",0,NA,NA,"Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Years","6 Years","591","August 2009","October 2013","To provide information concerning the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) after primary vaccination.","0","0","0","0","0","0","0","0","0"
"147","NCT01002222","Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)","Lower Urinary Tract Symptoms",0,"MCS-2","Drug","Health Ever Bio-Tech Co., Ltd.","Industry",0,0,"Male","40 Years","N/A","200","January 2011","February 2014","Incidence of treatment-emergent adverse events (TEAE)","0","0","0","0","0","0","0","0","0"
"148","NCT01002248","Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients","Multiple Myeloma",0,"Perifosine","Drug","AEterna Zentaris","Industry",0,0,"All","18 Years","N/A","135","December 2009","March 2013","Determine the PFS (progression free survival) in patients with multiple myeloma, treated with perifosine, bortezomib and dexamethasone compared to patients treated with placebo, bortezomib and dexamethasone","0","0","0","0","0","0","0","0","0"
"149","NCT01002274","Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms","Lower Urinary Tract Symptoms",0,"MCS-2","Drug","Health Ever Bio-Tech Co., Ltd.","Industry",0,0,"Male","40 Years","N/A","180","August 2010","June 2014","Incidence of treatment-emergent adverse events","0","0","0","0","0","0","0","0","0"
"150","NCT01002417","MCS in the Treatment of Lower Urinary Tract Symptoms","Lower Urinary Tract Symptoms",0,"MCS-2 15 mg/day","Drug","Health Ever Bio-Tech Co., Ltd.","Industry",0,0,"Male","40 Years","N/A","274","July 2010","February 2014","Changes from baseline in International Prostate Symptom Scores","0","0","0","0","0","0","0","0","0"
"151","NCT01002573","Safety, Efficacy, and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients","Fever",0,"ibuprofen","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","N/A","16 Years","118","July 2010","June 2013","Fever Reduction","0","0","0","0","0","0","0","0","0"
"152","NCT01002664","Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms","Lower Urinary Tract Symptoms",0,"MCS-2","Drug","Health Ever Bio-Tech Co., Ltd.","Industry",0,0,"Male","40 Years","N/A","272","May 2010","June 2014","Changes in total International Prostate Symptom Scores (I-PSS)","0","0","0","0","0","0","0","0","0"
"153","NCT01004432","Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","Arthritis",0,"Golimumab 50 mg SC","Drug","Janssen Biotech, Inc.","Industry",0,0,"All","18 Years","N/A","433","December 2009","July 2013","Percentage of Participants Achieving Erythrocyte Sedimentation Rate (ESR)-Based American College of Rheumatology [ACR] 20 Response at Week 14","<0.0001","One sided test adjusting for conducting one interim analysis","Chi-squared","34.9","Percentage achive ACR 20 response","95","2-Sided","30.4","39.4"
"154","NCT01008410","Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis","Proctitis",0,"Budesonide","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","265","November 2009","April 2013","The proportion of subjects who achieve remission.","0","0","0","0","0","0","0","0","0"
"155","NCT01008423","Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis","Proctitis",0,"Budesonide","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","281","November 2009","March 2013","The proportion of subjects who achieve remission.","0","0","0","0","0","0","0","0","0"
"156","NCT01011205","Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation","Liver Transplantation",0,"Advagraf","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","893","September 2009","January 2013","Glomerular filtration rate (GFR) at 24 Weeks after transplantation estimated using the MDRD4 formula","0","0","0","0","0","0","0","0","0"
"157","NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","Lymphoma, Large-Cell, Diffuse",0,"OFATUMUMAB + DHAP","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","447","March 2010","February 2014","Progression-free Survival as Assessed by Independent Reviewers","0.333","p-value from stratified log-rank test are adjusted for stratification factors.","Stratified Log-rank test","1.12","Hazard Ratio (HR)","95","2-Sided","0.89","1.42"
"158","NCT01015287","A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction","Acute Coronary Syndromes",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","4033","December 2009","January 2013","The Percentage of Participants With Occurrence of Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, Urgent Revascularization (UR), or Glycoprotein (GP) IIb/IIIa Inhibitor Bailout","0","0","0","0","0","0","0","0","0"
"159","NCT01016067","Tibial Delayed Healing Pivotal Clinical Trial","Tibial Delayed Healing",0,"INFUSE/MASTERGRAFT","Device","Medtronic Spinal and Biologics","Industry",0,0,"All","21 Years","N/A","23","November 2010","October 2013","Overall Success","0","0","0","0","0","0","0","0","0"
"160","NCT01017874","A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer","Non Small Cell Lung Cancer",0,"Pemetrexed","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","236","November 2009","April 2013","Progression Free Survival (PFS)","0.217","0","Wilcoxon (Mann-Whitney)","0.85","Hazard Ratio (HR)","95","2-Sided","0.63","1.13"
"161","NCT01020487","Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)","Chronic Kidney Disease Stage 3 and 4",0,"Paricalcitol","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","10 Years","16 Years","47","February 2010","May 2014","Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax)","0","0","0","0","0","0","0","0","0"
"162","NCT01022424","A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]","Autosomal Dominant Polycystic Kidney Disease",0,"OPC-41061","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","N/A","N/A","13","November 2009","July 2014","combined renal volume (right and left kidneys) and renal function test","0","0","0","0","0","0","0","0","0"
"163","NCT01023308","Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma","Multiple Myeloma",0,"Panobinostat","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","768","December 2009","March 2013","Progression-free Survival Events in Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","0","0","0","0","0","0","0","0","0"
"164","NCT01025817","Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients","Kidney Transplant",0,"Everolimus and tacrolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","613","January 2010","March 2013","Number of Participants With Incidence of Composite Efficacy Failure","0","0","0","0","0","0","0","0","0"
"165","NCT01026870","Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)","Asthma",0,"SCH 32088 mometasone furoate (MF) metered-dose inhaler","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","0","June 2012","December 2013","Change from Baseline to Endpoint in the morning (AM trough) forced expiratory volume in 1 second (FEV1)","0","0","0","0","0","0","0","0","0"
"166","NCT01027884","Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)","Muscular Dystrophy, Duchenne",0,"Placebo","Drug","Santhera Pharmaceuticals","Industry",0,0,"Male","10 Years","18 Years","65","July 2009","January 2014","Change From Baseline in Percent Predicted Peak Expiratory Flow (PEF) at Week 52","0","0","0","0","0","0","0","0","0"
"167","NCT01028053","Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease","Mild Cognitive Impairment",0,"Flutemetamol (18F) Injection","Drug","GE Healthcare","Industry",0,0,"All","60 Years","N/A","365","December 2009","January 2014","Hazard Ratio (HR) by PET Scan Readers for Conversion to Probable Alzheimer's Disease Based on Visual Image Interpretation.","0","0","0","0","0","0","0","0","0"
"168","NCT01029262","A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q","Anemia",0,"Lenalidomide","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","239","January 2010","March 2013","Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC)","<0.001","0","Fisher Exact","10.616","Risk Ratio (RR)","95","2-Sided","2.639","42.702"
"169","NCT01032304","The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Erdosteine","Drug","Edmond Pharma","Industry",0,0,"All","40 Years","80 Years","492","August 2009","March 2014","number of acute exacerbations","0","0","0","0","0","0","0","0","0"
"170","NCT01034137","A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","Rheumatoid Arthritis",0,"methotrexate","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","317","January 2010","September 2014","Percentage of Participants Achieving Sustained Remission Rate At Week 104","< 0.001","0","Cochran-Mantel-Haenszel","1.996","Risk Ratio (RR)","95","2-Sided","1.589","2.506"
"171","NCT01035229","Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.","Carcinoma",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","546","April 2010","October 2013","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"172","NCT01038739","Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis","Diverticulitis",0,"Mesalazine","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","30 Years","80 Years","330","January 2010","January 2013","Proportion of recurrence-free patients at 48 weeks and at 96 weeks:","0","0","0","0","0","0","0","0","0"
"173","NCT01039376","Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy","Leukaemia, Lymphocytic, Chronic",0,"Ofatumumab","Biological","Novartis Pharmaceuticals","Industry",0,0,"All","N/A","N/A","480","May 6, 2010","June 19, 2014","Progression-free Survival, as Assessed by the Investigator","<0.0001","0","Stratified log rank test","0.50","Hazard Ratio (HR)","95","2-Sided","0.38","0.66"
"174","NCT01039688","Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","Arthritis, Rheumatoid",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","968","January 2010","March 2013","Comparison of baseline and month 6 scores of PA hand and AP foot radiographs obtained, read and scored by a central facility","0","0","0","0","0","0","0","0","0"
"175","NCT01047839","Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries","Encephalitis",0,"IC51","Biological","Valneva Austria GmbH","Industry",0,0,"All","2 Months","17 Years","100","January 2010","August 2013","Rate of Subjects With Serious Adverse Events (SAEs) and Medically Attended AEs up to Day 56 After the First Vaccination","0","0","0","0","0","0","0","0","0"
"176","NCT01051531","A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia","Schizophrenia",0,"Paliperidone palmitate","Drug","Johnson & Johnson Pte Ltd","Industry",0,0,"All","18 Years","50 Years","546","April 2010","May 2013","Treatment response will be evaluated by findings from the PANSS-a 30-item questionnaire that is administered to the patient by a qualified person (ie, rater) to measure the presence/absence and severity of positive and negative symptoms of schizophrenia","0","0","0","0","0","0","0","0","0"
"177","NCT01052558","GTS400 Stent Implantation in Conjunction With Cataract Surgery in Subjects With Open-angle Glaucoma","Glaucoma",0,"iStent Inject (GTS400)","Device","Glaukos Corporation","Industry",0,0,"All","18 Years","90 Years","164","January 2010","December 2013","Proportion of subjects with 12 month diurnalIOP </= 21 mmHg without use of ocular hypotensive medications for >/= 4 weeks prior to 12 month visit.","0","0","0","0","0","0","0","0","0"
"178","NCT01059630","A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)","Non-Hodgkin's Lymphoma",0,"Obinutuzumab","Drug","Genentech, Inc.","Industry",0,0,"All","18 Years","N/A","396","April 30, 2010","September 30, 2014","Number of Participants With Progressive Disease (PD) as Assessed by Independent Review Committee (IRC) or Death","0","0","0","0","0","0","0","0","0"
"179","NCT01061736","Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","Rheumatoid Arthritis",0,"Sarilumab","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","1675","March 2010","October 2013","Part A: Percentage of patients who achieved the American College of Rheumatology score of 20% improvement (ACR20) at Week 12","0","0","0","0","0","0","0","0","0"
"180","NCT01064401","Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","Relapsing-Remitting Multiple Sclerosis",0,"BIIB019 (Daclizumab High Yield Process)","Biological","Biogen","Industry",0,0,"All","18 Years","55 Years","1841","May 2010","March 2014","Adjusted Annualized Relapse Rate (ARR)","< 0.0001","Estimated from a negative binomial regression model adjusted for the baseline relapse rate, history of prior IFN beta use, baseline EDSS (≤ 2.5 vs > 2.5) and baseline age (≤ 35 vs > 35 years).","Negative Binomial Regression","0.550","Rate Ratio","95","2-Sided","0.469","0.645"
"181","NCT01074047","Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)","Acute Myeloid Leukemia",0,"Azacitidine","Drug","Celgene","Industry",0,0,"All","65 Years","N/A","488","June 2010","January 2014","Kaplan-Meier Estimates for Overall Survival From Any Cause","0.1009","0","Log Rank","0.85","Hazard Ratio (HR)","95","2-Sided","0.69","1.03"
"182","NCT01076010","An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)","Advanced Renal Cell Carcinoma",0,"Tivozanib","Drug","AVEO Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","350","March 2010","July 2014","To allow access to tivozanib for subjects who participated in Protocol AV-951-09-301 and AV-951-09-902, and failed sorafenib treatment on either protocol.","0","0","0","0","0","0","0","0","0"
"183","NCT01076764","Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy","Acute Coronary Syndrome",0,"Otamixaban","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","13220","April 2010","May 2013","Efficacy: Adjudicated double composite of all-cause of death and new myocardial infarction","0","0","0","0","0","0","0","0","0"
"184","NCT01077908","Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study","Cytomegalovirus Infection",0,"Adoptive Cellular Therapy","Biological","Cell Medica Ltd","Industry",0,0,"All","18 Years","N/A","91","July 2008","September 2014","CMV reactivations","0","0","0","0","0","0","0","0","0"
"185","NCT01078675","An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia","Familial Hypercholesterolaemia",0,"rosuvastatin calcium","Drug","AstraZeneca","Industry",0,0,"All","6 Years","17 Years","315","February 2010","February 2013","Percent Change From Baseline in LDL-C","<0.001","P-value<0.001 at Month 24. No adjustment for multiple comparisons is made for individual age group.","ANCOVA","-42.88","Mean Difference (Final Values)","-42.88","2-Sided","-45.44","-40.32"
"186","NCT01079806","A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection","Chronic Hepatitis B Virus, Pediatric",0,"Entecavir","Drug","Bristol-Myers Squibb","Industry",1,0,"All","2 Years","17 Years","180","June 2010","March 2013","Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48","0.0049","0","Normal approximation","20.2","Difference estimate","95","2-Sided","9.1","31.4"
"187","NCT01080391","Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma","Relapsed Multiple Myeloma",0,"Dexamethasone","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","792","July 2010","June 2014","Progression-free Survival (PFS)","< 0.0001","Analysis was stratified by β2 microglobulin levels (< 2.5 mg/L vs. ≥ 2.5 mg/L), prior bortezomib (no vs. yes), and prior lenalidomide (no vs. yes)","Log Rank","0.690","Hazard Ratio (HR)","95","2-Sided","0.570","0.834"
"188","NCT01081132","Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl","Attention-Deficit/Hyperactivity Disorder",0,"Extended-release Guanfacine Hydrochloride","Drug","Shire","Industry",0,0,"All","13 Years","17 Years","314","September 2011","May 2013","Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 13","<0.001","0","Mixed Models Repeated Measures Analysis","-6.026","Mean Difference (Final Values)","95","2-Sided","-8.865","-3.187"
"189","NCT01081769","Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics","Schizophrenia",0,"paliperidone palmitate injection","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","65 Years","769","February 2010","February 2013","Time to First Relapse Event","0.0191","0","Log Rank","0","0","0","0","0","0"
"190","NCT01082549","Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","Squamous Cell Lung Cancer",0,"gemcitabine/carboplatin","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","780","March 2010","April 2013","overall survival","0","0","0","0","0","0","0","0","0"
"191","NCT01083615","A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","Castrate-Resistant Prostate Cancer",0,"custirsen sodium","Drug","OncoGenex Technologies","Industry",0,0,"Male","18 Years","99 Years","14","March 2010","March 2013","To ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm.","0","0","0","0","0","0","0","0","0"
"192","NCT01087723","European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","Acute Coronary Syndrome",0,"Bivalirudin","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","2198","March 2010","August 2013","The Composite Incidence of Death and Non-coronary Artery Bypass Graft (CABG) Major Bleeding","0.0014","0","Chi-squared","0.60","Relative risk","95","2-Sided","0.43","0.82"
"193","NCT01090037","TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)","Chronic Renal Failure",0,"TRK-100STP high dose","Drug","Toray Industries, Inc","Industry",0,0,"All","18 Years","75 Years","892","March 2010","August 2014","Renal composite endpoints [Time to first occurrence of one of the following events:]","0","0","0","0","0","0","0","0","0"
"194","NCT01090427","A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)","Psoriasis",0,"Ustekinumab - Half-Standard Dosage","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","12 Years","18 Years","110","May 2010","January 2013","The Percentage of Participants Achieving a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 12","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"195","NCT01091168","Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer","Breast Cancer",0,"vinflunine","Drug","Pierre Fabre Medicament","Industry",0,0,"Female","18 Years","75 Years","594","September 2009","January 2013","Overall survival","0","0","0","0","0","0","0","0","0"
"196","NCT01092832","A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients","Candidiasis",0,"voriconazole","Drug","Pfizer","Industry",0,0,"All","2 Years","17 Years","23","October 2010","May 2013","Percentage of Participants With Adverse Events - Overall Summary","0","0","0","0","0","0","0","0","0"
"197","NCT01095666","A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","445","June 2010","March 2013","Change from baseline in HbA1c for each dose of dapagliflozin vs placebo","0","0","0","0","0","0","0","0","0"
"198","NCT01096524","Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty","Knee Osteoarthritis",0,"Standard Physiotherapy","Other","Bio-Medical Research, Ltd.","Industry",0,0,"All","18 Years","N/A","200","March 2010","June 2014","Efficacy of Kneehab in promoting early recovery of quadriceps performance following knee arthoplasty.","0","0","0","0","0","0","0","0","0"
"199","NCT01098110","6-week Trial of the Efficacy and Safety of Asenapine Compared to Placebo in Participants With an Acute Exacerbation of Schizophrenia (P06124)","Schizophrenia",0,"Asenapine 5 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","64 Years","532","May 2010","April 2014","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score.","<0.0001","Statistical significant: p=<0.05, two sided","ANCOVA","-11.29","Least square (LS) means difference","95","2-Sided","-15.42","-7.16"
"200","NCT01100502","A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)","Disease, Hodgkin",0,"brentuximab vedotin","Drug","Seattle Genetics, Inc.","Industry",0,0,"All","18 Years","N/A","329","April 2010","August 2014","Progression-free Survival by Independent Review","0.001","0","Log Rank","0.57","Hazard Ratio (HR)","95","2-Sided","0.40","0.81"
"201","NCT01100684","Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)","Diarrhea Predominant Irritable Bowel Syndrome",0,"Asimadoline","Drug","Tioga Pharmaceuticals","Industry",0,0,"All","18 Years","79 Years","611","May 2010","June 2013","12 Week Abdominal Pain and Stool (APS) Frequency Responder","0","0","0","0","0","0","0","0","0"
"202","NCT01102413","Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related Anaemia","Iron Deficiency Anemia",0,"Monofer","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","351","April 2010","June 2014","Change in Hemoglobin (Hb) Concentration From Baseline to Week 4.","0","0","0","0","0","0","0","0","0"
"203","NCT01103063","Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa","Intermittent Preventive Treatment In Pregnancy (IPTp)",0,"Azithromycin plus chloroquine","Drug","Pfizer","Industry",0,0,"Female","16 Years","35 Years","2891","October 2010","October 2013","Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population","0.12237","Mantel-Haenszel estimate of the common relative risk is presented, adjusting for randomization strata. A relative risk less than 1 favors Azithromycin + Chloroquine treatment group (reduction in risk for the endpoint)","Mantel Haenszel","1.11","Risk Ratio (RR)","95","2-Sided","0.97","1.25"
"204","NCT01103284","Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults","Type 1 Diabetes Mellitus",0,"DiaPep277","Drug","Andromeda Biotech Ltd.","Industry",0,0,"All","20 Years","45 Years","475","April 2010","October 2014","Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months","0.33","The a priori threshold for statistical significance was 0.05","Mixed Models Analysis","0","0","0","0","0","0"
"205","NCT01103505","HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device","Age Related Macular Degeneration",0,"ForeseeHome","Device","Notal Vision Ltd","Industry",0,0,"All","55 Years","N/A","1520","May 2010","October 2013","Early detection","0","0","0","0","0","0","0","0","0"
"206","NCT01103713","Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa","Asymptomatic Parasitemia In Pregnancy",0,"Azithromycin plus chloroquine","Drug","Pfizer","Industry",0,0,"Female","16 Years","35 Years","168","March 2011","June 2013","Percentage of Participants With Parasitologic Response (Polymerase Chain Reaction (PCR) Corrected) at Day 28 Post First Dose of Study Medication","0","0","0","0","0","0","0","0","0"
"207","NCT01104792","Long-term Study of Cariprazine in Patients With Schizophrenia","Schizophrenia",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","60 Years","588","April 2010","January 2013","Safety: adverse event recording, clinical laboratory parameters, vital signs, electrocardiograms and other","0","0","0","0","0","0","0","0","0"
"208","NCT01106014","Selexipag (ACT-293987) in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"Selexipag","Drug","Actelion","Industry",0,0,"All","18 Years","75 Years","1156","December 2009","April 2014","Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake","<0.0001","one-sided p-value","Log Rank","0.6","Hazard Ratio (HR)","99","2-Sided","0.46","0.78"
"209","NCT01108705","Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment","Carcinoma, Hepatocellular",0,"Brivanib","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","87","May 2010","October 2013","Compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to sorafenib and receive brivanib plus best supportive care (BSC) to those receiving placebo plus BSC","0","0","0","0","0","0","0","0","0"
"210","NCT01109498","Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]","Familial Lipoprotein Lipase Deficiency",0,"Alipogene Tiparvovec (AMT-011), Human LPL [S447X]","Genetic","Amsterdam Molecular Therapeutics","Industry",0,0,"All","18 Years","N/A","14","August 2007","June 2013","Reduction of fasting triglyceride (TG) concentrations","0","0","0","0","0","0","0","0","0"
"211","NCT01110382","A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections","Abscess, Intra-Abdominal",0,"Doripenem","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","3 Months","18 Years","41","December 2010","September 2013","The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit","0","0","0","0","0","0","0","0","0"
"212","NCT01110408","A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections","Complicated Urinary Tract Infections or Pyelonephritis",0,"Doripenem","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","3 Months","18 Years","41","December 2010","June 2013","The Number of Participants With Clinical Cure Rate at Test Of Cure (TOC) Visit","0","0","0","0","0","0","0","0","0"
"213","NCT01110447","Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation","Hepatic Encephalopathy",0,"VSL#3","Drug","CD Pharma India Pvt. Ltd.","Industry",0,0,"All","18 Years","70 Years","130","April 2010","March 2013","The primary end point will be development of overt HE or completion of a follow-up of 6 months after enrollment","0","0","0","0","0","0","0","0","0"
"214","NCT01114529","Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","Kidney Transplantation",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","828","August 9, 2010","October 30, 2014","Estimated Glomerular Filtration Rate (eGFR)","0","0","0","0","0","0","0","0","0"
"215","NCT01114737","Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) Patients","Phenylketonuria",0,"Sapropterin dihydrochloride","Drug","BioMarin Pharmaceutical","Industry",0,0,"All","8 Years","65 Years","206","August 2010","March 2013","Change in Attention-Deficit Hyperactivity Disorder Rating Scale-IV (ADHD-RS) / Adult ADHD Self-Report Scale (ASRS) Total Score From Baseline to Week 13","0.085","0","ANCOVA","-4.2","Mean Difference (Final Values)","95","2-Sided","-8.9","0.6"
"216","NCT01115907","Freedom SOLO Stentless Heart Valve Study","Aortic Stenosis",0,"Freedom SOLO Stentless Heart Valve","Device","Sorin Group USA, Inc.","Industry",0,0,"All","18 Years","N/A","251","December 2010","October 2014","Safety will be determined by incidence rate of adverse events","0","0","0","0","0","0","0","0","0"
"217","NCT01117012","Rollover Study of VX-770 in Cystic Fibrosis Subjects","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","6 Years","N/A","192","July 2010","May 2014","Number of Participants With Non-Serious Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"218","NCT01117987","Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)","Pulmonary Arterial Hypertension",0,"Imatinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","144","April 2010","April 2014","Number of Participants With Adverse Events, Serious Adverse Events and Deaths","0","0","0","0","0","0","0","0","0"
"219","NCT01119963","Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)","Preterm Delivery",0,"17-alpha-hydroxy-progesterone caproate, Makena®","Drug","Obstetrix Medical Group","Industry",0,0,"Female","18 Years","N/A","152","October 2011","April 2014","Interval from PROM until delivery of 34w0d which ever comes first.","0","0","0","0","0","0","0","0","0"
"220","NCT01120600","A Study to Assess Safety and Efficacy of Odanacatib (MK-0822) in Men With Osteoporosis (MK-0822-053)","Osteoporosis",0,"Odanacatib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Male","40 Years","95 Years","294","June 2010","July 2013","Percent change from baseline in lumbar spine bone mineral density (BMD)","0","0","0","0","0","0","0","0","0"
"221","NCT01121536","Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression",0,"Armodafinil","Drug","Cephalon","Industry",0,0,"All","18 Years","65 Years","867","April 2010","October 2013","Participants With Treatment-Emergent Adverse Events (TEAE)","0","0","0","0","0","0","0","0","0"
"222","NCT01122927","Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.","Adolescent Schizophrenia",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","10 Years","17 Years","524","July 2010","August 2014","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"223","NCT01123512","The Kiva® System as a Vertebral Augmentation Treatment","Spinal Fractures",0,"Vertebral augmentation","Device","Benvenue Medical, Inc.","Industry",0,0,"All","50 Years","N/A","300","July 2010","May 2013","Proportion of Participants With Study Success","0","0","0","99.92","% Probability of Equivalence = 99.92","0","2-Sided","0","0"
"224","NCT01124643","Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease","Fabry Disease",0,"Replagal","Biological","Shire","Industry",0,0,"All","18 Years","N/A","35","April 2010","July 2013","Change From Baseline in Left Ventricular Mass Indexed to Height (LVMI)","0","0","0","0","0","0","0","0","0"
"225","NCT01127048","Prospan® Hustenzäpfchen - Investigation on Efficacy and Tolerability in Children","Symptoms of Acute Bronchitis Accompanied by Coughing",0,"Suppositories containing Ivy leaves dry extract","Drug","Engelhard Arzneimittel GmbH & Co.KG","Industry",0,0,"All","N/A","6 Years","1400","October 2008","August 2013","Primary outcome measure","0","0","0","0","0","0","0","0","0"
"226","NCT01127633","Continued Safety Monitoring of Solanezumab in Alzheimer's Disease","Alzheimer's Disease",0,"Solanezumab","Drug","Eli Lilly and Company","Industry",0,0,"All","55 Years","N/A","1457","December 2010","July 2014","Assess the Number of Participants with One or More Drug-Related Adverse Events (AEs) or any Serious AEs (SAEs)","0","0","0","0","0","0","0","0","0"
"227","NCT01128959","Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy","Epilepsy",0,"Intravenous Carbamazepine (IV CBZ)","Drug","Lundbeck LLC","Industry",0,0,"All","18 Years","N/A","108","June 2010","January 2013","Adverse Events","0","0","0","0","0","0","0","0","0"
"228","NCT01130025","Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","Venous Thromboembolism",0,"Warfarin","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","900","August 2010","April 2014","Composite end-point represented by the time in days from randomisation to the first occurrence of VTE","0","0","0","0","0","0","0","0","0"
"229","NCT01131065","Efficacy and Safety of Niuliva® for the Prevention of Hepatitis B Virus Recurrence in Newly Orthotopic Liver Transplant Recipients","Hepatitis B",0,"Hepatitis B immune globulin","Drug","Instituto Grifols, S.A.","Industry",0,0,"All","18 Years","70 Years","15","July 2010","June 2014","HBV Recurrence","0","0","0","0","0","0","0","0","0"
"230","NCT01131624","Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) Versus Oral Iron for Iron Deficiency Anaemia in Pregnant Women","Anaemia",0,"ferrous sulphate","Drug","Vifor Inc.","Industry",0,0,"Female","18 Years","N/A","252","May 2010","May 2014","Average Hb increase after 3 weeks in FCM compared to oral iron treated subjects (superiority).","0","0","0","0","0","0","0","0","0"
"231","NCT01132326","Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304)","Primary Autonomic Failure",0,"Droxidopa","Drug","Chelsea Therapeutics","Industry",0,0,"All","18 Years","N/A","350","January 2009","February 2013","Patients With Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"232","NCT01137474","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","89 Years","2996","July 2010","February 2013","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (BP) at Week 12","0.0010","Endpoint tested following a sequential testing procedure at two-sided alpha=0.05 to control the family-wise Type I error rate related to primary and secondary efficacy endpoints. Test performed since previous tests were significant.","Longitudinal repeated measures analysis","-3.05","Mean Difference (Final Values)","95","2-Sided","-4.87","-1.24"
"233","NCT01137682","Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","Acromegaly",0,"Pasireotide (SOM230)","Drug","Novartis Pharmaceuticals","Industry",1,0,"All","18 Years","N/A","198","July 19, 2010","January 22, 2013","Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.","0","0","0","0","0","0","0","0","0"
"234","NCT01138657","Efficacy and Safety of Adalimumab in Patients With Active Uveitis","Uveitis",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","239","August 2010","July 2014","Time to Treatment Failure on or After Week 6","<0.001","0","Log Rank","0.50","Hazard Ratio (HR)","95","2-Sided","0.36","0.70"
"235","NCT01140347","A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","Hepatocellular Carcinoma",0,"Placebo","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","565","October 2010","March 2014","Overall Survival (OS)","0.1391","0","Log Rank","0.866","Hazard Ratio (HR)","95","2-Sided","0.717","1.046"
"236","NCT01140451","Extension Study of Ataluren (PTC124) in Cystic Fibrosis","Cystic Fibrosis",0,"Ataluren (PTC124)","Drug","PTC Therapeutics","Industry",0,0,"All","6 Years","N/A","191","August 2010","December 2013","Long-term safety of ataluren in patients with nonsense mutation CF, as determined by adverse events and laboratory abnormalities","0","0","0","0","0","0","0","0","0"
"237","NCT01142726","Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","511","December 2010","September 2013","Percentage of Participants Who Achieved Remission by Disease Activity Score 28 Based on C-reactive Protein (DAS28-CRP) Criteria at Month 12 and at Both Months 12 and 18","0.010","0","Regression, Logistic","2.01","Odds Ratio (OR)","95","2-Sided","1.18","3.43"
"238","NCT01143064","Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury","Brain Injuries",0,"Progesterone","Drug","BHR Pharma, LLC","Industry",0,0,"All","16 Years","70 Years","1195","June 2010","March 2014","Glasgow Outcome Scale (GOS)","0","0","0","0","0","0","0","0","0"
"239","NCT01143246","A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin","HRS",0,"Terlipressin","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","N/A","196","September 2010","February 2013","Confirmed Hepatorenal syndrome reversal","0","0","0","0","0","0","0","0","0"
"240","NCT01144611","Efficacy and Safety of Bovine Intestinal Alkaline Phosphatase (bIAP) During Heart Surgery","Inflammation",0,"bIAP bolus and 8h infusion","Drug","Alloksys Life Sciences B.V.","Industry",0,0,"All","18 Years","N/A","53","April 2010","December 2013","TNF-alpha","0","0","0","0","0","0","0","0","0"
"241","NCT01144637","A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects","Smallpox",0,"IMVAMUNE®","Biological","Bavarian Nordic","Industry",0,0,"All","18 Years","40 Years","4005","February 2013","November 2013","Geometric Mean Titers (GMTs) measured by PRNT","0","0","0","0","0","0","0","0","0"
"242","NCT01145638","A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)","Non-myeloid Malignancies",0,"iron isomaltoside 1000","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","350","October 2010","April 2014","Change in Hb Concentration","0","0","0","0","0","0","0","0","0"
"243","NCT01146418","Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031)","Infertility",0,"Corifollitropin alfa","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","35 Years","42 Years","307","June 2010","July 2013","Percentage of Participants With ≥1 Vital Pregnancy (Cumulative Vital Pregnancy Rate)","0","0","0","-1.8","Estimated Difference","95","2-Sided","-6.5","3.0"
"244","NCT01147926","Evaluation of Prucalopride in Male Subjects With Chronic Constipation.","Male Subjects With Chronic Constipation",0,"Placebo","Drug","Shire","Industry",0,0,"Male","18 Years","N/A","374","September 2010","October 2013","The Percentage of Subjects With an Average of ≥3 Spontaneous Complete Bowel Movements (SCBM) Per Week","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"245","NCT01147939","Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)","Acute Myeloid Leukemia (AML)",0,"Elacytarabine","Drug","Clavis Pharma","Industry",0,0,"All","18 Years","N/A","381","June 2010","February 2013","Overall survival","0","0","0","0","0","0","0","0","0"
"246","NCT01148017","Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine","Meningococcal Meningitis",0,"Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","37 Months","63 Months","433","July 2010","April 2013","Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 1:8 Directed Against N. Meningitidis Serogroups A, C, W-135, and Y","0","0","0","0","0","0","0","0","0"
"247","NCT01149655","Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia","Schizophrenia",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","13 Years","17 Years","252","July 2011","November 2013","Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse.","0.0161","0","Log Rank","0.461","Cox Proportional Hazard","95","2-Sided","0.242","0.879"
"248","NCT01150097","Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients","Liver Transplant Recipient",0,"Tacrolimus (reduced tacrolimus)","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","20 Years","75 Years","284","March 2010","May 2013","Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death","0","0","0","0","0","0","0","0","0"
"249","NCT01152996","Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","Depressive Disorder, Major",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","77 Years","1075","September 2010","May 2013","Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%","0","0","0","0","0","0","0","0","0"
"250","NCT01154140","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","Non Squamous Lung Cancer",0,"treatment","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","343","January 13, 2011","November 30, 2013","Progression-Free Survival (PFS) Based on Independent Radiology Review (IRR) by Treatment Arm","<0.0001","The study was to be considered positive if the 1‑sided log‑rank test for PFS, stratified for baseline stratification factors (ECOG PS, race group, brain metastases) was significant at the 0.0247 level.","Log Rank","0.454","Hazard Ratio (HR)","95","2-Sided","0.346","0.596"
"251","NCT01155310","Efficacy of Helium/Oxygen Compared to Air/Oxygen in Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"Helium/Oxygen 78%/22%","Drug","Air Liquide Santé International","Industry",0,0,"All","35 Years","N/A","446","May 2010","October 2013","Reduction of NIV failure","0","0","0","0","0","0","0","0","0"
"252","NCT01155479","A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)","Parkinson Disease",0,"Preladenant 2 mg tablet","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","85 Years","1022","July 2010","July 2013","Change From Baseline in the Sum of Unified Parkinson's Disease Rating Scale Parts 2 and 3 Scores (UPDRS2+3)","0.0033","0","constrained longitudinal analysis","2.60","Difference in Estimated Means","95","2-Sided","0.86","4.30"
"253","NCT01158196","Safety and Efficacy of Infrared Diode Laser on Improvement of Scar and Prevention of Recurrence of Excised Keloid","Keloid",0,"infra-red diode laser","Device","Ekkyo","Industry",0,0,"All","18 Years","70 Years","60","June 2010","April 2013","treatment tolerability assessed by natures, intensity and incidences of the side effects, with a special oversight of skin burn lesion","0","0","0","0","0","0","0","0","0"
"254","NCT01158378","Safety and Effectiveness of the Adherus Dural Sealant System When Used as a Dural Sealant in Cranial Procedures","Elective Cranial Procedures With Dural Incision",0,"Adherus Dural Sealant","Device","HyperBranch Medical Technology, Inc","Industry",0,0,"All","18 Years","75 Years","250","June 2010","January 2013","Proportion of Treated Subjects Who Were Free of Intra-operative Cerebrospinal Fluid (CSF) Leakage From Dural Repair During Valsalva Maneuver, CSF Leak / Pseudomeningocele, and Unplanned Retreatment of the Original Surgical Site","0.0049","0","one-sided z-test","0","0","0","0","0","0"
"255","NCT01160380","A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma","Fatigue",0,"armodafinil","Drug","Oncotherapeutics","Industry",0,0,"All","18 Years","N/A","50","June 2010","June 2013","BFI Score","0.289","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"256","NCT01161420","Stimulation Therapy for Apnea Reduction (Www.theSTARtrial.Com)","Obstructive Sleep Apnea",0,"Inspire Upper Airway Stimulation System","Device","Inspire Medical Systems, Inc.","Industry",0,0,"All","22 Years","N/A","929","July 2010","March 2013","Apnea Hypopnea Index","0","0","0","0","0","0","0","0","0"
"257","NCT01164540","Study on the Effect of Rosuvastatin Treatment on the Prevention of Thrombosis in Patients With Previous Thrombosis","Venous Thrombosis",0,"Rosuvastatin (AZD4522)","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","3000","February 2011","March 2013","Any event of venous thromboembolism (i.e. Deep Vein Thrombosis (DVT) and/or fatal or non-fatal Pulmonary Embolism(PE))","0","0","0","0","0","0","0","0","0"
"258","NCT01166711","Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent","Coronary Artery Disease",0,"Coroflex Blue (BMS) followed by SeQuent Please (DEB)","Device","Aesculap AG","Industry",0,0,"All","18 Years","N/A","1000","August 2010","February 2013","Major adverse cardiac events (MACE) - target vessel failure (TVF)","0","0","0","0","0","0","0","0","0"
"259","NCT01166997","ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism","Submassive Pulmonary Embolism",0,"EkoSonic Endovascular System","Device","EKOS Corporation","Industry",0,0,"All","18 Years","80 Years","59","July 2010","April 2013","Reduction of RV/LV Ratio","0","0","0","0","0","0","0","0","0"
"260","NCT01168791","Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma","Soft Tissue Sarcoma",0,"doxorubicin in combination with palifosfamide-tris","Drug","Ziopharm","Industry",0,0,"All","18 Years","N/A","447","July 2010","March 2013","Progression Free Survival followed by Overall Survival","0","0","0","0","0","0","0","0","0"
"261","NCT01168973","A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy","Non-Small Cell Lung Cancer",0,"Ramucirumab","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1253","December 2010","December 2013","Overall Survival","0","0","0","0","0","0","0","0","0"
"262","NCT01170663","A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma","Gastric Cancer",0,"Ramucirumab (IMC-1211B) DP","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","665","December 2010","July 2013","Overall Survival Time (OS)","0.0169","0","Stratified Log Rank Test","0.807","Hazard Ratio (HR)","95","2-Sided","0.678","0.962"
"263","NCT01173601","A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder","Major Depressive Disorder",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1344","November 2010","October 2013","Change from baseline to week 11 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score","0","0","0","0","0","0","0","0","0"
"264","NCT01175213","Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID","Primary Immunodeficiency Diseases (PID)",0,"IGSC - rHuPH20 then IGSC or IGIV","Biological","Baxalta US Inc.","Industry",0,0,"All","2 Years","N/A","66","July 2010","August 2013","Annual Rate of Serious Bacterial Infections","<0.0001","Testing the null hypothesis of 1 VASBI/year against a one-sided alternative at the 0.01 level of statistical significance.","Poisson","0.020","Poisson","99","1-Sided","0","0.045"
"265","NCT01177384","Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)","Type 2 Diabetes Mellitus",0,"Sitagliptin phosphate","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","380","January 25, 2011","March 25, 2013","Change From Baseline in Hemoglobin A1c (A1C) at Week 24","<.001","The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (on acarbose monotherapy, or on acarbose in combination with other AHA(s)) and a covariate for baseline A1C.","ANCOVA","-0.62","Difference in least squares mean","95","2-Sided","-0.79","-0.44"
"266","NCT01178073","A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)","Hypertension, Pulmonary",0,"ambrisentan","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","610","October 2010","April 2014","Number of Participants With First Adjudicated Clinical Failure (CF) Event, Death, Hospitalisation for Worsening PAH, Disease Progression, Unsatisfactory Long-term Clinical Response, All Through FAV","0.0002","0","Stratified Log Rank","0.502","Hazard Ratio (HR)","95","2-Sided","0.348","0.724"
"267","NCT01178125","A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy","Contraception",0,"DR-102","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"Female","18 Years","40 Years","2858","August 2010","January 2013","All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule","0","0","0","0","0","0","0","0","0"
"268","NCT01178281","Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence","Primary Myelofibrosis",0,"Pomalidomide 0.5 mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","252","September 2010","January 2013","Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence","1.000","0","Fisher Exact","0","0","0","0","0","0"
"269","NCT01178294","Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A","Hemophilia A",0,"OBI-1","Biological","Baxalta US Inc.","Industry",0,0,"All","18 Years","N/A","29","November 2010","July 2013","Percentage of Serious Bleeding Episodes Responsive to OBI-1","<0.001","0","one-sided binomial exact test","0","0","0","0","0","0"
"270","NCT01179217","A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia","Sickle Cell Anemia",0,"L-glutamine","Drug","Emmaus Medical, Inc.","Industry",0,0,"All","5 Years","N/A","230","May 2010","March 2014","The number of occurrences of sickle cell crises","0","0","0","0","0","0","0","0","0"
"271","NCT01179672","A Study in Participants With Diabetic Peripheral Neuropathic Pain in China","Diabetic Neuropathy, Painful",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","405","April 2011","August 2013","Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score","0.030","0","Mixed Models Analysis","-0.43","Mean Difference (Final Values)","95","2-Sided","-0.82","-0.04"
"272","NCT01182441","Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy","Atrial Fibrillation",0,"WATCHMAN Device","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","475","November 2010","January 2013","Primary Endpoints","0","0","0","0","0","0","0","0","0"
"273","NCT01183780","A Study in Second Line Metastatic Colorectal Cancer","Colorectal Cancer",0,"Ramucirumab","Biological","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1072","December 2010","July 2014","Overall Survival (OS)","0.0219","0","Log Rank","0.844","Hazard Ratio (HR)","95","2-Sided","0.730","0.976"
"274","NCT01185340","A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor","Major Depressive Disorder",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","793","March 2011","April 2013","Change From Baseline to week 11 in Montgomery-Asberg Depression Rating Scale (MADRS) total score","0","0","0","0","0","0","0","0","0"
"275","NCT01186744","A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis","Psoriasis",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","666","September 2010","January 2013","Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)","0.0008","0","Log Rank","0","0","0","0","0","0"
"276","NCT01187407","A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment","Major Depressive Disorder (MDD)",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1178","March 2011","August 2013","Change from baseline to week 11 in the Montgomery-Asberg Depression Rating Scale (MADRS) total score","0","0","0","0","0","0","0","0","0"
"277","NCT01187628","Long-term Study in Chronic Kidney Disease (Extension From Study 14817)","Hyperphosphatemia",0,"Fosrenol (Lanthanum Carbonate, BAY77-1931)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","123","September 2010","April 2013","Incidence of treatment emergent adverse events","0","0","0","0","0","0","0","0","0"
"278","NCT01187953","Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","Renal Failure",0,"Prograf (tacrolimus)","Drug","Veloxis Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","543","September 2010","March 2013","The Primary Efficacy Endpoint for the Study is the Proportion of Treatment Failures Within 12 Months After Randomization to Study Drug.",">0.999","Endpoint: Death","Fisher Exact","0","0","0","0","0","0"
"279","NCT01188759","Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects","Aspergillosis",0,"Voriconazole","Drug","Pfizer","Industry",0,0,"All","2 Years","17 Years","0","May 2012","August 2014","Safety and tolerability of voriconazole and anidulafungin in combination versus voriconazole alone as determined by rates of adverse events","0","0","0","0","0","0","0","0","0"
"280","NCT01190254","Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)","Schizophrenia, Paranoid",0,"asenapine 2.5 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","17 Years","306","September 2010","March 2013","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56","0.070","p-value is adjusted by Hochberg's method for testing two asenapine groups versus the placebo group","Mixed Model for Repeated Measures (MMRM)","-4.8","Difference in Least Squares (LS) Means","95","2-Sided","-9.9","0.4"
"281","NCT01190267","Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)","Schizophrenia, Paranoid",0,"asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","17 Years","204","September 2010","October 2013","Number of Participants With a Treatment-Emergent Adverse Event (AE) During Extension Study","0","0","0","0","0","0","0","0","0"
"282","NCT01190839","A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence","Crohn's Disease",0,"Infliximab","Biological","Janssen Biotech, Inc.","Industry",0,0,"All","18 Years","99 Years","297","November 2010","December 2014","Percentage of Participants With Clinical Recurrence (CR) of Crohn's Disease (CD) Prior to or at Week 76","0.097","p-value was based on the Cochran-Mantel-Haenszel chi-square test stratified by the number of risk factors for recurrence of active CD and baseline use of an immunomodulator.","Cochran-Mantel-Haenszel chi-square test","0","0","0","0","0","0"
"283","NCT01191255","A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis","Hyperphosphatemia",0,"ferric citrate, ca acetate, sevelamer carbonate, placebo","Drug","Keryx Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","441","October 2010","January 2013","Change in Mean Serum Phosphorus From Baseline (Week 52) to the End of the Efficacy Assessment Period (EAP; Week 56)","<0.0001","The P-value for the change in mean serum phosphorus was calculated via an ANCOVA model with treatment as the fixed effect and Week-52-baseline as the co-variate.","ANCOVA","0","0","0","0","0","0"
"284","NCT01191801","Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML","Acute Myeloid Leukemia",0,"vosaroxin + cytarabine","Drug","Sunesis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","711","December 17, 2010","September 26, 2014","Overall Survival","0.0305","Unstratified one sided P-Value","Unstratified Log Rank","0.87","Cox Proportional Hazard","95","1-Sided","0","0"
"285","NCT01192022","TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery","Hemorrhage",0,"TachoSil®","Biological","Takeda","Industry",0,0,"All","N/A","N/A","253","August 2010","May 2013","Percentage of Participants With Intraoperative Hemostasis at Target Bleeding Site Within 3 Minutes","<0.001","Logistic regression model with treatment and pooled center as factors.","Regression, Logistic","4.87","Odds Ratio (OR)","95","2-Sided","2.55","9.29"
"286","NCT01192295","Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids","Pain",0,"Oxycodone HCl controlled-release tablets","Drug","Purdue Pharma LP","Industry",0,0,"All","6 Years","16 Years","155","November 2010","July 2014","The Number of Participants With Adverse Events as a Measure of Safety.","0","0","0","0","0","0","0","0","0"
"287","NCT01193153","A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder","Schizoaffective Disorder",0,"Placebo","Drug","Janssen Scientific Affairs, LLC","Industry",0,0,"All","18 Years","65 Years","667","September 2010","October 2013","Double-blind: Percentage of Participants Who Experienced Relapse","<0.001","0","Log Rank","2.49","Hazard Ratio (HR)","95","2-Sided","1.55","3.99"
"288","NCT01193244","Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer","Prostate Cancer",0,"Orteronel","Drug","Millennium Pharmaceuticals, Inc.","Industry",1,0,"Male","18 Years","N/A","1560","October 1, 2010","January 1, 2014","Radiographic Progression-free Survival (rPFS)","<0.00001","0","Log Rank","0.707","Hazard Ratio (HR)","95","0","0.626","0.799"
"289","NCT01193257","Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer","Prostate Cancer",0,"Orteronel + prednisone","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"Male","18 Years","N/A","1099","November 2010","September 2014","Overall survival (OS)","0","0","0","0","0","0","0","0","0"
"290","NCT01195662","A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","89 Years","2245","October 2010","February 2013","Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure for 12 Week Double-Blind Treatment Period - Randomized Participants","0.0002","Endpoint was tested at alpha=0.05. Hierarchical closed testing procedure used.","Longitudinal repeated measures","-4.28","Mean Difference (Final Values)","95","2-Sided","-6.54","-2.02"
"291","NCT01196091","A Study of LY2127399 in Patients With Systemic Lupus Erythematosus","Systemic Lupus Erythematosus",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1164","December 2010","July 2014","Proportion of patients achieving an SLE Responder Index response at week 52","0","0","0","0","0","0","0","0","0"
"292","NCT01197534","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.","Rheumatoid Arthritis",0,"fostamatinib","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","913","September 2010","March 2013","Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo","<0.001","Week 24","Mantel Haenszel","0.15","Weighted difference in proportions","95","2-Sided","0.08","0.22"
"293","NCT01197560","Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","Diffuse Large B-cell Lymphoma",0,"Lenalidomide","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","111","September 1, 2010","July 4, 2013","Stage 1: Percentage of Participants With an Overall Response Rate (ORR) According to the International Working Group (IWG) Response Criteria for Non Hodgkin's Lymphoma (NHL), Cheson 1999.","0.079","0","Fisher Exact","0","0","0","0","0","0"
"294","NCT01197755","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist","Rheumatoid Arthritis",0,"fostamatinib","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","323","September 2010","February 2013","Proportion of Patients Achieving ACR20 at Week 24, Comparison Between Fostamatinib and Placebo","0.004","Week 24","Mantel Haenszel","0.17","Weighted difference in proportion","95","2-Sided","0.05","0.28"
"295","NCT01200992","Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer","Bladder Neoplasm",0,"EN3348","Biological","Bioniche Life Sciences Inc.","Industry",0,0,"All","18 Years","N/A","84","November 2010","April 2013","Comparison of Event-free Survival of Intravesical EN3348 With Mitomycin C.","0","0","0","0","0","0","0","0","0"
"296","NCT01202773","A Study in Patients With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","555","January 2011","March 2013","Percentage of patients with American College of Rheumatology 20% response (ACR20)","0","0","0","0","0","0","0","0","0"
"297","NCT01202903","Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","Persistent Allergic Asthma",0,"Omalizumab","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","616","September 2010","October 2013","Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period","0","0","0","0","0","0","0","0","0"
"298","NCT01203397","Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate In The Superficial Varicose Veins Treatment","VARICOSE VEINS",0,"TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G","Drug","EMS","Industry",0,0,"All","18 Years","80 Years","70","September 2014","December 2014","Efficacy - Symptoms reduction","0","0","0","0","0","0","0","0","0"
"299","NCT01204749","TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer","Fallopian Tube Cancer",0,"AMG 386","Drug","Amgen","Industry",0,0,"Female","18 Years","N/A","919","November 2010","March 2013","Progression-Free Survival","0","0","0","0","0","0","0","0","0"
"300","NCT01205438","A Study of LY2127399 in Patients With Systemic Lupus Erythematosus","Systemic Lupus Erythematosus",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1124","January 2011","August 2014","Proportion of patients achieving an SLE Responder Index response at week 52","0","0","0","0","0","0","0","0","0"
"301","NCT01206907","Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects","Chronic Pain",0,"oxymorphone IR","Drug","Endo Pharmaceuticals","Industry",0,0,"All","2 Years","6 Years","0","October 2010","December 2013","Change in pain intensity from baseline to last assessment using the Face, Legs, Activity, Cry, Consolability (FLACC) pain scale.","0","0","0","0","0","0","0","0","0"
"302","NCT01208181","A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)","Arthritis, Rheumatoid",0,"Etoricoxib 60 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1404","September 2010","June 2014","Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)","0.004","0","Tukey-Ciminera-Heysetrend test","-0.29","Difference in least squares mean","95","2-Sided","-0.49","-0.09"
"303","NCT01208207","A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","Spondylitis, Ankylosing",0,"Part I - etoricoxib 60 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1015","September 2010","November 2014","Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen","0","0","0","-0.64","Difference in Least Squares Mean","95","2-Sided","-5.47","4.19"
"304","NCT01210365","Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema","Congestive Heart Failure",0,"Diurisa®","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","N/A","60","January 2011","February 2013","Evaluate the effect on kalemia of the fixed combination of furosemide and amiloride compared with furosemide alone in the treatment of patients with HF functional class II (NYHA)","0","0","0","0","0","0","0","0","0"
"305","NCT01211444","US Clinical Study of the Apnex Medical Hypoglossal Nerve Stimulation (HGNS) System to Treat Obstructive Sleep Apnea","Obstructive Sleep Apnea",0,"HGNS Treatment","Device","Apnex Medical, Inc.","Industry",0,0,"All","21 Years","70 Years","20","July 2010","August 2013","Mean change in AHI measured with in-lab nighttime polysomnography (PSG) compared to baseline","0","0","0","0","0","0","0","0","0"
"306","NCT01212991","A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer","Prostate Cancer",0,"Enzalutamide","Drug","Medivation, Inc.","Industry",0,0,"Male","18 Years","N/A","1717","September 2010","September 2013","Overall Survival","<0.0001","A 2-stage group sequential method (Lan DeMets OBF) assigned the level of significance for the pre-specified interim overall survival analysis (p<0.015) based on overall 2-sided type I error rate of 0.049. Final results based upon interim analysis.","Log Rank","0.706","Hazard Ratio (HR)","95","2-Sided","0.596","0.837"
"307","NCT01214096","Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure","Chronic Heart Failure",0,"rhNRG-1","Drug","Zensun Sci. & Tech. Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","120","July 2010","December 2014","cardiac function measured by MRI","0","0","0","0","0","0","0","0","0"
"308","NCT01215227","An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)","Parkinson Disease",0,"Preladenant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","85 Years","839","November 2010","July 2013","Percentage of Participants With Systolic Blood Pressure ≥180 mmHg","0","0","0","0","0","0","0","0","0"
"309","NCT01215942","An Open Label Study for Patients With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"LY2127399","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1505","June 2011","February 2014","Percentage of patients developing anti-LY2127399 antibodies","0","0","0","0","0","0","0","0","0"
"310","NCT01217606","Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","Glaucoma, Open-Angle",0,"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","185","January 2011","September 2014","Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test","0","0","0","0","0","0","0","0","0"
"311","NCT01217671","International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema","Emphysema",0,"Kamada AAT for inhalation","Biological","Kamada, Ltd.","Industry",0,0,"All","18 Years","N/A","168","December 2009","November 2014","Exacerbation events and lung density","0","0","0","0","0","0","0","0","0"
"312","NCT01218659","Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease","Fabry Disease",0,"migalastat hydrochloride","Drug","Amicus Therapeutics","Industry",0,0,"All","16 Years","74 Years","60","December 2010","May 2014","renal function assessed by iohexol Glomerular Filtration Rate (GFR)","0","0","0","0","0","0","0","0","0"
"313","NCT01222663","Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock","Peritonitis",0,"standard therapy","Device","Meditor SAS","Industry",0,0,"All","18 Years","N/A","243","October 2010","April 2013","Mortality","0","0","0","0","0","0","0","0","0"
"314","NCT01222884","A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D","Chronic Kidney Disease Stage 5 (Dialysis Dependent)",0,"Monofer","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","351","June 2011","October 2013","Ability to Maintain Hemoglobin Level","0","0","0","0","0","0","0","0","0"
"315","NCT01223027","Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma",0,"Dovitinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","564","March 2011","June 2014","Progression Free Survival (PFS) Per Independent Central Radiology Review","0","0","0","0","0","0","0","0","0"
"316","NCT01223131","Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.","Type 1 Diabetes Mellitus",0,"Insulin glargine (HOE901)","Drug","Sanofi","Industry",0,0,"All","6 Years","17 Years","162","February 2011","March 2014","Absolute change of glycosylated hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"317","NCT01223352","Effects of Two Dosing Regimens of Bosentan in Children With Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension",0,"bosentan","Drug","Actelion","Industry",0,0,"All","3 Months","12 Years","64","March 2011","April 2013","Daily exposure [AUC(0-24c)] to bosentan","0","0","0","0","0","0","0","0","0"
"318","NCT01224522","Axial Alignment in Patients Operated Using the Visionaire Patient Matched Cutting Blocks","Osteoarthritis of the Knee",0,"Visionaire","Procedure","Smith & Nephew Orthopaedics AG","Industry",0,0,"All","40 Years","75 Years","70","March 2011","August 2014","Axial Alignment","0","0","0","0","0","0","0","0","0"
"319","NCT01226511","A Study in Pediatric Participants With Generalized Anxiety Disorder","Anxiety Neuroses",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","7 Years","17 Years","281","June 2011","February 2013","Change From Baseline to 10-Week Endpoint in the Pediatric Anxiety Rating Scale (PARS) Severity Score Evaluated for Symptoms Identified on the Generalized Anxiety Subsection of the PARS Symptom Checklist","<0.001","0","Mixed Models Analysis","-2.65","Least squares (LS) mean difference","95","2-Sided","-4.03","-1.27"
"320","NCT01227265","Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)","Parkinson Disease",0,"Preladenant","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","30 Years","85 Years","476","November 2010","April 2013","Change From Baseline in Average ""Off"" Time (Hours Per Day) at Week 12","0.4933","0","cLDA","-0.2","Difference in Estimated Means","95","2-Sided","-0.72","0.35"
"321","NCT01227512","Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia","Hyponatremia",0,"tolvaptan","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","N/A","124","October 2010","May 2013","Length of Hospital Stay (LoS)","0.9495","The alpha level was set at 0.05","Generalized Wilcoxon Test","0","0","0","0","0","0"
"322","NCT01228747","A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)","Epilepsy",0,"Levetiracetam","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","16 Years","N/A","361","October 2010","April 2014","Percentage Change From the Combined Baseline in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 28-week Treatment Period (Dose Adjustment + Evaluation Periods)","<0.0001","Statistical testing was 2-sided, and was performed using a significance (α) level of 0.05.","ANCOVA","- 56.13","Mean Difference (Net)","95","2-Sided","- 68.24","- 44.02"
"323","NCT01230827","A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)","Juvenile Idiopathic Arthritis",0,"CNTO 148 (Golimumab)","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","2 Years","18 Years","173","December 2010","September 2013","Percentage of Participants With American College of Rheumatology (ACR) 30 Response at Week 16 Who Did Not Experienced a Flare of Disease Through Week 48","0","0","0","0","0","0","0","0","0"
"324","NCT01231516","A Study of GSK1349572 Versus Raltegravir (RAL) With Investigator Selected Background Regimen in Antiretroviral-Experienced, Integrase Inhibitor-Naive Adults","Infection, Human Immunodeficiency Virus",0,"GSK1349572","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","724","October 2010","February 2013","Percentage of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) at Week 48","0.030","P-value is for test of superiority.","Cochran-Mantel-Haenszel","7.4","Difference in percentage","95","2-Sided","0.7","14.2"
"325","NCT01232556","A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy","Lymphoma, Non-Hodgkin",0,"Inotuzumab ozogamicin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","340","April 2011","March 2014","Overall Survival","0","0","0","0","0","0","0","0","0"
"326","NCT01234337","Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer","Breast Cancer",0,"Sorafenib (Nexavar, BAY43-9006)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","537","February 21, 2011","May 12, 2014","Progression-free Survival (PFS) Assessed by the Independent Review Panel According to Response Evaluation Criteria for Solid Tumors (RECIST) 1.1","=0.405618","One-sided p-value from log rank test (stratified per randomization as in interactive voice response system [IVRS]).","Log Rank","0.973","Hazard Ratio (HR)","95","2-Sided","0.779","1.217"
"327","NCT01235234","Trial of CF101 to Treat Patients With Dry Eye Disease","Keratoconjunctivitis Sicca",0,"CF101","Drug","Can-Fite BioPharma","Industry",0,0,"All","18 Years","N/A","236","July 2011","November 2013","Efficacy by Proportion of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24","0","0","0","0","0","0","0","0","0"
"328","NCT01237288","Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets","Primary Hypophosphatemic Rickets",0,"Z-521","Drug","Zeria Pharmaceutical","Industry",0,0,"All","1 Year","14 Years","16","September 2010","April 2013","Serum ALP level","0","0","0","0","0","0","0","0","0"
"329","NCT01239797","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","Lymphoma (Myeloma)",0,"Lenalidomide","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","761","March 2011","September 2014","Median Progression Free Survival (PFS)","0.0014","0","Log Rank","0.73","Hazard Ratio (HR)","95","2-Sided","0.60","0.89"
"330","NCT01241240","Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","Glaucoma, Open-Angle",0,"bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","192","March 2011","September 2013","Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) at Week 12","0","0","0","0","0","0","0","0","0"
"331","NCT01241552","A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)","Clostridium Difficile Infection",0,"MK-3415","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1452","October 2011","December 2014","Percentage of Participants With Clostridium Difficile Infection (CDI) Recurrence","0.3182","One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).","Miettinen and Nurminen","-1.7","Adjusted Difference","95","2-Sided","-8.6","5.5"
"332","NCT01241591","A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis","Psoriasis",0,"CP 690,550 5 mg","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1101","November 2010","January 2013","Percentage of Participants With a Physician's Global Assessment (PGA) Response of ""Clear"" or ""Almost Clear"" at Week 12","0","0","0","-19.16","Mean Difference","95","2-Sided","-26.55","-11.76"
"333","NCT01244191","Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","Non Squamous, Non-small-cell Lung Cancer",0,"Tivantinib","Drug","Daiichi Sankyo Inc.","Industry",0,0,"All","18 Years","N/A","1048","November 2010","August 2013","Overall survival of participants","0","0","0","0","0","0","0","0","0"
"334","NCT01244490","Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder",0,"Extended-release Guanfacine Hydrochloride","Drug","Shire","Industry",0,0,"All","6 Years","17 Years","338","January 2011","May 2013","Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 10/13 - Last Observation Carried Forward (LOCF)","<0.001","0","ANCOVA","-8.9","Difference in Least Squares Mean","95","2-Sided","-11.9","-5.8"
"335","NCT01244659","A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment","Renal Transplant",0,"Tacrolimus from EMS","Drug","EMS","Industry",0,0,"All","18 Years","N/A","60","May 2014","August 2014","Efficacy","0","0","0","0","0","0","0","0","0"
"336","NCT01244815","Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)","Bipolar Disorder, Pediatric",0,"asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","10 Years","17 Years","404","June 2011","August 2013","Change From Baseline in Y-MRS Total Score at Day 21","0.008","p-value is adjusted by Hochberg's method for testing three asenapine groups versus the placebo group","Mixed Model for Repeated Measures (MMRM)","-3.2","Difference in Least Squares (LS) Means","95","2-Sided","-5.6","-0.8"
"337","NCT01244828","Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)","Schizophrenia",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","157","April 2011","August 2014","Change From Baseline in Weight at Week 52","0","0","0","0","0","0","0","0","0"
"338","NCT01245582","Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients","Hepatic Neoplasm Malignant",0,"oxaliplatin (SR96669)","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","0","July 2011","February 2014","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"339","NCT01245764","GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)","Papillomavirus Infections",0,"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","9 Years","26 Years","250","March 21, 2011","April 15, 2013","Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6","0","0","0","0","0","0","0","0","0"
"340","NCT01245816","A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)","Familial Adenomatous Polyposis",0,"Eflornithine plus Sulindac","Drug","Cancer Prevention Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","0","March 2011","May 2013","Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.","0","0","0","0","0","0","0","0","0"
"341","NCT01249352","A Study of Chemoradiation Associated With Nimotuzumab as the Treatment of Locally Advanced Esophageal Cancer","Esophageal Cancer",0,"Nimotuzumab","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","N/A","104","January 2009","November 2013","Overall survival and assessment of the complete endoscopic response","0","0","0","0","0","0","0","0","0"
"342","NCT01249404","Dysport® Adult Lower Limb Spasticity Study","Leg Spasticity",0,"Botulinum type A toxin (Dysport®)","Drug","Ipsen","Industry",0,0,"All","18 Years","80 Years","348","March 2011","December 2013","Intensity of muscle tone rated by the Modified Ashworth scale","0","0","0","0","0","0","0","0","0"
"343","NCT01249417","Dysport® Pediatric Lower Limb Spasticity Study","Cerebral Palsy",0,"Botulinum type A toxin (Dysport®)","Drug","Ipsen","Industry",0,0,"All","2 Years","17 Years","241","July 2011","February 2014","Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb","0.0029","0","ANCOVA","-0.38","Difference in LS means","95","2-Sided","-0.64","-0.13"
"344","NCT01249664","VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)","Myopia, Pathological",0,"VEGF Trap-Eye (BAY86-5321)","Biological","Bayer","Industry",0,0,"All","18 Years","N/A","122","December 2010","February 2013","Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)","<0.0001","No adjustment on P value, this is for the primary efficacy analysis.","ANCOVA","14.1","Difference in least square means","95","2-Sided","10.8","17.4"
"345","NCT01251614","A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","Plaque Psoriasis",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","4 Years","17 Years","114","December 2010","December 2013","Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16","0.027","0","Chi-squared","-25.5","Difference","95","2-Sided","-47.2","-3.7"
"346","NCT01252069","PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)","Uterine Fibroids",0,"PGL4001, placebo, drug free period","Drug","PregLem SA","Industry",0,0,"Female","18 Years","48 Years","132","January 2011","August 2013","percentage of subjects in amennorrhoea at the end of each PGL4001 treatment course received","0","0","0","0","0","0","0","0","0"
"347","NCT01252355","Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta","Multiple Sclerosis Relapse",0,"Teriflunomide","Drug","Sanofi","Industry",0,0,"All","18 Years","55 Years","534","January 2011","April 2013","Annualized Relapse Rate (ARR) (Poisson Regression Estimates)","0","0","0","0","0","0","0","0","0"
"348","NCT01252732","Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection","Wound Infection",0,"Single-Dose IV Oritavancin Diphosphate","Drug","The Medicines Company","Industry",0,0,"All","18 Years","N/A","1019","December 2010","June 2013","Cessation of spread or reduction in size of baseline lesion, absence of fever, and no rescue antibiotic medication at ECE (48 to 72 hours)","0","0","0","0","0","0","0","0","0"
"349","NCT01253200","Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter","Atrial Flutter",0,"Blazer® Open-Irrigated Ablation Catheter","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","302","January 2011","September 2013","Procedure-related complication-free rate","0","0","0","0","0","0","0","0","0"
"350","NCT01254019","A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy","Muscular Dystrophies",0,"GSK2402968 6mg/kg/week","Drug","GlaxoSmithKline","Industry",0,0,"Male","5 Years","N/A","186","December 2010","June 2013","Change from Baseline in muscle function using the 6 Minute Walking Distance (6MWD) test assessed at Week 48","0","0","0","0","0","0","0","0","0"
"351","NCT01254292","LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study","Contraception",0,"Levonorgestrel IUD (LCS, BAY86-5028)","Drug","Bayer","Industry",0,0,"Female","18 Years","29 Years","567","January 2011","January 2013","Overall Satisfaction Rate at 18 Months (Last Observation Carried Forward, LOCF)","0","0","0","82.1","single proportion","95","2-Sided","77.1","86.5"
"352","NCT01254604","Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)","Glaucoma",0,"Preservative-Free Tafluprost or vehicle","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","190","December 2011","May 2013","Mean Diurnal IOP Change From Baseline at Week 4 - Study Eye","0","0","0","-1.7","Difference in Least Squares Means","95","2-Sided","-2.6","-0.7"
"353","NCT01254643","A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).","Papillomavirus Infections",0,"V503","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","9 Years","15 Years","100","January 2011","August 2013","Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine","0","0","0","0","0","0","0","0","0"
"354","NCT01257061","Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment","Eczema",0,"Group 1","Drug","EMS","Industry",0,0,"All","5 Years","50 Years","30","September 2012","June 2013","Reduction / improvement of signs and symptoms","0","0","0","0","0","0","0","0","0"
"355","NCT01257243","Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment","Cough",0,"Syrup of oxomemazine, guaifenesin and potassium iodate","Drug","EMS","Industry",0,0,"All","18 Years","65 Years","120","February 2013","July 2013","Reduction/improvement of cough symptoms","0","0","0","0","0","0","0","0","0"
"356","NCT01257399","Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase","Ulcerative Colitis in Remission",0,"Asacol®","Drug","Tillotts Pharma AG","Industry",0,0,"All","18 Years","64 Years","251","November 2010","January 2013","Rate of non-emergence of bloody stool","0","0","0","0","0","0","0","0","0"
"357","NCT01257412","Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","19 Years","N/A","375","January 2012","June 2013","change in glycosylated haemoglobin A1c (HbA1c).","0","0","0","0","0","0","0","0","0"
"358","NCT01259713","Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia","Invasive Fungal Disease",0,"Liposomal amphotericin B","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","355","April 2011","December 2013","Percentage of Participants With Proven or Probable IFIs During Remission-induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)","0.24","P-value was from a stratum-adjusted (stratified by region) CMH test.","Cochran-Mantel-Haenszel","0.33","Relative risk reduction","95.03","2-Sided","-0.32","0.66"
"359","NCT01261325","Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures","Epilepsy",0,"Placebo","Drug","UCB Pharma","Industry",0,0,"All","16 Years","80 Years","768","December 2010","May 2014","Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration","<0.001","Type I error rate of 0.05 based on a Hochberg multiple comparison procedure would be considered statistically significant"" or similar, as accurate and appropriate.","ANCOVA","22.8","Percent reduction over PBO","95","2-Sided","13.3","31.2"
"360","NCT01264887","Tapentadol in Chronic Malignant Tumour Related Pain","Cancer",0,"Tapentadol Prolonged Release","Drug","Grünenthal GmbH","Industry",0,0,"All","18 Years","N/A","31","March 2011","May 2014","Severity of Adverse Events","0","0","0","0","0","0","0","0","0"
"361","NCT01266811","A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","Multiple Myeloma",0,"Placebo, Velcade and dexamethasone","Drug","Centocor, Inc.","Industry",0,0,"All","18 Years","N/A","0","July 2011","April 2014","Progression-free survival (PFS)","0","0","0","0","0","0","0","0","0"
"362","NCT01270464","A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma","Eosinophilic Asthma",0,"Reslizumab","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","75 Years","315","February 2011","September 2013","Change From Baseline In Forced Expiratory Volume In 1 Second (FEV1) Over 16 Weeks Using Mixed Model for Repeated Measures","0.0018","The overall treatment effect for each reslizumab dose was compared to placebo using a 2-sided t-test at the a priori significance level of 0.05.","Mixed Models Analysis","0.160","Mean Difference (Final Values)","95","2-Sided","0.060","0.259"
"363","NCT01270828","Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia","Post Herpetic Neuralgia",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","806","March 2011","September 2014","Number of Participants With Loss of Therapeutic Response.","<0.0001","0","Log Rank","0","0","0","0","0","0"
"364","NCT01272219","Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes","Metabolism and Nutrition Disorder",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","3731","June 2011","March 2013","Change From Baseline in Fasting Body Weight","<0.0001","0","ANCOVA","-5.39","Estimated mean difference","95","2-Sided","-5.82","-4.95"
"365","NCT01272232","Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes","Metabolism and Nutrition Disorder",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","846","June 1, 2011","January 1, 2013","Change (%) From Baseline in Body Weight (Fasting)","<0.0001","Superiority was established only if all preceding hypotheses had been rejected. p values are 2-sided; 5% pre-defined significance level.","ANCOVA","-3.97","Treatment contrast","95","0","-4.84","-3.11"
"366","NCT01273779","Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis","Severe Sepsis",0,"Talactoferrin alfa","Drug","Agennix","Industry",0,0,"All","18 Years","N/A","1280","June 2011","January 2014","All Cause Mortality","0","0","0","0","0","0","0","0","0"
"367","NCT01274559","Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)","Primary Hypercholesterolemia",0,"Extended-release niacin/laropiprant (ERN/LRPT)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1173","March 2011","February 2013","Percent Change From Baseline at Week 12 in Low Density Lipoprotein-Cholesterol (LDL-C)","0","0","0","0","0","0","0","0","0"
"368","NCT01276639","A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis","Psoriasis",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","901","March 2011","April 2013","Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16","<0.0001","Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).","Cochran-Mantel-Haenszel","6.46","Odds Ratio (OR)","95","2-Sided","4.40","15.03"
"369","NCT01277211","A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)","Contraception",0,"ENG 120 µg + EE 15 µg intravaginal ring","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","40 Years","983","September 2011","September 2013","Pearl Index, by Treatment Group","0.531","0","Poisson distribution method","0.61","Ratio of Pearl Indices","95","2-Sided","0.19","2.29"
"370","NCT01277510","Pediatric Chronic Kidney Disease Safety and Efficacy","Chronic Kidney Disease",0,"cinacalcet capsule","Drug","Amgen","Industry",0,0,"All","6 Years","17 Years","43","June 2011","April 2014","Percentage of Participants Achieving ≥ 30% Reduction in Mean iPTH From Baseline to the Efficacy Assessment Phase","0.017","0","Cochran-Mantel-Haenszel","35.50","Difference (Cinacalcet - Placebo)","95","2-Sided","8.76","62.24"
"371","NCT01277666","A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease","Crohn's Disease",0,"GSK1605786A","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","608","December 2010","July 2013","Proportion of subjects achieving clinical response","0","0","0","0","0","0","0","0","0"
"372","NCT01278082","SOIBD Collagenous Colitis Maintenance Study","Induction and Maintaining Remission of Collagenous Colitis",0,"Budesonide","Drug","Dr. Falk Pharma GmbH","Industry",0,0,"All","18 Years","N/A","92","April 2008","March 2013","Proportion of patients being in remission over 52 weeks.","0","0","0","0","0","0","0","0","0"
"373","NCT01280721","A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","Autosomal Dominant Polycystic Kidney Disease （ADPKD)",0,"tolvaptan","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","23 Years","53 Years","135","November 2010","August 2014","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","0","0","0","0","0","0","0","0","0"
"374","NCT01281254","AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)","Fallopian Tube Cancer",0,"AMG386 plus PLD","Drug","Amgen","Industry",0,0,"Female","18 Years","N/A","223","April 18, 2011","August 29, 2014","To determine if AMG 386 plus PLD is superior to placebo plus PLD as measured by progression-free survival, defined as the time from randomization to the earliest of the dates of first radiologic disease progression per RECIST 1.1 with modifications","0","0","0","0","0","0","0","0","0"
"375","NCT01281839","An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","Hepatitis C",0,"TMC435","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","N/A","394","February 2011","February 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","<0.001","0","Cochran-Mantel-Haenszel","43.8","Difference in proportions of SVR12","95","2-Sided","34.6","53.0"
"376","NCT01284166","Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","Glaucoma",0,"dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","0","July 2013","May 2014","Change from Baseline in Intraocular Pressure (IOP)","0","0","0","0","0","0","0","0","0"
"377","NCT01284205","First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC","Bladder Cancer",0,"Mycobacterial Cell-Wall DNA Complex","Biological","Bioniche Life Sciences Inc.","Industry",0,0,"All","18 Years","N/A","0","January 2010","February 2014","Duration of disease-free survival (time to recurrence, progression or death) in all patients","0","0","0","0","0","0","0","0","0"
"378","NCT01284348","Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer","Anemia",0,"ACE-011 - 15 mg","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","25","January 2011","April 2013","Hematopoietic response","0","0","0","0","0","0","0","0","0"
"379","NCT01284556","Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures","Epilepsy",0,"Phenobarbital","Drug","West-Ward Pharmaceutical","Industry",0,0,"All","17 Years","70 Years","314","November 2010","January 2013","Evaluate the efficacy of OD administration of 60 mg and 100 mg phenobarbital in reduction of seizure frequency","0","0","0","0","0","0","0","0","0"
"380","NCT01285323","A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma","Eosinophilic Asthma",0,"Reslizumab","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","75 Years","464","March 2011","April 2014","Frequency of Clinical Asthma Exacerbations (CAEs) During 12 Months of Treatment","<0.0001","The treatment effect was tested using the likelihood based Chi-square test at the 0.05 significance level.","Chi-squared","0.4063","CAE rate ratio (reslizumab vs placebo)","95","2-Sided","0.2819","0.5855"
"381","NCT01286116","A Multinational Trial To Evaluate The Parachute Implant System","Heart Failure",0,"Parachute Implant","Device","CardioKinetix, Inc","Industry",0,0,"All","18 Years","79 Years","59","May 2011","January 2013","The successful delivery and deployment of the Parachute Implant through 6-month follow-up without the occurrence of Major Adverse Cardiac Events (MACE)","0","0","0","0","0","0","0","0","0"
"382","NCT01289782","An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients","Hepatitis C",0,"Placebo","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","N/A","395","February 2011","January 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","<0.001","0","Cochran-Mantel-Haenszel","29.3","Difference in proportions of SVR12","95","2-Sided","20.1","38.6"
"383","NCT01290679","An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Participants","Hepatitis C",0,"Placebo","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","N/A","393","March 2011","February 2013","The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","<0.001","0","Cochran-Mantel-Haenszel","32.2","Difference in proportions of SVR12","95","2-Sided","23.3","41.2"
"384","NCT01290783","Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC","Metastatic Colorectal Cancer",0,"Irintoecan","Drug","Alchemia Oncology","Industry",0,0,"All","18 Years","N/A","390","December 2011","October 2014","Progression Free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"385","NCT01291160","Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers","Diabetic Foot Ulcers",0,"Epiflo","Device","Neogenix, LLC dba Ogenix","Industry",0,0,"All","20 Years","90 Years","130","October 2009","February 2013","Number of 100% Wound Closure","0","0","0","0","0","0","0","0","0"
"386","NCT01292837","A Study of Levetiracetam in Japanese Pediatric Patients With Generalized Tonic-clonic Seizures","Epilepsy",0,"Levetiracetam","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","4 Years","15 Years","13","February 2011","June 2013","The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week Over the 24-week Treatment Period (Up-Titration and Evaluation Periods)","0","0","0","0","0","0","0","0","0"
"387","NCT01294150","The Safety and Effectiveness of UroLift: LIFT Pivotal Study","Benign Prostatic Hyperplasia",0,"UroLift System","Device","NeoTract, Inc.","Industry",0,0,"Male","50 Years","N/A","206","February 2011","February 2013","Collection of Post-treatment Catheterization for Safety","0","0","0","0","0","0","0","0","0"
"388","NCT01294163","Xenon Compared to Sevoflurane and Total Intravenous Anaesthesia for Coronary Artery Bypass Graft Surgery","Coronary Artery Disease",0,"Xenon","Drug","Air Liquide Santé International","Industry",0,0,"All","18 Years","N/A","509","April 2011","April 2014","Blood Level of Troponin I","0.02","0","ANCOVA","-0.4","Mean Difference (Final Values)","95","2-Sided","-1.27","0.47"
"389","NCT01299272","A Study in Prevention of Re-emergence of Depression Symptoms","Major Depressive Disorder",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","2045","May 2011","November 2013","Time to re-emergence of depressive symptoms","0","0","0","0","0","0","0","0","0"
"390","NCT01300351","Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women","Breast Cancer",0,"Fulvestrant","Drug","AstraZeneca","Industry",0,0,"Female","18 Years","N/A","249","March 2011","March 2014","Progression-free Survival","0.078","With a sample size of 220 randomised patients and 150 progression events, if treatment effect is consistent between ethnicities/the study populations, there is an 89% chance the HR <1.","Log Rank","0.75","Hazard Ratio (HR)","95","2-Sided","0.54","1.03"
"391","NCT01302392","A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma","Multiple Myeloma",0,"Carfilzomib","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","315","September 2010","July 2014","Overall Survival","0.4172","Based on 1-sided test.","Log Rank","0.975","Hazard Ratio (HR)","95","2-Sided","0.760","1.249"
"392","NCT01302860","Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","Cryopyrin-associated Periodic Syndromes",0,"ACZ885","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","1 Month","60 Months","17","November 2010","November 2014","Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56","0","0","0","0","0","0","0","0","0"
"393","NCT01304706","Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study","Diabetic Macular Edema",0,"Fluocinolone Acetonide","Drug","Alimera Sciences","Industry",0,0,"All","N/A","N/A","120","April 2011","November 2013","Number of Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"394","NCT01305109","A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E","Viral Gastroenteritis Due to Rotavirus",0,"ORV 116E","Biological","Bharat Biotech International Limited","Industry",0,0,"All","6 Weeks","7 Weeks","6800","March 2011","December 2013","Efficacy against severe rotavirus gastroenteritis (>=11 on the 20 point Vesikari scoring scale) caused by non vaccine rotavirus","0","0","0","0","0","0","0","0","0"
"395","NCT01305356","Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions","Degenerative Joint Disease",0,"Augment(tm) Injectable Bone Graft","Device","BioMimetic Therapeutics","Industry",0,0,"All","21 Years","N/A","201","March 2011","April 2013","Subject performance composite","0","0","0","0","0","0","0","0","0"
"396","NCT01305408","Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression",0,"Armodafinil","Drug","Cephalon","Industry",0,0,"All","18 Years","65 Years","399","March 2011","July 2013","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)","0.2717","Statistical tests were 2-tailed at the 0.05 level of significance.","mixed-model repeated measures (MMRM)","-1.4","Mean Difference (Final Values)","95","2-Sided","-3.76","1.06"
"397","NCT01306331","Study of the Contraceptive Efficacy and Safety of Amphora Gel Compared to Conceptrol Vaginal Gel","Contraception",0,"Conceptrol","Drug","Evofem Inc.","Industry",0,0,"Female","18 Years","35 Years","3389","April 2011","June 2014","• Evaluation of contraceptive effectiveness over six months (183 days) of Amphora™ gel use when compared to Conceptrol® Vaginal Gel.","0","0","0","0","0","0","0","0","0"
"398","NCT01307423","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)","Psoriatic Arthritis",0,"Apremilast 20mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","529","December 9, 2010","February 21, 2013","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16","0.0062","0","Chi-squared","12.1","Risk Difference (RD)","95","2-Sided","3.5","20.7"
"399","NCT01307436","Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines","Hepatitis A",0,"Epaxal","Biological","Crucell Holland BV","Industry",0,0,"All","12 Months","15 Months","327","March 2011","July 2013","Anti-hepatitis A virus (HAV) antibody concentrations","0","0","0","0","0","0","0","0","0"
"400","NCT01308437","Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics","Type I Diabetes",0,"Wosulin (N or 70/30 with R)","Biological","Wockhardt","Industry",0,0,"All","18 Years","55 Years","134","March 2011","April 2013","Change in HbAlc from baseline to 6 months of treatment between Wosulin arm and Novolin arm(as surrogate indicator of change in insulin antibodies titers between the two treatment arms).","0","0","0","0","0","0","0","0","0"
"401","NCT01309204","Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","Open-Angle Glaucoma",0,"Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","1184","May 2011","January 2013","Mean Diurnal IOP Change From Baseline at Month 3","0","0","0","0","0","0","0","0","0"
"402","NCT01309737","A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis","Psoriasis",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","960","March 2011","April 2013","Percentage of Participants With Physician Global Assessment (PGA) of Psoriasis Score of 'Clear' or 'Almost Clear' at Week 16","<0.0001","Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested against placebo at significance level of 0.05 (2-sided).","Cochran-Mantel-Haenszel","10.20","Odds Ratio (OR)","95","2-Sided","5.33","17.68"
"403","NCT01310777","Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","Open-Angle Glaucoma",0,"Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","771","May 2011","January 2013","Mean Diurnal IOP Change From Baseline at Month 3","0","0","0","0","0","0","0","0","0"
"404","NCT01311687","A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study","Multiple Myeloma",0,"pomalidomide","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","455","March 2011","March 2013","Progression-free Survival (PFS)","<0.001","0","Stratified Log Rank Test","0.45","Hazard Ratio (HR)","95","2-Sided","0.35","0.59"
"405","NCT01311791","A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure","Heart Failure",0,"Algisyl-LVR","Device","LoneStar Heart, Inc.","Industry",0,0,"All","18 Years","79 Years","78","August 2012","April 2014","peak VO2","0","0","0","0","0","0","0","0","0"
"406","NCT01312766","Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients","Infertility",0,"Menotropins","Drug","IBSA Institut Biochimique SA","Industry",0,0,"Female","18 Years","40 Years","270","February 2011","April 2013","Total Number of Oocytes Retrieved","0.012","0","ANOVA","1.9","Mean Difference (Final Values)","95","2-Sided","0.43","3.43"
"407","NCT01313273","Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients","Prostate Cancer",0,"Lanreotide, non steroidal anti androgens and LHRH-a","Drug","Ipsen","Industry",0,0,"Male","18 Years","N/A","3","June 2011","June 2013","Progression-free Survival","0","0","0","0","0","0","0","0","0"
"408","NCT01313312","Dysport® Adult Upper Limb Spasticity Extension Study","Nervous System Disorders",0,"Dysport®","Drug","Ipsen","Industry",0,0,"All","18 Years","80 Years","258","November 2011","December 2014","Assessment of the Long-term Safety of Dysport® Through the Collection of Treatment Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"409","NCT01313624","Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","Bronchiectasis",0,"AZLI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","266","April 2011","March 2013","Change in QOL-B Respiratory Symptoms Score at Day 28","0.68","P-value was based on T-test from mixed-effect model repeated measures (MMRM).","MMRM","0.8","Difference in least squares mean","95","2-Sided","-3.1","4.7"
"410","NCT01313689","Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia","Leukaemia, Lymphocytic, Chronic",0,"Ofatumumab","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","122","April 14, 2011","March 18, 2014","Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC)","0.2677","0","Log Rank","0.79","Hazard Ratio (HR)","95","2-Sided","0.50","1.24"
"411","NCT01314716","Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis","Bronchiectasis",0,"AZLI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","274","April 2011","April 2013","Change in QOL-B Respiratory Symptoms Score at Day 28","0.011","P-value was based on T-test from mixed-effect model repeated measures (MMRM).","MMRM","4.6","Differences in least squares mean","95","2-Sided","1.1","8.2"
"412","NCT01315496","GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock","Severe Sepsis",0,"Immunoglobulin G","Drug","Green Cross Corporation","Industry",0,0,"All","18 Years","N/A","214","October 2009","December 2013","All cause mortality","0","0","0","0","0","0","0","0","0"
"413","NCT01315678","Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections","Pseudomonas Aeruginosa Infection",0,"Liposomal amikacin for inhalation (Arikayce) using the PARI Investigational eFlow® Nebulizer.","Drug","Insmed Incorporated","Industry",0,0,"All","6 Years","N/A","302","March 2012","June 2013","Relative change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of study (Day 168)","0","0","0","0","0","0","0","0","0"
"414","NCT01316861","Efficacy and Safety of Oral Acarbose Treatment in Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"EMS Acarbose","Drug","EMS","Industry",0,0,"All","18 Years","N/A","79","September 2012","March 2013","Glycosylated hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"415","NCT01316939","GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease","Crohn's Disease",0,"GSK1605786A","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","229","May 2011","September 2013","Remission (CDAI score less than 150 points)","0","0","0","0","0","0","0","0","0"
"416","NCT01318200","Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)","Recurrent Hepatocellular Carcinoma",0,"Transarterial Chemoembolization","Procedure","Accuray Incorporated","Industry",0,0,"All","18 Years","N/A","0","February 2011","February 2014","Freedom from local progression","0","0","0","0","0","0","0","0","0"
"417","NCT01318434","A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)","Major Depressive Disorder",0,"EB-1010 25mg BID","Drug","Euthymics BioScience, Inc.","Industry",0,0,"All","18 Years","65 Years","342","February 2011","February 2013","Change from baseline in MADRS Score","0","0","0","0","0","0","0","0","0"
"418","NCT01318694","Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants","Hepatitis C",0,"Alisporivir","Drug","Debiopharm International SA","Industry",0,0,"All","18 Years","70 Years","1081","March 2011","August 2013","Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"419","NCT01318993","Open-Label Extension Study of GSK1605786A","Crohn's Disease",0,"GSK1605786A","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","400","April 2011","September 2013","Number of subjects with adverse events and serious adverse events","0","0","0","0","0","0","0","0","0"
"420","NCT01320202","Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients","Renal Failure Chronic Requiring Hemodialysis",0,"Soluble Ferric Pyrophosphate (SFP)","Drug","Rockwell Medical Technologies, Inc.","Industry",0,0,"All","18 Years","N/A","305","March 2011","May 2013","Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean","0.011","LS Mean (SE) and p-value are from ANCOVA model with baseline Hgb as covariate. Model also includes indicator variable for baseline ESA dose stratum.","ANCOVA","3.6","Difference in LS Means between SFP & PBO","0","2-Sided","0","0"
"421","NCT01321554","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)","Thyroid Cancer",0,"Lenvatinib","Drug","Eisai Inc.","Industry",0,0,"All","18 Years","N/A","392","March 17, 2011","November 15, 2013","Progression Free Survival (PFS)","0","0","0","0.21","Cox Proportional Hazard","99","2-Sided","0.14","0.31"
"422","NCT01322347","Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)","Renal Failure Chronic Requiring Hemodialysis",0,"Soluble Ferric Pyrophosphate (SFP)","Drug","Rockwell Medical Technologies, Inc.","Industry",0,0,"All","18 Years","N/A","294","April 2011","January 2014","Change From Baseline Hemoglobin at End-of-Treatment: Least-Squares Mean","0.011","LS Mean (SE) and p-value are from ANCOVA model with baseline Hgb as covariate. Model also includes indicator variable for baseline ESA dose stratum.","ANCOVA","3.6","Difference in LS Means between SFP & PBO","95","2-Sided","0","0"
"423","NCT01324544","Pharmacokinetics, Safety, and Efficacy of Intravenous Dosing of Buprenorphine in Pediatric Patients Who Require Opioid Analgesia for Acute Moderate to Severe Pain","Other Acute Postoperative Pain",0,"Buprenorphine IV","Drug","Purdue Pharma LP","Industry",0,0,"All","N/A","6 Years","0","November 2011","August 2014","The primary outcome measures are clearance (CL/F) and apparent central volume of distribution (Vc/F) estimated using standard population nonlinear mixed effects methodology.","0","0","0","0","0","0","0","0","0"
"424","NCT01324947","Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma","Multiple Myeloma",0,"pomalidomide","Drug","Celgene Corporation","Industry",0,0,"All","18 Years","N/A","74","March 2011","July 2014","Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria Based on Investigator Assessment","0","0","0","0","0","0","0","0","0"
"425","NCT01325220","Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome","Fragile X Syndrome",0,"arbaclofen","Drug","Seaside Therapeutics, Inc.","Industry",0,0,"All","5 Years","11 Years","172","June 2011","June 2013","Aberrant Behavior Checklist-Lethargy Social Withdrawal subscale","0","0","0","0","0","0","0","0","0"
"426","NCT01325571","A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis","Myasthenia Gravis",0,"Tacrolimus capsule","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","83","March 2011","May 2014","Change from baseline in quantitative myasthenia gravis (QMG) score for disease severity","0","0","0","0","0","0","0","0","0"
"427","NCT01327508","TRIGEN SURESHOT™ Distal Targeting System Study","Femoral Shaft Fracture",0,"TRIGEN SURESHOT Distal Targeting Instrumentation.","Device","Smith & Nephew, Inc.","Industry",0,0,"All","18 Years","80 Years","60","April 2011","January 2013","Radiation Exposure Measurement","0","0","0","0","0","0","0","0","0"
"428","NCT01327976","The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity","Obesity",0,"vBloc (Active Device)","Device","EnteroMedics","Industry",0,0,"All","18 Years","65 Years","239","May 2011","February 2013","Percentage of Subjects Experiencing Implant/Revision Procedure, Device or Therapy Related Serious Adverse Events (SAEs).","0","0","0","0","0","0","0","0","0"
"429","NCT01330355","Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis","Bacterial Conjunctivitis",0,"Besivance","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","N/A","31 Days","33","May 2011","January 2013","Clinical Resolution","0","0","0","0","0","0","0","0","0"
"430","NCT01330381","Prucalopride in Pediatric Subjects With Functional Constipation","Functional Constipation",0,"prucalopride","Drug","Shire","Industry",0,0,"All","6 Months","17 Years","215","April 2011","March 2013","Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period","0.9002","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"431","NCT01330628","Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis","Peripheral Arterial Disease",0,"Turbo Elite Laser and Turbo Tandem Laser Guide Catheters","Device","Spectranetics Corporation","Industry",0,0,"All","18 Years","85 Years","252","June 2011","March 2014","Freedom From Target Lesion Revascularization (TLR)","0","0","0","0","0","0","0","0","0"
"432","NCT01331655","Clinical Study of a Conventional and Flexible Extended Oral Contraceptive of EE/DRSP With or Without Metafolin in Latin America","Contraception",0,"EE20/DRSP (BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","0","April 2013","November 2014","Number of bleeding days","0","0","0","0","0","0","0","0","0"
"433","NCT01331681","Intravitreal Aflibercept Injection in Vision Impairment Due to DME","Diabetes Mellitus",0,"VEGF Trap-Eye (BAY86-5321)","Biological","Bayer","Industry",0,0,"All","18 Years","N/A","406","May 2011","June 2013","Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)","<0.0001","Significance level alpha=0.025 for two sided test to adjust for multiplicity. Since this p-value was below the significance level of 0.025, the fixed sequence testing did continue with the first secondary endpoint.","ANCOVA","9.3","Mean Difference (Final Values)","97.5","2-Sided","6.5","12.0"
"434","NCT01332149","Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","626","July 2011","April 2014","Baseline Mean Pain Score","0","0","0","0","0","0","0","0","0"
"435","NCT01333111","Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients","Congenital Bleeding Disorder",0,"nonacog beta pegol","Drug","Novo Nordisk A/S","Industry",0,0,"Male","13 Years","70 Years","74","April 2011","April 2013","Incidence of inhibitory antibodies against factor IX defined as titre equal to or above 0.6 BU (Bethesda Units)","0","0","0","0","0","0","0","0","0"
"436","NCT01334892","L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients","Bronchiolitis Obliterans",0,"Cyclosporine Inhalation Solution","Drug","Pari Pharma GmbH","Industry",0,0,"All","18 Years","N/A","130","December 2009","July 2013","The primary objective is to compare cumulative BOS-free survival of patients recieving L-CsA or placebo.","0","0","0","0","0","0","0","0","0"
"437","NCT01335061","Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B","Hemophilia B",0,"Nonacog alfa","Biological","Pfizer","Industry",0,0,"Male","12 Years","65 Years","25","September 2011","April 2014","Annualized Number of Bleeding Episodes.","<0.0001","0","Paired t-test","0","0","0","0","0","0"
"438","NCT01335698","Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients","HIV",0,"Atazanavir Sulphate","Drug","Bristol-Myers Squibb","Industry",0,0,"All","3 Months","11 Years","167","May 27, 2011","September 10, 2014","Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block, Tachycardia, and Rash","0","0","0","0","0","0","0","0","0"
"439","NCT01337167","Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","Bacterial Infections",0,"V419","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","46 Days","89 Days","1473","April 2011","May 2013","Percentage of Participants Responding to Polyribosylribitol Phosphate Antigen","<0.001","0","Miettinen and Nurminen","9.68","Response Rate Difference (V419 - Ctrl)","95","2-Sided","4.83","14.83"
"440","NCT01339923","A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years","Meningococcal Disease",0,"rMenB + OMV NZ vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","71 Days","10 Years","1409","April 2011","January 2014","Percentages of Subjects With Serum Bactericidal Activity Using Human Serum (hSBA) Titers ≥ 4 or hSBA Titers ≥ 5 (Strain M10713) Following a 2-dose Primary Series of rMenB+OMV Vaccination.","0","0","0","0","0","0","0","0","0"
"441","NCT01340872","Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1)","Iron Deficiency Anaemia",0,"ST10-021","Drug","Shield Therapeutics","Industry",0,0,"All","18 Years","N/A","58","August 2011","October 2013","Change in Hb concentration from baseline to Week 12","0","0","0","0","0","0","0","0","0"
"442","NCT01341522","Clinical Evaluation of the Sorin Group's REPLY MR-conditional Pacing System","Dual-chamber Pacemaker Placement",0,"MRI exam","Procedure","LivaNova","Industry",0,0,"All","18 Years","N/A","0","January 2012","May 2013","assess the pacing system-, MRI- and implant procedure-related complication-free rate","0","0","0","0","0","0","0","0","0"
"443","NCT01341639","Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","Bacterial Infections",0,"V419","Biological","MCM Vaccines B.V.","Industry",0,0,"All","46 Days","74 Days","1250","May 2011","March 2013","Number of responders to polyribosylribitol phosphate (PRP) antigen","0","0","0","0","0","0","0","0","0"
"444","NCT01342016","A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients","Lupus Nephritis",0,"tacrolimus capsule","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","65 Years","84","April 2011","May 2013","remission rate (partial remission + complete remission)","0","0","0","0","0","0","0","0","0"
"445","NCT01343004","Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women","Osteoporosis",0,"Placebo","Drug","Radius Health, Inc.","Industry",0,0,"Female","50 Years","85 Years","2463","April 2011","October 2014","Number of Participants With New Vertebral Fractures at 18 Months","<0.0001","0","Fisher Exact","0","0","0","0","0","0"
"446","NCT01344447","Gadobutrol Enhanced MRA of the Supra-aortic Vessels","Carotid Stenosis",0,"Gadobutrol (Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","479","May 2011","May 2014","Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA","<0.0001","0","McNemar","22.3","Percentage difference","95.1","2-Sided","20.4","Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study."
"447","NCT01345084","Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab","Carcinoma",0,"Radiation Therapy","Radiation","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","75 Years","0","November 2013","November 2013","Overall survival","0","0","0","0","0","0","0","0","0"
"448","NCT01345630","Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1","HIV-1",0,"Maraviroc","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","813","September 2011","August 2013","Percentage of Participants With Plasma HIV-1 RNA <50 Copies/mL.","0","0","0","-9.54","Mean Difference (Final Values)","95","2-Sided","-14.83","-4.24"
"449","NCT01345929","Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis","Complicated Urinary Tract Infection",0,"CXA-201","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","N/A","558","June 1, 2011","August 1, 2013","The Percentage of Subjects Who Have Both a Per-subject Microbiological Outcome of Eradication and a Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Modified ITT (mMITT) Population","0","0","0","8.5","Risk Difference (RD)","95","2-Sided","2.31","14.57"
"450","NCT01346293","Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","Tetanus",0,"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","4 Years","6 Years","3372","April 2011","May 2013","Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","0","0","0","5.4","Mean Difference (Final Values)","95","2-Sided","0.7","10.2"
"451","NCT01347073","Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)","Urea Cycle Disorders",0,"HPN-100","Drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Industry",0,0,"All","N/A","6 Years","23","July 2011","February 2013","Adverse Events","0","0","0","0","0","0","0","0","0"
"452","NCT01347710","A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.","Coronary Artery Disease",0,"Flurpiridaz F18","Drug","Lantheus Medical Imaging","Industry",0,0,"All","18 Years","N/A","795","June 2011","July 2013","Diagnostic Efficacy of Flurpiridaz F 18 PET Myocardial Perfusion Imaging (MPI) Sensitivity Versus SPECT Myocardial Perfusion Imaging Sensitivity","<0.001","P-value for sensitivity comparison of flurpiridaz F18 PET MPI vs SPECT MPI for majority rule","McNemar","0","0","0","0","0","0"
"453","NCT01347983","Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients","Rheumatoid Arthritis",0,"Tocilizumab+Methotrexate(MTX)","Drug","Chugai Pharma Taiwan","Industry",0,0,"All","20 Years","75 Years","72","May 2011","March 2013","Proportion of patients with an American College of Rheumatology 70 (ACR70) response","0","0","0","0","0","0","0","0","0"
"454","NCT01348126","Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer","Non-small Cell Lung Cancer Stage IIIB",0,"Docetaxel","Drug","Synta Pharmaceuticals Corp.","Industry",0,0,"All","18 Years","N/A","385","May 2011","April 2014","Progression-free survival in two co-primary populations","0","0","0","0","0","0","0","0","0"
"455","NCT01348243","Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis","Postmenopausal Osteoporosis",0,"disodium clodronate 200 mg/4 ml with 1% lidocaine","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"Female","50 Years","N/A","260","October 2011","March 2013","Lumbar Bone Mineral Density","0","0","0","0","0","0","0","0","0"
"456","NCT01349673","The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis","Proctitis",0,"Budesonide Foam","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","114","June 2011","December 2014","To evaluate safety and tolerability of cyclically dosed rectal budesonide foam in subjects who present with a diagnosis of active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).","0","0","0","0","0","0","0","0","0"
"457","NCT01349790","Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia","Primary Thrombocytopenia",0,"NewGam","Drug","Octapharma","Industry",0,0,"All","18 Years","65 Years","40","October 2011","July 2013","Percentage of Responders","0","0","0","0","0","0","0","0","0"
"458","NCT01349907","Extension Study of Asenapine [P06107 (NCT01244815)] for Pediatric Bipolar Disorder (P05898)","Bipolar Disorder",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","10 Years","18 Years","322","June 2011","September 2014","Number of Participants Who Experienced Clinical or Laboratory Adverse Events","0","0","0","0","0","0","0","0","0"
"459","NCT01352221","Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)","Iron Deficiency Anaemia",0,"ST10-021","Drug","Shield Therapeutics","Industry",0,0,"All","18 Years","N/A","70","August 2011","October 2013","Change in Hb concentration from baseline to Week 12","0","0","0","0","0","0","0","0","0"
"460","NCT01352793","A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years","Meningitis, Meningococcal",0,"rLP2086 vaccine","Biological","Pfizer","Industry",0,0,"All","10 Years","25 Years","5715","November 2012","September 2014","Percentage of Participants With at Least One Serious Adverse Event (SAE) Throughout the Study","0","0","0","0","0","0","0","0","0"
"461","NCT01354145","Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI","Knee Osteoarthritis",0,"Chondroitin sulfate","Drug","Bioiberica","Industry",0,0,"All","40 Years","N/A","194","June 2011","September 2014","Cartilage Volume Loss of the Lateral Compartment","0","0","0","0","0","0","0","0","0"
"462","NCT01355484","Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)","Muscle Wasting",0,"GTx-024","Drug","GTx","Industry",0,0,"All","30 Years","N/A","321","July 2011","May 2013","Physical Function","0","0","0","0","0","0","0","0","0"
"463","NCT01355497","Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum","Muscle Wasting",0,"GTx-024","Drug","GTx","Industry",0,0,"All","30 Years","N/A","330","July 2011","May 2013","Improved Physical function","0","0","0","0","0","0","0","0","0"
"464","NCT01355627","TASALL - TachoSil® Against Liquor Leak","Cerebrospinal Fluid Leaks",0,"TachoSil®","Procedure","Takeda","Industry",0,0,"All","18 Years","N/A","726","April 2011","June 2013","Percentage of Participants With Clinically Evident Verified Post-Operative Cerebrospinal Fluid Leak or Clinically Evident Pseudomeningocele or Treatment Failure","0.485","0","Regression, Logistic","0.82","Odds Ratio (OR)","0","0","0","0"
"465","NCT01356992","Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","Non ST Segment Elevation Myocardial Infarction",0,"Enoxaparin","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","75 Years","62","July 2012","July 2013","Frequency of death and infarction within 30 days after the admission in emergency","0","0","0","0","0","0","0","0","0"
"466","NCT01357252","Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"vildagliptin","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","279","April 2011","January 2013","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"467","NCT01357616","Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","Open-Angle Glaucoma",0,"Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","328","November 2010","January 2013","Mean Diurnal IOP Change From Baseline at Week 8","0","0","0","0","0","0","0","0","0"
"468","NCT01357993","A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder","Attention-Deficit / Hyperactivity Disorder",0,"JNS001","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","18 Years","65 Years","253","May 2011","March 2013","Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability","0","0","0","0","0","0","0","0","0"
"469","NCT01358175","16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis","Ankylosing Spondylitis",0,"Secukinumab (75 mg)","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","371","October 2011","December 2014","Assessment of Responders for the SpondyloArthritis International Society / ASAS 20 Response","<0.0001","0","Regression, Logistic","3.76","Odds Ratio (OR)","95","2-Sided","2.20","6.42"
"470","NCT01358578","Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis","Chronic Plaque Psoriasis",0,"Placebo","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","1306","June 2011","July 2013","Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .","0","0","0","0","0","0","0","0","0"
"471","NCT01359566","Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis","Multiple Sclerosis",0,"Arbaclofen placarbil 15 mg BID","Drug","Indivior Inc.","Industry",0,0,"All","18 Years","70 Years","228","May 2011","February 2013","Change from Baseline in Maximum Ashworth Scale score (6 hour post-dose time point)","0","0","0","0","0","0","0","0","0"
"472","NCT01360554","ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer",0,"Dacomitinib (PF-00299804)","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","878","June 16, 2011","September 30, 2013","Progression-Free Survival (PFS) Per Independent Radiologic Review.","0.195","One-sided P-value.","1-sided stratified log-rank test","0.933","Hazard Ratio (HR)","95","2-Sided","0.797","1.093"
"473","NCT01360632","Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)","Depressive Disorder",0,"OPC-34712 + ADT","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","1539","June 2011","August 2013","Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set","0.0925","0","Mixed Models Analysis","-1.19","Mean Difference (Final Values)","95","2-Sided","-2.58","0.2"
"474","NCT01360645","Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)","Depressive Disorder",0,"OPC-34712 + ADT","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","826","July 2011","May 2013","Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample.","0.0001","0","Mixed Models Analysis","-3.12","Mean Difference (Final Values)","95","2-Sided","-4.70","-1.54"
"475","NCT01361607","Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer","Pain",0,"Sativex®","Drug","GW Pharmaceuticals Ltd.","Industry",0,0,"All","18 Years","N/A","399","May 2011","October 2014","The primary endpoint is the percent improvement from baseline to the end of treatment in NRS average pain score.","0","0","0","0","0","0","0","0","0"
"476","NCT01361815","Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)","Major Depressive Disorder, Recurrent, Unspecified",0,"H-Coil Deep TMS in combination with SSRIs","Device","Brainsway","Industry",0,0,"All","22 Years","68 Years","75","July 2011","December 2014","The tolerability and safety of H-coil deep rTMS treatment in combination with SSRI medications","0","0","0","0","0","0","0","0","0"
"477","NCT01362530","A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)","Chemotherapy Induced Nausea and Vomiting",0,"Aprepitant 125 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Months","17 Years","307","September 13, 2011","March 14, 2013","Percentage of Participants With a Complete Response in the Delayed Phase of Cycle 1","<0.01","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"478","NCT01362725","Spinal Cord Stimulation For Heart Failure","Systolic Heart Failure",0,"Spinal cord stimulation system","Device","St. Jude Medical","Industry",0,0,"All","18 Years","95 Years","20","April 2011","August 2014","Safety and efficacy markers","0","0","0","0","0","0","0","0","0"
"479","NCT01363011","Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","Acquired Immunodeficiency Syndrome",0,"E/C/F/TDF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","106","May 2011","January 2013","Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) Using the Cockcroft-Gault (CG) Equation at Week 24 (Cohort 1)","0","0","0","0","0","0","0","0","0"
"480","NCT01363349","Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia","Schizophrenia",0,"CYP-1020","Drug","BioLineRx, Ltd.","Industry",0,0,"All","18 Years","50 Years","269","May 2011","March 2013","Cognition","0","0","0","0","0","0","0","0","0"
"481","NCT01363440","Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","Diabetic Macular Edema",0,"Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","466","May 2011","January 2013","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)","<.0001","0","ANCOVA","12.19","Mean Difference (Net)","97.5","2-Sided","9.35","15.04"
"482","NCT01364649","Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction","Treatment Outcome",0,"Vortioxetine","Drug","Takeda","Industry",0,0,"All","18 Years","55 Years","447","June 2011","December 2013","Change From Baseline in the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) Total Score at Week 8","0.013","0","Mixed Model Repeated Measurements","2.2","LS mean difference","95","2-Sided","0.48","4.02"
"483","NCT01365546","Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery","Prevent Bleeding in Major Surgery",0,"human VWF/FVIII concentrate","Biological","Octapharma","Industry",0,0,"All","6 Years","N/A","30","June 2011","February 2014","Overall Hemostatic Efficacy (Success or Failure) of Wilate, Based on the Intra-operative Assessment of the Surgeon and the Post-operative Assessment by the Investigator Using a 4-point Ordinal Efficacy Scale.","0","0","0","0","0","0","0","0","0"
"484","NCT01366209","Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)","Idiopathic Pulmonary Fibrosis",0,"Pirfenidone","Drug","Genentech, Inc.","Industry",0,0,"All","40 Years","80 Years","555","June 2011","February 2014","Change in Percent Predicted Forced Vital Capacity (%FVC) From Baseline to Week 52","0","0","0","0","0","0","0","0","0"
"485","NCT01368666","Safety and Effectiveness Study of Perceval S Valve for Extended CE Mark","Aortic Valve Replacement",0,"Perceval S Valve Prosthesis","Device","LivaNova","Industry",0,0,"All","65 Years","N/A","658","February 2010","October 2014","Evaluation of the safety and effectiveness","0","0","0","0","0","0","0","0","0"
"486","NCT01369329","A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)","Crohn's Disease",0,"Group 2 ustekinumab 130 mg","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","769","July 2011","June 2013","Number of Participants With Clinical Response at Week 6","0.002","A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.","Cochran-Mantel-Haenszel chi-square test","0","0","0","0","0","0"
"487","NCT01369342","A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)","Crohn's Disease",0,"Group 1: Placebo","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","99 Years","640","July 2011","August 2014","Number of Participants With Clinical Response at Week 6","< 0.001","A fixed sequence testing procedure was used to control alpha at 0.05 over the outcome measures.","Cochran-Mantel-Haenszel chi-square test","0","0","0","0","0","0"
"488","NCT01369576","Effect of Zopiclone on Compliance With Continuous Positive Airway Pressure in Obstructive Sleep Apnea","Obstructive Sleep Apnea",0,"Placebo","Drug","OSR Medical Inc.","Industry",0,0,"All","18 Years","N/A","264","May 2011","May 2014","CPAP adherence","0","0","0","0","0","0","0","0","0"
"489","NCT01369615","Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001","Pain",0,"Oxycodone hydrochloride controlled-release tablets","Drug","Purdue Pharma LP","Industry",0,0,"All","6 Years","17 Years","23","October 2011","December 2013","The Number of Participants With Adverse Events as a Measure of Safety.","0","0","0","0","0","0","0","0","0"
"490","NCT01370499","A Study of LY2216684 in Patients With Major Depression Disorder","Major Depressive Disorder",0,"LY2216684","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","237","August 2011","January 2014","Number of participants with clinically significant events","0","0","0","0","0","0","0","0","0"
"491","NCT01370616","Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)","Infection; Diabetic Foot",0,"Ertapenem sodium","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","565","September 2011","December 2013","Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV)","0","0","0","-3.8","Estimated Difference","95","2-Sided","-8.3","0.0"
"492","NCT01370642","Vaniprevir Administered With Pegylated-interferon and Ribavirin in Japanese Treatment-Naïve Chronic Hepatitis C Participants (MK-7009-043)","Hepatitis C, Chronic",0,"vaniprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","70 Years","294","June 2011","July 2013","Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)","<0.001","0","Miettinen and Nurminen method","29.0","Adjusted Difference in Percentages","95","2-Sided","17.2","40.5"
"493","NCT01370733","Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder","Major Depressive Disorder",0,"NEST-1 (NeoSync EEG Synchronized TMS)","Device","NeoSync, Inc.","Industry",0,0,"All","22 Years","65 Years","202","May 2012","August 2013","Mean HAM-D17 Total Score Change (Intent to Treat - All)","0","0","0","0","0","0","0","0","0"
"494","NCT01371825","SurVival of Lysosomal Acid Lipase Deficiency (LAL-D) Infants Treated With SebelipAse aLfa","Lysosomal Acid Lipase Deficiency",0,"Sebelipase alfa (SBC-102)","Drug","Alexion Pharmaceuticals","Industry",0,0,"All","N/A","24 Months","9","May 2011","August 2014","Percentage of Subjects in the PES Surviving to 12 Months of Age","0","0","0","0","0","0","0","0","0"
"495","NCT01373281","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia","Dengue",0,"Live, attenuated, dengue serotype 1, 2, 3, 4 virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Years","14 Years","10275","June 2011","August 2014","Number of Symptomatic Virologically Confirmed Dengue Cases (Vaccine Efficacy) Due to Any Serotype During the Active Phase Post-dose 3 Injection With CYD Dengue Vaccine","0","0","0","56.5","Vaccine efficacy","95","2-Sided","43.8","66.4"
"496","NCT01374516","Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","Dengue Fever",0,"Live, attenuated, dengue serotype 1, 2, 3, 4 virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Years","16 Years","20869","June 2011","November 2014","Information on the symptomatic virologically confirmed dengue cases occurring > 28 days after Dose 3 (during the active phase) in terms of (i) Acute febrile illness and (ii) Virologically confirmed","0","0","0","0","0","0","0","0","0"
"497","NCT01375374","Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide","Epilepsy, Partial",0,"Lacosamide","Drug","UCB Pharma","Industry",0,0,"Male","18 Years","45 Years","11","July 2011","March 2013","Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)","0","0","0","0","0","0","0","0","0"
"498","NCT01376908","Kuvan® in Phenylketonuria Patients Less Than 4 Years Old","Phenylketonuria",0,"Kuvan®","Drug","BioMarin Pharmaceutical","Industry",0,0,"All","N/A","4 Years","56","June 2011","July 2014","Dietary Phenylalanine (Phe) Tolerance at Week 26","0","0","0","0","0","0","0","0","0"
"499","NCT01377922","A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)","Lambert Eaton Myasthenic Syndrome",0,"Amifampridine Phosphate","Drug","Catalyst Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","38","June 2011","September 2014","Change from Baseline Quantitative Myasthenia Gravis (QMG)at 14 days","0","0","0","0","0","0","0","0","0"
"500","NCT01378286","Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria","Malaria",0,"ARTESUNATE + AMODIAQUINE","Drug","Sanofi","Industry",0,0,"All","6 Months","N/A","380","January 2012","June 2013","Assessment of clinical and parasitological efficacy based on temperature and parasitemia after Polymerase chain reaction (PCR) correction","0","0","0","0","0","0","0","0","0"
"501","NCT01379365","Cryo-Touch III Refinement Study Investigational Plan","Facial Wrinkles",0,"Cryo-Touch III","Device","MyoScience, Inc","Industry",0,0,"All","30 Years","70 Years","88","June 2011","December 2014","Wrinkle Severity and incidence of device-related serious adverse events","0","0","0","0","0","0","0","0","0"
"502","NCT01379677","Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head Comparison","Coronary Artery Disease",0,"Rubidium-82","Drug","Advanced Accelerator Applications","Industry",0,0,"All","40 Years","N/A","135","February 2011","November 2013","The specificity of detecting significant coronary artery disease (as defined as being >70% stenosis, on coronary CT angiography)","0","0","0","0","0","0","0","0","0"
"503","NCT01379846","Study of TAK-816 in Healthy Infants","Immunization",0,"TAK-816+ DPT-TAKEDA","Biological","Takeda","Industry",0,0,"All","3 Months","6 Months","416","June 2011","February 2013","Proportion of participants with an anti-polyribosylribitol phosphate (PRP) titer ≥1 ϻg/mL","0","0","0","0","0","0","0","0","0"
"504","NCT01382199","Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients","Diarrhea",0,"Lactoferrin","Drug","Ventria Bioscience","Industry",0,0,"All","50 Years","N/A","340","September 2011","September 2013","Reduction in the number of days of antibiotic associated diarrhea during the treatment period","0","0","0","0","0","0","0","0","0"
"505","NCT01386125","A Study of the Effectiveness and Safety of Mometasone Furoate Nasal Spray (MFNS, SCH 032088) for the Treatment of Nasal Polyps (P05604)","Nasal Polyps",0,"Mometasone Furoate Nasal Spray (MFNS)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","748","June 2011","February 2013","Change From Baseline in Congestion/Obstruction Score","0.0007","0","ANCOVA","-0.14","Difference in LS Means","95","2-Sided","-0.22","-0.06"
"506","NCT01386528","Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B","Congenital Bleeding Disorder",0,"nonacog beta pegol","Drug","Novo Nordisk A/S","Industry",0,0,"Male","13 Years","70 Years","13","June 7, 2012","December 1, 2013","Haemostatic effect during surgery evaluated by the four-point response scale (excellent, good, moderate, poor)","0","0","0","0","0","0","0","0","0"
"507","NCT01387269","Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1)","Cachexia",0,"Anamorelin HCl","Drug","Helsinn Therapeutics (U.S.), Inc","Industry",0,0,"All","18 Years","N/A","484","July 2011","January 2014","Evaluate the effect of Anamorelin on lean body mass as measured by DXA scan","0","0","0","0","0","0","0","0","0"
"508","NCT01387282","Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)","Cachexia",0,"Anamorelin HCl","Drug","Helsinn Therapeutics (U.S.), Inc","Industry",0,0,"All","18 Years","N/A","495","July 2011","November 2013","Evaluate the effect of Anamorelin on lean body mass as measured by DXA scan","0","0","0","0","0","0","0","0","0"
"509","NCT01389323","BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","448","September 2011","September 2013","Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"510","NCT01389856","Persistent Pulmonary Hypertension of the Newborn","Persistent Pulmonary Hypertension of the Newborn",0,"Bosentan","Drug","Actelion","Industry",0,0,"All","N/A","7 Days","23","December 2011","December 2013","Percentage of Patients With Treatment Failure","1","0","Fisher Exact","0","0","0","0","0","0"
"511","NCT01390038","Simpliciti IDE Trial; Replacing the Humeral Head in Total Shoulder Arthroplasty","Primary Generalized (Osteo)Arthritis",0,"Simpliciti™ Shoulder System","Device","Tornier, Inc.","Industry",0,0,"All","22 Years","N/A","157","July 2011","November 2014","Device Success Rate","0","0","0","0","0","0","0","0","0"
"512","NCT01391546","Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Subjects Aged From 50 Years Old","Herpes Zoster",0,"1 dose at Day 0","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","354","June 2011","July 2013","VZV Glycoprotein enzyme-linked immunosorbent assay (gpELISA) antibody Geometric Mean of Titres (GMT)","0","0","0","0","0","0","0","0","0"
"513","NCT01392300","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke","Post-stroke Spasticity of the Upper Limb",0,"IncobotulinumtoxinA (400 Units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","80 Years","317","September 2011","March 2013","Change From Baseline in Ashworth Scale (AS) Score of Primary Target Clinical Pattern","<0.001","0","ANCOVA","-0.5","Mean Difference (Final Values)","95","2-Sided","-0.7","-0.3"
"514","NCT01392326","Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)","Psoriatic Arthritis",0,"Secukinumab (75 mg)","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","606","September 2011","October 2014","Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo","<0.0001","0","Regression, Logistic","5.53","Odds Ratio (OR)","95","2-Sided","3.46","8.85"
"515","NCT01392495","Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)","Pulmonary Arterial Hypertension",0,"Imatinib","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","N/A","N/A","17","June 2011","March 2014","Number of Patients With Adverse Events, Serious Adverse Events and Deaths","0","0","0","0","0","0","0","0","0"
"516","NCT01392677","Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea","Type 2 Diabetes Mellitus",0,"dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","311","October 2011","January 2013","Adjusted Mean Change From Baseline in HbA1c Levels","<0.0001","Significant at alpha=0.05 (2-sided). A hierarchical closed testing procedure was used to control Type I error across the primary & key secondary objectives","Mixed Models Analysis","-0.69","Mean Difference (Final Values)","95","2-Sided","-0.89","-0.49"
"517","NCT01393561","Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis","Nasal Congestion and Inflammations",0,"Group 1","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","12 Years","N/A","167","July 2014","October 2014","Improvement of nasal congestion and runny nose, after 48 hours of treatment","0","0","0","0","0","0","0","0","0"
"518","NCT01393613","Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia","Acute Schizophrenia",0,"OPC-34712","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","674","July 2011","February 2014","Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score.","0.0093","0","Mixed Models Analysis","0","0","0","0","0","0"
"519","NCT01394913","Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Reumatocept (etanercept)","Drug","EMS","Industry",0,0,"All","18 Years","70 Years","216","August 2013","March 2014","Efficacy","0","0","0","0","0","0","0","0","0"
"520","NCT01395147","Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder","Major Depressive Disorder",0,"Lu AA21004","Drug","Takeda","Industry",0,0,"All","20 Years","75 Years","119","July 2011","May 2013","Number of Participants Reporting One or More Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"521","NCT01395810","Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773","Congenital Bleeding Disorder",0,"nonacog beta pegol","Drug","Novo Nordisk A/S","Industry",0,0,"Male","13 Years","70 Years","71","April 16, 2012","March 31, 2014","Incidence of inhibitory antibodies against FIX defined as titre above or equal to 0.6 BU (Bethesda Units)","0","0","0","0","0","0","0","0","0"
"522","NCT01395914","Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)","Cachexia",0,"Anamorelin HCl","Drug","Helsinn Therapeutics (U.S.), Inc","Industry",0,0,"All","18 Years","N/A","345","July 2011","June 2014","Evaluate the safety and tolerability of Anamorelin","0","0","0","0","0","0","0","0","0"
"523","NCT01395966","Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients","Acute Otitis Media",0,"DF289","Drug","Salvat","Industry",0,0,"All","6 Months","12 Years","331","June 2011","June 2014","Time to Cessation of Otorrhea","0","0","0","0","0","0","0","0","0"
"524","NCT01395992","Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)","Bipolar I Disorder",0,"asenapine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","165","April 2012","December 2014","Number of participants experiencing clinical and laboratory adverse events (AEs)","0","0","0","0","0","0","0","0","0"
"525","NCT01396512","Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers","Japanese Encephalitis",0,"Live attenuated Japanese encephalitis chimeric virus vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","24 Months","274","July 2011","March 2013","Percentage of Participants With Seroconversion to Japanese Encephalitis Chimeric Virus Following Vaccination With Either IMOJEV™ or CD.JEVAX™ Japanese Encephalitis Vaccine","0","0","0","0","0","0","0","0","0"
"526","NCT01397097","LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study","Contraception",0,"LNG-IUS (BAY 86-5028)","Drug","Bayer","Industry",0,0,"Female","18 Years","35 Years","766","September 2011","June 2013","Discontinuation rate by treatment group","0","0","0","0","0","0","0","0","0"
"527","NCT01397422","Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)","Dyskinesia",0,"ADS-5102 (extended release amantadine HCl)","Drug","Adamas Pharmaceuticals, Inc.","Industry",0,0,"All","30 Years","85 Years","83","July 2011","May 2013","Change in the Unified Dyskinesia Rating Scale (UDysRS) total score","0","0","0","0","0","0","0","0","0"
"528","NCT01398670","Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","Type I Diabetes",0,"Insulin Lispro","Biological","Wockhardt","Industry",0,0,"All","18 Years","55 Years","0","February 2012","March 2013","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"529","NCT01400139","Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.","Chronic Nonmalignant and Nonneuropathic Pain",0,"Hydrocodone bitartrate q24h film-coated tablets","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","922","July 2011","August 2013","The Number of Participants With Adverse Events as a Measure of Safety","0","0","0","0","0","0","0","0","0"
"530","NCT01400828","Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg in Korean Patients With Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"Bilastine","Drug","Yuhan Corporation","Industry",0,0,"All","12 Years","70 Years","239","June 2011","June 2013","AUC of TSS","0","0","0","0","0","0","0","0","0"
"531","NCT01400867","Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","Infections, Pediatrics",0,"Ceftaroline fosamil","Drug","Forest Laboratories","Industry",0,0,"All","2 Months","17 Years","163","December 2011","May 2014","Evaluate the safety and tolerability of ceftaroline versus comparator in pediatric subjects ages 2 months to < 18 years with ABSSSI.","0","0","0","0","0","0","0","0","0"
"532","NCT01402713","To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children","Bacterial Infections",0,"GC1107","Biological","Green Cross Corporation","Industry",0,0,"All","10 Years","17 Years","311","August 2011","November 2013","Step I-the seroprotection rate of diphtheria and tetanus","0","0","0","0","0","0","0","0","0"
"533","NCT01402908","A Phase III Study of PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma After Surgical Resection","Cancer",0,"PI-88","Drug","Medigen Biotechnology Corporation","Industry",0,0,"All","18 Years","N/A","520","August 2011","July 2014","Disease-Free Survival (DFS)","0","0","0","0","0","0","0","0","0"
"534","NCT01403116","Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU) in Hypogonadal Men","Male Hypogonadism",0,"oral testosterone undecanoate","Drug","Clarus Therapeutics, Inc.","Industry",0,0,"Male","18 Years","75 Years","325","July 2011","September 2013","Percentage of oral TU treated patients with average serum testosterone (T)concentrations (Cavg) between 300 and 1000 ng/dL.","0","0","0","0","0","0","0","0","0"
"535","NCT01404234","Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways","Cystic Fibrosis",0,"AZLI","Drug","Gilead Sciences","Industry",0,0,"All","N/A","12 Years","61","December 2011","April 2013","Percentage of Participants Who Discontinued Study Drug Due to Safety or Tolerability Reasons","0","0","0","0","0","0","0","0","0"
"536","NCT01404611","Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients","Acute Otitis Media",0,"DF289","Drug","Salvat","Industry",0,0,"All","6 Months","12 Years","331","June 2011","May 2013","Time to Cessation of Otorrhea","0","0","0","0","0","0","0","0","0"
"537","NCT01405560","Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)","Hepatitis C, Chronic",0,"Vaniprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","70 Years","42","September 2011","March 2013","Percentage of Participants Achieving Sustained Virologic Response (SVR)24","0","0","0","0","0","0","0","0","0"
"538","NCT01405937","Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)","Hepatitis C, Chronic",0,"vaniprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","70 Years","51","August 2011","February 2013","Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)","<0.001","The Type-I error rate over the multiple tests comparisons was controlled by the Hochberg testing procedure.","exact test for binomial proportion","0","0","0","0","0","0"
"539","NCT01406470","Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency","Immunologic Deficiency Syndrome",0,"Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™","Drug","Green Cross Corporation","Industry",0,0,"All","2 Years","70 Years","45","September 2011","July 2013","Incidence of acute serious bacterial infections","0","0","0","0","0","0","0","0","0"
"540","NCT01406938","Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens","Moderate to Severe Plaque-type Psoriasis",0,"AIN457 150mg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","967","August 2011","May 2013","For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 52","0","0","0","0","0","0","0","0","0"
"541","NCT01408069","Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia","Tensional-type Headache",0,"MIGRANE","Drug","EMS","Industry",0,0,"All","18 Years","65 Years","108","March 2014","October 2014","Efficacy of treatment in relieve headache symptoms.","0","0","0","0","0","0","0","0","0"
"542","NCT01408550","Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids","Bullous Pemphigoid",0,"NPB-01","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","56","August 2011","September 2013","The score using Pemphigus Disease Area Index (PDAI)","0","0","0","0","0","0","0","0","0"
"543","NCT01410227","Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)","Von Willebrand Disease",0,"Recombinant von Willebrand factor (rVWF)","Biological","Baxalta US Inc.","Industry",0,0,"All","18 Years","65 Years","49","November 2011","February 2014","Percentage of Participants With Treatment Success for Treated Bleeding Episodes","0","0","0","100","Clopper-Pearson","90","2-Sided","84.7","100"
"544","NCT01410383","Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care","Heterozygous Familial Hypercholesterolaemia",0,"Placebo","Drug","Karo Bio AB","Industry",0,0,"All","18 Years","N/A","236","October 2011","October 2013","Percent reduction in low-density lipoprotein cholesterol (LDL-C) from baseline","0","0","0","0","0","0","0","0","0"
"545","NCT01410435","Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel Disease","Inflammatory Bowel Disease",0,"Monofer","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","39","June 2011","August 2013","Long term efficacy","0","0","0","0","0","0","0","0","0"
"546","NCT01410565","Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer","Bladder Cancer",0,"Apaziquone","Drug","Spectrum Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","66","July 2011","March 2014","Time to Recurrence","0","0","0","0","0","0","0","0","0"
"547","NCT01410695","A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug","Rheumatoid Arthritis (RA)",0,"masitinib","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","450","July 2011","December 2013","ACR50","0","0","0","0","0","0","0","0","0"
"548","NCT01410955","Prevention of Irinotecan Induced Diarrhea by Probiotics","Colorectal Cancer",0,"Probiotic formula","Dietary Supplement","Monsea Ltd.","Industry",0,0,"All","18 Years","N/A","46","December 2011","December 2013","Prevention of grade 3-4 diarrhea by probiotics in patients treated by irinotecan based chemotherapy","0","0","0","0","0","0","0","0","0"
"549","NCT01411137","Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study","Parkinson's Disease",0,"IPX066","Drug","IMPAX Laboratories, Inc.","Industry",0,0,"All","30 Years","N/A","43","August 2011","March 2013","Patient Global Impression (PGI)","0","0","0","0","0","0","0","0","0"
"550","NCT01411228","A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease","Gaucher Disease",0,"Taliglucerase alfa","Drug","Protalix","Industry",0,0,"All","2 Years","18 Years","15","September 2011","July 2014","Hemoglobin","0","0","0","0","0","0","0","0","0"
"551","NCT01411241","Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","Dengue",0,"Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Months","12 Months","720","July 2011","February 2014","Information on the antibody to diphtheria toxoid, tetanus toxoid, pertussis, Filamentous haemagglutinin, polyribosylribitol phosphate (PRP) and polio post-Pentaxim booster vaccination","0","0","0","0","0","0","0","0","0"
"552","NCT01412060","Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia","Schizophrenia",0,"Cariprazine","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","60 Years","766","August 2011","August 2014","Time from baseline to the first symptom relapse during the Double-Blind phase","0","0","0","0","0","0","0","0","0"
"553","NCT01412385","Immune Globulin Subcutaenous (Human), 20%","Primary Immunodeficiency Diseases (PID)",0,"Immune Globulin Subcutaneous (Human), 20%","Biological","Baxalta US Inc.","Industry",0,0,"All","2 Years","N/A","55","August 2011","May 2014","Acute serious bacterial infection rate defined as the mean number of acute serious bacterial infections per subject per year in the intent-to-treat population","0","0","0","0","0","0","0","0","0"
"554","NCT01412424","Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly","Acromegaly",0,"Octreotide capsules","Drug","Chiasma, Inc.","Industry",0,0,"All","18 Years","75 Years","155","March 2012","May 2014","Percentage of Responders at the End of the Core Treatment Period","0","0","0","0","0","0","0","0","0"
"555","NCT01412957","Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer","Metastatic Colorectal Cancer",0,"Best Supportive Care (BSC)","Other","Amgen","Industry",0,0,"All","18 Years","N/A","377","November 2011","June 2014","Overall Survival","0.0096","0","Log Rank","-2.59","Normal score","0","0","0","0"
"556","NCT01413581","Comparison of rhBSSL With Placebo When Added to Infant Formula or Pasteurized Breast Milk During 4 Weeks of Treatment in Preterm Infants","Prevention of Growth Restriction",0,"rhBSSL (recombinant human bile-salt-stimulated lipase)","Drug","Swedish Orphan Biovitrum","Industry",0,0,"All","N/A","10 Weeks","415","May 2011","July 2013","Growth velocity in grams per kilogram per day during 4 weeks of treatment.","0","0","0","0","0","0","0","0","0"
"557","NCT01414166","Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)","Dyslipidemia",0,"ERN/LRPT","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","244","September 2011","February 2013","Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) Averaged Across Week 12 and Week 16","0","0","0","0","0","0","0","0","0"
"558","NCT01414192","A Study to Design a Model Cohort for Analysis of Dyslipidemia (MK-0653A-204)","Dyslipidemia",0,NA,NA,"Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","3215","November 2008","September 2014","Rate of Cardiovascular (CV) Events","0","0","0","0","0","0","0","0","0"
"559","NCT01415505","Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension","Hypertension",0,"Nebivolol, Valsartan and Hydrochlorothiazide","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","812","August 2011","January 2013","Adverse Event Recording","0","0","0","0","0","0","0","0","0"
"560","NCT01415908","INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine","Lumbar Spine Degeneration",0,"INFUSE Bone Graft","Device","Medtronic Spinal and Biologics","Industry",0,0,"All","18 Years","N/A","15","July 2011","September 2014","Rate of Overall Success","0","0","0","0","0","0","0","0","0"
"561","NCT01415960","Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer","Prostate Cancer",0,"Leuprolide acetate 22.5 mg depot, GP-Pharm SA","Drug","GP-Pharm","Industry",0,0,"Male","18 Years","N/A","163","September 2011","May 2013","Percentage of Participants Achieving Chemical Castration (Defined as Testosterone Levels ≤ 0.5 ng/mL) at Days 28, 84, and 168.","0","0","0","0","0","0","0","0","0"
"562","NCT01416441","Safety & Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","Tourette's Disorder",0,"aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","7 Years","18 Years","170","August 2011","March 2014","Number and percentage of subjects with adverse events","0","0","0","0","0","0","0","0","0"
"563","NCT01418339","Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","Tourette's Disorder",0,"aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","7 Years","17 Years","135","July 2011","November 2013","Primary efficacy measure is change from Baseline to endpoint (week 8) of the Yale Global Tic Severity Scale (YGTSS).","0","0","0","0","0","0","0","0","0"
"564","NCT01418352","Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","Tourette's Disorder",0,"aripiprazole 52.5 mg","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","7 Years","17 Years","83","July 2011","March 2014","Primary efficacy measure is change from Baseline to endpoint (week 8) of the Yale Global Tic Severity Scale (YGTSS).","0","0","0","0","0","0","0","0","0"
"565","NCT01419964","Efficacy and Safety of ACH24 in the Treatment of Vitiligo","Vitiligo",0,"Group 01","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","18 Years","65 Years","0","January 2012","December 2013","Repigmentation of the affected area assessed by VASI (vitiligo area scoring index).","0","0","0","0","0","0","0","0","0"
"566","NCT01420549","Efficacy and Safety of FDC in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","Hypercholesterolemia",0,"Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","18 Years","70 Years","129","March 2013","November 2014","Changes in LDL-Cholesterol level","0","0","0","0","0","0","0","0","0"
"567","NCT01420653","Maxigesic 325 Acute Dental Pain Study","Dental Pain",0,"Maxigesic 325","Drug","AFT Pharmaceuticals, Ltd.","Industry",0,0,"All","18 Years","60 Years","408","April 2013","December 2014","SPID (Summed Pain Intensity Differences)","0","0","0","0","0","0","0","0","0"
"568","NCT01421082","Evaluation of Physiologic Parameters to Study the Mechanism of Action of the Lung Volume Reduction Coil in Subjects With Homogeneous Emphysema","Emphysema",0,"Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)","Device","PneumRx, Inc.","Industry",0,0,"All","35 Years","N/A","10","February 2012","March 2013","6 minute walk test (6MWT)","0","0","0","0","0","0","0","0","0"
"569","NCT01421134","Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","Major Depressive Disorder With Mixed Features",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","211","September 2011","October 2014","Mean Change From Baseline to the 6-week Study Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Scores","<0.0001","0","Mixed Models Analysis","-7.5","Least Square Mean Difference","95","2-Sided","-10.2","-4.8"
"570","NCT01421511","TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections","Skin and Subcutaneous Tissue Bacterial Infections",0,"TR-701 FA","Drug","Trius Therapeutics LLC","Industry",0,0,"All","18 Years","N/A","666","September 15, 2011","January 10, 2013","The Early Clinical Response Rate","0","0","0","2.6","Risk Difference (RD)","95","2-Sided","-3.0","8.2"
"571","NCT01422187","A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease","Gaucher Disease",0,"Taliglucerase alfa","Drug","Protalix","Industry",0,0,"All","18 Years","N/A","19","August 2011","May 2014","Spleen Volume","0","0","0","0","0","0","0","0","0"
"572","NCT01422213","Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","598","December 2011","May 2013","Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores","<0.0001","To adjust for multiplicity, the 10 and 20 mg doses of vortioxetine were tested separately versus placebo in the primary and key secondary efficacy analyses at a Bonferroni-corrected significance level of 0.05/2 = 0.025.","Mixed Models Analysis","0.363","Mean Difference (Final Values)","95","2-Sided","0.22","0.50"
"573","NCT01423253","Major Depressive Disorder With Mixed Features - Extension","Major Depressive Disorder",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","48","September 2011","October 2013","Percentage of Subjects With Treatment Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"574","NCT01424670","Safety and Efficacy Trial of Delamanid for 6 Months in Patients With Multidrug Resistant Tuberculosis","Multidrug Resistant Tuberculosis",0,"Delamanid","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","69 Years","511","September 2011","May 2014","Time to Sputum Culture Conversion","0","0","0","0","0","0","0","0","0"
"575","NCT01424813","A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma","Asthma",0,"Placebo MDPI","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","158","December 2012","October 2013","Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period","<0.0001","Significance at the 0.05 level.","mixed-model repeated-measures (MMRM)","0.83","Mean Difference (Final Values)","95","2-Sided","0.57","1.08"
"576","NCT01425203","The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)","Chronic Hepatitis C Genotype 1",0,"Boceprevir","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","238","November 2011","October 2013","Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)","<0.0001","Multiplicity adjustment for controlling type 1 error for the primary comparison was based on the step-down approach.","Miettinen and Nurminen Method","29.2","Adjusted Difference in Percentages","95","2-Sided","16.4","41.5"
"577","NCT01425463","A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized Trial to Evaluate Efficacy & Safety in Anemia Subjects","Iron Deficiency Anemia",0,"Ferrous (II) Glycine Sulphate Complex","Drug","Sanol GmbH","Industry",0,0,"All","16 Years","75 Years","256","March 2011","October 2013","Change in Hemoglobin (Hb) From Baseline (Week 0) to Week 12","0","0","0","-2.19","LS-Mean of ANCOVA","95","2-Sided","-8.47","4.09"
"578","NCT01426035","Safety And Efficacy Study Of Topic Mucopolysaccharide Polysulfate Cream In The Superficial Varicose Veins Treatment","VARICOSE VEINS",0,"TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G","Drug","EMS","Industry",0,0,"All","18 Years","80 Years","76","September 2014","December 2014","Efficacy - Symptoms reduction","0","0","0","0","0","0","0","0","0"
"579","NCT01426113","A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma","Glaucoma",0,"bimatoprost ophthalmic solution formulation A","Drug","Allergan","Industry",0,0,"All","2 Months","17 Years","6","September 2011","October 2014","Change From Baseline in Intraocular Pressure (IOP) in the Study Eye","0","0","0","0","0","0","0","0","0"
"580","NCT01426373","Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area","Moderate or Severe Submental Fullness",0,"Deoxycholic acid injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","165","August 2011","June 2013","Number of Participants With Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"581","NCT01427270","Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain","Low Back Pain",0,"Oxycodone/Naloxone controlled-release","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","455","August 2011","October 2014","Overall complete spontaneous bowel movement (CSBM) responder rates","0","0","0","0","0","0","0","0","0"
"582","NCT01427283","A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain","Low Back Pain",0,"Oxycodone/Naloxone controlled-release","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","450","August 2011","October 2014","Overall complete spontaneous bowel movement (CSBM) responder rates","0","0","0","0","0","0","0","0","0"
"583","NCT01428661","Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"tasimelteon","Drug","Vanda Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","507","September 2011","January 2013","Change From Baseline to Endpoint at Week 8 Using the Total Score of the Hamilton Depression Rating Scale (HAM-D)","0","0","0","0","0","0","0","0","0"
"584","NCT01429051","A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain","Break Through Pain",0,"Intranasal Fentanyl Spray (INFS)","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","46","August 2011","January 2013","Induction Phase: Pain Intensity Difference at 10 Minutes (PID10) After Treatment","0.002","0","Mixed Models Analysis","1.1","LS Mean Difference","95","2-Sided","0.41","1.179"
"585","NCT01429441","Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole","Vitreomacular Adhesion Including Macular Hole",0,"Ocriplasmin","Drug","ThromboGenics","Industry",0,0,"All","18 Years","N/A","220","October 2011","October 2014","Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28","0","0","0","0","0","0","0","0","0"
"586","NCT01431638","Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","Acute Gouty Arthritis",0,"Canakinumab 150mg in prefilled syringe","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","85 Years","233","August 2011","May 2013","Safety and tolerability of repeated dosing of canakinumab 150mg s.c. PFS","0","0","0","0","0","0","0","0","0"
"587","NCT01431742","Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain","Pain",0,"BEMA Buprenorphine","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","0","July 2012","July 2013","Mean change in pain intensity","0","0","0","0","0","0","0","0","0"
"588","NCT01431807","Long-term Study of SYR-472","Diabetes Mellitus",0,"SYR-472","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","680","September 2011","June 2013","Adverse events","0","0","0","0","0","0","0","0","0"
"589","NCT01431820","Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis","Distal and Lateral Subungual Onychomycosis",0,"Luliconazole Solution, 10%","Drug","Topica Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","334","May 2012","June 2014","The proportion of subjects who achieve complete cure of the target great toenail","0","0","0","0","0","0","0","0","0"
"590","NCT01431963","Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy","Epilepsy",0,"Lamictal","Drug","GlaxoSmithKline","Industry",0,0,"All","16 Years","N/A","70","September 2011","March 2013","Number of Participants Who Were Seizure Free in the Maintenance Phase (Across Seizure Types and by Seizure Type Within 6 Months Prior to the Start of the Study)","0","0","0","43.1","percentage of participants","95","2-Sided","30.85","55.96"
"591","NCT01431976","Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents","Epilepsy",0,"Lamictal","Drug","GlaxoSmithKline","Industry",0,0,"All","2 Years","15 Years","20","September 2011","February 2014","Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP)","0","0","0","35.0","percentage of participants","95","2-Sided","15.39","59.22"
"592","NCT01432236","A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression","Fibromyalgia",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","197","October 2011","July 2013","Mean NRS Pain Score at End of Period.","0.0001","Primary analysis was two-sided and performed at the 0.05 significance level.","Mixed Models Analysis","-0.61","Mean Difference (Final Values)","95","2-Sided","-0.91","-0.31"
"593","NCT01432444","Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole","Schizophrenia",0,"Aripiprazole (Abilify®) IM Depot Injection","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","493","September 2011","December 2013","Number of Inpatient Psychiatric Hospitalization for Retrospective Period (Months 4-6) and Prospective Period (Months 4-6).","<.0001","P-value was derived from Exact McNemar test.","McNemar","0","0","0","0","0","0"
"594","NCT01433354","Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)","Fragile X Syndrome",0,"AFQ056","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","12 Years","18 Years","119","November 2011","September 2014","Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"595","NCT01433406","Long-term Study of TAK-875","Diabetes Mellitus",0,"TAK-875","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","1222","October 2011","December 2013","Adverse events","0","0","0","0","0","0","0","0","0"
"596","NCT01433523","House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma","Asthma",0,"ALK HDM AIT Placebo","Drug","ALK-Abelló A/S","Industry",0,0,"All","18 Years","N/A","834","August 2011","April 2013","Time to first moderate or severe asthma exacerbation after ICS reduction","0","0","0","0","0","0","0","0","0"
"597","NCT01433978","A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)","Idiopathic Thrombocytopenic Purpura",0,"Eltrombopag","Drug","Eisai Inc.","Industry",0,0,"All","18 Years","99 Years","23","April 2012","September 2013","Durable platelet response as defined by the proportion of subjects who have at least 6 of 8 weekly platelet responses during the last 8 weeks of treatment over the 6-month treatment period in absence of rescue therapy","0","0","0","0","0","0","0","0","0"
"598","NCT01434160","LCS12 Adolescent Study","Contraception",0,"Skyla (Levonorgestrel, BAY86-5028)","Drug","Bayer","Industry",0,0,"Female","12 Years","17 Years","304","September 2011","June 2013","Number of adverse events reported by study subjects","0","0","0","0","0","0","0","0","0"
"599","NCT01434511","Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A","Hemophilia A",0,"OBI-1","Biological","Baxalta US Inc.","Industry",0,0,"All","6 Years","N/A","1","August 2011","July 2013","Proportion of Serious Bleeding Episodes Responsive to OBI-1","0","0","0","0","0","0","0","0","0"
"600","NCT01435616","A Study in Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1516","October 2011","January 2014","Change from baseline to 52 week endpoint in hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"601","NCT01435655","The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin","Transthyretin Familial Amyloid Polyneuropathy",0,"tafamidis","Drug","Pfizer","Industry",0,0,"All","20 Years","75 Years","10","November 2011","February 2014","Number of Participants With Transthyretin (TTR) Stabilization at Week 8 Compared With Baseline as Measured by a Validated Immunoturbidimetric Assay","0","0","0","0","0","0","0","0","0"
"602","NCT01435928","PEARL Schizophrenia Maintenance","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","676","September 2011","August 2013","Time to First Relapse Event During Double-blind Phase","0.039","0","Log Rank","0.66","Odds Ratio (OR)","95","2-Sided","0.45","0.98"
"603","NCT01436396","Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","Dengue",0,"Live, attenuated dengue serotype 1, 2, 3, and 4 virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","13 Months","792","September 2011","September 2013","Information on the antibody to yellow fever virus post Stamaril vaccination","0","0","0","0","0","0","0","0","0"
"604","NCT01437397","Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium Bromide/Formoterol Fumarate","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","1692","September 2011","February 2013","Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)","<0.0001","0","Mixed Models Analysis","0.108","Least squares mean difference","95","2-Sided","0.073","0.144"
"605","NCT01437540","Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease",0,"Aclidinium Bromide/Formoterol Fumarate","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","590","September 19, 2011","March 31, 2013","Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE)","0","0","0","0","0","0","0","0","0"
"606","NCT01438775","Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)","Benign Prostatic Hyperplasia",0,"NX-1207","Drug","Nymox Corporation","Industry",0,0,"Male","45 Years","N/A","192","September 2011","January 2013","Safety","0","0","0","0","0","0","0","0","0"
"607","NCT01438840","Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","Chronic Thrombocytopenia",0,"Avatrombopag","Drug","Eisai Inc.","Industry",0,0,"All","18 Years","N/A","49","February 2012","November 2013","Cumulative Number Of Weeks Of Platelet Response Over 6 Months of Treatment","0","0","0","0","0","0","0","0","0"
"608","NCT01439958","Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)","Bronchiolitis Obliterans",0,"Inhalation","Drug","Pari Pharma GmbH","Industry",0,0,"All","18 Years","80 Years","14","February 2012","July 2013","Long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS)","0","0","0","0","0","0","0","0","0"
"609","NCT01440946","Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B","Hemophilia B",0,"rFIXFc","Drug","Bioverativ Therapeutics Inc.","Industry",0,0,"Male","N/A","11 Years","30","June 2012","November 2014","Occurence of Factor IX (FIX) Inhibitor Development","0","0","0","0","0","0","0","0","0"
"610","NCT01441440","Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"venlafaxine ER 75 mg/day (fixed dose)","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","538","November 2011","March 2014","Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination","0.031","Two-sided p-value from an analysis of covariance model including treatment as a factor and baseline as a covariate.","ANCOVA","1.50","Mean Difference (Final Values)","95","2-Sided","0.14","2.87"
"611","NCT01442207","Cerclage for Prevention on Preterm Birth in Women With Placenta Previa","Premature Birth",0,"Placement of a Cervical Cerclage","Procedure","Obstetrix Medical Group","Industry",0,0,"Female","18 Years","N/A","0","March 2012","May 2013","Gestational age (GA) at birth","0","0","0","0","0","0","0","0","0"
"612","NCT01442337","A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients","Kidney Transplantation",0,"ASP8597","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","70 Years","21","December 2011","July 2013","Pharmacokinetic (PK) variable for ASP8597: Maximum concentration (Cmax)","0","0","0","0","0","0","0","0","0"
"613","NCT01442987","Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia","Hypertension",0,"Irbesartan/Atorvastatin A","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","19 Years","75 Years","230","May 2011","April 2013","Percent change from baseline to 8 week in LDL-Cholesterol","0","0","0","0","0","0","0","0","0"
"614","NCT01444118","A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients","Carcinoma, Non-Small-Cell Lung",0,"Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)","Biological","Bioven Europe","Industry",0,0,"All","20 Years","65 Years","0","November 2011","December 2014","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"615","NCT01444781","Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants","Diphtheria",0,"DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","12 Months","24 Months","1106","September 2011","April 2013","Summary of Diphtheria and Tetanus Post Primary Series Antibodies, Persistence and Booster Response Following Vaccination With Either DTaP-IPV Hep B-PRP T Vaccine or Infanrix Hexa Vaccine","0","0","0","0","0","0","0","0","0"
"616","NCT01445678","Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","Complicated Intra-abdominal Infection",0,"CXA-201 and metronidazole","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","N/A","494","December 1, 2011","October 1, 2013","The Percentage of Subjects With Clinical Outcome of Cure at the Test of Cure (TOC) Visit in the Microbiological Intent to Treat (MITT) Population","0","0","0","-4.2","Risk Difference (RD)","95","2-Sided","-8.91","0.54"
"617","NCT01445951","Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period","Type 1 Diabetes Mellitus",0,"Technosphere® Insulin with MedTone C Inhaler","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","N/A","518","September 2011","May 2013","Change From Baseline to Week 24 in HbA1c","0","0","0","0.19","Mean Difference (Net)","95","2-Sided","0.02","0.36"
"618","NCT01446601","Apnex Clinical Study of the Hypoglossal Nerve Stimulation (HGNS®) System to Treat Obstructive Sleep Apnea","Obstructive Sleep Apnea",0,"Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )","Device","Apnex Medical, Inc.","Industry",0,0,"All","21 Years","80 Years","132","August 2011","August 2013","Reduction in OSA Severity","0","0","0","0","0","0","0","0","0"
"619","NCT01447394","Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C","Hepatitis C Virus (HCV)",0,"Pegylated Interferon Lambda","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","70 Years","0","March 2012","March 2014","Efficacy of Lambda + Ribavirin (RBV) compared to Alfa + RBV in achieving a sustained virological response","0","0","0","0","0","0","0","0","0"
"620","NCT01448044","Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C","Hepatitis C",0,"BMS-790052 (NS5A Replication Complex Inhibitor)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","152","December 2011","October 2013","Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)","<0.0001","The pvalue was based on the CochranMantelHaenszel (CMH) test, stratified by IL28B host genotype, geography, and baseline cirrhosis status.","Cochran-Mantel-Haenszel","38.850","difference in percentages","95","2-Sided","21.703","55.997"
"621","NCT01448707","A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","Human Immunodeficiency Virus (HIV) Infections",0,"Darunavir","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","N/A","274","March 2012","June 2014","Virologic Response (Food Drug and Administration [FDA] Snapshot, Switch = Failure)","0.2331","P-Value for non-inferiority of DRV/rtv MONO vs DRV/rtv + 2NRTIs (delta = 12%).","Mixed Models Analysis","-7.9","Non-Linear mixed","95","2-Sided","-14.64","-1.19"
"622","NCT01448720","Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate","Schizophrenia",0,"Paliperidone palmitate","Drug","Janssen-Cilag Farmaceutica Ltda.","Industry",0,0,"All","18 Years","49 Years","142","September 2011","December 2013","Change in the Positive and Negative Syndrome Scale (PANSS)","0","0","0","0","0","0","0","0","0"
"623","NCT01449162","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids","Asthma",0,"masitinib 6 mg/kg/day","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","300","June 2011","December 2013","asthma exacerbation rate","0","0","0","0","0","0","0","0","0"
"624","NCT01449292","Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)","Pulmonary Emphysema",0,"Treatment plus Optimal Medical Therapy","Device","Aeris Therapeutics","Industry",0,0,"All","40 Years","N/A","300","June 2012","November 2013","Forced Expiratory Volume in 1 second (FEV1)","0","0","0","0","0","0","0","0","0"
"625","NCT01449929","Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects","Infection, Human Immunodeficiency Virus",0,"dolutegravir 50 mg OAD","Drug","ViiV Healthcare","Industry",0,0,"All","18 Years","N/A","488","October 2011","April 2013","Percentage of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) at Week 48","0.025","P-value is for test of superiority.","Cochran-Mantel-Haenszel","7.1","Difference in percentage","95","2-Sided","0.9","13.2"
"626","NCT01450774","Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children","Childhood Asthma",0,"CHF 1535 50/6µg","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","5 Years","11 Years","72","September 2011","November 2013","Lower leg growth rate measured by knemometry","0","0","0","0","0","0","0","0","0"
"627","NCT01451203","Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Placebo","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","64 Years","319","October 2011","August 2013","Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52","<0.001","The ANCOVA on the ranks with treatment as factors and Baseline rank as covariate was used.","ANCOVA","0.00","Hodges-Lehmann point estimate of shift","95","2-Sided","0.00","0.00"
"628","NCT01451398","Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus","Type 2 Diabetes",0,"Technosphere® Insulin","Drug","Mannkind Corporation","Industry",0,0,"All","18 Years","N/A","353","November 2011","June 2013","Change From Baseline to Week 24 in HbA1c","<0.0001","0","Mixed Models Analysis","-0.40","Mean Difference (Final Values)","95","2-Sided","-0.57","-0.23"
"629","NCT01451411","A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia","Hyponatremia",0,"Conivaptan hydrochloride","Drug","Cumberland Pharmaceuticals","Industry",0,0,"All","2 Years","17 Years","4","February 2012","January 2014","Mean Change From Baseline to the End of the 48-hour Treatment Period in Serum Sodium","0","0","0","0","0","0","0","0","0"
"630","NCT01452529","Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain","Chronic Low Back Pain",0,"Hydrocodone bitartrate q24h film-coated tablets","Drug","Purdue Pharma LP","Industry",0,0,"All","18 Years","N/A","905","October 2011","September 2013","Mean Pain Intensity for ""Average Pain Over the Last 24 Hours"" Score","0","0","0","0","0","0","0","0","0"
"631","NCT01452724","Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer","Duodenal Ulcer",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","372","October 2011","February 2013","Endoscopic Healing Rate of Duodenal Ulcer Over 6 Weeks","0","0","0","0","0","0","0","0","0"
"632","NCT01452750","Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Non-steroidal Anti-inflammatory Drug (NSAID)","Gastric Ulcers",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","642","October 2011","June 2013","Recurrence rate of gastric or duodenal ulcer within 24 weeks","0","0","0","0","0","0","0","0","0"
"633","NCT01452763","Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin","Gastric Ulcers",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","621","October 2011","April 2013","Recurrence rate of gastric or duodenal ulcer within 24 weeks","0","0","0","0","0","0","0","0","0"
"634","NCT01452776","Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis","Erosive Esophagitis",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","305","September 2011","July 2013","Incidence of Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"635","NCT01453725","Effect of Golimumab in Participants With Active Axial Spondyloarthritis (P07642, MK-8259-006)","Spondylitis, Ankylosing",0,"Golimumab","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","45 Years","198","February 2012","March 2014","Percentage of Participants Achieving an Assessment in Ankylosing Spondylitis (ASAS) 20 Response at Week 16","<0.0001","Stratification factors: Baseline evidence of sacroiliitis on magnetic resonance imaging (MRI) and Screening C-reactive protein (CRP) level","Stratified Miettinen and Nurminen Method","31.2","Difference in Percent vs Placebo","95","2-Sided","17.5","43.6"
"636","NCT01454284","A Study in Patients With Type I Diabetes Mellitus","Diabetes Mellitus, Type 1",0,"Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1113","January 2012","February 2014","Hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"637","NCT01454544","A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet","House Dust Mite Allergy",0,"AIT Tablet","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","992","October 2011","April 2013","Evaluation of allergy symptoms and use of symptomatic medication","0","0","0","0","0","0","0","0","0"
"638","NCT01455194","Effect of High Dose Ciclesonide on Asthma Control","Bronchial Asthma",0,"Ciclesonide","Drug","AstraZeneca","Industry",0,0,"All","12 Years","70 Years","520","November 2011","August 2014","Asthma Control Questionnaire (ACQ) Score at Baseline","0","0","0","0","0","0","0","0","0"
"639","NCT01455415","Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain","Painful Diabetic Peripheral Neuropathy",0,"pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","306","December 2011","November 2013","Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)","0.3287","Secondary analysis was two-sided and performed at the 0.05 significance level, without multiple comparisons' adjustment.","Regression, Logistic","1.20","Odds Ratio (OR)","95","2-Sided","0.83","1.73"
"640","NCT01455857","A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes","Type 2 Diabetes",0,"ITCA 650","Drug","Intarcia Therapeutics","Industry",0,0,"All","18 Years","80 Years","460","March 2013","August 2014","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"641","NCT01456000","HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)","Paroxysmal Atrial Fibrillation",0,"EAS-AC (HeartLight)","Device","CardioFocus","Industry",0,0,"All","18 Years","75 Years","405","January 2012","December 2014","Number of Participants That Meeting the Efficacy Success Criteria as Described in the Outcome Measure Description","0","0","0","0","0","0","0","0","0"
"642","NCT01456195","Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Placebo","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","421","November 2011","July 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c)","<0.001","MMRM model with treatment, country, visit and visit by treatment interaction as fixed factors and with baseline value and baseline value by visit interaction as covariates with an unstructured covariance structure.","Mixed model for repeated measurements","-0.48","LS Mean Difference","95","2-Sided","-0.72","-0.24"
"643","NCT01456247","Long-term Extension Study of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin","Gastric Ulcers",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","439","March 2012","October 2013","Incidence of treatment-emergent adverse events","0","0","0","0","0","0","0","0","0"
"644","NCT01457911","Evaluation of Fixed Dose Combination of Glimepiride and Metformin in Chinese Type 2 Diabetes Patients Inadequately Controlled With Metformin","Type 2 Diabetes Mellitus",0,"Glimepiride and Metformin hydrochloride combination (HOE490)","Drug","Sanofi","Industry",0,0,"All","18 Years","80 Years","244","October 2011","February 2013","Absolute change in HbA1c","0","0","0","0","0","0","0","0","0"
"645","NCT01458106","Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A","Hemophilia A",0,"BIIB031 (rFVIIIFc)","Drug","Bioverativ Therapeutics Inc.","Industry",0,0,"Male","N/A","11 Years","71","November 2012","December 2013","Occurrence of FVIII Inhibitor Development","0","0","0","0","0","0","0","0","0"
"646","NCT01458275","A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)","Seasonal Allergic Rhinitis",0,"Ciclesonide nasal aerosol 37 mcg","Drug","Sunovion","Industry",0,0,"All","6 Years","11 Years","847","November 2011","March 2013","Change From Baseline in Average Daily Subject Reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Over the 2-week Double-blind Treatment Period","0","0","0","0","0","0","0","0","0"
"647","NCT01459367","Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis","Erosive Esophagitis",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","607","October 2011","March 2013","Endoscopically confirmed recurrence rate of erosive esophagitis after 24 weeks of maintenance treatment","0","0","0","0","0","0","0","0","0"
"648","NCT01459796","Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares","Gout",0,"Rilonacept","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","80 Years","219","November 2011","June 2013","Summary of TEAEs (Treatment-Emergent Adverse Events)","0","0","0","0","0","0","0","0","0"
"649","NCT01459809","Efficacy and Safety Comparison of Metformin/Glimepiride Combination Versus Each Compound Alone in New Diagnosed Type 2 Diabetes Patients","Diabetes Mellitus, Type 2",0,"GLIMEPIRIDE","Drug","Sanofi","Industry",0,0,"All","18 Years","78 Years","538","February 2012","January 2014","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"650","NCT01459913","Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype","Hepatitis C, Chronic",0,"Telaprevir","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","18 Years","70 Years","239","November 2011","January 2014","Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)","0","0","0","0","0","0","0","0","0"
"651","NCT01462266","Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","660","January 13, 2012","June 6, 2013","Change From Baseline in Daily Insulin Dose at Week 24","0.009","0","Longitudinal data analysis","-4.7","Mean Difference (Final Values)","95","2-Sided","-8.3","-1.2"
"652","NCT01462942","Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination","Chronic Obstructive Pulmonary Disease (COPD)",0,"Aclidinium Bromide/Formoterol Fumarate","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","2443","October 2011","January 2013","Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)","<0.0001","0","Mixed Models Analysis","0.125","Least Squares Mean Difference","95","2-Sided","0.090","0.160"
"653","NCT01463293","B. Lactis HN019 for Functional Constipation","Constipation",0,"B. lactis HN019","Dietary Supplement","Fonterra Research Centre","Industry",0,0,"All","18 Years","70 Years","224","March 2012","March 2013","Whole Gut Transit Time","0","0","0","0","0","0","0","0","0"
"654","NCT01464307","Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke","Post-stroke Spasticity of the Lower Limb",0,"IncobotulinumtoxinA (400 Units)","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","80 Years","290","December 2011","August 2014","Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4","0.777","0","Mixed-Model Repeated Measures","0.0","Least Square Mean Difference","95","2-Sided","-0.1","0.2"
"655","NCT01464476","Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)","Arrhythmias, Cardiac",0,"Azimilide Dihydrochloride","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","240","November 2011","May 2013","Time to first cardiovascular event","0","0","0","0","0","0","0","0","0"
"656","NCT01464905","Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)","Relapsing Remitting Multiple Sclerosis",0,"NU100","Biological","Nuron Biotech Inc.","Industry",0,0,"All","18 Years","60 Years","500","October 2011","December 2013","New CALs after 4 months of treatment based on the MRI outcomes obtained at 4 and 12 months","0","0","0","0","0","0","0","0","0"
"657","NCT01466192","Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients","Chronic Hepatitis C",0,"MP-424 (generic name:Telaprevir)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","108","May 2012","August 2013","Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"658","NCT01467427","Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B","Congenital Bleeding Disorder",0,"nonacog beta pegol","Drug","Novo Nordisk A/S","Industry",0,0,"Male","N/A","12 Years","25","May 16, 2012","April 1, 2014","Incidence of inhibitory antibodies against coagulation factor IX (FIX) defined as titre above or equal to 0.6 Bethesda Units (BU)","0","0","0","0","0","0","0","0","0"
"659","NCT01467479","A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)","Hepatitis C",0,"Telaprevir","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","18 Years","65 Years","185","December 2011","February 2014","Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)","0","0","0","0","0","0","0","0","0"
"660","NCT01467882","Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty","Central Precocious Puberty",0,"Triptorelin","Drug","Debiopharm International SA","Industry",0,0,"All","2 Years","9 Years","44","April 2012","August 2013","Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6","0","0","0","0","0","0","0","0","0"
"661","NCT01468181","A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","394","November 2011","December 2013","Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","0","0","0","0","0","0","0","0","0"
"662","NCT01468207","Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","Hidradenitis Suppurativa (HS)",0,"adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","99 Years","307","November 2011","January 2014","Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12","=0.003","P-value adjusted for baseline Hurley Stage.","Cochran-Mantel-Haenszel","15.9","Adjusted mean difference","95","2-Sided","5.3","26.5"
"663","NCT01468233","Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","Hidradenitis Suppurativa (HS)",0,"adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","99 Years","326","November 2011","April 2014","Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12","<0.001","P-value adjusted for baseline Hurley Stage and for baseline antibiotic use (Y/N).","Cochran-Mantel-Haenszel","31.5","Adjusted mean difference","95","2-Sided","20.7","42.2"
"664","NCT01468584","Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients","Chronic Hepatitis C",0,"MP-424 (generic name:Telaprevir)","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","10","November 2011","September 2013","Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"665","NCT01468987","A Study in Participants With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"LY2605541","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1325","December 2011","August 2013","Change from baseline in hemoglobin A1c (HbA1c) at 26 weeks","0","0","0","0","0","0","0","0","0"
"666","NCT01469039","A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia","Schizophrenia",0,"ALKS 9072","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","70 Years","623","December 2011","January 2014","The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score","<0.001","0","ANCOVA","0","0","0","0","0","0"
"667","NCT01469169","Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study","Hypertension, Pulmonary",0,"Iloprost (Ventavis inhaled, BAYQ6256)","Drug","Bayer","Industry",0,0,"All","18 Years","75 Years","27","June 19, 2012","December 26, 2014","Change in Pulmonary vascular resistance (PVR) from screening (baseline) to week 12 (after inhalation)","0","0","0","0","0","0","0","0","0"
"668","NCT01470131","A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma","Multiple Myeloma",0,"masitinib 6 mg/kg/day","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","300","May 2011","April 2013","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"669","NCT01470989","β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)","Acute Gouty Arthritis Flares",0,"ACZ885","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","135","November 2011","May 2013","safety and tolerability","0","0","0","0","0","0","0","0","0"
"670","NCT01471041","Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae","End Stage Renal Disease",0,"Venous Window Needle Guide","Device","Vital Access Corp.","Industry",0,0,"All","18 Years","N/A","54","December 2011","March 2013","Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis","0","0","0","0","0","0","0","0","0"
"671","NCT01471392","Identigene STD Test Collection Kit Validation Study","Infection",0,"STD Diagnostic Kit (Identigene)","Device","Identigene","Industry",0,0,"All","14 Years","N/A","3000","November 2011","June 2014","Effectiveness of the Identigene STD Test Collection Kit in comparison to the Gen-Probe Aptima Combo 2 Assay","0","0","0","0","0","0","0","0","0"
"672","NCT01471574","Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus","Hepatitis C, Genotype 1",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","70 Years","549","December 2011","June 2014","Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"673","NCT01471886","Comparison Of Ketorolac Tromethamine Versus Naproxen For Moderate to Severe Back Pain Treatment","Back Pain",0,"Ketorolac Tromethamine","Drug","EMS","Industry",0,0,"All","18 Years","65 Years","78","June 2013","December 2013","Efficacy of treatment in back pain relief based on Visual Analog Scale (VAS).","0","0","0","0","0","0","0","0","0"
"674","NCT01471899","Comparison Of Ketorolac Tromethamine Oral Drops Versus Naproxen For Moderate to Severe Back Pain Treatment","Back Pain",0,"Ketorolac Tromethamine","Drug","EMS","Industry",0,0,"All","18 Years","65 Years","78","October 2013","June 2014","Efficacy of treatment in back pain relief based on Visual Analogic Score (VAS).","0","0","0","0","0","0","0","0","0"
"675","NCT01472185","Ranolazine Monotherapy in Subjects With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Ranolazine","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","75 Years","465","November 2011","October 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","< 0.0001","P-value is from a mixed effects model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.","Mixed Effects Model Analysis","-0.56","difference in least squares mean (LSM)","95","2-Sided","-0.76","-0.36"
"676","NCT01472614","Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus","Type-2 Diabetes Mellitus",0,"DLBS3233","Drug","Dexa Medica Group","Industry",0,0,"All","40 Years","70 Years","54","September 2011","January 2013","Reduction of A1c level","0","0","0","0","0","0","0","0","0"
"677","NCT01473407","A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin","Chronic Kidney Disease",0,"Epoetin Hospira","Biological","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","80 Years","612","November 2011","February 2014","Difference between treatments (Epoetin Hospira and Epogen [Amgen]) in mean weekly Hb level during the last 4 weeks of the double-blind Treatment Period (i.e., Week 21 to Week 24)","0","0","0","0","0","0","0","0","0"
"678","NCT01473420","A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin","Chronic Renal Failure",0,"Epoetin Hospira","Biological","Hospira, now a wholly owned subsidiary of Pfizer","Industry",0,0,"All","18 Years","80 Years","320","November 2011","February 2014","Difference between treatments (Epoetin Hospira and Epogen [Amgen]) in mean weekly Hb level during the last 4 weeks of the double-blind Maintenance Period","0","0","0","0","0","0","0","0","0"
"679","NCT01473524","Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis","Primary Biliary Cirrhosis",0,"Obeticholic Acid (OCA)","Drug","Intercept Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","217","January 2012","December 2013","Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg OCA vs. Placebo","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"680","NCT01473589","Effect of Teriparatide on Hip Fracture Healing","Femur Neck Fracture",0,"Teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"All","50 Years","N/A","122","February 2012","December 2013","Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture","0","0","0","0","0","0","0","0","0"
"681","NCT01473602","Second Study of the Effect of Teriparatide on Hip Fracture Healing","Femur Neck Fracture",0,"Teriparatide","Drug","Eli Lilly and Company","Industry",0,0,"All","50 Years","N/A","39","January 2012","November 2013","Percentage of Participants With No Revision Surgery at 12 Months After Internal Fixation of a Low-Trauma Femoral Neck Fracture","0","0","0","0","0","0","0","0","0"
"682","NCT01473875","Children With Lysosomal Acid Lipase Deficiency Who Previously Received Treatment With SBC-102","Lysosomal Acid Lipase Deficiency",0,"SBC-102","Drug","Alexion Pharmaceuticals","Industry",0,0,"All","N/A","N/A","10","November 2011","December 2014","Overall survival","0","0","0","0","0","0","0","0","0"
"683","NCT01474109","Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","Systemic Sclerosis",0,"macitentan 3mg","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","289","December 2011","November 2013","Incidence Rate of New Digital Ulcers (DUs) up to Week 16","0.706","0","negative binomial-2 regression (NB-2)","1.103","NB-2 estimate of new DUs per patient","95","2-Sided","0.663","1.834"
"684","NCT01474122","Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients","Digital Ulcers",0,"Macitentan 3 mg","Drug","Actelion","Industry",0,0,"All","18 Years","N/A","265","December 2011","February 2014","Incidence Rate of New Digital Ulcers (DUs) up to Week 16","0.434","0","negative binomial-2 regression (NB-2)","1.194","NB-2 estimate of new DUs per patient","95","2-Sided","0.766","1.861"
"685","NCT01474369","Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease","Non-erosive Gastroesophageal Reflux Disease",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","827","December 2011","February 2013","Percentage of symptom-free days of heartburn symptoms","0","0","0","0","0","0","0","0","0"
"686","NCT01474512","A Phase 3 Study in Participants With Moderate to Severe Psoriasis","Psoriasis",0,"80 mg Ixekizumab Dosing Regimens 1, 2, and 3","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1296","November 2011","June 2014","Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA)","<0.001","0","Regression, Logistic","0","0","0","0","0","0"
"687","NCT01474538","Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy","Type 2 Diabetes Mellitus",0,"Insulin Lispro","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","85 Years","122","December 2011","February 2013","Glycosylated Hemoglobin A1C (HbA1c) at Endpoint","0","0","0","0.10","LS Mean difference","95","2-Sided","-0.002","0.210"
"688","NCT01474590","Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne","Acne",0,"Epiduo/Tactuo + doxycycline 200mg","Drug","Galderma","Industry",0,0,"All","12 Years","35 Years","266","November 2011","July 2013","The primary outcome is overall success, a composite endpoint including efficacy and safety measurements","0","0","0","0","0","0","0","0","0"
"689","NCT01474772","Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)","Diabetic Peripheral Neuropathy",0,"Pregabalin","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","217","October 2011","July 2013","Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)","0.0659","Primary analysis was two-sided and performed at the 0.05 significance level. The study was considered positive only if both co-primary endpoints had p-values that were less than 0.05, hence there was no need for multiplicity adjustment.","Linear mixed effects model","-0.22","Mean Difference (Final Values)","95","2-Sided","-0.46","0.01"
"690","NCT01475266","Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)","Bladder Cancer",0,"EO9 (Apaziquone)","Drug","Nippon Kayaku Co.,Ltd.","Industry",0,0,"All","20 Years","N/A","51","November 2011","April 2013","The recurrence rate at 2 years in patients with histologically diagnosed stage Ta, grade G1 or G2 bladder cancer","0","0","0","0","0","0","0","0","0"
"691","NCT01475617","Efficacy of a Novel Multivitamin-Mineral Supplement in Preventing Vitamin Deficiency in Postoperative Bariatric Patients","Bariatric Surgery Candidate",0,"AquaVanta Chewable Tablet","Dietary Supplement","Yasoo Health","Industry",0,0,"All","18 Years","65 Years","61","November 2011","January 2014","Plasma vitamin and mineral levels","0","0","0","0","0","0","0","0","0"
"692","NCT01475669","Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery","Surgical Blood Loss",0,"Fibrinogen Concentrate (Human) (FCH)","Biological","CSL Behring","Industry",0,0,"All","18 Years","N/A","152","January 2012","July 2014","Total units of allogeneic blood products","0","0","0","0","0","0","0","0","0"
"693","NCT01475838","Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","Acquired Immunodeficiency Syndrome",0,"PI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","438","November 2011","November 2013","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","0.025","0","Fisher Exact","6.7","Difference in proportions","95","2-Sided","0.4","13.7"
"694","NCT01475851","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs","Hepatitis B, Chronic",0,"GSK548470 300 mg tablet","Drug","GlaxoSmithKline","Industry",0,0,"All","16 Years","69 Years","34","December 2011","June 2013","Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24","0","0","0","0","0","0","0","0","0"
"695","NCT01478347","A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults","Meningococcal Disease",0,"Recombinant meningococcal B + OMV NZ","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","65 Years","18","May 2013","March 2014","Number of Subjects Reporting Unsolicited Adverse Events, Following Vaccination With Two Injections of rMenB+OMV NZ Vaccine Between Day 1 Through Day 91.","0","0","0","0","0","0","0","0","0"
"696","NCT01478607","A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients","Painful Diabetic Peripheral Neuropathy (PDPN)",0,"QUTENZA","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","468","November 2011","February 2014","Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale","0","0","0","0","0","0","0","0","0"
"697","NCT01478971","Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis","Chronic Kidney Disease",0,"Epoetin","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","184","October 2011","February 2013","Percentage of Participants Undergoing Conversion to Peginesatide Injection","0","0","0","0","0","0","0","0","0"
"698","NCT01479530","Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China","Parkinson's Disease",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","30 Years","N/A","321","December 2011","June 2013","Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary","0.0228","0","ANCOVA","-0.50","Median Difference (Final Values)","95","2-Sided","-0.92","-0.07"
"699","NCT01479868","A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1","Hepatitis C Virus Genotype-1",0,"TMC435","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","70 Years","109","October 2011","August 2013","Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)","0","0","0","0","0","0","0","0","0"
"700","NCT01480245","Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy","Muscular Dystrophies",0,"GSK2402968","Drug","GlaxoSmithKline","Industry",0,0,"Male","5 Years","N/A","233","September 2011","March 2014","Differences between the 6MWD at baseline and Week 104","0","0","0","0","0","0","0","0","0"
"701","NCT01480258","Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","Bacterial Infections",0,"V419","Biological","MCM Vaccines B.V.","Industry",0,0,"All","46 Days","89 Days","1315","November 2011","October 2013","Number of responders to polyribosylribitol phosphate (PRP) antigen","0","0","0","0","0","0","0","0","0"
"702","NCT01480284","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue","Hepatitis B, Chronic",0,"GSK548470 300 mg tablet","Drug","GlaxoSmithKline","Industry",0,0,"All","16 Years","69 Years","166","November 2011","January 2013","Mean Change From Baseline in Serum HBV DNA Level at Week 24","<0.0001","p-value was compared with the significance level of 0.025","ANCOVA","-0.13","Mean Difference (Final Values)","95","2-Sided","-0.28","0.02"
"703","NCT01481116","Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"TAK-875","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","2454","January 2012","March 2014","Change From Baseline in HbA1c at Weeks 78 and 104","0","0","0","0","0","0","0","0","0"
"704","NCT01481779","A Study in Participants With Type 1 Diabetes Mellitus","Diabetes Mellitus, Type 1",0,"Glargine","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","450","January 2012","May 2013","Hemoglobin A1c (HbA1c) at 26 weeks","0","0","0","0","0","0","0","0","0"
"705","NCT01482364","BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem","Hypertension",0,"Integrated hemodynamic management (IHM) - HOTMAN System","Device","Hemo Sapiens, Inc.","Industry",0,0,"All","18 Years","75 Years","183","October 2011","June 2013","Absolute change in daytime SBP, under ambulatory conditions (ABPM) after a 6 months follow-up.","0","0","0","0","0","0","0","0","0"
"706","NCT01482910","VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)","Macular Degeneration",0,"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Biological","Bayer","Industry",0,0,"All","50 Years","N/A","304","December 2011","March 2014","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)","<0.0001","Hierarchical testing procedure was used in the order of pre-defined fixed sequence (primary endpoint first, then confirmatory secondary efficacy point next). A two-sided significance level of 0.05 was used.","ANCOVA","10.1","Mean Difference (Final Values)","95","2-Sided","6.8","13.4"
"707","NCT01483898","An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)","Critical Limb Ischemia",0,"Ixmyelocel-T","Biological","Vericel Corporation","Industry",0,0,"All","35 Years","90 Years","41","February 2012","April 2014","Amputation free survival (AFS) at 12 months post-injection","0","0","0","0","0","0","0","0","0"
"708","NCT01484977","eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam","Epilepsy",0,"Lacosamide","Drug","UCB Pharma","Industry",0,0,"All","18 Years","N/A","120","December 2011","December 2013","Retention at the End of the 21-week Treatment Period","0","0","0","73.3","Retention Rate","95","2-Sided","65.42","81.25"
"709","NCT01485640","Lurasidone Extended Use Study","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","N/A","N/A","162","June 2011","February 2014","Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs","0","0","0","0","0","0","0","0","0"
"710","NCT01485796","Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","Primary Immunodeficiency Disorders",0,"Immune Globulin Infusion (Human), 10%","Biological","Baxalta US Inc.","Industry",0,0,"All","2 Years","N/A","54","December 1, 2011","January 1, 2013","Number of Related Systemic Adverse Events (Excluding Infections)","0","0","0","0","0","0","0","0","0"
"711","NCT01485887","Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"Venlafaxine ER","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","50","January 2012","January 2014","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"712","NCT01485991","TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy","Hepatitis C",0,"TMC435","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","70 Years","771","February 2012","April 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","0.001","based on the asymptotic distribution of the generalized Cochran-Mantel-Haenszel statistic controlling for stratification factors, using a non-inferiority margin of 12 percent","Stratified Cochran-Mantel-Haenszel","-1.1","Difference in proportions","95","2-Sided","-7.8","5.5"
"713","NCT01488994","BAX 326 Pediatric Study","Hemophilia B",0,"BAX326","Biological","Baxalta US Inc.","Industry",0,0,"All","N/A","12 Years","23","December 2011","May 2013","Adverse Events (AEs) Possibly or Probably Related to BAX326","0","0","0","0","0","0","0","0","0"
"714","NCT01492426","Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","605","January 2012","December 2013","Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","0","0","0","4.3","Percentage difference","95","2-Sided","-3.3","11.9"
"715","NCT01492686","Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis","Amyotrophic Lateral Sclerosis (ALS)",0,"MCI-186","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","75 Years","137","December 2011","September 2014","Revised ALS functional rating scale (ALSFRS-R) scores","0","0","0","0","0","0","0","0","0"
"716","NCT01493245","A Study of JNS020QD in Patients With Chronic Pain","Chronic Pain",0,"JNS020QD","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","20 Years","N/A","77","October 2011","March 2013","Proportion of patients who maintained the adequate analgesia","0","0","0","0","0","0","0","0","0"
"717","NCT01493531","Combining Lesinurad With Allopurinol in Inadequate Responders","Gout",0,"Lesinurad","Drug","Ardea Biosciences, Inc.","Industry",0,0,"All","18 Years","85 Years","610","December 2011","May 2014","Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6.","<0.0001","0","Cochran-Mantel-Haenszel","0.32","Risk Difference (RD)","95","2-Sided","0.23","0.41"
"718","NCT01493687","Phase 3 Papulopustular Rosacea Study","Papulopustular Rosacea (PPR)",0,"CD5024","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","683","December 2011","July 2013","Success Rate","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"719","NCT01493947","CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study","Papulopustular Rosacea",0,"Ivermectin 1% cream","Drug","Galderma R&D","Industry",0,0,"All","18 Years","N/A","962","April 2012","December 2013","Percent Change in Inflammatory Lesions From Baseline to Week 16","0","0","0","0","0","0","0","0","0"
"720","NCT01493960","The Efficacy and Safety of Kappaproct in Chronic Active Treatment Refractory Ulcerative Colitis Patients","Colitis, Ulcerative",0,"Kappaproct","Drug","InDex Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","131","December 2011","June 2013","Clinical remission","0","0","0","0","0","0","0","0","0"
"721","NCT01494467","Phase 3 Papulopustular Rosacea Study","Papulopustular Rosacea",0,"CD5024","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","688","December 2011","August 2013","Success Rate","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"722","NCT01494506","Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer","Metastatic Pancreatic Cancer",0,"MM-398","Drug","Merrimack Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","417","November 2011","February 2014","Overall Survival","0.9416","0","Log Rank","0.99","Hazard Ratio (HR)","95","2-Sided","0.77","1.28"
"723","NCT01494987","Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Ranolazine","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","75 Years","431","January 2012","August 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","<0.001","P-value is from a mixed-effect model including terms for baseline HbA1c value, prior antihyperglycemia therapy, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.","Mixed Effects Model Analysis","-0.51","difference in least squares mean (LSM)","95","2-Sided","-0.71","-0.32"
"724","NCT01495000","A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab","Osteoporosis, Postmenopausal",0,"denosumab","Drug","GlaxoSmithKline","Industry",0,0,"Female","55 Years","75 Years","250","January 2012","February 2013","Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6","<0.0001","0","ANCOVA","3.05","Mean Difference (Final Values)","95","2-Sided","1.91","4.19"
"725","NCT01495013","A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"1mg Glimepiride/10mg Atorvastatin FDC","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","427","December 2011","April 2013","Non inferiority of glimepiride/atorvastatin compared with glimepiride + atorvastatin taken as separate tablets in reducing HbA1c levels","0","0","0","0","0","0","0","0","0"
"726","NCT01495702","Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","Acquired Immunodeficiency Syndrome",0,"NNRTI","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","439","December 2011","November 2013","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","0.066","0","Fisher Exact","5.3","Difference in proportions","95","2-Sided","-0.5","12.0"
"727","NCT01496274","A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","Hemophilia B",0,"rIX-FP","Biological","CSL Behring","Industry",0,0,"Male","12 Years","65 Years","63","February 2012","July 2014","Change in Frequency of Spontaneous Bleeding Events Between On-demand and Prophylaxis Treatments (Annualized)","<0.0001","P value is based on a Wilcoxon signed-rank test of H0: AsBR ratio (prophylaxis regimen/on-demand regimen) ≥ 0.50. The ratio was based on the original scale.","Wilcoxon signed-rank test","0","0","0","0","0","0"
"728","NCT01496430","Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes","Hypertension",0,"Placebo","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","105","January 2012","May 2013","Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure","0.007","Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.","ANCOVA","0","0","0","0","0","0"
"729","NCT01497197","A Trial to Compare the Efficacy and Safety of Ovarian Stimulation With GONAL-f® and Luveris® Starting on Day 1 Versus Day 6 in Women Undergoing Assisted Reproductive Technique","Infertility",0,"GONAL-f®","Drug","Merck KGaA","Industry",0,0,"Female","36 Years","42 Years","174","May 2012","January 2014","Total Number of Oocytes Retrieved Per Subject Following Ovarian Stimulation","0","0","0","0","0","0","0","0","0"
"730","NCT01497366","Phase 3 Study of Sofosbuvir and Ribavirin","Hepatitis C",0,"Sofosbuvir","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","527","December 2011","January 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Stopping All Study Drugs (SVR12)","0","0","0","0.3","Difference in percentages","95","2-Sided","-7.5","8.0"
"731","NCT01497834","A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients","Hepatitis C",0,"BMS-790052 (Daclatasvir)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","20 Years","75 Years","224","January 2012","April 2013","Antiviral activity, as determined by the proportion of subjects with SVR24","0","0","0","0","0","0","0","0","0"
"732","NCT01497938","Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature","Type 1 Diabetes",0,"Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature","Device","Medtronic Diabetes","Industry",0,0,"All","16 Years","70 Years","247","December 2011","June 2013","Change in A1C From Baseline to End of Study Participation","0","0","0","0.05","Mean Difference (Final Values)","97.5","1-Sided","0","0.15"
"733","NCT01498653","Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry","Asthma",0,"GW685698/GW642444","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","100 Years","313","January 2012","February 2013","Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period","<0.001","0","ANCOVA","28.5","Least Squares Mean Difference","95","2-Sided","20.1","36.9"
"734","NCT01498679","Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.","Asthma",0,"GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","100 Years","311","January 2012","July 2013","Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period","<0.001","0","ANCOVA","51.0","Least Squares Mean Difference","95","2-Sided","42.2","59.7"
"735","NCT01499095","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy","Type 2 Diabetes Mellitus",0,"Lantus (Insulin glargine)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","811","December 2011","April 2013","Change in HbA1c From Baseline to Month 6 Endpoint","0","0","0","-0.01","Least Squares (LS) Mean difference","95","2-Sided","-0.139","0.119"
"736","NCT01499849","Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","Chemotherapy-induced Nausea and Vomiting",0,"Rolapitant","Drug","Tesaro, Inc.","Industry",0,0,"All","18 Years","N/A","532","February 2012","May 2014","No Emetic Episodes and No Rescue Medication","<0.001","To control for multiplicity, analyses were performed hierarchically. For the CR delayed the threshold for statistical significance was 0.05; no further adjustment for multiplicity were required for the primary endpoint.","Cochran-Mantel-Haenszel","1.9","Odds Ratio (OR)","95","2-Sided","1.3","2.7"
"737","NCT01500083","Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia","Indolent Non-Hodgkin's Lymphoma",0,"Bendamustine at a dose of 100 mg/m2","Drug","Lundbeck Canada Inc.","Industry",0,0,"All","18 Years","N/A","90","March 2012","June 2013","Number of Adverse Events","0","0","0","0","0","0","0","0","0"
"738","NCT01500213","Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy","Chemotherapy-induced Nausea and Vomiting",0,"Rolapitant","Drug","Tesaro, Inc.","Industry",0,0,"All","18 Years","N/A","555","February 2012","March 2014","No Emetic Episodes and No Rescue Medication","0.043","To control for multiplicity, analyses were performed hierarchically. For the CR delayed the threshold for statistical significance was 0.05; no further adjustment for multiplicity were required for the primary endpoint.","Cochran-Mantel-Haenszel","1.4","Odds Ratio (OR)","95","2-Sided","1.0","2.1"
"739","NCT01500226","Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy","Chemotherapy-induced Nausea and Vomiting",0,"Rolapitant","Drug","Tesaro, Inc.","Industry",0,0,"All","18 Years","N/A","1369","February 2012","February 2014","No Emetic Episodes and No Rescue Medication","<0.001","To control for multiplicity, analyses were performed hierarchically. For the CR delayed the threshold for statistical significance was 0.05; no further adjustment for multiplicity were required for the primary endpoint.","Cochran-Mantel-Haenszel","1.6","Odds Ratio (OR)","95","2-Sided","1.2","2.0"
"740","NCT01500616","Telaprevir Open-Label Study in Co-Infected Patients","Hepatitis C, Chronic",0,"Telaprevir","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","70 Years","122","June 2012","August 2014","Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"741","NCT01501513","A Safety Study of 3 Different Bowel Cleansing Preparations","Colonoscopy",0,"PEG-3350 based bowel preparation","Drug","Braintree Laboratories","Industry",0,0,"All","18 Years","N/A","540","December 2011","April 2013","Frequency of adverse events","0","0","0","0","0","0","0","0","0"
"742","NCT01503021","Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis","End Stage Renal Disease",0,"SFP","Drug","Rockwell Medical Technologies, Inc.","Industry",0,0,"All","18 Years","N/A","718","November 2011","January 2014","Incidence of Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"743","NCT01505088","Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis","Anterior Uveitis",0,"40 mg/mL Dexamethasone phosphate ophthalmic solution","Drug","Eyegate Pharmaceuticals, Inc.","Industry",0,0,"All","12 Years","85 Years","193","December 2011","February 2013","Proportion of patients with with ACC count of zero at Day 14","0","0","0","0","0","0","0","0","0"
"744","NCT01505127","Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori","H. Pylori Infection",0,"TAK-438","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","650","January 2012","June 2013","H. pylori eradication rate 4 weeks after completion of first-line therapy","0","0","0","0","0","0","0","0","0"
"745","NCT01505426","A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients","Type II Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","171","November 2011","January 2013","Change in HbA1c from baseline to end of treatment","0","0","0","0","0","0","0","0","0"
"746","NCT01505985","Hip Fracture Surgery and Oral Nutritional Supplements","Hip Fracture",0,"Oral nutritional Supplement","Dietary Supplement","Nestlé","Industry",0,0,"All","70 Years","N/A","24","January 2012","September 2013","The Short Physical Performance Battery (SPPB)","0","0","0","0","0","0","0","0","0"
"747","NCT01506882","An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy","Epilepsy",0,"Levetiracetam (LEV)","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","16 Years","N/A","71","December 2011","October 2013","Percentage of Subjects in the Levetiracetam (LEV) 1000 mg/Day to 2000 mg/Day Group Who Are Seizure Free for 26 Consecutive Weeks of Treatment During the Evaluation Period","0","0","0","73.8","Percent","95","2-Sided","60.9","84.2"
"748","NCT01507831","Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","Hypercholesterolemia",0,"Placebo (for alirocumab)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","2341","January 2012","November 2014","Percentage of Participants Who Experienced Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"749","NCT01507857","An Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine","Hand, Foot and Mouth Disease",0,"400U /0.5ml EV71 vaccine","Biological","Sinovac Biotech Co., Ltd","Industry",0,0,"All","6 Months","35 Months","10077","January 2012","March 2013","The incidence rate of Hand, Foot and Mouth disease caused by EV71 within one year observation period after the second vaccination","0","0","0","0","0","0","0","0","0"
"750","NCT01507896","BAX 326 Surgery Study in Hemophilia B Patients","Hemophilia B",0,"Recombinant factor IX","Biological","Baxalta US Inc.","Industry",0,0,"All","12 Years","65 Years","30","December 2011","May 2014","Intraoperative Hemostatic Efficacy","0","0","0","0","0","0","0","0","0"
"751","NCT01508026","Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension","Stage 1 Hypertension",0,"Nebivolol and Valsartan 1","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","4161","January 2012","March 2013","Change in Sitting Diastolic Blood Pressure (DBP)","0","0","0","0","0","0","0","0","0"
"752","NCT01508702","Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors","Gout",0,"lesinurad","Drug","Ardea Biosciences, Inc.","Industry",0,0,"All","18 Years","85 Years","214","January 2012","October 2013","Number of Subjects With an sUA Level That is < 6.0 mg/dL","<0.0001","0","Cochran-Mantel-Haenszel","0.28","Risk Ratio (RR)","95","2-Sided","0.19","0.37"
"753","NCT01508936","Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma","Eosinophilic Asthma",0,"Reslizumab","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","65 Years","511","February 2012","August 2013","Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 16 in Full Analysis Set","0.2407","The interaction was tested at the significance level 0.10 using the FAS","Regression, Linear","0.3007","slope difference","0","2-Sided","0","0"
"754","NCT01509209","Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis","Vasomotor Rhinitis",0,"Pseudoephedrine / Levocetirizine","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","12 Years","75 Years","137","May 2011","April 2013","TVRSS(Total Vasomotor Rhinitis Symptom Score)","0","0","0","0","0","0","0","0","0"
"755","NCT01510158","Combining Lesinurad With Allopurinol in Inadequate Responders","Gout",0,"Lesinurad","Drug","Ardea Biosciences, Inc.","Industry",0,0,"All","18 Years","85 Years","607","January 2012","July 2014","Proportion of Subjects With an sUA Level That is < 6.0 mg/dL","<0.0001","0","Cochran-Mantel-Haenszel","0.26","Risk Difference (RD)","95","2-Sided","0.17","0.36"
"756","NCT01510769","Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat","Tophaceous Gout",0,"Lesinurad","Drug","Ardea Biosciences, Inc.","Industry",0,0,"All","18 Years","85 Years","330","January 2012","June 2014","Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6","0.1298","0","Cochran-Mantel-Haenszel","0.10","Risk Difference (RD)","95","2-Sided","-0.03","0.23"
"757","NCT01510912","Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain","Osteoarthritis",0,"Diclofenac","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","40 Years","N/A","602","January 2012","March 2013","Safety of Diclofenac 35 mg Capsules as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination","0","0","0","0","0","0","0","0","0"
"758","NCT01512108","Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","20 Years","N/A","363","January 2012","April 2013","Incidence of Treatment Emergent Adverse Events (AEs)","0","0","0","0","0","0","0","0","0"
"759","NCT01512446","Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy","Osteoporosis",0,"Alendronate","Drug","Evangelisches Krankenhaus Lutherhaus gGmbH","Industry",0,0,"All","60 Years","N/A","7000","January 2012","December 2014","Incidence of new osteoporotic fractures","0","0","0","0","0","0","0","0","0"
"760","NCT01512745","Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer","Advanced or Metastatic Gastric Cancer",0,"apatinib","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","267","January 2011","May 2013","Progression Free Survival(PFS)","0","0","0","0","0","0","0","0","0"
"761","NCT01512966","Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)","Macular Edema",0,"VEGF Trap-Eye (BAY86-5321)","Biological","Bayer","Industry",0,0,"All","18 Years","N/A","73","January 2012","September 2013","Adverse Event collection","0","0","0","0","0","0","0","0","0"
"762","NCT01513473","A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","1 Year","17 Years","350","January 2012","July 2013","Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%) at 26 Weeks (Analysed by Central Laboratory)","0","0","0","0","0","0","0","0","0"
"763","NCT01513759","A Prospective, Single-arm, Multi-center Trial of EkoSonic® Endovascular System and Activase for Treatment of Acute Pulmonary Embolism (PE).","Pulmonary Embolism",0,"recombinant tissue plasminogen activator","Drug","EKOS Corporation","Industry",0,0,"All","18 Years","N/A","150","May 2012","February 2013","RV to LV Diameter Ratio","0","0","0","0","0","0","0","0","0"
"764","NCT01513850","A Confirmatory Study of Hepabulin IV in HBsAg Positive Liver Transplantation Recipients","Hepatitis B",0,"Hepabulin IV","Drug","SK Chemicals Co.,Ltd.","Industry",0,0,"All","18 Years","64 Years","87","October 2010","March 2014","HBV(HBsAg) recurrence","0","0","0","0","0","0","0","0","0"
"765","NCT01513941","An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)","Chronic Hepatitis C",0,"Telaprevir","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","70 Years","163","April 2012","March 2014","Proportion of patients achieving undetectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels","0","0","0","0","0","0","0","0","0"
"766","NCT01515397","Comparison of Two Gelatine Solutions","Hypovolemia",0,"Gelofusine balanced","Drug","B. Braun Melsungen AG","Industry",0,0,"All","18 Years","90 Years","40","December 2011","January 2013","base excess [mmol/l]","0","0","0","0","0","0","0","0","0"
"767","NCT01515644","Study on the Effect of Inulin in Infant Formula on Gut Health","Healthy Infants",0,"Powder based infant formula","Other","PT. Sari Husada","Industry",0,0,"All","3 Months","4 Months","164","October 2011","February 2013","Difference between beneficial bacteria I level in stool at week 4 and week 8.","0","0","0","0","0","0","0","0","0"
"768","NCT01515826","VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","Cataracts",0,"Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","0","March 2014","October 2014","Percentage of patients with a score of 0 (<5 cells) for cells in the anterior chamber","0","0","0","0","0","0","0","0","0"
"769","NCT01516008","A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy","Hallux Valgus",0,"Tapentadol IR 50 mg","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","20 Years","80 Years","353","January 2012","February 2013","Sum of Pain Intensity Differences (SPID) Over 48 Hours","<0.001","P-value adjusted for multiple treatment group comparisons using the Hochberg method.","ANCOVA","76.35","Mean Difference (Net)","95","2-Sided","51.0","101.7"
"770","NCT01516424","Efficiency Study to Investigate Blonanserin in Treatment of Schizophrenia When Compared With Risperidone","Schizophrenia",0,"Blonanserin","Drug","Sumitomo Pharmaceutical (Suzhou) Co., Ltd.","Industry",0,0,"All","18 Years","64 Years","267","February 2012","February 2013","Mean change in PANSS total score","0","0","0","0","0","0","0","0","0"
"771","NCT01516736","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","Chemotherapy-induced Neutropenia",0,"LA-EP2006","Drug","Sandoz","Industry",0,0,"Female","18 Years","N/A","308","March 2012","December 2013","Mean duration of Grade 4 neutropenia during Cycle 1 of chemotherapy","0","0","0","0","0","0","0","0","0"
"772","NCT01516814","Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients","Pulmonary Embolism",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","40","February 2012","October 2013","Number of participants with newly onset of symptomatic venous thromboembolism (VTE)","0","0","0","0","0","0","0","0","0"
"773","NCT01516840","Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients","Deep Vein Thrombosis",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","20 Years","N/A","60","March 2012","December 2013","Number of participants with newly onset of symptomatic venous thromboembolism (VTE)","0","0","0","0","0","0","0","0","0"
"774","NCT01516879","Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","Hypercholesterolemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","905","January 2012","November 2013","Percent Change From Baseline in LDL-C at Week 52","<0.001","0","Repeated measures linear effects model","-56.97","LS Mean Treatment Difference","95","2-Sided","-61.08","-52.85"
"775","NCT01516970","Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","Human Immunodeficiency Virus (HIV)",0,"Darunavir/Ritonavir (DRV/r)","Drug","Janssen-Cilag G.m.b.H","Industry",0,0,"All","18 Years","N/A","312","November 2011","August 2013","Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP)","0.2434","The discontinuation rates were compared with a statistical test (Cochran-Mantel-Haenszel [CMH]-Test) with p-value: 0.2434","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"776","NCT01517334","Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)","Peri-Implantitis",0,"Minocycline HCl Microspheres","Drug","OraPharma","Industry",0,0,"All","21 Years","N/A","208","May 2012","September 2014","Change in mean Probing Depth of qualifying implant sites","0","0","0","0","0","0","0","0","0"
"777","NCT01517412","Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin","Type 2 Diabetes Mellitus",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","451","February 2012","May 2013","Change in HbA1c From Baseline to Week 24","0","0","0","0.09","Least square (LS) mean difference","95","2-Sided","-0.067","0.242"
"778","NCT01518348","Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents","Contact Dermatitis",0,"Patch Test","Biological","Allerderm","Industry",0,0,"All","6 Years","18 Years","0","December 2012","December 2013","Change in Frequency and characterization of positive reactions per allergen.","0","0","0","0","0","0","0","0","0"
"779","NCT01518517","GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia, in Relapse",0,"GRASPA","Drug","ERYtech Pharma","Industry",0,0,"All","1 Year","55 Years","80","December 2009","September 2014","efficacy and toxicity combined","0","0","0","0","0","0","0","0","0"
"780","NCT01519089","A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis","Psoriasis",0,"CP-690,550","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","95","March 2012","January 2014","Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16","0","0","0","0","0","0","0","0","0"
"781","NCT01519700","Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim","Chemotherapy Associated Neutropenia",0,"EP2006","Drug","Sandoz","Industry",0,0,"Female","18 Years","N/A","218","December 2011","June 2013","Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy","0","0","0","0.04","Mean Difference (Net)","97.5","1-Sided","-0.26","0"
"782","NCT01519791","A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis","Rheumatoid Arthritis",0,"Certolizumab Pegol","Biological","UCB Pharma SA","Industry",0,0,"All","18 Years","N/A","880","January 2012","July 2014","Percentage of Subjects in Sustained Remission at Week 52","<0.001","0","Regression, Logistic","2.283","Odds Ratio (OR)","95","2-Sided","1.503","3.468"
"783","NCT01520909","Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.","Idiopathic Thrombocytopenic Purpura",0,"Eltrombopag","Drug","GlaxoSmithKline","Industry",0,0,"All","1 Year","17 Years","92","March 2012","January 2014","Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1","<0.001","0","Cochran-Mantel-Haenszel","17.96","Odds Ratio (OR)","95","2-Sided","2.29","140.93"
"784","NCT01521559","Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","Branch Retinal Vein Occlusion",0,"Macular Laser Photocoagulation","Procedure","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","183","April 2012","August 2013","Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF","0.0003","P-value was calculated using 2-sided Cochran-Mantel-Haenszel test adjusted by regions (Japan vs North America) and baseline Best Corrected Visual Acuity (BCVA ≤20/200 and BCVA >20/200).","Cochran-Mantel-Haenszel","26.6","Mean Difference (Net)","95","2-Sided","13.0","40.1"
"785","NCT01522443","Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer","Prostate Cancer",0,"cabozantinib","Drug","Exelixis","Industry",0,0,"Male","18 Years","N/A","119","March 2012","October 2014","Confirmed pain response at Week 12 durable since Week 6","0","0","0","0","0","0","0","0","0"
"786","NCT01524289","Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)","Hyperlipoproteinemia Type II",0,"Anacetrapib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","306","February 2012","February 2014","Percent Change from Baseline in Low Density Lipoprotein Cholesterol (LDL-C)(beta quantification method)","0","0","0","0","0","0","0","0","0"
"787","NCT01524497","A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression","Depression",0,"Trazodone","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Years","65 Years","382","November 2011","August 2013","Change in Hamilton Depression Rating Scale-17 score","0","0","0","0","0","0","0","0","0"
"788","NCT01524783","Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)","Advanced NET of GI Origin",0,"Everolimus","Drug","Novartis Pharmaceuticals","Industry",1,0,"All","18 Years","N/A","302","March 30, 2012","November 28, 2014","Progression Free Survival (PFS) Based on Central Radiology Assessment Per Kaplan-Meier","<0.001","0","Log Rank","0.48","Hazard Ratio (HR)","95","2-Sided","0.35","0.67"
"789","NCT01524887","Phase 3 IGIV, 10% in Alzheimer´s Disease","Alzheimer´s Disease",0,"Immune Globulin Intravenous (Human), 10% Solution","Biological","Baxalta US Inc.","Industry",0,0,"All","50 Years","89 Years","508","January 2012","July 2013","Change From Baseline to Month 18 in Cognitive Subscale of the Alzheimer´s Disease Assessment Scale (ADAS-Cog)","0.243","0","Mixed Models Analysis","1.4","Difference in least square means","95","0","-1.0","3.9"
"790","NCT01527110","A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection","Influenza, Human",0,"Intravenous (IV) zanamivir","Drug","GlaxoSmithKline","Industry",0,0,"All","16 Years","N/A","21","January 2012","March 2013","Incidence of AE","0","0","0","0","0","0","0","0","0"
"791","NCT01527357","Phase 3 Study of Fibrocaps™ in Surgical Bleeding","Mild or Moderate Surgical Bleeding",0,"Fibrocaps (PRO-0601)","Biological","Mallinckrodt","Industry",0,0,"All","18 Years","N/A","719","May 2012","April 2013","Time to Hemostasis (TTH)","0","0","0","0","0","0","0","0","0"
"792","NCT01527370","Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","Herpes Zoster",0,"Zoster Vaccine Live","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","50 Years","N/A","250","October 2012","April 2013","The Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody at 6 Weeks Postvaccination","0","0","0","0","0","0","0","0","0"
"793","NCT01528449","Babesia Testing in Blood Donors","Transfusion Transmitted Babesiosis",0,"B.microti diagnostic blood tests","Biological","Imugen","Industry",0,0,"All","16 Years","N/A","90116","December 2011","September 2014","number of blood donors testing positive for evidence of Babesia infection","0","0","0","0","0","0","0","0","0"
"794","NCT01529203","Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range","Aging",0,"Botulinum Toxin Type A (Azzalure)","Drug","Galderma","Industry",0,0,"All","18 Years","64 Years","60","February 2012","April 2013","Subject Satisfaction for the Full Face","0","0","0","0","0","0","0","0","0"
"795","NCT01529229","Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment","Allergic Rhinitis",0,"Dexchlorpheniramine + Betamethasone","Drug","EMS","Industry",0,0,"All","2 Years","11 Years","210","November 2013","October 2014","Efficacy of treatment in persistent allergic rhinitis based on nasal symptoms score","0","0","0","0","0","0","0","0","0"
"796","NCT01529515","A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia","Schizophrenia",0,"PP3M 175 mg eq.","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","70 Years","509","May 2012","April 2014","Time to Relapse During the Double-Blind Phase","0","0","0","0","0","0","0","0","0"
"797","NCT01529541","Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone","Type 2 Diabetes Mellitus",0,"Anagliptin","Drug","JW Pharmaceutical","Industry",0,0,"All","19 Years","75 Years","200","May 2011","May 2013","The Change in HbA1c from baseline to week24.","0","0","0","0","0","0","0","0","0"
"798","NCT01530763","Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)","Infections",0,"Ceftaroline fosamil","Drug","Forest Laboratories","Industry",0,0,"All","2 Months","18 Years","161","September 2012","April 2014","Evaluate the safety and tolerability of ceftaroline versus ceftriaxone in pediatric subjects age 2 months to <18 years with CABP requiring hospitalization","0","0","0","0","0","0","0","0","0"
"799","NCT01532414","Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism","Secondary Hypogonadism",0,"Androxal","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","151","August 2012","March 2013","Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range","0","0","0","0","0","0","0","0","0"
"800","NCT01532453","Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients","Actinic Keratoses",0,"MD-3511356","Device","Spirig Pharma Ltd.","Industry",0,0,"All","40 Years","N/A","244","November 2010","January 2014","Number of New Clinically Diagnosed Actinic Keratoses or Squamous Cell Carcinomas","0.0278","Rank ANCOVA With treatment, center, gender, transplanted organ as factors and age of organ transplant as a covariable.","ANCOVA","0","0","0","0","0","0"
"801","NCT01532570","Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions","Behcet's Disease",0,"TA-650","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","16 Years","75 Years","18","January 2012","May 2014","Percentage of Participants With Complete Response at Week 30","0","0","0","0","0","0","0","0","0"
"802","NCT01532648","Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).","Ulcerative Colitis",0,"Budesonide","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","75 Years","509","February 2012","July 2013","The induction of Clinical remission in patients with active, mild or moderate ulcerative colitis (UC) after 8 weeks of study therapy.","0","0","0","0","0","0","0","0","0"
"803","NCT01532869","A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis","Sclerosis, Systemic",0,"Placebo","Drug","Hoffmann-La Roche","Industry",0,0,"All","18 Years","N/A","87","March 2012","January 2014","Change From Baseline in Modified Rodnan Skin Score (mRSS) at Week 24","0.0915","0","Mixed Models Analysis","-2.70","Difference in Least Square (LS) mean","95","2-Sided","-5.85","0.45"
"804","NCT01532882","Efficacy and Safety of Diosmin 600mg Versus Placebo on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs","Chronic Venous Disease of Lower Limbs",0,"Diosmin","Drug","Laboratoire Innotech International","Industry",0,0,"All","18 Years","N/A","378","January 2012","March 2013","Change of Visual analog Scale score for assessment of the painful venous symptomatology","0","0","0","0","0","0","0","0","0"
"805","NCT01533220","Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal","Flu",0,"naphazoline hydrocloride","Drug","EMS","Industry",0,0,"All","12 Years","N/A","212","June 2013","October 2013","Efficacy of treatment in nasal congestion reduction based on Peak Flow Nasal Inspiratory (PFNI) assay","0","0","0","0","0","0","0","0","0"
"806","NCT01533428","A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)","Diabetic Peripheral Neuropathy",0,"Capsaicin 8%","Drug","Astellas Pharma Inc","Industry",0,0,"All","18 Years","N/A","369","February 2012","February 2014","Percent Change in the Average Daily Pain Score From Baseline to Between Weeks 2 and 8","0.025","0","ANCOVA","-6.6","LS Mean Difference","95","2-Sided","-12.3","-0.8"
"807","NCT01534208","Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism","Secondary Hypogonadism",0,"Androxal","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","65 Years","499","May 2012","October 2013","Change From Baseline in Total Morning Testosterone at 26 Weeks","0","0","0","0","0","0","0","0","0"
"808","NCT01534351","Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)","Benign Prostatic Hyperplasia",0,"Finasteride","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Male","50 Years","N/A","1","August 2013","November 2013","Change From Baseline in International Prostate Symptom Score (IPSS)","0","0","0","0","0","0","0","0","0"
"809","NCT01535014","Clinical Trial of Safety and Efficiency of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients","Obesity",0,"Dietressa","Drug","Materia Medica Holding","Industry",0,0,"All","18 Years","65 Years","493","December 2011","June 2013","Proportion of patients with body weight reduction by 5 percent and more after 24 weeks of treatment","0","0","0","0","0","0","0","0","0"
"810","NCT01535599","Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","Acute Otitis Externa",0,"AL-60371, 0.3% Otic Suspension","Drug","Alcon Research","Industry",0,0,"All","6 Months","N/A","768","March 2012","May 2013","Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit","0","0","0","0","0","0","0","0","0"
"811","NCT01536015","Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction","Advanced Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","30 Years","N/A","25","January 2012","October 2013","Change in Rotigotine Versus Placebo in the Absolute Time Spent ""Off"" From Baseline to the End of the 7-week Maintenance Period","0","0","0","0","0","0","0","0","0"
"812","NCT01536405","Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)","Measles",0,"MMRV (AMP)","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Months","23 Months","1412","June 2012","July 2013","Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 gpELISA Units/mL","<0.001","0","Miettinen and Nurminen","4.2","Risk Difference (RD)","95","2-Sided","1.8","6.8"
"813","NCT01536418","An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease","Crohn's Disease",0,"GSK1605786A","Drug","GlaxoSmithKline","Industry",1,0,"All","18 Years","N/A","255","November 11, 2011","October 17, 2013","Percentage of participants achieving clinical response at Week 12","0","0","0","0","0","0","0","0","0"
"814","NCT01537042","A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis","Restless Legs Syndrome",0,"Rotigotine","Drug","UCB BIOSCIENCES GmbH","Industry",0,0,"All","18 Years","85 Years","30","April 2012","October 2013","Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)","0.0232","0","ANCOVA","0.44","Treatment Ratio","95","2-Sided","0.22","0.88"
"815","NCT01538225","Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity","Multiple Sclerosis",0,"Sativex®","Drug","Almirall, S.A.","Industry",0,0,"All","18 Years","N/A","45","April 2012","November 2013","H/M reflex ratio","0","0","0","0","0","0","0","0","0"
"816","NCT01538251","Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis","Ulcerative Colitis",0,"Propionyl-L-Carnitine","Drug","sigma-tau i.f.r. S.p.A.","Industry",0,0,"All","18 Years","75 Years","147","April 2012","October 2013","Proportion of clinical/endoscopic remissions","0","0","0","0","0","0","0","0","0"
"817","NCT01538628","SpaceOAR System Pivotal Study","Prostate Cancer",0,"SpaceOAR System","Device","Augmenix, Inc.","Industry",0,0,"Male","18 Years","N/A","222","January 2012","July 2014","Proportion of subjects achieving a reduction of 25% or greater in percent volume of the rectum receiving at least 70 Gy measured from CT scans acquired pre and post SpaceOAR hydrogel injection","0","0","0","0","0","0","0","0","0"
"818","NCT01539200","Effects of Daily Nutritional Supplementation in Combination With a Eurhythmics Training (NUDAL)","Improvement of Functionality",0,"ONS+JDR","Dietary Supplement","Nestlé","Industry",0,0,"All","65 Years","N/A","80","March 2012","January 2014","Normal walking velocity","0","0","0","0","0","0","0","0","0"
"819","NCT01539512","A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)","Chronic Lymphocytic Leukemia",0,"Idelalisib","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","220","April 2012","October 2013","Progression-Free Survival","< 0.0001","0","Log Rank","0.18","Hazard Ratio (HR)","95","2-Sided","0.10","0.32"
"820","NCT01539564","Arestin - Use in Subjects With Peri-Implantitis","Peri-Implantitis",0,"Minocycline HCl Microspheres","Drug","OraPharma","Industry",0,0,"All","21 Years","N/A","215","April 2012","May 2014","Change in mean Probing Depth of qualifying implant sites","0","0","0","0","0","0","0","0","0"
"821","NCT01539642","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery","Post-Operative Pain",0,"Sufentanil NanoTab PCA System/15 mcg","Drug","AcelRx Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","172","February 2012","January 2013","Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID-48).","0.001","0","ANCOVA","50.02","Mean Difference (Final Values)","95","2-Sided","19.89","80.14"
"822","NCT01541202","Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients","Chronic Heart Failure",0,"rhNRG-1","Drug","Zensun Sci. & Tech. Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","1600","February 2012","June 2013","All-cause mortality","0","0","0","0","0","0","0","0","0"
"823","NCT01541254","Feasibility Study of the LVIS™ (Low-profile Visualized Intraluminal Support)Device","Intracranial Aneurysms",0,"Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)","Device","Microvention-Terumo, Inc.","Industry",0,0,"All","18 Years","80 Years","30","March 2012","June 2013","Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks)","0","0","0","0","0","0","0","0","0"
"824","NCT01541553","A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp","Actinic Keratosis",0,"Cryotherapy","Procedure","LEO Pharma","Industry",0,0,"All","18 Years","N/A","367","March 2012","July 2013","Complete Clearance of AKs at Week 11","0","0","0","0","0","0","0","0","0"
"825","NCT01541774","Endovascular Atherectomy Safety and Effectiveness Study","Peripheral Vascular Disease",0,"Phoenix Atherectomy System","Device","AtheroMed, Inc","Industry",0,0,"All","18 Years","N/A","128","August 2010","April 2013","Safety: Freedom from Major Adverse Events","0","0","0","0","0","0","0","0","0"
"826","NCT01541943","Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia","Essential Hypertension",0,"Atorvastatin","Drug","HanAll BioPharma Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","356","March 2012","November 2014","Change from baseline to 8 week in SiDBP (Sitting Diastolic Blood Pressure)","0","0","0","0","0","0","0","0","0"
"827","NCT01542034","Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","Moderate or Severe Submental Fullness",0,"Deoxycholic acid injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","506","February 2012","May 2013","Percentage of Participants Who Achieved a Composite 1-grade Response","<0.001","0","Cochran-Mantel-Haenszel","3.702","Risk Ratio (RR)","95","2-Sided","2.808","4.880"
"828","NCT01542814","Collection of FUJIFILM's 3Dimensional Mammograms","Breast Cancer",0,"3Dimensional Mammography","Device","Fujifilm Medical Systems USA, Inc.","Industry",0,0,"Female","40 Years","N/A","600","February 2012","June 2013","Acquire screening cases with and without breast cancer.","0","0","0","0","0","0","0","0","0"
"829","NCT01543178","Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study","Irritable Bowel Syndrome With Diarrhea",0,"open-label rifaximin","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","18 Years","N/A","2583","February 2012","June 2014","Repeat Treatment Responders","0.0232","The a priori threshold for statistical significance was p < 0.05.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"830","NCT01544179","A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone","Non-Small Cell Lung Cancer",0,"Gefitinib","Drug","AstraZeneca","Industry",0,0,"All","18 Years","130 Years","287","March 15, 2012","May 5, 2014","Progression-Free Survival (Site Read, Investigator Assessment)","0.273","0","Cox Proportional Hazards","0.86","Hazard Ratio (HR)","95","2-Sided","0.65","1.13"
"831","NCT01545388","Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","74 Years","337","February 23, 2012","March 12, 2013","Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)","<0.001","0","cLDA","-0.678","Difference in least squares means","95","2-Sided","-0.868","-0.489"
"832","NCT01546142","Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area","Moderate or Severe Submental Fullness",0,"Deoxycholic acid injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","516","March 2012","May 2013","Percentage of Participants Who Achieved a Composite 1-grade Response","<0.001","0","Cochran-Mantel-Haenszel","2.983","Risk Ratio (RR)","95","2-Sided","2.311","3.849"
"833","NCT01546623","A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy","Prostate Cancer",0,"TAP-144-SR(6M)","Drug","Takeda","Industry",0,0,"Male","20 Years","85 Years","160","March 2012","April 2014","The Rate of Suppression of Serum Testosterone to Castrate Level","0","0","0","0","0","0","0","0","0"
"834","NCT01547715","Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India","Bacterial Meningitis",0,"Meningococcal ACWY conjugate vaccine","Biological","Novartis","Industry",0,0,"All","2 Years","75 Years","180","March 2012","April 2014","Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse Against N.Meningitidis Serogroup A.","0","0","0","0","0","0","0","0","0"
"835","NCT01549847","A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome","Postpoliomyelitis Syndrome",0,"L-carnitine and piracetam","Drug","Biolab Sanus Farmaceutica","Industry",0,0,"All","18 Years","60 Years","0",NA,"February 2013","Changes in Muscle Weakness","0","0","0","0","0","0","0","0","0"
"836","NCT01549964","Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes","Glycemic Control",0,"Fasiglifam (TAK-875)","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","916","April 2012","March 2014","Change From Baseline in Glycosylated Hemoglobin (HbA1c)","<0.001","MMRM model with treatment, country, schedule, visit and visit by treatment interaction as fixed factors and with baseline value and baseline value by visit interaction as covariates with an unstructured covariance structure.","Mixed model for repeated measurements","-0.55","LS Mean Difference","95","2-Sided","-0.77","-0.34"
"837","NCT01551069","Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion","Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus",0,"hydroxychloroquine (Z0188)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","103","March 2012","December 2013","A change in CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) activity score","0","0","0","0","0","0","0","0","0"
"838","NCT01551290","A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis","Ulcerative Colitis",0,"Infliximab","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"All","18 Years","65 Years","99","April 2012","March 2014","Number of participants with a clinical response at Week 8","0","0","0","0","0","0","0","0","0"
"839","NCT01552057","A Study of Duloxetine in Fibromyalgia","Fibromyalgia",0,"Duloxetine 60 mg","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","74 Years","393","March 2012","December 2013","Change From Baseline to 14-Week Endpoint in the BPI 24-Hour Average Pain Severity Item of the BPI-Modified Short Form Score (MMRM)","0.0988","Statistical tests were conducted at a 2-sided alpha level of 0.05.","MMRM","-0.32","Mean Difference (Final Values)","95","2-Sided","-0.70","0.06"
"840","NCT01553123","Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma","Leiomyomas",0,"Ulipristal Acetate","Drug","Watson Pharmaceuticals","Industry",0,0,"Female","18 Years","50 Years","0","April 2012","November 2013","Change from baseline in hemoglobin levels (g/dL)","0","0","0","0","0","0","0","0","0"
"841","NCT01553279","Immunogenicity and Safety of V419 Given at 2, 3 and 4 Months of Age With Meningococcal Serogroup C Conjugate Vaccines","Neisseria Meningitidis",0,"V419 (PR5I)","Biological","MCM Vaccines B.V.","Industry",0,0,"All","46 Days","74 Days","284","March 2012","September 2013","Meningococcal serogroup C seroprotection rate","0","0","0","0","0","0","0","0","0"
"842","NCT01553591","Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3001)","Irritable Bowel Syndrome",0,"JNJ-27018966","Drug","Furiex Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","80 Years","1282","May 2012","January 2014","Composite response based on improvements from baseline in daily abdominal pain and daily stool consistency scores.","0","0","0","0","0","0","0","0","0"
"843","NCT01553747","Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d) (Protocol JNJ-27018966IBS3002)","Irritable Bowel Syndrome",0,"JNJ-27018966","Drug","Furiex Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","80 Years","1150","May 2012","January 2014","Composite response based on improvements from baseline in daily abdominal pain and daily stool consistency scores.","0","0","0","0","0","0","0","0","0"
"844","NCT01554163","Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","Osteoarthritis of the Knee",0,"Etoricoxib 30 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","40 Years","N/A","239","March 2012","March 2013","Time-Weighted Mean Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale","0.390","0","ANCOVA","-1.63","Difference in LS Mean Change","95","2-Sided","-5.37","2.10"
"845","NCT01554709","Safety and Performance Study of the CardioGard Cannula","Aortic Valve Replacement",0,"Aortic Cannulas (CardioGard)","Device","CardioGard Medical Ltd.","Industry",0,0,"All","50 Years","85 Years","71","March 2012","December 2013","DWI- Diffusion Weighted Imaging","0","0","0","0","0","0","0","0","0"
"846","NCT01554956","Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients","Ligneous Conjunctivitis",0,"Human Plasminogen","Biological","Kedrion S.p.A.","Industry",0,0,"All","N/A","N/A","12","September 2012","April 2014","Number of eyes with recurrent ligneous membranes after initially showing total regression after treatment or after surgical excision.","0","0","0","0","0","0","0","0","0"
"847","NCT01554982","A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis","End Stage Renal Disease",0,"ferric citrate","Drug","Keryx Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","168","August 2012","June 2014","Safety Parameters","0","0","0","0","0","0","0","0","0"
"848","NCT01555164","A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone","Type 2 Diabetes Mellitus",0,"Ranolazine","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","75 Years","442","June 2012","September 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0.306","P-value from a mixed-effect model including terms for baseline HbA1c value, treatment group, visit week, and treatment by visit week interaction. Unstructured covariance matrix was used.","Mixed Effects Model Analysis","-0.11","difference in least squares mean (LSM)","95","2-Sided","-0.31","0.10"
"849","NCT01555333","An Open Label Extension Study in Subjects With Fragile X Syndrome","Fragile X Syndrome",0,"arbaclofen","Drug","Seaside Therapeutics, Inc.","Industry",0,0,"All","5 Years","50 Years","357","November 2011","July 2013","Safety Measures","0","0","0","0","0","0","0","0","0"
"850","NCT01556165","Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China","Parkinson's Disease",0,"rasagiline","Drug","H. Lundbeck A/S","Industry",0,0,"All","35 Years","N/A","130","April 2012","December 2013","Change From Baseline to Week 26 in UPDRS Total Score","0.0254","No adjustments for multiple comparisons were made.","ANCOVA","-3.00","Mean Difference (Final Values)","75","2-Sided","-4.53","-1.47"
"851","NCT01556997","Perindopril Amlodipine for the Treatment of Hypertension","Essential Hypertension",0,"XOMA 985","Drug","Symplmed Pharmaceuticals LLC","Industry",0,0,"All","18 Years","75 Years","837","February 2012","February 2013","Change From Baseline to End of Treatment in the Mean Seated Trough Cuff Diastolic Blood Pressure (DBP).","0.025","The statistical model was an analysis of covariance model with treatment as the main effect and baseline DBP (<100 mmHg versus ≥100 mmHg), current type 2 diabetes status (yes versus no), and race (black versus non-black) as covariates.","ANCOVA","0","0","0","0","0","0"
"852","NCT01557166","Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea","Metabolism and Nutrition Disorder",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","64 Years","359","June 7, 2012","June 1, 2013","Change From Baseline in Apnoea-hypopnoea Index (AHI)","0.015","0","ANCOVA","-6.10","Estimated treatment difference","95","0","-11.0","-1.19"
"853","NCT01558271","A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","492","March 2012","October 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","<0.001","0","Mixed Models Analysis","-1.57","LS Mean Difference","95","2-Sided","-1.79","-1.35"
"854","NCT01558466","Sildenofil in Persistent Pulmonary Hypertension in Newborns","Persistent Fetal Circulation Syndrome",0,"Sildenafil","Drug","Hamad Medical Corporation","Industry",0,0,"All","36 Weeks","41 Weeks","100","November 2011","November 2014","Oxygen index","0","0","0","0","0","0","0","0","0"
"855","NCT01559922","Use of Artefill® for Moderate to Severe Atrophic Acne Scar Correction","Atrophic Acne Scar",0,"Normal Saline","Drug","Suneva Medical, Inc.","Industry",0,0,"All","18 Years","N/A","175","February 2012","April 2013","ASRS Responder Rate at 6 Months","0","0","0","0","0","0","0","0","0"
"856","NCT01560195","A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy","NSCLC",0,"Pegylated rhG-CSF: 100µg/kg","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","150","April 2012","January 2013","Rate of grade 3/4 neutropenia in cycle 1","0","0","0","0","0","0","0","0","0"
"857","NCT01560403","A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021","Short Bowel Syndrome",0,"Teduglutide","Drug","Shire","Industry",0,0,"All","18 Years","N/A","14","May 2012","August 2013","Summary of Treatment-emergent Adverse Events","0","0","0","0","0","0","0","0","0"
"858","NCT01563367","A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof","Non-anaemic Patients Undergoing Cardiac Surgery",0,"Iron isomaltoside 1000 (Monofer®)","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","74","January 2012","August 2013","Change in haemoglobin (Hb) concentrations","0","0","0","0","0","0","0","0","0"
"859","NCT01564537","A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma","Relapsed Multiple Myeloma",0,"Ixazomib","Drug","Millennium Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","722","August 2012","October 2014","Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)","0.012","0","Log Rank","0.742","Hazard Ratio (HR)","95","2-Sided","0.587","0.939"
"860","NCT01565707","A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug","Urinary Bladder, Overactive",0,"Solifenacin Succinate Suspension","Drug","Astellas Pharma Europe B.V.","Industry",0,0,"All","5 Years","17 Years","189","June 2012","December 2013","Change From Baseline to End of Treatment (EoT) in Mean Volume Voided (MVV) Per Micturition","0.046","0","ANCOVA","12.1","Adjusted Mean Difference","95","2-Sided","0.2","24.0"
"861","NCT01566162","A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","N/A","191","April 2012","November 2013","Safety - Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation, and Serious AEs (SAEs)","0","0","0","0","0","0","0","0","0"
"862","NCT01567735","A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients","Hepatitis C",0,"TMC435","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","70 Years","107","March 27, 2012","March 20, 2014","Proportion of participants achieving sustained virologic response 12 weeks after planned end of treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"863","NCT01567956","Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study","Ulcerative Colitis",0,"Propionyl-L-Carnitine","Drug","sigma-tau i.f.r. S.p.A.","Industry",0,0,"All","18 Years","75 Years","150","April 2012","October 2013","Proportion of clinical/endoscopic remissions","0","0","0","0","0","0","0","0","0"
"864","NCT01568073","Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With ""Wearing-off"" Phenomenon","Parkinson's Disease",0,"BIA 9-1067","Drug","Bial - Portela C S.A.","Industry",0,0,"All","30 Years","83 Years","600","March 2011","November 2013","Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,","0","0","0","0","0","0","0","0","0"
"865","NCT01568593","Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome","Dry Eye Syndromes",0,"T2750","Device","Laboratoires Thea","Industry",0,0,"All","18 Years","N/A","93","March 2012","March 2013","Global Ocular Staining (With Oxford Scale - Ranges :0-15)","0","0","0","0","0","0","0","0","0"
"866","NCT01568866","Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients","Multiple Myeloma",0,"Carfilzomib","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","929","June 2012","November 2014","Progression Free Survival","< 0.0001","0","Stratified Log Rank","0.533","Hazard Ratio (HR)","95","2-Sided","0.437","0.651"
"867","NCT01569464","Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)","Restless Legs Syndrome",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","18 Years","75 Years","150","March 2012","April 2013","Change From Baseline To The End Of The Maintenance Period in International Restless Legs Scale (IRLS) Sum Score","0.8451","A hierarchical test procedure was done for the primary efficacy variables at an α-level of 5 %. If a test was statistically significant, a test for the next variable was performed. If a test was not statistically significant the procedure stopped.","ANCOVA","-0.27","LS Mean","95","2-Sided","-2.96","2.42"
"868","NCT01570478","A Study in Patients With Asthma","Asthma",0,"Foster® NEXThaler® 100/6 µg/unit dose","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","N/A","108","July 2012","February 2014","Change from baseline to end of treatment in post-dose peripheral airway resistance [R(5Hz)-R(20Hz)].","0","0","0","0","0","0","0","0","0"
"869","NCT01570751","A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","145","April 2012","January 2014","Change From Baseline (Visit 18) in Glycosylated Haemoglobin (HbA1c) at the End of Each 16 Week Treatment Period","0","0","0","0","0","0","0","0","0"
"870","NCT01570829","Clinical Trial of Safety and Efficiency of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients","Obesity",0,"Dietressa","Drug","Materia Medica Holding","Industry",0,0,"All","18 Years","65 Years","332","December 2011","June 2013","Proportion of patients with body weight reduction by 5 percent and more after 24 weeks of treatment","0","0","0","0","0","0","0","0","0"
"871","NCT01571219","An Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patient With Rheumatoid Arthritis Who Were Treated With Infliximab (Remicade or CT-P13) in Study CT-P13 3.1","Rheumatoid Arthritis",0,"Infliximab","Biological","Celltrion","Industry",0,0,"All","18 Years","75 Years","302","March 2012","July 2013","Long term efficacy evaluated by American College of Rheumatology(ACR) criteria and Long term safety evaluated by immunogenicity and clinical laboratory test","0","0","0","0","0","0","0","0","0"
"872","NCT01571362","A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain","Chronic Pain",0,"ALO-02","Drug","Pfizer","Industry",1,0,"All","18 Years","N/A","410","June 2012","June 2013","Change in Weekly Average Electronic Diary (eDiary) Numeric Rating Scale -Pain (NRS-Pain) Score From Randomization Baseline to Final 2 Weeks (Average of Weeks 11 and 12)","0.0114","No adjustment was made for multiple comparisons. Statistical significance was if unadjusted p was less than or equal to (<=) 0.05.","ANCOVA","-0.62","Difference of LS Means","95","2-Sided","-1.11","-0.14"
"873","NCT01571453","Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries","Major Depressive Disorder",0,"Vortioxetine (Lu AA21004)","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","437","May 2012","October 2013","Change From Baseline in MADRS Total Score at Week 8","0.199","No adjustments for multiple comparisons were made.","ANCOVA","-1.20","Mean Difference (Final Values)","95","0","-3.03","0.63"
"874","NCT01571583","An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation","Chronic Hepatitis C Virus (HCV) Infection",0,"Telaprevir","Drug","Janssen-Cilag International NV","Industry",0,0,"All","18 Years","70 Years","74","February 2012","April 2014","Number of patients achieving sustained virologic response (SVR) 12 planned","0","0","0","0","0","0","0","0","0"
"875","NCT01572792","Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","921","April 2012","June 2013","Percentage of Patients to Experience Any Treatment-emergent Adverse Event","0","0","0","0","0","0","0","0","0"
"876","NCT01573351","Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)","Hepatitis C Virus",0,"Asunaprevir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","398","May 2012","September 2013","Proportion of genotype 1 subjects with SVR12, defined as HCV RNA < LOQ at post-treatment Week 12, for all subjects infected with HCV genotype 1","0","0","0","0","0","0","0","0","0"
"877","NCT01573910","An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","Bacterial Conjunctivitis",0,"Moxifloxacin ophthalmic solution, 0.5%","Drug","Alcon Research","Industry",0,0,"All","1 Year","N/A","985","May 2012","April 2014","Clinical Cure Rate","0","0","0","0","0","0","0","0","0"
"878","NCT01574651","The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","934","May 2012","April 2013","St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis).","0","0","0","0","0","0","0","0","0"
"879","NCT01575054","BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity","Muscle Spasticity",0,"botulinum toxin Type A","Biological","Allergan","Industry",0,0,"All","18 Years","85 Years","468","May 2012","September 2014","Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Score of Ankle Plantar Flexors Using a 6-Point Scale","0","0","0","0","0","0","0","0","0"
"880","NCT01575808","Multi-center Study for Stent Graft System for Peripheral Artery","Peripheral Arterial Disease",0,"GP1101","Device","W.L.Gore & Associates","Industry",0,0,"All","20 Years","N/A","142","April 2012","August 2014","Primary Assisted Patency","0","0","0","0","0","0","0","0","0"
"881","NCT01576341","HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)","Chronic Kidney Disease",0,"HX575 epoetin alfa (Sandoz)","Drug","Sandoz","Industry",0,0,"All","18 Years","N/A","417","April 2012","October 2014","Incidence of antibody formation against epoetin","0","0","0","0","0","0","0","0","0"
"882","NCT01578707","A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia","Relapsed or Refractory Chronic Lymphocytic Leukemia",0,"ofatumumab","Drug","Pharmacyclics LLC.","Industry",0,0,"All","18 Years","N/A","391","June 2012","November 2013","PFS (Progression Free Survival)","<0.0001","0","Log Rank","0","0","0","0","0","0"
"883","NCT01580228","A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)","Chronic Lymphocytic Leukemia (CLL)",0,"Dinaciclib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","44","August 2012","December 2014","Participant Progression Free Survival","0","0","0","0","0","0","0","0","0"
"884","NCT01580293","A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A","Hemophilia A",0,"BAY94-9027","Biological","Bayer","Industry",0,0,"Male","12 Years","65 Years","141","April 23, 2012","June 13, 2014","Annualized Number of Total Bleeds in On-demand Treatment arm (Weeks 0-36) and Prophylaxis arm (Weeks 10 - 36, excluding rescue bleeds) - Part A","0","0","0","0","0","0","0","0","0"
"885","NCT01581203","Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)","Hepatitis C Virus",0,"Asunaprevir (ASV)","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","748","May 2012","October 2013","Proportion of treated subjects with SVR12, defined as HCV RNA < LOQ at post treatment Week 12, for subjects who are prior null or partial responders to P/R or are treatment-naive","0","0","0","0","0","0","0","0","0"
"886","NCT01581398","Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients","Chronic Hepatitis C",0,"Ypeginterferon alfa-2b","Drug","Xiamen Amoytop Biotech Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","770","April 2012","April 2014","Proportion of patients with sustained virologic response (defined as HCV RNA<15IU/ml at 24 weeks after the end of therapy)","0","0","0","0","0","0","0","0","0"
"887","NCT01581593","Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)","Primary Immunodeficiency",0,"Kedrion IVIG 10%","Biological","Kedrion S.p.A.","Industry",0,0,"All","2 Years","70 Years","50","November 2012","August 2014","Incidence of acute, serious bacterial infections","0","0","0","0","0","0","0","0","0"
"888","NCT01582451","A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2",0,"LY2605541","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","426","April 2012","May 2013","Change from baseline to 26 week endpoint in hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"889","NCT01582854","Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)","Post-Stroke Cognitive Impairment (PSCI)",0,"Actovegin","Drug","Takeda","Industry",0,0,"All","60 Years","N/A","503","June 2012","November 2014","Change From Baseline in Alzheimer's Disease Assessment Scale + Cognitive Subscale Extended Version (ADAS-cog+) at Month 6","0.005","0","ANCOVA","-2.3","LS Mean Difference","95","2-Sided","-3.9","-0.7"
"890","NCT01583374","Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis","Ankylosing Spondyloarthritis",0,"Apremilast tablet 20 mg","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","490","May 2012","February 2014","Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) for the Comparison Between Apremilast 30 mg BID and Placebo at 16 Week of Treatment","0.4383","Adjusting for CRP category and baseline BASDAI score category","Cochran-Mantel-Haenszel","-4.1","Risk Difference (RD)","95","2-Sided","-14.3","6.2"
"891","NCT01584232","A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","361","April 2012","July 2013","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","<0.001","P-value is from the pairwise comparison of LS means using a mixed effects model with repeated measurements (MMRM).","Mixed Models Analysis","-0.54","LS Mean Difference","95","2-Sided","-0.67","-0.41"
"892","NCT01584648","A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma","Melanoma",0,"dabrafenib","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","422","May 2012","August 2013","Progression-Free Survival (PFS) as Assessed by the Investigator","0.035","0","Log Rank","0.75","Hazard Ratio (HR)","95","2-Sided","0.57","0.99"
"893","NCT01584674","A Clinical Trial Evaluating the Safety and Efficacy of the KLOX Biophotonic System in Moderate to Severe Acne","Acne Vulgaris",0,"KLOX Biophotonic System","Device","KLOX Technologies Inc.","Industry",0,0,"All","16 Years","30 Years","98","March 2012","April 2013","Proportion of patients achieving a total reduction of at least 2 grades in the Investigator's Global Assessment (IGA) scale","0","0","0","0","0","0","0","0","0"
"894","NCT01584830","Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy","Colorectal Neoplasms",0,"Regorafenib (BAY73-4506)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","204","April 2012","November 2013","Overall Survival (OS)","0","0","0","0","0","0","0","0","0"
"895","NCT01584843","Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus","Strabismus",0,"GSK1358820","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","41","May 2012","July 2013","Change From Baseline in Strabismus Angle Prism Dioptre (PD) in the Primary Position at Week 4 of the FTP in Observed Cases (OC)","0.091","LSD=Least Significant Difference","Fisher LSD method","-9.83","Mean Difference (Final Values)","95","2-Sided","-21.81","2.14"
"896","NCT01585155","Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis","Pediatric Ulcerative Colitis",0,"TA-650","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","6 Years","17 Years","21","February 2012","September 2014","Change from baseline of percent of participants with clinical remission as defined by CAI score ≦4","0","0","0","0","0","0","0","0","0"
"897","NCT01587508","Study Comparing A New Drug Containing The Combination Meloxicam And Cyclobenzaprine In The Treatment Of Acute Lumbago","Acute Lumbago",0,"meloxicam/cyclobenzaprine hydrochloride","Drug","Eurofarma Laboratorios S.A.","Industry",0,0,"All","18 Years","75 Years","0","May 2013","May 2013","Pain Reduction","0","0","0","0","0","0","0","0","0"
"898","NCT01588496","Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities","Homozygous Familial Hypercholesterolemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","12 Years","80 Years","58","April 2012","January 2014","Part A: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","0","0","0","0","0","0","0","0","0"
"899","NCT01590771","A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","498","July 9, 2012","June 10, 2014","Change From Baseline in A1C Levels at Week 24 in Participants Receiving Sitagliptin and Sulfonylurea Alone or in Combination With Metformin","<0.001","The ANCOVA model controlled for treatment, metformin strata (on or not on metformin), and baseline A1C value.","ANCOVA","-0.61","Robust regression","95","2-Sided","-0.77","-0.44"
"900","NCT01590797","A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","Type 2 Diabetes Mellitus",0,"Sitagliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","467","July 10, 2012","June 11, 2014","Change From Baseline in Hemoglobin A1C (HbA1C) Levels at Week 24 in Participants Receiving Insulin Alone or in Combination With Metformin","<0.001","0","Robust Regression","-0.34","Mean Difference (Final Values)","95","2-Sided","-0.50","-0.19"
"901","NCT01591161","Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","Cataract",0,"Mapracorat","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","369","July 2012","June 2013","AC Cells","0","0","0","0","0","0","0","0","0"
"902","NCT01591655","Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","Cataract",0,"Mapracorat","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","363","July 2012","September 2013","AC Cells","0","0","0","0","0","0","0","0","0"
"903","NCT01593787","Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction","Hypertension With Renal Dysfunction",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","20 Years","N/A","32","May 2012","March 2013","Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death)","0","0","0","0","0","0","0","0","0"
"904","NCT01594749","Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","Chemotherapy-Induced Nausea and Vomiting (CINV)",0,"Fosaprepitant dimeglumine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1015","September 2012","November 2014","Percentage of Participants With Complete Response From 25 to 120 Hours After Initiation of Moderately Emetogenic Chemotherapy (MEC)","<0.001","P-value based on Cochran-Mantel-Haenszel (CMH) method with stratification of gender","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"905","NCT01596335","Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease","Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin",0,"TA-650","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","1 Year","10 Years","31","May 2012","October 2014","Defervescence rate within 48 hours after the start of the study drug administration","0","0","0","0","0","0","0","0","0"
"906","NCT01596829","Effect of Probiotic Formula on Reducing the Risk for Antibiotic-associated Diarrhoea","Antibiotic-associated Diarrhoea",0,"Probiotic","Dietary Supplement","Danisco","Industry",0,0,"All","18 Years","65 Years","258","December 2012","December 2014","Incidence of AAD","0","0","0","0","0","0","0","0","0"
"907","NCT01597245","A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)","Psoriasis",0,"80 mg ixekizumab Dosing Regimen","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1224","May 2012","March 2014","Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"908","NCT01597908","Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma","Melanoma",0,"Dabrafenib","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","701","June 4, 2012","April 1, 2014","Overall Survival","0.005","0","Stratified log-rank test","0.69","Hazard Ratio (HR)","95","2-Sided","0.53","0.89"
"909","NCT01599104","Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension","Essential Hypertension",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","20 Years","N/A","1161","June 2012","April 2013","Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)","0","0","0","0","0","0","0","0","0"
"910","NCT01599702","Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel Disease","Inflammatory Bowel Disease",0,"Iron Isomaltoside 1000","Drug","Pharmacosmos A/S","Industry",0,0,"All","18 Years","N/A","21","May 2012","December 2014","The primary objective of the study is to evaluate the safety of a high IV iron dosing regimen of iron isomaltoside 1000 in subjects with IDA secondary to IBD.","0","0","0","0","0","0","0","0","0"
"911","NCT01600014","Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","Actinic Keratosis",0,"Ingenol mebutate gel, 0.015%","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","463","May 2012","February 2014","Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation","0.001","Chi-square test for stratified data with a significance level of 5%. No adjustment for multiple tests was needed, due to the analyses were based on distinct subject groups","Cochran-Mantel-Haenszel","2.44","Risk Ratio (RR)","95","2-Sided","1.32","4.51"
"912","NCT01600092","A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)","Rotavirus Gastroenteritis",0,"RotaTeq™ experimental formulation","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","6 Weeks","12 Weeks","1020","April 2013","March 2014","Geometric Mean Titer of Serum Neutralizing Antibody Response to Human Rotavirus Serotypes G1, G2, G3, G4, and P1A[8]","0","0","0","0.92","GMT Ratio (Experimental/Existing)","95","2-Sided","0.79","1.07"
"913","NCT01600716","Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)","Urinary Incontinence",0,"OnabotulinumtoxinA","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","144","June 2012","April 2014","Change From Baseline in Daily Average Frequency of Urinary Incontinence Episodes","0","0","0","0","0","0","0","0","0"
"914","NCT01601483","Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration","Nonexudative Age Related Macular Degeneration",0,"MC-1101","Drug","MacuCLEAR, Inc.","Industry",0,0,"All","50 Years","85 Years","22","October 2012","March 2013","Visual Function","0","0","0","0","0","0","0","0","0"
"915","NCT01602562","Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients","Herpes Simplex",0,"VACV tablets (Adults or pediatrics) or granules (pediatrics)","Drug","GlaxoSmithKline","Industry",0,0,"All","1 Year","64 Years","40","May 2012","May 2013","Number of Participants With a Herpes Simplex Virus (HSV) Infection","0","0","0","0.00","percentage of participants","95","2-Sided","0.00","16.11"
"916","NCT01602874","Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia","Community Acquired Bacterial Pneumonia",0,"Tigecycline","Drug","Pfizer","Industry",0,0,"All","8 Years","17 Years","0","January 2011","May 2014","Clinical efficacy response (cure, failure, or indeterminate) at the test of cure (TOC) visit for 2 co-primary populations: the clinically evaluable (CE) and clinical modified Intent-to-Treat (c-mITT) populations","0","0","0","0","0","0","0","0","0"
"917","NCT01603459","Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm","Spasticity of the Upper and Lower Limb Due to Cerebral Causes",0,"IncobotulinumtoxinA","Drug","Merz Pharmaceuticals GmbH","Industry",0,0,"All","18 Years","80 Years","155","May 2012","September 2014","Occurrence of Treatment-Emergent Adverse Events (AEs), AEs of Special Interest (AESIs), and Serious AEs (SAEs) by Injection Cycle, Overall and Related to the Administration of Study Medication","0","0","0","0","0","0","0","0","0"
"918","NCT01604746","Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801","Prophylaxis of Ross River Virus Infection",0,"Ross River Virus (RRV) Vaccine","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","16 Years","N/A","1146","July 2012","April 2013","Incidence of SAEs and AESI, such as arthritis, Guillain Barré Syndrome (GBS), encephalitis, convulsions, Bell´s palsy, neuritis, vasculitis, demyelinating disorders (ADEM and myelitis) and vaccination failure","0","0","0","0","0","0","0","0","0"
"919","NCT01604850","Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)","Chronic Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","202","June 2012","February 2013","Percentage of Participants Achieving SVR12","< 0.001","P-value is from the Cochran-Mantel-Haenszel (CMH) test stratified by the randomization stratification factor (ie, presence/absence of cirrhosis, genotype 2 or 3).","Cochran-Mantel-Haenszel","-22.4","Proportion difference","95","2-Sided","-34.4","-10.3"
"920","NCT01605084","Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","HIV",0,"Atazanavir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","0","June 2012","August 2014","Proportion of subjects with Human immunodeficiency virus 1 (HIV-1) Ribonucleic Acid (RNA) < 50 c/mL","0","0","0","0","0","0","0","0","0"
"921","NCT01605136","Phase III Confirmatory Study in Erythropoietic Protoporphyria","Erythropoietic Protoporphyria",0,"Afamelanotide","Drug","Clinuvel Pharmaceuticals Limited","Industry",0,0,"All","18 Years","N/A","93","May 2012","April 2013","Duration of direct sunlight exposure between 10:00 and 18:00 hours on days when no pain was experienced (pain score of 0).","0","0","0","0","0","0","0","0","0"
"922","NCT01605227","Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","Prostate Cancer",0,"cabozantinib","Drug","Exelixis","Industry",0,0,"Male","18 Years","N/A","1028","June 2012","September 2014","Overall survival","0","0","0","0","0","0","0","0","0"
"923","NCT01606007","Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","1282","July 2012","January 2014","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","<0.0001","Primary endpoint was tested at alpha=0.05; significance was claimed only if Saxagliptin+Dapagliflozin+Metformin was superior to both Saxagliptin+Metformin and Dapagliflozin+Metformin.","Mixed Models Analysis","-0.59","Mean Difference (Final Values)","95","2-Sided","-0.81","-0.37"
"924","NCT01608100","Evaluation of a New Cardiac Biomarker Assay","Acute Coronary Syndrome",0,"ARCHITECT STAT High Sensitive Troponin I Assay","Device","Abbott Diagnostics Division","Industry",0,0,"All","18 Years","N/A","1101","June 2012","August 2014","Clinical Performance - Area Under the Curve","0","0","0","0.9326","Area Under the Curve","95","2-Sided","0.9048","0.9604"
"925","NCT01609582","Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease","Type 2 Diabetes",0,"TAK-875","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","3207","June 2012","May 2014","Time to First Occurrence of Any Component of Primary Major Adverse Cardiovascular Event (MACE) Composite","0","0","0","0","0","0","0","0","0"
"926","NCT01611051","A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy","Breast Cancer",0,"Drug: Pegylated rhG-CSF: 100µg/kg","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","330","March 2012","January 2013","Rate and the duration of grade 3/4 neutropenia in cycle 1","0","0","0","0","0","0","0","0","0"
"927","NCT01612078","Phase 3 Study to Evaluate the Efficacy and Safety of Droxidopa on Orthostatic Hypotension Treatment in Hemodialysis Patients","Orthostatic Hypotension",0,"Droxidopa","Drug","TSH Biopharm Corporation Limited","Industry",0,0,"All","20 Years","80 Years","25","June 2012","February 2013","Change in mean ΔSBP after hemodialysis","0","0","0","0","0","0","0","0","0"
"928","NCT01613326","Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease",0,"NVA237","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","657","June 2012","January 2013","Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)","0","0","0","0","0","0","0","0","0"
"929","NCT01614457","Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","6 Years","N/A","70","July 2012","October 2013","Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24","0.1979","0","Mixed Model Repeated Measures","2.1114","Least squares (LS) Mean Difference","95","2-Sided","-1.1305","5.3532"
"930","NCT01614470","Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","6 Years","N/A","39","July 2012","October 2013","Part 1: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 8","<0.0001","0","Mixed Models Analysis","10.6780","Least squares (LS) mean difference","95","2-Sided","7.2559","14.1000"
"931","NCT01614574","Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease","Gaucher Disease",0,"velaglucerase alfa","Biological","Shire","Industry",0,0,"All","2 Years","N/A","6","March 2012","May 2013","Number of Severe Adverse Events (SAE)","0","0","0","0","0","0","0","0","0"
"932","NCT01614886","Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","Alzheimer's Disease",0,"Active Comparator","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","50 Years","85 Years","216","July 2012","May 2014","Percentage of Patients With Adverse Events Leading to Study Drug Discontinuation","0","0","0","0","0","0","0","0","0"
"933","NCT01614899","A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","Schizophrenia",0,"SM-13496 40mg","Drug","Sumitomo Dainippon Pharma Co., Ltd.","Industry",0,0,"All","18 Years","74 Years","457","June 2012","November 2014","Change from baseline in PANSS total score","0","0","0","0","0","0","0","0","0"
"934","NCT01616524","Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3","Hepatitis C Virus (HCV)",0,"Pegylated interferon lambda (pegIFNλ)","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","880","July 2012","June 2014","Proportion of subjects who achieve Sustained Virologic Response at post-treatment follow-up week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"935","NCT01617187","A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)","Schizophrenia",0,"Asenapine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","360","December 2012","August 2014","Change From Baseline in PANSS Total Score at Day 42","0.6043","Adjusted p-value from graphical approach to control Type 1 error rate among primary and secondary efficacy hypotheses","Mixed Model Repeated Measures (MMRM)","-1.3","Least Squares (LS) means difference","95","2-Sided","-6.1","3.6"
"936","NCT01617434","The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","451","September 2012","October 2013","Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26","<0.0001","0","Mixed Models Analysis","-1.19","Mean Difference (Final Values)","95","0","-1.39","-0.99"
"937","NCT01617655","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","Hypercholesterolaemia",0,"Alirocumab","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","107","June 2012","May 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-39.1","LS mean difference","95","2-Sided","-51.1","-27.1"
"938","NCT01618162","The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy","Diabetes",0,"insulin degludec/liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","435","August 2012","October 2013","Change in Glycosylated Haemoglobin (HbA1c)","< 0.001","0","ANCOVA","-1.02","Estimated treatment difference","95","2-Sided","-1.18","-0.87"
"939","NCT01618370","Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases","Prostatic Neoplasms",0,"Radium-223 dichloride (BAY88-8223)","Drug","Bayer","Industry",0,0,"Male","18 Years","N/A","705","July 22, 2012","August 13, 2014","Acute safety, variables will be summarized using descriptive statistics based on adverse events collection","0","0","0","0","0","0","0","0","0"
"940","NCT01618448","Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure","Cardiac-induced Edema",0,"Tolvaptan","Drug","Taiwan Otsuka Pharm. Co., Ltd","Industry",0,0,"All","20 Years","85 Years","85","July 2012","May 2014","Change in body weight at 4-day of treatment.","0","0","0","0","0","0","0","0","0"
"941","NCT01618617","Multistrain Probiotic for Functional Constipation","Functional Constipation",0,"High dose Multistrain probiotic, 100 billion cfu/day","Dietary Supplement","Renew Life Formulas Inc","Industry",0,0,"All","18 Years","65 Years","81","June 2012","March 2013","Whole gut transit time","0","0","0","0","0","0","0","0","0"
"942","NCT01618669","A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)","Coronary Artery Disease (CAD)",0,"Regadenoson","Drug","Astellas Pharma Global Development, Inc.","Industry",0,0,"All","18 Years","N/A","1147","June 2012","December 2014","Proportion of Participants With Majority Reader Self-agreement in Ischemia Assessment Between First and Second Stress Scans","0","0","0","-0.03","Difference","95","2-Sided","-0.06","-0.00"
"943","NCT01619059","Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","Type 2 Diabetes",0,"Saxagliptin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","315","June 2012","June 2014","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","<0.0001","Tested at alpha=0.05","Mixed Models Analysis","-0.35","Mean Difference (Final Values)","95","2-Sided","-0.52","-0.18"
"944","NCT01619683","Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism","Effect of Treatment on Bone Mineral Density",0,"enclomiphene citrate","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","300","September 2012","September 2014","Bone Mineral Density","0","0","0","0","0","0","0","0","0"
"945","NCT01620489","Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment","Diabetes",0,"liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","80 Years","279","June 2012","August 2013","Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)","<0.0001","Adjustment for multiple comparisons was not used since there was only one primary endpoint.","Mixed Models Analysis","-0.66","Estimated treatment difference","95","0","-0.90","-0.43"
"946","NCT01620528","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","Endometriosis",0,"Elagolix","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"Female","18 Years","49 Years","872","May 2012","November 2014","Proportion of responders based on daily assessment of dysmenorrhea (DYS)","0","0","0","0","0","0","0","0","0"
"947","NCT01621191","An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)","Fibromyalgia",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","74 Years","149","June 2012","February 2014","Number of Participants Who Experienced an Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"948","NCT01622075","A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent","Coronary Instent Restenosis",0,"SeQuent® Please","Device","B. Braun Medical International Trading Company Ltd.","Industry",0,0,"All","18 Years","80 Years","220","March 2011","April 2013","Late lumen loss in segment section at M9","0","0","0","0","0","0","0","0","0"
"949","NCT01622088","Phase 3 Extension Study of Dexpramipexole in ALS","Amyotrophic Lateral Sclerosis",0,"Dexpramipexole","Drug","Knopp Biosciences","Industry",0,0,"All","18 Years","80 Years","616","June 2012","February 2013","Incidence of Adverse Events and Serious Adverse Events","0","0","0","0","0","0","0","0","0"
"950","NCT01623115","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","Hypercholesterolemia",0,"Alirocumab","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","486","July 2012","April 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-57.9","LS mean difference","95","2-Sided","-63.3","-52.6"
"951","NCT01624233","A Study in Japanese Participants With Moderate-to-Severe Psoriasis","Psoriasis",0,"80 mg ixekizumab","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","91","June 2012","September 2013","Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)","0","0","0","0","0","0","0","0","0"
"952","NCT01624259","A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes","Type 2 Diabetes",0,"LY2189265","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","599","June 2012","November 2013","Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)","<0.001","1-sided raw p-value (no multiplicity adjustment).","Mixed Models Analysis","-0.06","LS Mean Difference","95","2-Sided","-0.19","0.07"
"953","NCT01624675","A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder","Autistic Disorder in Children and Adolescents",0,"Risperidone","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","5 Years","17 Years","39","September 2012","October 2014","The change from baseline in the Aberrant Behavior Checklist−Japanese Version (ABC-J) Irritability Subscale scores","0","0","0","0","0","0","0","0","0"
"954","NCT01625338","Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies","Chronic Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","534","June 2012","October 2014","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"955","NCT01625390","A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150","Hemophilia A, Hemophilia B",0,"BAY86-6150","Drug","Bayer","Industry",0,0,"Male","12 Years","62 Years","10","June 2012","March 2014","Successful treatments of bleeding episodes.","0","0","0","0","0","0","0","0","0"
"956","NCT01625494","Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy","Hypertension",0,"Irbesartan/Amlodipine (150/5mg)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","158","May 2012","January 2013","Proportion of patients with controlled OBPM (SBP<140 mmHg and DBP<90 mmHg) at the end of the study","0","0","0","0","0","0","0","0","0"
"957","NCT01626222","4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","Metastatic Breast Cancer",0,"Exemestane","Drug","Novartis Pharmaceuticals","Industry",0,0,"Female","18 Years","N/A","301","June 2012","November 2013","Overall Response Rate (ORR) after 24 weeks of treatment","0","0","0","0","0","0","0","0","0"
"958","NCT01626742","A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study","Hospitalized Elderly",0,"Ready to Drink Flavored Beverage","Other","Abbott Nutrition","Industry",0,0,"All","65 Years","N/A","652","May 2012","October 2014","Return to hospital or death","0","0","0","0","0","0","0","0","0"
"959","NCT01628393","Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)","Relapsing Multiple Sclerosis",0,"RPC1063","Drug","Celgene","Industry",0,0,"All","18 Years","55 Years","258","July 2012","April 2014","Total number of new GdE lesions, assessed on brain MRIs","0","0","0","0","0","0","0","0","0"
"960","NCT01629966","Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Placebo","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","680","June 2012","February 2014","Hamilton Rating Scale for Anxiety (HAM-A) total score","0","0","0","0","0","0","0","0","0"
"961","NCT01630434","International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation","Lung Preservation",0,"OCS Lung","Device","TransMedics","Industry",0,0,"All","18 Years","N/A","316","November 2011","September 2014","A composite of patient survival at day 30 post transplantation, and absence of International Society for Heart & Lung Transplantation (ISHLT) Primary Graft Dysfunction (PGD3) Grade 3 within the first 72 hours post-transplantation.","0","0","0","0","0","0","0","0","0"
"962","NCT01631227","Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension","Essential Hypertension",0,"Eprosartan","Drug","Abbott","Industry",0,0,"All","18 Years","N/A","665","June 2012","April 2013","Assess the Therapeutic Equivalence of Eprosartan (a New Formulation Containing Only the Active Moiety Eprosartan) With Eprosartan Mesylate (Currently Marketed Formulation) on Change of Sitting Diastolic Blood Pressure (DBP) From Baseline","0","0","0","0","0","0","0","0","0"
"963","NCT01632007","Double-blind Comparative Study of SYR-472","Diabetes Mellitus",0,"SYR-472","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","245","May 2012","July 2013","Glycosylated hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"964","NCT01632137","Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome","Dry Eye Syndrome",0,"Rebamipide 2% ophthalmic suspension","Drug","Acucela Inc.","Industry",0,0,"All","18 Years","N/A","564","June 2012","June 2013","Primary ocular sign: Fluorescein corneal staining total score","0","0","0","0","0","0","0","0","0"
"965","NCT01632904","Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","Polycythemia Vera",0,"Ruxolitinib","Drug","Incyte Corporation","Industry",0,0,"All","18 Years","N/A","110","June 2012","March 2014","Percentage of Subjects Achieving a ≥ 50% Improvement From Baseline in Total Symptom Score-Cytokine (TSS-C) at Week 16, as Measured by the Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Diary","0.139","0","Chi-squared","1.82","Odds Ratio (OR)","95","2-Sided","0.82","4.04"
"966","NCT01633879","Addressing Proven Factors in HIV Prevention for Latino Youth","HIV",0,"audio-CD parent education","Behavioral","Education Development Center, Inc.","Industry",0,0,"All","10 Years","14 Years","3400","July 2009","December 2013","reduction in risk behavior","0","0","0","0","0","0","0","0","0"
"967","NCT01633944","Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects","Low Back Pain",0,"Buprenorphine","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","752","August 2012","December 2013","Change From Baseline to Week 12 in Average Daily Pain Intensity Scores","0.0012","0","ANCOVA","-0.67","Median Difference (Net)","95","2-Sided","-1.07","-0.26"
"968","NCT01634295","Efficacy and Safety of CKD-828 to Stage 2 Hypertension","Hypertension",0,"CKD-828 2.5/40mg","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","N/A","103","July 2012","May 2013","Mean Sitting systolic Blood Pressure (MSSBP)","0","0","0","0","0","0","0","0","0"
"969","NCT01636206","Safety Study of Lifitegrast to Treat Dry Eye","Dry Eye",0,"Lifitegrast","Drug","Shire","Industry",0,0,"All","18 Years","N/A","332","July 2012","March 2014","Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year","0","0","0","0","0","0","0","0","0"
"970","NCT01636713","A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD","Pulmonary Disease, Chronic Obstructive",0,"GSK573719/VI 62.5/25","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","581","July 2012","October 2013","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)","<0.001","0","Mixed Models Analysis","0.151","Least squares mean difference","95","2-Sided","0.110","0.191"
"971","NCT01637168","Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders","Memory Deficit",0,"Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin","Drug","EMS","Industry",0,0,"All","18 Years","60 Years","138","November 2013","June 2014","Study to evaluate the efficacy and safety of the association Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamins compared to Ginkgo Biloba (Tebonin ®) for the symptomatic treatment of disorders of cognitive function.","0","0","0","0","0","0","0","0","0"
"972","NCT01638000","A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.","Urologic Diseases",0,"Mirabegron","Drug","Astellas Pharma Europe Ltd.","Industry",0,0,"All","18 Years","N/A","1887","June 2012","April 2013","Change From Baseline to Final Visit in the Mean Number of Micturitions Per 24 Hours","0.15","If p<0.05, this indicated superiority in favor of the treatment group with the largest improvement at specified visit.","ANCOVA","-0.18","least squares mean difference","95","2-Sided","-0.42","0.06"
"973","NCT01638910","Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects","Contraception",0,"EV/DNG (Qlaira, BAY86-5027)","Drug","Bayer","Industry",0,0,"Female","18 Years","50 Years","955","June 2012","November 2014","Number of unintended pregnancies","0","0","0","0","0","0","0","0","0"
"974","NCT01638988","Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin","Polycystic Ovary Syndrome",0,"Metformin","Drug","OVO R & D","Industry",0,0,"Female","18 Years","35 Years","0","September 2013","November 2013","Biochemical pregnancy","0","0","0","0","0","0","0","0","0"
"975","NCT01639495","THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS","Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation",0,"THERMOCOOL® SMARTTOUCH™ Catheter","Device","Biosense Webster, Inc.","Industry",0,0,"All","18 Years","N/A","148","July 2012","June 2014","Freedom from atrial tachyarrhythmias","0","0","0","0","0","0","0","0","0"
"976","NCT01640535","Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients","Perennial Allergic Rhinitis",0,"Montelukast + Levocetirizine","Drug","Hanmi Pharmaceutical Company Limited","Industry",0,0,"All","15 Years","N/A","283","June 2012","February 2013","Mean Daytime Nasal Symptom Score","0","0","0","0","0","0","0","0","0"
"977","NCT01640756","AqueSys Microfistula Implant in Refractory Glaucoma","Glaucoma",0,"AqueSys Microfistula Implant","Device","AqueSys, Inc.","Industry",0,0,"All","45 Years","N/A","60","July 2012","November 2014","Proportion of subjects achieving a 20% or greater reduction in IOP from baseline on the same or less number of medications","0","0","0","0","0","0","0","0","0"
"978","NCT01641393","Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.","Exocrine Pancreatic Insufficiency: Cystic Fibrosis",0,"EUR-1008 25,000 Units","Drug","Forest Laboratories","Industry",0,0,"All","12 Years","N/A","96","June 2012","February 2014","Coefficient of Fat Absorption over 72 hours (CFA-72h)","0","0","0","0","0","0","0","0","0"
"979","NCT01641640","Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection","Chronic Hepatitis C",0,"Sofosbuvir","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","328","June 2012","January 2013","Percentage of Participants Achieving Sustained Virologic Response (SVR)12","< 0.001","0","Binomial exact test","0","0","0","0","0","0"
"980","NCT01642004","Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)","Squamous Cell Non-small Cell Lung Cancer",0,"Nivolumab","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","352","September 2012","November 2014","Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint","0.0004","Stratified by region (US/Canada, Rest Of World (ROW), Europe) and prior treatment regimen (Paclitaxel, Another agent) as entered in the Interactive Voice Response System (IVRS).","Log Rank","0.62","Hazard Ratio (HR)","95","2-Sided","0.47","0.81"
"981","NCT01642589","Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea","Meningitis",0,"Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","11 Years","55 Years","300","July 2012","January 2013","Percentage of Participants With Seroconversion Following Vaccination With Either Menactra® or Adacel® Vaccine","0","0","0","0","0","0","0","0","0"
"982","NCT01642914","Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating","Chronic Constipation",0,"Linaclotide 290 micrograms","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","N/A","487","August 2012","May 2013","9/12 Week Complete Spontaneous Bowel Movement (CSBM) 3+1 Responder","0","0","0","0","0","0","0","0","0"
"983","NCT01644175","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","Hypercholesterolemia",0,"Placebo (for alirocumab)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","316","July 2012","April 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-45.9","LS Mean Difference","95","2-Sided","-52.5","-39.3"
"984","NCT01644188","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","Hypercholesterolemia",0,"Alirocumab","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","720","August 2012","May 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","<0.0001","Threshold for significance ≤0.05.","Mixed Models Analysis","-29.8","LS Mean Difference","95","2-Sided","-34.4","-25.3"
"985","NCT01644201","A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics","Type II Diabetes Mellitus",0,"PolyGlycopleX® - PGX®","Dietary Supplement","InovoBiologic Inc.","Industry",0,0,"All","18 Years","75 Years","200","October 2012","January 2014","HbA1c","0","0","0","0","0","0","0","0","0"
"986","NCT01644474","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","Hypercholesterolemia",0,"Alirocumab","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","103","July 2012","July 2013","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-31.6","LS Mean Difference","95","2-Sided","-40.2","-23.0"
"987","NCT01644500","A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Dulaglutide","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","807","July 2012","August 2014","Change From Baseline in HbA1c at 26 Weeks","0","0","0","-0.60","Mean Difference (Net)","95","2-Sided","-0.78","-0.41"
"988","NCT01645189","Safety and Efficacy of Hunterase","Hunter Syndrome",0,"Hunterase","Biological","Green Cross Corporation","Industry",0,0,"Male","N/A","5 Years","6","July 2012","September 2013","Incidence of adverse events","0","0","0","0","0","0","0","0","0"
"989","NCT01645332","Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus","Type-2-diabetes Mellitus",0,"Placebo of DLBS3233","Drug","Dexa Medica Group","Industry",0,0,"All","18 Years","60 Years","104","July 2012","August 2014","Reduction of A1c level","0","0","0","0","0","0","0","0","0"
"990","NCT01646073","Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis","Plaque Psoriasis",0,"Adalimumab","Biological","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","N/A","425","August 2012","December 2013","Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12","0","0","0","0","0","0","0","0","0"
"991","NCT01646177","A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)","Psoriasis",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","1346","July 2012","May 2014","Number of Participants Achieving a Static Physician Global Assessment (sPGA) of (0, 1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: sPGA)","<0.001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"992","NCT01646255","Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients","Idiopathic Parkinson's Disease",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","30 Years","N/A","346","July 2012","October 2014","Absolute Change in Absolute Time Spent 'Off' From Baseline to the End of Double-blind Maintenance Period","=0.0002","Primary efficacy analyses was made with confirmatory 2-sided test with significance level 0.05.","ANCOVA","-1.20","Least Square Mean","95","2-Sided","-1.83","-0.57"
"993","NCT01646268","Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients","IDIOPATHIC PARKINSON'S DISEASE",0,"Rotigotine","Drug","UCB Pharma","Industry",0,0,"All","30 Years","N/A","249","July 2012","May 2014","Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts II+III, a UPDRS Subtotal) From Baseline to the End of Double-blind Maintenance Period","<0.0001","0","ANCOVA","-4.82","LS Means","95","2-Sided","-7.18","-2.45"
"994","NCT01646320","Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","Type 2 Diabetes",0,"Dapagliflozin","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","320","September 2012","August 2014","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24","<0.0001","Tested at alpha=0.05","Longitudinal Repeated Measures Analysis","-0.72","Mean Difference (Final Values)","95","2-Sided","-0.91","-0.53"
"995","NCT01646619","Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy","Severe Hypoxic Ischemic Encephalopathy",0,"Magnesium Sulphate","Drug","Sajjad Rahman","Industry",0,0,"All","N/A","6 Hours","300","May 2012","December 2013","Combined outcome of Mortality and Severe Neurodevelopmental Disability","0","0","0","0","0","0","0","0","0"
"996","NCT01646671","Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients","Severe Hypertension",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","20 Years","N/A","35","July 2012","February 2013","Percentage of Participants With Adverse Events (AEs), Serious Adverse Events and Deaths","0","0","0","0","0","0","0","0","0"
"997","NCT01647542","Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes","Type 2 Diabetes Mellitus",0,"TAK-875","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","393","October 2012","February 2014","Change From Baseline in HbA1c at Week 24","<0.001","Stepwise Comparison: 1) TAK-875 50 mg versus (vs.) placebo, 2) TAK-875 25 mg vs. placebo. Step 2 was performed only if p-value at step 1 was <=0.050.","Mixed Model Repeated Measures","-1.03","Least squares mean difference","95","2-Sided","-1.27","-0.78"
"998","NCT01648101","Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","Epilepsy",0,"Retigabine 900mg/day","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","N/A","76","August 2012","December 2013","Number of Placebo and Retigabine 900 mg Responders During the Maintenance Phase (MP)","0","0","0","0","0","0","0","0","0"
"999","NCT01648582","A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Dulaglutide","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","789","July 2012","August 2014","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks","0","0","0","-0.55","Mean Difference (Net)","95","2-Sided","-0.71","-0.38"
"1000","NCT01650051","Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)","Uncomplicated Urinary Tract Infections",0,"Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"Female","18 Years","N/A","424","February 2012","February 2013","Self-assessments","0","0","0","0","0","0","0","0","0"
"1001","NCT01650246","Open-Label Lesinurad Monotherapy Extension Study in Gout","Gout",0,"lesinurad","Drug","Ardea Biosciences, Inc.","Industry",0,0,"All","18 Years","85 Years","143","August 2012","April 2014","Proportion of Subjects With a Serum Urate (sUA) Level That is < 6.0 mg/dL","0","0","0","0","0","0","0","0","0"
"1002","NCT01650805","Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)","Chronic Myeloid Leukemia",0,"ponatinib","Drug","Ariad Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","307","June 2012","October 2013","Major Molecular Response (MMR) Rate at 12 Months","0.074","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1003","NCT01651000","Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","Chronic Kidney Disease",0,"CTAP101 30 μg capsules","Drug","OPKO IP Holdings II, Inc.","Industry",0,0,"All","18 Years","85 Years","213","September 2012","July 2014","Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1004","NCT01651156","Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema","Cardiac Edema",0,"Tolvaptan","Drug","Otsuka Beijing Research Institute","Industry",0,0,"All","20 Years","85 Years","244","July 2012","July 2013","body weight (change from baseline)","0","0","0","0","0","0","0","0","0"
"1005","NCT01651949","Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)","Genital Warts",0,"9vHPV Vaccine","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","16 Years","26 Years","2520","October 29, 2012","August 4, 2014","Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine","<0.001","0","ANOVA","1.11","GMT Ratio","95","2-Sided","1.02","1.21"
"1006","NCT01652664","Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients","Pediatric Glaucoma",0,"Travoprost 0.004% PQ ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","2 Months","17 Years","184","September 2012","March 2014","Mean Change From Baseline in IOP at Month 3","0","0","0","0","0","0","0","0","0"
"1007","NCT01652716","Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Exenatide once weekly suspension","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","377","January 2013","August 2014","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","0.0072","0","Mixed model for repeated measure (MMRM)","-0.37","LS Mean Difference","95","2-Sided","-0.63","-0.10"
"1008","NCT01652729","Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus","Diabetes Type 2",0,"Exenatide once weekly suspension","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","365","February 2013","April 2014","Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","0.0010","0","mixed model for repeated measure","-0.72","LS Mean Difference","95","2-Sided","-1.15","-0.30"
"1009","NCT01653262","Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)","Epilepsy",0,"Brivaracetam","Drug","UCB Pharma SA","Industry",0,0,"All","16 Years","N/A","29","July 2012","November 2013","Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study Entry to the End of the Treatment Period","0","0","0","0","0","0","0","0","0"
"1010","NCT01653743","Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women","Anovulation",0,"MSJ-0011","Drug","Merck KGaA","Industry",0,0,"Female","20 Years","39 Years","81","September 2012","November 2014","Percentage of Subjects With Ovulation Mid-luteal Serum Progesterone (P4) Level of Greater Than or Equal (>=) 5 Nanogram Per Milliliter (ng/mL) or Clinical Pregnancy","0","0","0","0","0","0","0","0","0"
"1011","NCT01655069","A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076","Urinary Bladder, Overactive",0,"Solifenacin succinate","Drug","Astellas Pharma Europe B.V.","Industry",0,0,"All","5 Years","17 Years","148","October 2012","October 2014","Incidence and severity of adverse events","0","0","0","0","0","0","0","0","0"
"1012","NCT01656161","Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer","Prostate Cancer",0,"Triptorelin embonate 22.5 mg","Drug","Debiopharm International SA","Industry",0,0,"Male","N/A","N/A","120","July 2012","August 2013","Percentage of Participants Achieving and Maintaining Castrate Levels of Serum Testosterone (<1.735 Nmol/L)","0","0","0","0","0","0","0","0","0"
"1013","NCT01656434","Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)","Contraception",0,"NOMAC-E2","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","18 Years","50 Years","3173","November 2012","February 2014","Number of In-Treatment Pregnancies Per 100 Woman Years of Exposure (Pearl Index)","0","0","0","0","0","0","0","0","0"
"1014","NCT01656668","Study of the Safety and Effectiveness of BC1036 Capsules to Treat Frequent Long-Term Cough","Cough",0,"BC1036","Drug","Respicopea Limited","Industry",0,0,"All","18 Years","75 Years","288","July 2012","August 2013","Leicester Cough Questionnaire (LCQ)","0","0","0","0","0","0","0","0","0"
"1015","NCT01656772","Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study","Atrial Fibrillation",0,"Vdrive Lasso navigation","Device","Stereotaxis","Industry",0,0,"All","18 Years","80 Years","120","August 2012","December 2013","The Primary Effectiveness Endpoint is the Successful Navigation and EGM Recording of Each Pre-specified Pulmonary Vein Per Procedure Between Both the Control and the Investigational Device Groups.","0.0405","Adjusted to take into account the correlation between multiple PVs on the same subject. The sample estimate of the intraclass correlation coefficient was calculated as the Pearson sample correlation coefficient for all pairs of observations.","Farrington and Manning","0","0","0","0","0","0"
"1016","NCT01656889","Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers","Venous Leg Ulcers",0,"HP-802-247","Biological","Healthpoint","Industry",0,0,"All","18 Years","N/A","447","August 2012","December 2014","Compare the Treatment Groups for the Proportion of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline","0.5896","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1017","NCT01656980","Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma","Anaplastic Astrocytoma",0,"Carmustine","Drug","Shandong Lanjin Pharmaceuticals Co.,Ltd","Industry",0,0,"All","18 Years","70 Years","236","August 2012","August 2014","Overall Survival","0","0","0","0","0","0","0","0","0"
"1018","NCT01657253","Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye","Dry Eye",0,"PRO-148","Drug","Laboratorios Sophia S.A de C.V.","Industry",0,0,"All","18 Years","N/A","300","November 2013","May 2014","Tear film break up time","0","0","0","0","0","0","0","0","0"
"1019","NCT01657292","Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds","Burns",0,"Oleogel-S10 ointment","Drug","Birken AG","Industry",0,0,"All","18 Years","N/A","61","August 2012","July 2013","Percentage of Patients With Earlier Healing of the Wound Half Treated With Oleogel-S10 Compared to the Wound Half Receiving Standard of Care","<0.0001","1-sided, significance level = 0.025","Binomial test","0","0","0","0","0","0"
"1020","NCT01657305","Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites","Wounds",0,"Oleogel-S10 ointment and non-adhesive wound dressing","Drug","Birken AG","Industry",0,0,"All","18 Years","N/A","107","August 2012","August 2013","Intra-individual difference in time to wound closure","0","0","0","0","0","0","0","0","0"
"1021","NCT01657955","Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia","Chronic Lymphocytic Leukemia",0,"Bendamustine Hydrochloride Injection","Drug","Shandong Lanjin Pharmaceuticals Co.,Ltd","Industry",0,0,"All","18 Years","75 Years","96","January 2011","October 2013","Overall response rate (ORR)","0","0","0","0","0","0","0","0","0"
"1022","NCT01658020","A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg","Chronic Obstructive Pulmonary Disease",0,"Zabofloxacin","Drug","Dong Wha Pharmaceutical Co. Ltd.","Industry",0,0,"All","40 Years","N/A","345","August 2012","January 2014","Clinical Response in the Clinical Populations","0","0","0","0","0","0","0","0","0"
"1023","NCT01660256","Confirmatory Study of OPC-12759 Ophthalmic Solution","Dry Eye",0,"OPC-12759","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","209","August 2012","March 2013","Efficacy:Change in fluorescein","0","0","0","0","0","0","0","0","0"
"1024","NCT01660763","Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery","Post Operative Pain",0,"Sufentanil NanoTab PCA System/15 mcg","Drug","AcelRx Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","419","August 2012","April 2013","Time-weighted Summed Pain Intensity Difference (SPID) Over the 48-hour Study Period (SPID48).","<0.001","0","ANCOVA","87.59","Mean Difference (Final Values)","95","2-Sided","66.20","108.98"
"1025","NCT01660802","Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)","Macular Edema",0,"700 μg Dexamethasone","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","262","September 2012","March 2014","Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye","0","0","0","0","0","0","0","0","0"
"1026","NCT01660841","Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging","Magnetic Resonance Imaging",0,"Gadobutrol (Gadovist, BAY86-4875)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","223","September 2012","August 2013","Scores for visualization parameter: degree of contrast enhancement","0","0","0","0","0","0","0","0","0"
"1027","NCT01661270","A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","Colorectal Cancer Metastatic",0,"Aflibercept","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","332","July 2012","October 2014","Progression-free Survival (PFS)","0","0","0","0","0","0","0","0","0"
"1028","NCT01662102","Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)","Follicular Lymphoma",0,"Zevalin","Drug","Spectrum Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","75 Years","1","September 2012","July 2013","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"1029","NCT01662310","An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia","Schizophrenia",0,"Paliperidone","Drug","Janssen Research & Development, LLC","Industry",0,0,"All","18 Years","N/A","201","June 2011","April 2013","Double Blind (DB) Phase: Median Time to Relapse","0","0","0","0","0","0","0","0","0"
"1030","NCT01663233","Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine","Essential Hypertension",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","266","August 2012","May 2013","Change in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (maSBP)","0","0","0","0","0","0","0","0","0"
"1031","NCT01663363","Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors","Myopia",0,"LASIK correction of myopic refractive errors","Device","Abbott Medical Optics","Industry",0,0,"All","18 Years","N/A","170","August 2012","March 2014","Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)","0","0","0","0","0","0","0","0","0"
"1032","NCT01663532","Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia","Schizophrenia",0,"Aripiprazole IM Depot","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","340","October 2012","August 2013","Mean Change From Baseline to Endpoint in Positive and Negative Syndrome Scale (PANSS) Total Score.","0.0005","Kenward-Rodger degree of freedom was used to test the treatment effects and p-value was not adjusted as this is a primary efficacy endpoint.","Mixed Models Analysis","-3.9","Mean Difference (Final Values)","95","2-Sided","-6.1","-1.7"
"1033","NCT01664078","A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)","Abdominal Aortic Aneurysm",0,"Endovascular AAA repair","Device","Cordis Corporation","Industry",0,0,"All","20 Years","N/A","190","July 2012","October 2014","Incidence of MAE (major adverse events) based upon a composite MAE rate.","0","0","0","0","0","0","0","0","0"
"1034","NCT01664247","The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","346","October 2012","December 2013","Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)","0","0","0","0","0","0","0","0","0"
"1035","NCT01664949","A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease","Dry Eye Disease",0,"Carboxymethylcellulose Based Eye Drop Formulation A","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","460","January 2013","May 2014","Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Day 90","0","0","0","0","0","0","0","0","0"
"1036","NCT01665053","The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)","Coronary Artery Disease",0,"PROMUS Element Plus","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","1684","November 2012","September 2014","Percentage of Participants With Target Lesion Failure (TLF) at 12 Months","0","0","0","0","0","0","0","0","0"
"1037","NCT01665599","A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel","Adult Male Hypogonadism",0,"Testosterone gel (FE 999303)","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","75 Years","180","July 2012","April 2013","The percentage of subjects on day 90 whose Cavg (0-24) serum total testosterone levels are between 300 and 1050 ng/dL","0","0","0","0","0","0","0","0","0"
"1038","NCT01667679","Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura","Migraine",0,"100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally","Drug","Avanir Pharmaceuticals","Industry",0,0,"All","18 Years","65 Years","275","August 2012","March 2014","Mean Sum of Migraine Pain Intensity Differences (SPID)-30","<0.0001","0","ANCOVA","3.39","Mean Difference (Final Values)","95","2-Sided","1.76","5.01"
"1039","NCT01667731","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults","Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","224","July 2012","November 2013","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1040","NCT01668654","Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS","Epilepsy",0,"retigabine/ezogabine","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","29 Years","4","September 2012","June 2013","Number of Participants (Par.) With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period","0","0","0","0","0","0","0","0","0"
"1041","NCT01670032","Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo","Impetigo",0,"Experimental: CD07223 1.5 % Topical Gel BID","Drug","NovaBay Pharmaceuticals, Inc.","Industry",0,0,"All","2 Years","N/A","328","August 2012","August 2013","Clinical Success at Follow up (Day 15) in the intent-to-treat (ITTC) population","0","0","0","0","0","0","0","0","0"
"1042","NCT01672476","A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension","Hypertension",0,"Placebo","Drug","Boryung Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","75 Years","293","April 2012","March 2013","the difference of sitting DBP","0","0","0","0","0","0","0","0","0"
"1043","NCT01672762","A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients","Type 2 Diabetes Mellitus",0,"ASP1941","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","174","June 2012","April 2013","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"1044","NCT01674530","Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation","Chronic Idiopathic Constipation",0,"Lubiprostone","Drug","Dr. Reddy's Laboratories Limited","Industry",0,0,"All","18 Years","N/A","909","October 2012","January 2014","Primary Analysis","0","0","0","0","0","0","0","0","0"
"1045","NCT01674595","An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy","Allergic Rhinitis Due to Olea Europaea Pollen",0,"AVANZ olea","Biological","ALK-Abelló A/S","Industry",0,0,"All","18 Years","65 Years","93","September 2012","April 2013","Frequency of patients with adverse reactions.","0","0","0","0","0","0","0","0","0"
"1046","NCT01674634","Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures","Dupuytren's Contracture",0,"XIAFLEX / XIAPEX","Biological","Endo Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","715","September 2012","July 2013","Percent Change From Baseline in Total Fixed Flexion","0","0","0","0","0","0","0","0","0"
"1047","NCT01674647","Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","Atrial Fibrillation",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","1504","October 2012","January 2014","Number of Participants With Composite of the Following Events, Adjudicated Centrally: Stroke, Transient Ischemic Attack, Non-central Nervous System Systemic Embolism, Myocardial Infarction and Cardiovascular Death","0","0","0","0.50","Risk Ratio (RR)","95","2-Sided","0.15","1.73"
"1048","NCT01674725","A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","70 Years","187","August 2012","January 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses","0","0","0","100","Percentage of Participants","95","2-Sided","95.9","100.0"
"1049","NCT01674855","Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia","Chemotherapy Induced Neutropenia",0,"PEG-G-CSF","Drug","Dong-A ST Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","74","February 2012","February 2013","Duration of grade 4 neutropenia in cycle 1","0","0","0","0","0","0","0","0","0"
"1050","NCT01675167","Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects","Low Back Pain",0,"Buprenorphine","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","815","September 2012","June 2014","Change From Baseline to Week 12 in Average Daily Pain Intensity Scores","<.00001","P value was adjusted using weighted z-test (CHW).","ANCOVA","-0.98","Mean Difference (Net)","95","2-Sided","-1.32","-0.64"
"1051","NCT01676116","The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy","Diabetes",0,"insulin degludec/liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","438","August 2012","March 2014","Change in glycosylated haemoglobin (HbA1c) from baseline (randomisation, Visit 2)","0","0","0","0","0","0","0","0","0"
"1052","NCT01676220","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy","Type 2 Diabetes Mellitus",0,"HOE901-U300 (new formulation of insulin glargine)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","878","August 2012","September 2013","Change in HbA1c From Baseline to Month 6 Endpoint","0","0","0","0.04","Least Squares (LS) Mean Difference","95","2-Sided","-0.090","0.174"
"1053","NCT01676493","A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain","Pain",0,"Codeine","Drug","Roxane Laboratories","Industry",0,0,"All","2 Years","17 Years","31","August 2012","August 2013","tolerability and safety","0","0","0","0","0","0","0","0","0"
"1054","NCT01676701","Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"Tabalumab Auto-Injector","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","8","September 2012","August 2013","Pharmacokinetics (PK): Maximum serum concentration (Cmax) of tabalumab after loading dose","0","0","0","0","0","0","0","0","0"
"1055","NCT01677182","Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder","Bipolar Disorder",0,"Ramelteon","Drug","Takeda","Industry",0,0,"All","18 Years","75 Years","535","August 2012","August 2014","Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6","0.783","Mixed Model Repeated Measures (MMRM) model with baseline by week interaction, pooled center, week, treatment, baseline, and week by treatment interaction as factors was used for the analysis.","Mixed Model Repeated Measures","0.8","Least Squares Mean Differences","97.5","2-Sided","-1.4","3.0"
"1056","NCT01678820","A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","Type 2 Diabetes Mellitus",0,"Sitagliptin/Simvastatin FDC","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","299","October 10, 2012","November 1, 2013","Change From Baseline in Hemoglobin A1C (A1C) at Week 16 (Sitagliptin/Simvastatin FDC vs. Sitagliptin)","0.267","0","Longitudinal Data Analysis Model","0.19","Difference in least squares means","95","2-Sided","-0.14","0.52"
"1057","NCT01680016","A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults","Rabies",0,"Zagreb","Biological","Novartis Vaccines","Industry",0,0,"All","6 Years","N/A","644","September 2012","January 2013","Non-inferiority in Immune Response of the Zagreb Postexposure Schedule of Rabipur to That of the Conventional Essen Postexposure Schedule of Rabipur as Measured by GMC of RVNA Titer 14 Days After First Vaccination in Children Aged ≥6 to ≤17 Years.","0","0","0","0.84","Ratio of GMCs between two groups(Day 15)","95","2-Sided","0.69","1.02"
"1058","NCT01680341","Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","272","August 2012","August 2013","Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)","0","0","0","0","0","0","0","0","0"
"1059","NCT01681069","Efficacy and Safety of IQP-VV-102 in Weight Management","Obesity",0,"IQP-VV-102","Dietary Supplement","InQpharm Group","Industry",0,0,"All","18 Years","60 Years","120","October 2012","June 2013","Change in Body Weight at End of Study Compared to Baseline","0","0","0","0","0","0","0","0","0"
"1060","NCT01681524","Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI","Coronary Artery Disease",0,"Flurpiridaz F18","Drug","Lantheus Medical Imaging","Industry",0,0,"All","18 Years","N/A","0","November 2012","February 2014","Blinded Image assessment for PET & SPECT perfusion and for interventional coronary angiography","0","0","0","0","0","0","0","0","0"
"1061","NCT01681953","A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis","Alpha-Mannosidosis",0,"Lamazym","Drug","Zymenex A/S","Industry",0,0,"All","5 Years","35 Years","25","August 2012","May 2014","Reduction of oligosaccharides in serum","0","0","0","0","0","0","0","0","0"
"1062","NCT01682720","Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection","Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","421","September 2012","October 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1063","NCT01682863","A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation","Chronic Obstructive Pulmonary Disease (COPD)",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","614","October 2012","June 2014","Number of Patients With Adverse Events, Serious Adverse Events, and Death","0","0","0","0","0","0","0","0","0"
"1064","NCT01682876","Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","Meningococcal Disease",0,"MenACWY-CRM","Biological","Novartis Vaccines","Industry",0,0,"All","2 Years","10 Years","715","October 2012","July 2013","Non-inferiority of Two Vaccinations Versus One Vaccination of MenACWY-CRM, by Age Cohort, as Measured by the Percentage of Subjects With hSBA Seroresponse Against N. Meningitidis Serogroups A, C, W and Y, at 1 Month After Last Vaccination","0","0","0","19","Vaccine Group Differences at Day 86","97.5","2-Sided","10","28.9"
"1065","NCT01683058","Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole IM Depot","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","66 Years","74","January 2013","February 2014","Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious TEAEs and Outcome of Death","0","0","0","0","0","0","0","0","0"
"1066","NCT01683071","Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty","Postoperative Pain",0,"EXPAREL","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","278","September 2012","January 2014","Postoperative pain","0","0","0","0","0","0","0","0","0"
"1067","NCT01683266","Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"HOE901-U300 (Insulin glargine new formulation)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","549","September 2012","September 2013","Change In HbA1c From Baseline to Month 6 Endpoint","0","0","0","0.04","Least Squares (LS) Mean difference","95","2-Sided","-0.098","0.185"
"1068","NCT01685437","A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease","Peyronie's Disease",0,"AA4500","Biological","Endo Pharmaceuticals","Industry",0,0,"Male","18 Years","N/A","189","September 2012","December 2013","Percentage Change From Baseline in Penile Curvature","0","0","0","0","0","0","0","0","0"
"1069","NCT01685684","Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)","Chronic Low Back Pain",0,"Oxycodone DETERx","Drug","Collegium Pharmaceutical, Inc.","Industry",0,0,"All","18 Years","75 Years","740","August 2012","June 2014","Change in Average Pain Intensity Measured by the Change in Pain Intensity-Numeric Rating Scale (PI-NRS) Scores From Randomization Baseline to Week 12 of the Double-blind Maintenance Phase","<0.0001","0","z-test","-1.56","Marginal Mean Difference (Net)","0","2-Sided","0","0"
"1070","NCT01686152","Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis","Actinic Keratosis",0,"Imiquimod Cream, 3.75%","Drug","Teva Pharmaceuticals USA","Industry",0,0,"All","18 Years","N/A","589","September 2012","August 2013","Primary Efficacy Endpoint","0","0","0","0","0","0","0","0","0"
"1071","NCT01686633","An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.","Asthma",0,"Fluticasone Furoate/ Vilanterol 200/25 mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","1040","September 2012","October 2013","Change From Baseline in Weighted Mean Forced Expiratory Volume in One Second (FEV1) Over 0 to 24 Hours Post-dose at the End of the 12-week Treatment Period","<0.001","0","ANCOVA","0.108","Mean Difference (Final Values)","95","2-Sided","0.045","0.171"
"1072","NCT01687283","Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma","Asthma",0,"fluticasone propionate inhalation solution","Drug","GlaxoSmithKline","Industry",0,0,"All","17 Years","70 Years","316","September 2012","November 2013","Morning PEF","0","0","0","0","0","0","0","0","0"
"1073","NCT01687296","Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma","Asthma",0,"fluticasone propionate inhalation solution","Drug","GlaxoSmithKline","Industry",0,0,"All","4 Years","16 Years","261","November 2012","June 2013","morning PEF (peak expiratory flow)","0","0","0","0","0","0","0","0","0"
"1074","NCT01689129","Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"Insulin glargine new formulation (HOE901)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","243","September 2012","October 2013","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"1075","NCT01689142","Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"Insulin glargine new formulation (HOE901)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","240","September 2012","November 2013","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"1076","NCT01690221","Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures","Chronic Anal Fissures",0,"VEN 307","Drug","Ventrus Biosciences, Inc","Industry",0,0,"All","18 Years","75 Years","434","October 2012","December 2013","Change from baseline (average NRS during the last 3 days in which subject had a defecation during the 7 day screening period) in average of worst AF-related pain associated with or following defecation for Days 22-28 (Week 4).","0","0","0","0","0","0","0","0","0"
"1077","NCT01690299","Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis","Psoriasis",0,"Apremilast","Drug","Celgene","Industry",0,0,"All","18 Years","N/A","250","October 1, 2012","July 3, 2014","Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline","< 0.0001","The two-sided p-value is from a CMH test stratified by the BMI at screening.","Cochran-Mantel-Haenszel","27.5","Adjusted Difference","95","2-Sided","14.9","40.1"
"1078","NCT01691508","Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma","Asthma",0,"Mepolizumab","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","135","October 2012","December 2013","Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control","0.008","0","Proportional odds model","2.39","Odds Ratio (OR)","95","2-Sided","1.25","4.56"
"1079","NCT01691521","Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma","Asthma",0,"Mepolizumab IV","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","580","October 2012","January 2014","Number of Clinically Significant Exacerbations of Asthma Per Year","<0.001","Hochberg procedure with a gamma parameter of 1 used for multiplicity adjustment.","Negative binomial model","0.53","Rate Ratio","95","2-Sided","0.40","0.72"
"1080","NCT01691677","beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study","Acute Rhinosinusitis",0,"beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days","Drug","Chiesi Farmaceutici S.p.A.","Industry",0,0,"All","18 Years","65 Years","166","January 2013","January 2014","proportion of patients who will experience clinical success","0","0","0","0","0","0","0","0","0"
"1081","NCT01692886","A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China","Pneumococcal Infection",0,"7-valent Pneumococcal Conjugate Vaccine","Biological","Pfizer","Industry",0,0,"All","42 Days","77 Days","1674","August 2012","April 2014","Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Infant Series in Group 1 And Group 2.","0","0","0","0","0","0","0","0","0"
"1082","NCT01693029","Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa","Anemia",0,"HX575 epoetin alfa","Drug","Sandoz","Industry",0,0,"All","18 Years","N/A","437","September 2012","May 2014","Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)","0","0","0","-0.0926","Mean Difference (Final Values)","90","2-Sided","-0.2264","0.0413"
"1083","NCT01695135","A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy","Prostate Neoplasms",0,"Abiraterone acetate","Drug","Janssen Research & Development, LLC","Industry",0,0,"Male","18 Years","N/A","214","August 9, 2012","June 20, 2014","Time to prostate specific antigen (PSA) progression (TTPP)","0","0","0","0","0","0","0","0","0"
"1084","NCT01695187","NB-001 Treatment of Recurrent Herpes Labialis","Herpes Labialis",0,"NB-001 (0.3%)","Drug","NanoBio Corporation","Industry",0,0,"All","18 Years","N/A","362","October 2012","June 2013","Time to healing of the primary lesion complex (in days or fraction thereof) as assessed by the investigator.","0","0","0","0","0","0","0","0","0"
"1085","NCT01695239","A Study of Ixekizumab in Participants With Active Psoriatic Arthritis","Psoriasis, Arthritic",0,"Ixekizumab","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","417","December 2012","December 2014","Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24 (Efficacy of Ixekizumab in Participants With Active Psoriatic Arthritis. Measure: American College of Rheumatology 20 Index [ACR20])","<0.001","0","Regression, Logistic","0","0","0","0","0","0"
"1086","NCT01695616","Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms","Climacteric Syndrome",0,"Placebo","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"Female","40 Years","65 Years","0","August 2013","August 2014","Menopause Rating Scale - MRS","0","0","0","0","0","0","0","0","0"
"1087","NCT01696305","Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy","Thyroid Disease",0,"Hyalobarrier","Device","Green Cross Corporation","Industry",0,0,"All","18 Years","79 Years","198","December 2012","January 2014","The percentage of normal esophageal transit in marshmallow esophagography","0","0","0","0","0","0","0","0","0"
"1088","NCT01696500","Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.","Stevens-Johnson Syndrome",0,"Intravenous immunoglobulin","Drug","Nihon Pharmaceutical Co., Ltd","Industry",0,0,"All","20 Years","N/A","10","October 2012","June 2014","disease evaluation score","0","0","0","0","0","0","0","0","0"
"1089","NCT01697072","First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma","Gastric Cancer",0,"Rilotumumab","Drug","Amgen","Industry",0,0,"All","18 Years","99 Years","609","October 2012","November 2014","Overall Survival","0","0","0","0","0","0","0","0","0"
"1090","NCT01697111","Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis","Endometriosis",0,"EE20/DRSP(BAY86-5300)","Drug","Bayer","Industry",0,0,"Female","20 Years","N/A","312","October 2012","March 2014","Change of pelvic pain from baseline period (8 weeks before start of treatment) to period of treatment (weeks 17-24)","0","0","0","0","0","0","0","0","0"
"1091","NCT01697592","Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)","Type 2 Diabetes Mellitus",0,"Omarigliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","585","October 2012","May 2014","Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A","0","0","0","0","0","0","0","0","0"
"1092","NCT01697696","Long Term Safety Study of NVA237 vs QAB149 in COPD Patients","Chronic Obstructive Pulmonary Disease (COPD)",0,"NVA237","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","511","October 2012","November 2014","Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate","0","0","0","0","0","0","0","0","0"
"1093","NCT01697956","Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)","Allergic Rhinitis",0,"BDP","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","6 Years","11 Years","99","October 2012","February 2013","Change From Baseline (Expressed As A Ratio) In 24-Hr Serum Cortisol Weighted Mean Following 6 Weeks Of Treatment","0","0","0","0.91","ratio of BDP nasal aerosol to placebo","95","2-Sided","0.81","1.03"
"1094","NCT01698320","Safety Study of Albuterol Spiromax® in Subjects With Asthma","Asthma",0,"Placebo MDPI","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","12 Years","N/A","364","October 2012","December 2013","Participants With Adverse Experiences During Weeks 0-12 (Double-Blind Period)","0","0","0","0","0","0","0","0","0"
"1095","NCT01698554","Bimatoprost in the Treatment of Eyelash Hypotrichosis","Idiopathic Eyelash Hypotrichosis",0,"bimatoprost formulation A solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","464","November 2012","February 2014","Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA)","0","0","0","0","0","0","0","0","0"
"1096","NCT01698814","A Six-Week Safety Study of an Investigational Ophthalmic Solution","Allergic Conjunctivitis",0,"AL-4943A Ophthalmic Solution","Drug","Alcon Research","Industry",0,0,"All","2 Years","N/A","518","October 2012","January 2013","Adverse Events","0","0","0","0","0","0","0","0","0"
"1097","NCT01699685","Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.","Chronic Obstructive Pulmonary Disease: COPD",0,"QAB149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","79","November 2012","June 2014","Inspiratory Capacity (IC) Peak Value","0","0","0","0","0","0","0","0","0"
"1098","NCT01699932","Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled","Type 2 Diabetes Mellitus",0,"Glimepiride+metformin (Amaryl M®) - HOE4900","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","167","September 2012","April 2014","Change in HbA1c","0","0","0","0","0","0","0","0","0"
"1099","NCT01701024","Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne","Acne",0,"ACYC","Drug","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","12 Years","40 Years","498","October 2012","May 2013","Absolute Change in Inflammatory Lesion Count","0","0","0","0","0","0","0","0","0"
"1100","NCT01701401","Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV","Chronic Hepatitis C Virus",0,"LDV/SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","870","September 2012","March 2014","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Study Drug (SVR12)","<0.001","The p-value for the comparison of the LDV/SOF 12 week group against the adjusted historical null rate (60%) was based on a 2-sided 1-sample binomial test.","Binomial test","0","0","0","0","0","0"
"1101","NCT01702103","Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays","Nasal Obstruction",0,"Mometasone furoate","Drug","PH&T S.p.A.","Industry",0,0,"All","12 Years","65 Years","360","October 2012","January 2013","demonstrate the therapeutic clinical equivalence of two mometasone nasal sprays in the relief of the signs and symptoms of perennial allergic rhinitis, in term of changes at week 8 from baseline of Total Nasal Symptom Scores (TNSS).","0","0","0","0","0","0","0","0","0"
"1102","NCT01702233","TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study","Rotator Cuff Syndrome",0,"Traumeel S inj","Drug","Biologische Heilmittel Heel GmbH","Industry",0,0,"All","40 Years","65 Years","175","April 2013","April 2014","Change From Baseline in Abduction Rotation Pain VAS at Visit 5 (Day 22) (Traumeel® S Injections Versus Fortecortin) for Active External Rotation","<0.05","0","ANCOVA","13","Mean Difference (Final Values)","95","1-Sided","0","97.5"
"1103","NCT01702298","A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","Type 2 Diabetes Mellitus",0,"Sitagliptin 100 mg/simvastatin 40 mg FDC","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","79 Years","42","December 7, 2012","May 29, 2013","Change From Baseline in Fasting Plasma Glucose (FPG)","0","0","0","0","0","0","0","0","0"
"1104","NCT01702363","Long-term Safety Study for GSK573719 in Japanese","Pulmonary Disease, Chronic Obstructive",0,"GSK573719","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","131","August 2012","December 2013","Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) Throughout the Treatment Period","0","0","0","0","0","0","0","0","0"
"1105","NCT01703221","Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)","Type 2 Diabetes Mellitus",0,"Omarigliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","20 Years","N/A","414","October 2012","April 2014","Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24","<0.001","0","Constrained longitudinal analysis","-0.80","Difference in the least squares means","95","2-Sided","-0.96","-0.63"
"1106","NCT01703741","A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel","Adult Male Hypogonadism",0,"Testosterone Gel (FE 999093)","Drug","Ferring Pharmaceuticals","Industry",0,0,"Male","18 Years","75 Years","145","December 2012","October 2013","Percentage of subjects with a serum total testosterone level of 1500-1799, 1800-2499, or above 2500 ng/dL","0","0","0","0","0","0","0","0","0"
"1107","NCT01704079","Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","Chronic Kidney Disease",0,"CTAP101 30 μg capsules","Drug","OPKO IP Holdings II, Inc.","Industry",0,0,"All","18 Years","85 Years","216","November 2012","August 2014","Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline","<0.0001","0","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1108","NCT01704261","Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)","Type 2 Diabetes Mellitus",0,"Omarigliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","307","October 2012","December 2014","Change From Baseline in Hemoglobin A1c (A1C) at Week 24","<0.001","0","Difference in the least squares means","-0.61","Mean Difference (Final Values)","95","2-Sided","-0.85","-0.38"
"1109","NCT01704755","A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","70 Years","381","October 2012","January 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment","0","0","0","91.8","Percentage of Participants","97.5","2-Sided","87.6","96.1"
"1110","NCT01705145","Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation","Cystic Fibrosis",0,"Ivacaftor","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","2 Years","5 Years","35","January 2013","March 2014","Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs","0","0","0","0","0","0","0","0","0"
"1111","NCT01705197","This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.","Erectile Dysfunction",0,"Avanafil 100 or 200mg","Drug","JW Pharmaceutical","Industry",0,0,"Male","20 Years","N/A","195","February 2012","April 2013","Compare with the changes in IIEF(The International Index of Erectile Function)Erectile Function domain score between the study group and control group.","0","0","0","0","0","0","0","0","0"
"1112","NCT01706328","A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF/VI 100/25 Inhalation Powder NDPI","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","828","October 15, 2012","June 17, 2013","Change From Baseline Trough in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) on Treatment Day 84","0.137","0","ANCOVA","0.025","Mean Difference (Net)","95","2-Sided","-0.008","0.059"
"1113","NCT01706484","Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis","Chronic Sinusitis",0,"BNO 1016","Drug","Bionorica SE","Industry",0,0,"All","18 Years","75 Years","927","September 2012","April 2014","Average of investigator's Major Symptom Score ratings [score points] at V5 and V6","0","0","0","0","0","0","0","0","0"
"1114","NCT01706523","Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders","Autism Spectrum Disorders",0,"STX209 (arbaclofen)","Drug","Seaside Therapeutics, Inc.","Industry",0,0,"All","5 Years","21 Years","165","November 2011","July 2013","Safety and tolerability of STX209","0","0","0","0","0","0","0","0","0"
"1115","NCT01708590","Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects","Moderate to Severe Plaque Psoriasis",0,"210 mg brodalumab","Drug","Amgen","Industry",0,0,"All","18 Years","75 Years","661","August 2012","May 2014","Static Physician Global Assessment (sPGA) score","0","0","0","0","0","0","0","0","0"
"1116","NCT01708603","Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","Moderate to Severe Plaque Psoriasis",0,"210 mg brodalumab","Drug","Amgen","Industry",0,0,"All","18 Years","75 Years","1831","August 2012","September 2014","Improvement in Psoriasis Area and Severity Index (PASI)","0","0","0","0","0","0","0","0","0"
"1117","NCT01708629","Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects","Moderate to Severe Plaque Psoriasis",0,"210 mg brodalumab","Drug","Amgen","Industry",0,0,"All","18 Years","75 Years","1881","September 2012","August 2014","Improvement in Psoriasis Area and Severity Index (PASI)","0","0","0","0","0","0","0","0","0"
"1118","NCT01709240","Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure","Child Delivery Using an Elective C- Section",0,"BioWeld1 System","Device","IonMed Ltd","Industry",0,0,"Female","20 Years","40 Years","0","January 2013","April 2013","Safety","0","0","0","0","0","0","0","0","0"
"1119","NCT01709500","Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","Heterozygous Familial Hypercholesterolemia",0,"LMT (atorvastatin, simvastatin, or rosuvastatin)","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","249","December 2012","May 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-51.4","LS Mean Difference","95","2-Sided","-58.1","-44.8"
"1120","NCT01709513","Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","Hypercholesterolemia",0,"Atorvastatin","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","314","September 2012","May 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.05.","Mixed Models Analysis","-30.4","LS Mean Difference","95","2-Sided","-36.6","-24.2"
"1121","NCT01709864","NVA237 Versus Placebo 12-week Efficacy Study","Chronic Obstructive Pulmonary Disease",0,"NVA237","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","440","November 2012","October 2013","Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing","0","0","0","0","0","0","0","0","0"
"1122","NCT01709903","A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","744","November 2012","February 2014","Trough Forced Expiratory Volume in One Second (FEV1) Following 26 Weeks of Treatment to Demonstrate the Non-inferiority of QVA149 110/50 μg o.d. to Fluticasone/Salmeterol 500/50 μg b.i.d","0","0","0","0","0","0","0","0","0"
"1123","NCT01710514","A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment","Luteal Hormone Supplementation",0,"FE 999913 vaginal tablet","Drug","Ferring Pharmaceuticals","Industry",0,0,"Female","20 Years","42 Years","108","October 2012","August 2013","The Proportion of Subjects With Blood Progesterone Concentration Not Less Than 10 ng/ml","0","0","0","-0.9","Difference of % to historical control","95","2-Sided","-3.6","1.8"
"1124","NCT01710657","A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures","Epilepsy",0,"Lacosamide 50 mg","Drug","UCB Pharma SA","Industry",0,0,"All","16 Years","70 Years","548","September 2012","July 2014","Change in Partial-Onset Seizure Frequency Per 28 Days From Baseline to the Maintenance Period","<0.001","Significant at the 0.05 level. This testing procedure is considered a closed testing procedure and no adjustment of the significance level was necessary.","ANCOVA","39.6","% Reduction over Placebo","95","2-Sided","30.5","47.6"
"1125","NCT01710787","Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults","Anesthesia",0,"Tetracaine HCl 3% and Oxymetazoline HCl 0.05%","Drug","St. Renatus, LLC","Industry",0,0,"All","18 Years","N/A","110","October 2012","February 2013","Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).","0","0","0","0","0","0","0","0","0"
"1126","NCT01712516","A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation","Chronic Obstructive Pulmonary Disease (COPD)",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","1001","December 2012","February 2014","Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h))","0","0","0","0","0","0","0","0","0"
"1127","NCT01712984","Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years","Influenza",0,"Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","18 Years","64 Years","3360","October 2012","June 2013","Geometric Mean Titers Against the Influenza Virus Antigens Following Vaccination With Either a Quadrivalent Influenza Vaccine or a Trivalent Influenza Vaccine Administered by Intradermal Route","0","0","0","0","0","0","0","0","0"
"1128","NCT01713530","A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","274","February 2013","January 2014","Change From Baseline in HbA1c (%)","0","0","0","0","0","0","0","0","0"
"1129","NCT01715129","Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer","Prostate Cancer",0,"Triptorelin Pamoate 11.25mg","Drug","Ipsen","Industry",0,0,"Male","18 Years","N/A","126","January 2013","October 2013","Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183","0","0","0","0","0","0","0","0","0"
"1130","NCT01715298","NVA237 BID Versus Placebo Twelve-week Efficacy Study","Chronic Obstructive Pulmonary Disease",0,"NVA237","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","432","November 2012","December 2013","Change From Baseline in Standardized Area Under the Curve for Forced Expiratory Volume in One Second Post Dosing","0","0","0","0","0","0","0","0","0"
"1131","NCT01715415","A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","70 Years","395","November 2012","November 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","0","0","0","96.3","Percentage of Participants with SVR12","95","2-Sided","94.1","98.4"
"1132","NCT01716520","Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium/Vilanterol 62.5/25 mcg","Device","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","182","October 2012","March 2013","Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type","<0.001","Analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of treatment, period, mean Baseline, period Baseline, response type and treatment by response type interaction.","ANCOVA","0.121","Mean Difference (Final Values)","95","2-Sided","0.085","0.157"
"1133","NCT01716585","A Study to Evaluate Chronic Hepatitis C Infection","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","70 Years","636","November 2012","October 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","0","0","0","96.4","Percentage of Participants with SVR12","95","2-Sided","94.7","98.1"
"1134","NCT01716923","Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia","Focus:Use of S303 RBCs in Patients With Acute Anemia",0,"S-303 Red Blood Cells (RBCs) - Test","Biological","Cerus Corporation","Industry",0,0,"All","18 Years","N/A","81","April 2013","July 2014","Primary Efficacy Endpoint - mean hemoglobin content","0","0","0","0","0","0","0","0","0"
"1135","NCT01717300","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)","Hypercholesterolemia",0,"Anacetrapib 100 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","459","November 6, 2012","October 29, 2014","Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)","0","0","0","0","0","0","0","0","0"
"1136","NCT01717638","Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1","Meningococcal Disease",0,"1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","48 Months","60 Months","805","November 2012","September 2013","Percentages of Subjects With Persisting Serum Bactericidal Titers ≥1:5 and ≥1:8 (at 4 Years of Age), Who Had Previously Received Three Primary Doses and One Booster Dose of rMenB+OMV NZ Vaccine According to Different Schedules","0","0","0","0","0","0","0","0","0"
"1137","NCT01718119","Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel","Hyperovulation Induction for Assisted Reproduction Treatment",0,"r-hCG","Drug","Dong-A Pharmaceutical Co., Ltd.","Industry",0,0,"Female","20 Years","38 Years","180","February 2012","February 2013","the efficacy and safety of DA-3803(r-hCG)","0","0","0","0","0","0","0","0","0"
"1138","NCT01718145","A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects","Hepatitis C Virus Infection",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","20 Years","75 Years","258","November 2012","December 2013","Proportion of subjects with SVR12, defined as HCV RNA target detected or target not detected below LLOQ in the naive cohort","0","0","0","0","0","0","0","0","0"
"1139","NCT01718158","Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy","Hepatitis C",0,"Peginterferon Lambda-1a","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","444","January 2013","October 2014","Proportion of subjects with Sustained Virologic Response at post-treatment follow-up Week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"1140","NCT01718483","SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","Binge Eating Disorder",0,"SPD489 (Lisdexamfetamine dimesylate)","Drug","Shire","Industry",0,0,"All","18 Years","55 Years","383","November 2012","September 2013","Change From Baseline in the Number of Binge Days Per Week at Visit 8 (Weeks 11-12)","<0.001","0","Mixed Models Repeated Measures Analysis","-1.35","Least squares mean difference","95","2-Sided","-1.70","-1.01"
"1141","NCT01718509","SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder","Binge Eating Disorder",0,"SPD489 (Lisdexamfetamine dimesylate)","Drug","Shire","Industry",0,0,"All","18 Years","55 Years","390","November 2012","September 2013","Change From Baseline in the Number of Binge Days Per Week at Visit 8 Which Spans Weeks 11/12","<0.001","0","Mixed Models Repeated Measures Analysis","-1.66","Least Squares Mean Difference","95","2-Sided","-2.04","-1.28"
"1142","NCT01720485","Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment","Allergic Rhinitis",0,"Desloratadine + Prednisolone","Drug","EMS","Industry",0,0,"All","18 Years","N/A","234","October 2013","December 2013","Efficacy of treatment in persistent allergic rhinitis based on nasal symptoms score","0","0","0","0","0","0","0","0","0"
"1143","NCT01721044","A Moderate to Severe Rheumatoid Arthritis Study","Rheumatoid Arthritis",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","525","January 2013","June 2014","Proportion of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)","0","0","0","0","0","0","0","0","0"
"1144","NCT01721057","A Study in Moderate to Severe Rheumatoid Arthritis Participants","Rheumatoid Arthritis",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","684","December 2012","September 2014","Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)","0.001","0","Regression, Logistic","0","0","0","0","0","0"
"1145","NCT01721694","Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection","Ocular Inflammation",0,"azithromycin 1.5%/Loteprednol 0,5% + placebo","Drug","Adapt Produtos Oftalmológicos Ltda.","Industry",0,0,"All","18 Years","N/A","0","December 2012","March 2013","Clinical cure","0","0","0","0","0","0","0","0","0"
"1146","NCT01721707","Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH","Open Angle Glaucoma",0,"Latanoprost+Brinzolamide combination","Drug","Adapt Produtos Oftalmológicos Ltda.","Industry",0,0,"All","18 Years","N/A","0","December 2012","March 2013","IOP","0","0","0","0","0","0","0","0","0"
"1147","NCT01721772","Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma","Melanoma",0,"BMS-936558 (Nivolumab)","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","583","January 2013","June 2014","Overall Survival (OS)","<0.0001","0","Stratified Log Rank Test","0.42","Hazard Ratio (HR)","95","2-Sided","0.30","0.60"
"1148","NCT01722331","A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)","Plaque Psoriasis",0,"MK-3222 200 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","772","December 2012","June 2014","Proportion of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12","0","0","0","0","0","0","0","0","0"
"1149","NCT01722864","Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)","Osteoarthritis, Knee",0,"COV155","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","N/A","153","November 2012","February 2013","Safety and tolerability of COV155","0","0","0","0","0","0","0","0","0"
"1150","NCT01723072","Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","Chronic Spontaneous Urticaria",0,"Omalizumab","Biological","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","75 Years","91","January 2013","May 2014","Chronic urticaria quality of life questionnaire (CU-Q2oL)","0","0","0","0","0","0","0","0","0"
"1151","NCT01723904","A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease","Advanced Parkinson's Disease",0,"Rotigotine","Drug","UCB BIOSCIENCES GmbH","Industry",0,0,"All","30 Years","80 Years","90","October 2012","March 2013","Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period","0","0","0","0","0","0","0","0","0"
"1152","NCT01724268","Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient","RHEUMATOID ARTHRITIS",0,"Pred + Meth","Drug","Hamad Medical Corporation","Industry",0,0,"All","18 Years","N/A","80","May 2012","May 2014","Disease activity score","0","0","0","0","0","0","0","0","0"
"1153","NCT01724528","Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies","Tumor Lysis Syndrome",0,"Febuxostat","Drug","Menarini Group","Industry",0,0,"All","18 Years","N/A","346","October 2012","October 2013","Serum Uric Acid (sUA) Level Control","<0.0001","0","ANCOVA","-196.794","Least squares means difference","95","2-Sided","-238.600","-154.988"
"1154","NCT01725217","Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia","Meningococcal Disease",0,"MenACWY-CRM","Biological","Novartis Vaccines","Industry",0,0,"All","2 Years","N/A","198","November 2012","March 2013","Percentages of Overall Subjects With Seroresponse After MenACWY-CRM Vaccination","0","0","0","0","0","0","0","0","0"
"1155","NCT01725529","An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients","Hepatitis C, Chronic",0,"TMC435","Drug","Janssen R&D Ireland","Industry",0,0,"All","18 Years","70 Years","457","November 2012","August 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)","0","0","0","0","0","0","0","0","0"
"1156","NCT01725646","An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients","Hypertriglyceridemia",0,"Omacor®","Drug","Excelsior","Industry",0,0,"All","20 Years","79 Years","253","July 2011","July 2013","Change in Triglycerides from baseline","0","0","0","0","0","0","0","0","0"
"1157","NCT01725984","AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up","Urinary Incontinence, Stress",0,NA,NA,"American Medical Systems","Industry",0,0,"Male","40 Years","N/A","80","August 2012","January 2013","Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use","0","0","0","0","0","0","0","0","0"
"1158","NCT01726920","Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.","Migraine",0,"naratriptan + naproxen","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"All","18 Years","65 Years","0","July 2014","December 2014","Headache relief 2 hours after dosing, without use of rescue medication","0","0","0","0","0","0","0","0","0"
"1159","NCT01726933","LAS41008 in Moderate to Severe Chronic Plaque Psoriasis","Plaque Psoriasis",0,"LAS41008","Drug","Almirall, S.A.","Industry",0,0,"All","18 Years","N/A","839","November 2012","October 2014","PASI 75","0","0","0","0","0","0","0","0","0"
"1160","NCT01727141","A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.","Chronic Obstructive Pulmonary Disease (COPD)",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","40 Years","N/A","1042","November 2012","February 2014","Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h))","0","0","0","0","0","0","0","0","0"
"1161","NCT01727700","Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","Tourette's Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","7 Years","17 Years","133","November 2012","August 2013","Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS).","0.0020","The Hochberg procedure was used to adjust for multiplicity.","Mixed Models Analysis","-6.26","Treatment difference","95","2-Sided","-10.18","-2.34"
"1162","NCT01727713","Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","Tourette's Disorder",0,"Aripiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","7 Years","18 Years","110","January 2013","August 2014","Percentage of Participants With Adverse Events.","0","0","0","0","0","0","0","0","0"
"1163","NCT01729754","A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)","Plaque Psoriasis",0,"Tildrakizumab 200 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","1090","February 2013","August 2014","Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12","0","0","0","0","0","0","0","0","0"
"1164","NCT01729871","A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy","Atrial Fibrillation",0,"rivaroxaban","Drug","Janssen Scientific Affairs, LLC","Industry",0,0,"All","18 Years","N/A","253","February 2013","October 2014","Number of Participants With Incidence of Post-Procedure Major Bleeding Events","0","0","0","0","0","0","0","0","0"
"1165","NCT01730040","Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","Hypercholesterolemia",0,"Alirocumab","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","355","October 2012","April 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis","< 0.0001","0","Mixed Models Analysis","-39.1","LS Mean Difference","99","2-Sided","-55.9","-22.2"
"1166","NCT01730053","Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","Hypercholesterolemia",0,"Alirocumab","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","305","November 2012","April 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","<0.0001","Threshold for significance ≤ 0.0125.","Mixed Models Analysis","-34.2","LS Mean Difference","98.75","2-Sided","-49.2","-19.3"
"1167","NCT01730898","Lutein Absorption in Healthy Adults","Healthy Subjects",0,"Study product containing lutein","Other","Abbott Nutrition","Industry",0,0,"All","18 Years","45 Years","24","November 2012","March 2013","Plasma lutein","0","0","0","0","0","0","0","0","0"
"1168","NCT01731210","Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)","LV Lead",0,"implantation of the new LV lead: NANO system.","Device","LivaNova","Industry",0,0,"All","18 Years","N/A","128","November 2012","November 2013","Freedom from left ventricular lead related complications through 1 month","0","0","0","0","0","0","0","0","0"
"1169","NCT01732471","Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria","Phenylketonuria",0,"Kuvan®","Drug","Merck KGaA","Industry",0,0,"All","4 Years","18 Years","90","November 2012","October 2013","Percentage of Participants With Response to Kuvan® (Sapropterin Dihydrochloride) Treatment","0","0","0","0","0","0","0","0","0"
"1170","NCT01732536","Safety and Efficacy of a Steroid-Releasing Sinus Implant for Recurrent Sinus Obstruction","Chronic Sinusitis",0,"S8 Sinus Implant","Drug","Intersect ENT","Industry",0,0,"All","18 Years","N/A","100","January 2013","November 2013","nasal obstruction/congestion","0","0","0","0","0","0","0","0","0"
"1171","NCT01732692","Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation","Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.",0,"MOVIPREP","Drug","Takeda","Industry",0,0,"All","18 Years","85 Years","140","November 2012","April 2013","Percentage of Participants With Successful Colon Cleansing","<0.001","0","Exact Farrington - Manning","0.0286","Treatment Difference","95","1-Sided","-0.097","0"
"1172","NCT01733758","A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","Diabetes Mellitus, Type 2",0,"Albiglutide 30 mg weekly","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","494","February 2013","June 2014","Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0","0","0","-1.55","Mean Difference (Net)","95","2-Sided","-1.72","-1.39"
"1173","NCT01734239","A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)","Pneumococcal Disease",0,"Pneumovax™ 23","Biological","Merck Sharp & Dohme Corp.","Industry",0,0,"All","2 Years","N/A","102","June 2013","October 2013","Geometric Mean Concentration of Antibodies to Pneumococcal Serotypes Contained in the Vaccine","0","0","0","0","0","0","0","0","0"
"1174","NCT01735175","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®","Neutropenic Complications",0,"LA-EP2006","Drug","Sandoz","Industry",0,0,"Female","18 Years","N/A","316","June 2012","May 2013","Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy","0.05","0","ANCOVA","0.07","Mean Difference (Net)","95","2-Sided","-0.12","0.26"
"1175","NCT01736423","A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome","Diarrhea-predominant Irritable Bowel Syndrome",0,"YM060","Drug","Astellas Pharma Inc","Industry",0,0,"Female","20 Years","64 Years","151","September 2012","May 2014","Monthly responder rate of global assessment of relief of overall IBS symptoms","0","0","0","0","0","0","0","0","0"
"1176","NCT01736475","Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)","Hemophilia A",0,"Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method","Biological","Baxalta US Inc.","Industry",0,0,"Male","12 Years","65 Years","159","January 2013","July 2014","Annualized Bleeding Rate (ABR)","<0.0001","0","Regression, Negative binomial","0.10","Ratio of means","95","2-Sided","0.06","0.19"
"1177","NCT01736579","Long-Term Study of IGIV, 10% in Alzheimer´s Disease","Alzheimer´s Disease",0,"Immune Globulin Intravenous (Human), 10% (IGIV, 10%)","Drug","Baxalta US Inc.","Industry",0,0,"All","51 Years","N/A","6","November 2012","June 2013","Number and Severity of Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"1178","NCT01736891","Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations","Parkinson´s Disease",0,"Rasagiline","Drug","Chongqing Fortune Pharmaceutical Co., Ltd.","Industry",0,0,"All","30 Years","75 Years","268","November 2011","June 2013","Efficacy of rasagiline vs placebo as assessed by the change from baseline to week 14 in mean total daily OFF time measured by patients' home diaries in levodopa-treated PD patients with motor fluctuations.","0","0","0","0","0","0","0","0","0"
"1179","NCT01737697","Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia","Hyperkalemia",0,"Zirconium silicate (acute phase)","Drug","ZS Pharma, Inc.","Industry",0,0,"All","18 Years","N/A","750","November 2012","October 2013","Change in serum potassium levels from baseline after administration of zirconium silicate three times a day.","0","0","0","0","0","0","0","0","0"
"1180","NCT01737905","Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma","Asthma",0,"Epinephrine HFA-MDI (E004)","Drug","Amphastar Pharmaceuticals, Inc.","Industry",0,0,"All","4 Years","11 Years","28","October 2012","March 2013","Bronchodilator effect","0","0","0","0","0","0","0","0","0"
"1181","NCT01738282","Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients","Alcohol Dependence",0,"Baclofen","Drug","Ethypharm","Industry",0,0,"All","18 Years","N/A","316","December 2012","July 2014","Continuous abstinence rate in each group (baclofen or placebo) during 20 weeks of treatment, from Day 29 to Day 168.","0","0","0","0","0","0","0","0","0"
"1182","NCT01738698","Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia","Schizophrenia",0,"SPD489 40mg","Drug","Shire","Industry",0,0,"All","18 Years","65 Years","4","November 2012","April 2013","Change From Baseline in Negative Symptom Assessment - 16-item (NSA-16) Total Score at 12 Weeks","0","0","0","0","0","0","0","0","0"
"1183","NCT01739582","An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism","Secondary Hypogonadism",0,"Androxal","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","300","November 2012","April 2014","Testosterone levels","0","0","0","0","0","0","0","0","0"
"1184","NCT01739595","Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism","Secondary Hypogonadism",0,"enclomiphene citrate","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","181","November 2012","September 2013","Subjects With Testosterone in Normal Range After Treatment","0","0","0","0","0","0","0","0","0"
"1185","NCT01740388","Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis","Bacterial Conjunctivitis",0,"Besifloxacin","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","1 Year","N/A","136","February 2013","July 2013","Clinical Resolution","0","0","0","0","0","0","0","0","0"
"1186","NCT01742585","A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis","Chronic Kidney Disease",0,"ASP1585","Drug","Astellas Pharma Inc","Industry",0,0,"All","20 Years","N/A","163","October 2012","May 2014","Change from baseline in serum phosphorus level at the end of treatment","0","0","0","0","0","0","0","0","0"
"1187","NCT01743027","Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis","Allergic Conjunctivitis",0,"AL-4943A ophthalmic solution","Drug","Alcon Research","Industry",0,0,"All","18 Years","N/A","902","January 2013","July 2013","Mean Ocular Itching at Onset of Action","0","0","0","0","0","0","0","0","0"
"1188","NCT01743625","Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain","Pain, Postoperative",0,"COV155","Drug","Mallinckrodt","Industry",0,0,"All","18 Years","N/A","406","November 2012","May 2013","SPID48 (Summed pain intensity difference)","0","0","0","0","0","0","0","0","0"
"1189","NCT01743651","Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis","Spasticity",0,"arbaclofen","Drug","Osmotica Pharmaceutical US LLC","Industry",0,0,"All","18 Years","65 Years","353","November 2012","April 2014","Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb.","0","0","0","0","0","0","0","0","0"
"1190","NCT01743729","A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye","Dry Eye",0,"Lifitegrast","Drug","Shire","Industry",0,0,"All","18 Years","N/A","720","December 2012","October 2013","Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84","0.6186","0","ANCOVA","0.03","Treatment Effect","95","2-Sided","-0.10","0.17"
"1191","NCT01745380","Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults","Anesthesia",0,"Tetracaine HCl 3% and Oxymetazoline HCl 0.05%","Drug","St. Renatus, LLC","Industry",0,0,"All","18 Years","N/A","150","February 2013","May 2013","Number of Participants Who Completed the Study Dental Procedure Without Need for Rescue by Injection of Local Anesthetic.","0","0","0","0","0","0","0","0","0"
"1192","NCT01747629","Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics","Asthma",0,"Placebo MDPI","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","160","December 2012","October 2013","Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period","<0.0001","Significance at the 0.05 level.","mixed-model repeated-measures (MMRM)","0.92","Mean Difference (Final Values)","95","2-Sided","0.59","1.24"
"1193","NCT01747668","Lactation Fortification Study","Lactation",0,"Similac Prenatal Vitamin soft-gel capsule","Dietary Supplement","Abbott Nutrition","Industry",0,0,"Female","18 Years","N/A","89","November 2012","April 2013","Breast milk concentration of carotenoids","0","0","0","0","0","0","0","0","0"
"1194","NCT01749046","Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures","Epilepsy",0,"Remegal","Drug","Valexfarm","Industry",0,0,"All","18 Years","65 Years","224","March 2012","October 2013","Seizure Frequency Reduction","0","0","0","0","0","0","0","0","0"
"1195","NCT01750814","To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults","Prophylaxis Against Influenza",0,"GC3102C","Biological","Green Cross Corporation","Industry",0,0,"All","18 Years","60 Years","400","June 2013","July 2013","GMT, using the Hemagglutination inhibition(HI) antibody titer","0","0","0","0","0","0","0","0","0"
"1196","NCT01751360","SYR-472 Open-label Study","Diabetes Mellitus",0,"SYR-472","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","14","April 2013","August 2013","Blood Glucose","0","0","0","0","0","0","0","0","0"
"1197","NCT01751802","Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease","Lesch-Nyhan Disease",0,"Ecopipam","Drug","Psyadon Pharma","Industry",0,0,"All","6 Years","70 Years","9","December 2012","December 2013","Behavior Problems Inventory - Self-Injurious Behavior Subscale","0","0","0","0","0","0","0","0","0"
"1198","NCT01753102","Efficacy and Safety Of Spil's Estradiol Vaginal Tablet","Vulvar Atrophy",0,"Estradiol","Drug","Sun Pharmaceutical Industries Limited","Industry",0,0,"Female","N/A","N/A","49","November 2012","April 2013","Vaginal pH","0","0","0","0","0","0","0","0","0"
"1199","NCT01753310","Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.","Cervical Dystonia",0,"Dysport®","Drug","Ipsen","Industry",0,0,"All","18 Years","N/A","134","January 2013","October 2014","Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score at Week 4.","<0.001","0","t-test, 2 sided","-8.3","Mean Difference","95","2-Sided","-12.17","-4.47"
"1200","NCT01753557","Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C","Chronic Hepatitis C (CHC)",0,"MP-424","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","20 Years","65 Years","54","December 2012","November 2014","Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)","0","0","0","0","0","0","0","0","0"
"1201","NCT01754714","Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group","Non Alcoholic Fatty Liver Disease",0,"SAMe 1000 mg","Drug","Abbott","Industry",0,0,"All","18 Years","99 Years","108","December 2012","September 2014","Methionine Elimination Half-life Measured in Blood.","0","0","0","0","0","0","0","0","0"
"1202","NCT01754974","Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C","Hepatitis C Virus (HCV)",0,"Peginterferon Lambda-1a","Biological","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","70 Years","40","March 2013","September 2014","Proportion of subjects who develop treatment emergent cytopenic abnormalities (anemia as defined by Hb < 10 g/dL, and/or neutropenia as defined by ANC < 750 mm3 and/or thrombocytopenia as defined by platelets < 50,000 mm3) in treatment-naive subjects","0","0","0","0","0","0","0","0","0"
"1203","NCT01755364","A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old","Influenza",0,"AdimFlu-V","Biological","Adimmune Corporation","Industry",0,0,"All","3 Years","17 Years","120","November 2012","January 2013","The primary objective is to evaluate the immunogenicity profiles for influenza virus vaccine strains (2012-2013 season) of the AdimFlu-V.","0","0","0","0","0","0","0","0","0"
"1204","NCT01755546","Long-term Open-Label Safety Study to Evaluate EN3409","Low Back Pain",0,"EN3409","Drug","BioDelivery Sciences International","Industry",0,0,"All","18 Years","N/A","554","December 2012","October 2014","To determine the long-term safety and tolerability of BEMA Buprenorphine (dosed every 12 hours [Q12h]) in subjects with moderate to severe chronic pain (CP) requiring continuous around-the-clock (ATC) opioid analgesia for an extended period of time","0","0","0","0","0","0","0","0","0"
"1205","NCT01756339","Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia","Community-acquired Bacterial Pneumonia",0,"Solithromycin","Drug","Cempra Inc","Industry",0,0,"All","18 Years","N/A","860","December 2012","October 2014","Early clinical response rate in the Intent to Treat (ITT) population","0","0","0","0","0","0","0","0","0"
"1206","NCT01756430","Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension","Hypertension",0,"Carvedilol SR 32mg, QD","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","N/A","238","December 2012","September 2013","Mean Sitting Diastolic Blood Pressure (MSDBP)","0","0","0","0","0","0","0","0","0"
"1207","NCT01757405","Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen","Hemophilia A",0,"Recombinant Factor VIIa BI (rFVIIa BI)","Biological","Baxalta US Inc.","Industry",0,0,"Male","12 Years","65 Years","40","February 2013","November 2014","Percentage of Bleeding Episode With ""Treatment Success""","0","0","0","1.21","Ratio of success proportion","90","2-Sided","1.15","1.28"
"1208","NCT01760889","SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","Schizophrenia",0,"SPD489 low dose range (40mg, 80mg, and 100mg)","Drug","Shire","Industry",0,0,"All","18 Years","65 Years","1","February 2013","April 2013","Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 26 Weeks","0","0","0","0","0","0","0","0","0"
"1209","NCT01760993","Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia","Schizophrenia",0,"SPD489","Drug","Shire","Industry",0,0,"All","18 Years","65 Years","2","February 2013","April 2013","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks","0","0","0","0","0","0","0","0","0"
"1210","NCT01762761","Eltrombopag Phase III Study In Chinese Chronic ITP Patients","Purpura, Thrombocytopenic, Idiopathic and Hepatitis C",0,"eltrombopag","Drug","Novartis Pharmaceuticals","Industry",1,0,"All","18 Years","N/A","155","February 18, 2013","June 5, 2014","Number of Participants (Responders) Achieving a Platelet Count >=50×10^9/L After the First 6 Weeks of Stage 1","<0.001","0","Regression, Logistic","26.08","Odds Ratio (OR)","95","2-Sided","7.29","93.26"
"1211","NCT01763645","A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer",0,"Bevacizumab","Drug","Biocad","Industry",0,0,"All","18 Years","75 Years","138","October 2012","December 2014","Overall Response Rate","0","0","0","0","0","0","0","0","0"
"1212","NCT01763827","Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","Hyperlipidemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","615","January 2013","October 2013","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12","<0.001","Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.","Repeated measures linear effects model","-57.14","LS Mean Treatment Difference","95","2-Sided","-61.14","-53.14"
"1213","NCT01763866","LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","Hyperlipidemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","2067","January 2013","November 2013","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12","<0.001","Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.","Repeated measures linear effects model","-71.42","LS Mean Treatment Difference","95","2-Sided","-77.55","-65.29"
"1214","NCT01763905","Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2","Hyperlipidemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","307","January 2013","November 2013","Percent Change From Baseline in LDL-C at Week 12","<0.001","Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.","Repeated measures linear effects model","-38.06","LS Mean Treatment Difference","95","2-Sided","-43.73","-32.99"
"1215","NCT01763918","Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","Hyperlipidemia",0,"Evolocumab","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","331","February 2013","November 2013","Percent Change From Baseline in LDL-C at Week 12","<0.001","Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.","Repeated measures linear effects model","-59.23","LS Mean Treatment Difference","95","2-Sided","-65.11","-53.35"
"1216","NCT01764295","Clinical Study for Patients With Hypertension Associated With Dyslipidemia","Hypertension",0,"DWJ1276","Drug","Daewoong Pharmaceutical Co. LTD.","Industry",0,0,"All","20 Years","80 Years","150","September 2012","May 2013","LDL-C percent change of DWJ1276 from baseline","0","0","0","0","0","0","0","0","0"
"1217","NCT01764386","Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects","Obesity",0,"NB","Drug","Orexigen Therapeutics, Inc","Industry",0,0,"All","18 Years","60 Years","242","February 2013","September 2014","Percent Change in Body Weight From Baseline (Day 1) to Week 26","<0.0001","0","ANCOVA","-8.52","Mean Difference (Net)","95","2-Sided","-9.88","-7.15"
"1218","NCT01765179","Safety and Efficacy Trial of Testosterone Undecanoate","Male Hypogonadism",0,"Oral testosterone undecanoate","Drug","Clarus Therapeutics, Inc.","Industry",0,0,"Male","18 Years","75 Years","144","January 2013","July 2013","Percentage of treated patients with an average serum testosterone (T) concentration (Cavg) between 300 and 1000 ng/dL","0","0","0","0","0","0","0","0","0"
"1219","NCT01765296","Phase III Study of CG100649 in Osteoarthritis Patients","Localized Primary Osteoarthritis of Hip",0,"CG100649","Drug","CrystalGenomics, Inc.","Industry",0,0,"All","20 Years","N/A","350","March 2013","December 2013","WOMAC-Pain Subscale in the index joint","0","0","0","0","0","0","0","0","0"
"1220","NCT01765764","Bimatoprost for the Treatment of Eyebrow Hypotrichosis","Eyebrow Hypotrichosis",0,"bimatoprost solution","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","357","March 2013","January 2014","Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale","0","0","0","0","0","0","0","0","0"
"1221","NCT01765920","Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients","Acute Upper Respiratory Tract Infections",0,"Ergoferon","Drug","Materia Medica Holding","Industry",0,0,"All","18 Years","60 Years","282","December 2012","December 2014","Average duration of fever (body temperature over 37.0 С) (according to the patient's diary).","0","0","0","0","0","0","0","0","0"
"1222","NCT01766011","Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital","Pre-term Infants",0,"study pre-term formula","Other","Abbott Nutrition","Industry",0,0,"All","N/A","21 Days","28","November 2012","October 2013","Weight gain per day","0","0","0","0","0","0","0","0","0"
"1223","NCT01766401","Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Placebo","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","402","January 2013","January 2014","Hamilton Rating Scale for Anxiety (HAM-A) total score","0","0","0","0","0","0","0","0","0"
"1224","NCT01767116","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie (prior sponsor, Abbott)","Industry",0,0,"All","18 Years","70 Years","419","December 2012","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate","0","0","0","100","Percentage of Participants","95","2-Sided","98.2","100.0"
"1225","NCT01767376","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","Infections, Meningococcal",0,"Meningococcal vaccine GSK134612","Biological","GlaxoSmithKline","Industry",1,0,"All","11 Years","25 Years","692","January 10, 2013","January 16, 2014","Immunogenicity with respect to the components of the investigational vaccine in terms of antibody titres","0","0","0","0","0","0","0","0","0"
"1226","NCT01767519","A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence","Overactive Bladder",0,"BOTOX®","Biological","Allergan","Industry",0,0,"All","18 Years","N/A","356","March 2013","September 2014","Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1","0","0","0","0","0","0","0","0","0"
"1227","NCT01767714","Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","Non-Hodgkin's Lymphoma",0,"Granulocyte-colony stimulating factor (G-CSF)","Drug","Sanofi","Industry",0,0,"All","18 Years","75 Years","100","April 2013","November 2014","Number of patients who meet the target of ≥5 × 10^6 CD34+ cells/kg in 4 or fewer days of apheresis","0","0","0","0","0","0","0","0","0"
"1228","NCT01767896","Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine","Influenza",0,"ASP7374","Biological","Astellas Pharma Inc","Industry",0,0,"All","65 Years","N/A","1020","October 2012","March 2013","seroconversion rate of hemoagglutination inhibition (HI) antibody titer","0","0","0","0","0","0","0","0","0"
"1229","NCT01768286","Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection","Chronic Hepatitis C Virus",0,"LDV/SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","441","January 2013","November 2013","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","<0.001","A 2-sided 1-sample binomial test was used to compare over the historical SVR12 rate of 25%. To control the family-wise type I error rate at 0.05, the Hochberg procedure was applied, from which the adjusted p-values were obtained.","Binomial test","0","0","0","0","0","0"
"1230","NCT01768520","Evaluation of the Efficacy and Safety of Entelon Tab. 150mg in Patients With Osteoarthritis of Knee","Knee Osteoarthritis",0,"Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks","Drug","Hanlim Pharm. Co., Ltd.","Industry",0,0,"All","35 Years","75 Years","336","July 2012","December 2013","the change of total sum of K-WOMAC(Korean The Western Ontario and McMaster Universities Arthritis Index)","0","0","0","0","0","0","0","0","0"
"1231","NCT01768559","Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","Type 2 Diabetes",0,"Lixisenatide (AVE0010)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","894","January 2013","December 2014","Change in HbA1c From Baseline to Week 26","0","0","0","-0.05","Least Square (LS) Mean Difference","95","2-Sided","-0.17","0.064"
"1232","NCT01768572","To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","Rheumatoid Arthritis",0,"sarilumab SAR153191 (REGN88)","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","202","March 2013","October 2014","Safety as measured by adverse events/serious adverse events, physical examinations, clinical laboratory, ECGs.","0","0","0","0","0","0","0","0","0"
"1233","NCT01769378","Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)","Type 2 Diabetes Mellitus",0,"Placebo","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","300","January 2013","December 2014","Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at 24 Weeks","<0.001","0","Mixed Models Analysis","-1.27","LS Squares Mean Difference","95","2-Sided","-1.57","-0.97"
"1234","NCT01772134","Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium bromide 62.5mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","617","January 2013","July 2013","Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","<0.001","0","Mixed Models Analysis","0.147","Mean Difference (Net)","95","2-Sided","0.107","0.187"
"1235","NCT01772147","Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium bromide 62.5mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","608","January 2013","August 2013","Change From Baseline in the Trough Forced Expiratory Volume in One Second (FEV1) on Day 85","<0.001","0","Mixed Models Analysis","0.127","Mean Difference (Net)","95","2-Sided","0.089","0.164"
"1236","NCT01773928","Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","Influenza",0,"Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)","Biological","Baxter Healthcare Corporation","Industry",0,0,"All","18 Years","N/A","1928","January 2013","April 2013","Hemagglutination inhibition antibody (HIA) titer for each of the three antigens contained in the vaccine","0","0","0","0","0","0","0","0","0"
"1237","NCT01774032","H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older","Influenza",0,"H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","65 Years","N/A","91","March 2013","June 2013","Co-Primary Evaluation of Immunogenicity by Single Radial Hemolysis (SRH) Assay: Number of participants with antibody response to vaccine strain (A/Indonesia/05/2005)","0","0","0","0","0","0","0","0","0"
"1238","NCT01774825","IQP-CL-101 in IBS Management","Irritable Bowel Syndrome",0,"IQP-CL-101","Dietary Supplement","InQpharm Group","Industry",0,0,"All","18 Years","70 Years","100","January 2013","February 2014","IBS-SSS (Severity Symptom Score)","0","0","0","0","0","0","0","0","0"
"1239","NCT01777191","Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis","Plaque Psoriasis",0,"Ixekizumab Auto-Injector","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","204","March 2013","May 2014","Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) by Drug Delivery Device","0","0","0","0","0","0","0","0","0"
"1240","NCT01777334","The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD.","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium/Vilanterol 62.5/25 mcg","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","905","January 2013","September 2013","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)","<0.001","0","Mixed Models Analysis","0.112","Least squares mean difference","95","2-Sided","0.081","0.144"
"1241","NCT01778023","Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature","Growth Disorder",0,"somatropin","Drug","Novo Nordisk A/S","Industry",0,0,"All","4 Years","11 Years","54","January 17, 2013","December 17, 2014","Height Velocity (Ht-V)","<0.0001","0","ANOVA","5.15","Treatment Difference","95","2-Sided","4.09","6.21"
"1242","NCT01778062","Indacaterol EfectIveness In COPD Patients With Tuberculosis History","Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis",0,"Indacaterol","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","19 Years","N/A","136","February 2013","September 2014","Trough Forced Expiratory Volume in One Second Change","<0.0001","0","ANCOVA","0","0","0","0","0","0"
"1243","NCT01779258","Emollients in the Management of Atopic Dermatitis","Atopic Dermatitis",0,"glycerol, paraffin (liquid and white soft)","Drug","Pierre Fabre Medicament","Industry",0,0,"All","2 Years","6 Years","347","February 2013","February 2014","Percentage of patients with at least one flare over the treatment period","0","0","0","0","0","0","0","0","0"
"1244","NCT01780506","Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","HIV",0,"E/C/F/TAF","Drug","Gilead Sciences","Industry",1,0,"All","18 Years","N/A","872","December 26, 2012","August 26, 2014","Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48","0.78","P-value was from the Cochran-Mantel-Haenszel (CMH) test stratified by baseline HIV-1 RNA (≤ 100,000 or > 100,000 copies/mL) and region (US vs ex-US).","Cochran-Mantel-Haenszel","0.5","Difference in percentages","95.002","2-Sided","-3.0","4.0"
"1245","NCT01780987","AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients","Deep Vein Thrombosis",0,"Apixaban","Drug","Pfizer","Industry",0,0,"All","20 Years","N/A","80","January 2013","September 2014","Number of Participants With Major Bleeding Events ［Per International Society on Thrombosis and Homeostasis (ISTH) Definition］ or Clinically Relevant Non-major (CRNM) Bleeding Events Adjudicated by Clinical Event Committee During the Treatment Period","0","0","0","0","0","0","0","0","0"
"1246","NCT01782937","An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis","Psoriasis",0,"KHK4827","Drug","Kyowa Hakko Kirin Co., Ltd","Industry",0,0,"All","18 Years","N/A","30","February 2013","December 2014","Clinical Global Impression (CGI)","0","0","0","0","0","0","0","0","0"
"1247","NCT01783548","Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)","Allergic Rhinitis",0,"BDP Nasal Aerosol","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","4 Years","11 Years","547","January 2013","October 2013","Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) Over The First 6 Weeks Of Treatment In Subjects 6 To 11 Years Of Age","0.002","a priori statistical significance is <0.05.","mixed-model for repeated measures (MMRM)","-0.66","LSM treatment difference from placebo","95","2-Sided","-1.08","-0.24"
"1248","NCT01783678","A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults","Chronic Hepatitis C",0,"Sofosbuvir","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","275","January 2013","April 2014","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1249","NCT01785082","Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test","Liver Failure",0,"13-C-Methacetin","Drug","Humedics GmbH","Industry",0,0,"All","18 Years","N/A","120","January 2013","March 2014","number of correctly determined positive patients in each trial group","0","0","0","0","0","0","0","0","0"
"1250","NCT01785095","Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles","Oocyte Donation",0,"FSH (Follicle Stimulating Hormone)","Drug","IBSA Institut Biochimique SA","Industry",0,0,"Female","18 Years","35 Years","41","March 2013","July 2014","Number of Patients Producing Anti-FSH Antibodies.","0","0","0","0","0","0","0","0","0"
"1251","NCT01785472","Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension","Essential Hypertension",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","1438","April 2013","August 2014","Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg","<0.001","0","ANCOVA","-2.33","least Square Means net difference","95","0","-4.00","-0.66"
"1252","NCT01785849","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis","Hyperparathyroidism, Secondary",0,"Etelcalcetide","Drug","Amgen","Industry",0,0,"All","18 Years","100 Years","508","March 2013","May 2014","Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase","<0.001","0","Cochran-Mantel-Haenszel","32.46","Odds Ratio (OR)","95","2-Sided","18.71","56.31"
"1253","NCT01786473","Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism","Hypogonadism",0,"Testogel 1%","Drug","Laboratoires Besins International","Industry",0,0,"Male","18 Years","68 Years","240","December 2012","December 2014","Percentage of patients with morning serum Total Testosterone concentration within the physiological range (300 - 1000 ng/dL or 10.4 - 34.7 nmol/L) after 3 months of Testogel treatment compared to placebo-treatment","0","0","0","0","0","0","0","0","0"
"1254","NCT01786902","Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature","Idiopathic Short Stature",0,"DA-3002","Drug","Dong-A ST Co., Ltd.","Industry",0,0,"All","4 Years","13 Years","70","February 2012","April 2014","The Difference of Annualized Height Velocity Between Treatment Group and Non-treatment Group After 26 Weeks","0","0","0","0","0","0","0","0","0"
"1255","NCT01787188","Study of Meloxicam Capsules to Treat Osteoarthritis Pain","Osteoarthritis",0,"Meloxicam Test Capsules","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","40 Years","N/A","403","February 2013","October 2013","Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.","0.0005","0","Mixed Models Analysis","-10.84","Difference in Least Squares Mean","95","2-Sided","-16.93","-4.75"
"1256","NCT01787344","Phase III Clinical Trial of ""Botulax®"" to Treat Children With Cerebral Palsy","Other Infantile Cerebral Palsy",0,"Botulinum Toxin Type A(Botox®)","Drug","Hugel","Industry",0,0,"All","2 Years","10 Years","144","March 2012","June 2014","Rate of patients with an improvement more than two grade in Physician's Rating Scale score.","0","0","0","0","0","0","0","0","0"
"1257","NCT01787383","A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","Actinic Keratosis",0,"Ingenol mebutate gel 0.05 %","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","200","February 2013","January 2014","Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment Area","0.13","0","Wilcoxon (Mann-Whitney)","0","0","0","0","0","0"
"1258","NCT01787799","EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)","Atherosclerotic Lesion(s)",0,"SYNERGY","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","100","March 2013","August 2014","In-stent Late Loss","0","0","0","0","0","0","0","0","0"
"1259","NCT01788046","Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis","Hyperparathyroidism, Secondary",0,"Etelcalcetide","Drug","Amgen","Industry",0,0,"All","18 Years","100 Years","515","March 2013","April 2014","Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase","< 0.001","0","Cochran-Mantel-Haenszel","30.80","Odds Ratio (OR)","95","2-Sided","18.18","52.17"
"1260","NCT01788358","Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension","Hypertension",0,"Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","508","February 2013","May 2014","Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28","0","0","0","0","0","0","0","0","0"
"1261","NCT01789606","Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet","Analgesia",0,"Ibuprofen 600 mg Immediate Release/Extended Release Caplet","Drug","Pfizer","Industry",0,0,"All","12 Years","N/A","712","September 2012","June 2013","Self-Selection Arm: Percentage of participants who either correctly select to use or correctly de-select not to use the 600 mg IR/ER product, based on typical duration of pain.","0","0","0","0","0","0","0","0","0"
"1262","NCT01789970","Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain","Low Back Pain",0,"Hydrocodone ER","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","80 Years","625","March 2013","February 2014","Change From Baseline to Week 12 of the Treatment Period in Weekly Average of Daily Worst Pain Intensity (WPI)","<0.001","5% significance level","ANCOVA","0.63","Mean Difference (Final Values)","95","2-Sided","0.26","1.00"
"1263","NCT01790438","A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"LY2605541","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","630","March 2013","May 2014","Change from Baseline to 26 Weeks in Hemoglobin A1c (HbA1c)","0","0","0","0","0","0","0","0","0"
"1264","NCT01790997","Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke","Acute Ischemic Stroke",0,"DLBS1033","Drug","Dexa Medica Group","Industry",0,0,"All","20 Years","80 Years","126","May 2012","November 2013","Change in INR value","0","0","0","0","0","0","0","0","0"
"1265","NCT01791504","Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu® Surgical Adhesive","Disorder of Skin and/or Subcutaneous Tissue of Trunk",0,"TissuGlu Surgical Adhesive","Device","Cohera Medical, Inc.","Industry",0,0,"All","18 Years","N/A","130","March 2013","September 2013","Number of Post-Operative Invasive Treatments","0","0","0","0","0","0","0","0","0"
"1266","NCT01791972","Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)","Exercise-Induced Bronchoconstriction (EIB)",0,"Albuterol Spiromax","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","50 Years","38","March 2013","May 2013","Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge","<0.0001","Significance level is 0.05.","mixed-effect analysis of covariance","-16.2","Mean Difference (Final Values)","95","2-Sided","-20.19","-12.14"
"1267","NCT01792284","A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus",0,"LY2605541","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","167","February 2013","April 2014","Hemoglobin A1c (HbA1c) at 12 Weeks","0","0","0","0","0","0","0","0","0"
"1268","NCT01793259","Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)","Rheumatoid Arthritis",0,"methotrexate prefilled pen","Drug","medac GmbH","Industry",0,0,"All","18 Years","75 Years","120","July 2012","April 2013","number of patients preferring the MTX pre-filled pen to the pre-filled syringe","0","0","0","0","0","0","0","0","0"
"1269","NCT01793480","Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.","Pain Related to Cancer",0,"Methadone","Drug","Laboratoires Bouchara-Recordati","Industry",0,0,"All","18 Years","N/A","146","December 2011","September 2013","Binary main criterion based on success/failure rate related to methadone switch on Day 4.","0","0","0","0","0","0","0","0","0"
"1270","NCT01794559","Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression","Depressive Disorder",0,"PEER Interactive Report","Device","CNS Response","Industry",0,0,"All","18 Years","65 Years","1922","March 2013","March 2014","Quick Inventory of Depressive Symptomatology - Self Reported 16 (QIDS-SR16)","0","0","0","0","0","0","0","0","0"
"1271","NCT01794741","3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis","Allergic Rhinitis",0,"Dymista Nasal Spray","Drug","Meda Pharmaceuticals","Industry",0,0,"All","4 Years","11 Years","405","February 2013","November 2013","Adverse Events Report","0","0","0","0","0","0","0","0","0"
"1272","NCT01794923","Topical Ibuprofen for Delayed Onset Mulscle Soreness","Pain",0,"IBU BID","Drug","Pfizer","Industry",0,0,"All","18 Years","65 Years","205","May 2013","March 2014","Muscle Soreness with Movement (change from baseline) over 0-24 hours post Dose 1","0","0","0","0","0","0","0","0","0"
"1273","NCT01795547","Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole and aripiprazole once-monthly","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","60 Years","295","February 2013","September 2014","Change From Baseline to Week 28 in Quality of Life Scale (QLS) Total Score","0.036","0","Mixed Models Analysis","4.666","Least Squares Mean Difference","95","2-Sided","0.316","9.015"
"1274","NCT01795664","Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients","Asthma",0,"Functional Respiratory Imaging","Radiation","FLUIDDA nv","Industry",0,0,"All","18 Years","N/A","16","March 2013","August 2013","Total airway volume","0","0","0","0","0","0","0","0","0"
"1275","NCT01795859","First Time Use of SD-809 in Huntington Disease","Chorea",0,"SD-809","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","N/A","90","July 2013","November 2014","Total Maximal Chorea Score (TMC)","0","0","0","0","0","0","0","0","0"
"1276","NCT01796665","A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris","Acne",0,"Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%","Drug","Perrigo Company","Industry",0,0,"All","12 Years","40 Years","1180","February 2012","February 2013","Mean percent change in the inflammatory (papules and pustules) lesion count","0","0","0","0","0","0","0","0","0"
"1277","NCT01796925","Targeted Hypoglossal Neurostimulation Study #2","Sleep Apnea Syndromes",0,"aura6000 THN System","Device","ImThera Medical, Inc.","Industry",0,0,"All","18 Years","N/A","57","February 2013","September 2013","Reduction in Apnea-Hypopnea Index (AHI)","0","0","0","0","0","0","0","0","0"
"1278","NCT01797081","BOTOX® in the Treatment of Crow's Feet Lines in Japan","Lateral Canthus Rhytides",0,"botulinum toxin Type A (24 U)","Biological","Allergan","Industry",0,0,"All","20 Years","64 Years","300","January 2013","July 2013","Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)","0","0","0","0","0","0","0","0","0"
"1279","NCT01797094","BOTOX® in the Treatment of Upper Facial Lines in Japan","Upper Facial Rhytides",0,"botulinum toxin Type A (44U)","Biological","Allergan","Industry",0,0,"All","20 Years","64 Years","101","February 2013","July 2013","Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)","0","0","0","0","0","0","0","0","0"
"1280","NCT01797445","Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults","HIV",0,"E/C/F/TAF","Drug","Gilead Sciences","Industry",1,0,"All","18 Years","N/A","872","March 12, 2013","September 17, 2014","Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48","0.13","0","Cochran-Mantel-Haenszel","3.1","Difference in Percentages","95.002","2-Sided","-1.0","7.1"
"1281","NCT01798238","Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus",0,"MP-513","Drug","Handok Pharmaceuticals Co., Ltd.","Industry",0,0,"All","18 Years","N/A","142","November 2012","May 2014","Glycosylated hemoglobin","0","0","0","0","0","0","0","0","0"
"1282","NCT01801735","Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip","Osteoarthritis",0,"Meloxicam Test Capsules","Drug","Iroko Pharmaceuticals, LLC","Industry",0,0,"All","40 Years","N/A","600","March 2013","June 2014","Safety of Meloxicam 10 mg as Assessed by the Incidence of Adverse Events From Baseline to Week 52 or Early Termination","0","0","0","0","0","0","0","0","0"
"1283","NCT01802411","Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy","Posterolateral Thoracotomy",0,"Liposome bupivacaine","Drug","Pacira Pharmaceuticals, Inc","Industry",0,0,"All","18 Years","N/A","191","December 2012","June 2013","Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Scores at Rest for Pain Intensity","0","0","0","0","0","0","0","0","0"
"1284","NCT01803555","Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","Asthma",0,"Budesonide/Formoterol SPIROMAX®","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","12 Years","N/A","605","June 2013","March 2014","Change from baseline in weekly average of daily trough (predose and pre-rescue bronchodilator) AM Peak expiratory flow (PEF)","0","0","0","0","0","0","0","0","0"
"1285","NCT01803581","A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice","Head Lice",0,"X92001327","Other","Oystershell NV","Industry",0,0,"All","1 Year","N/A","50","February 2013","May 2013","proportion of subjects lice free at the end of the study (Day 10)","0","0","0","0","0","0","0","0","0"
"1286","NCT01803607","Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)","Osteoporosis",0,"odanacatib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"Female","60 Years","N/A","135","March 2013","November 2014","Percent Change From Baseline to Month 12 in Femoral BMD","0","0","0","0","0","0","0","0","0"
"1287","NCT01804361","Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes","Dry Eye Syndromes",0,"Haporine-S","Drug","DH Bio Co., Ltd.","Industry",0,0,"All","20 Years","N/A","90","March 2013","February 2014","Corneal staining","0","0","0","0","0","0","0","0","0"
"1288","NCT01805830","Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy","Type 2 Diabetes",0,"MP513","Drug","Handok Pharmaceuticals Co., Ltd.","Industry",0,0,"All","18 Years","N/A","189","May 2012","May 2013","HbA1c","0","0","0","0","0","0","0","0","0"
"1289","NCT01806623","The Study Of Fluconazole For Vulvovaginal Candidiasis","Vulvovaginal Candidiasis",0,"Fluconazole","Drug","Pfizer","Industry",0,0,"Female","18 Years","80 Years","157","March 5, 2013","November 22, 2013","Therapeutic Outcome: Response Rate","0","0","0","0","0","0","0","0","0"
"1290","NCT01807650","Oleogel-S10 in Wound Healing of Skin Graft Donor Sites","Wounds",0,"Oleogel-S10 ointment and non-adhesive wound dressing","Drug","Birken AG","Industry",0,0,"All","18 Years","N/A","112","March 2013","September 2013","Intra-individual difference in time to wound closure","0","0","0","0","0","0","0","0","0"
"1291","NCT01807923","A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",0,"Lumacaftor Plus Ivacaftor Combination","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","12 Years","N/A","559","May 2013","April 2014","Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24","<0.0001","0","MMRM","4.03","Least Squares (LS) Mean Difference","95","2-Sided","2.62","5.44"
"1292","NCT01807949","A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","Cystic Fibrosis, Homozygous for the F508del CFTR Mutation",0,"Placebo","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","12 Years","65 Years","563","April 2013","April 2014","Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24","0.0004","0","MMRM","2.62","Least Squares (LS) Mean Difference","95","2-Sided","1.18","4.06"
"1293","NCT01808313","Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)","Vascular Disease",0,"ambrisentan","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","75 Years","134","December 1, 2012","August 15, 2014","Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12","<0.001","0","t-test, 2 sided","53.59","Mean Difference (Final Values)","95","2-Sided","42.53","64.66"
"1294","NCT01808612","A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing","Major Depressive Disorder",0,"Fluoxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","N/A","513","March 2013","July 2014","Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score","0.264","0","Mixed Models Analysis","0.73","LS Mean Difference","95","2-Sided","-0.55","2.00"
"1295","NCT01809223","A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV","Choroid Neovascularization Secondary to Degenerative Myopia",0,"conbercept, Fixed","Drug","Chengdu Kanghong Biotech Co.,Ltd.","Industry",0,0,"All","18 Years","N/A","176","August 2012","February 2014","mean change from baseline of visual acuity","0","0","0","0","0","0","0","0","0"
"1296","NCT01809327","A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","Diabetes Mellitus, Type 2",0,"Canagliflozin 100 mg","Drug","Janssen Research & Development, LLC","Industry",1,0,"All","18 Years","75 Years","1182","June 4, 2013","December 2, 2014","Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26","0.001","0","Mixed Model for Repeated Measures (MMRM)","-0.46","Least-Squares Mean Difference","95","2-Sided","-0.657","-0.269"
"1297","NCT01809587","IQP-PO-101 for the Regulation of Bowel Movement Frequency","Constipation",0,"IQP-PO-101","Device","InQpharm Group","Industry",0,0,"All","18 Years","65 Years","50","March 2013","August 2013","Bowel movement frequency","0","0","0","0","0","0","0","0","0"
"1298","NCT01810380","Brexpiprazole in Patients With Acute Schizophrenia","Schizophrenia",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","468","March 2013","December 2014","Change From Baseline to Week 6 in PANSS Total Score","0.0560","For all efficacy analyses the primary comparison is the difference between brexpiprazole 2 to 4 mg/day and placebo at Week 6.","Mixed Models Analysis","-4.1","Least square mean difference","95","2-Sided","-8.2","0.1"
"1299","NCT01810900","To Assess the Anti-adhesive Effect and Safety of Protescal","Laparoscopic Myomectomy",0,"Protescal","Device","LG Life Sciences","Industry",0,0,"Female","20 Years","N/A","50","September 2012","November 2013","presence/absence of postoperative adhesions at second-look procedure","0","0","0","0","0","0","0","0","0"
"1300","NCT01810939","A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)","Chronic Kidney Disease (CKD)",0,"Patiromer","Drug","Relypsa, Inc.","Industry",0,0,"All","18 Years","80 Years","243","February 2013","July 2013","Change in Serum Potassium From Part A Baseline to Part A Week 4","0","0","0","0.76","Proportion","95","2-Sided","0.7","0.81"
"1301","NCT01811485","Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy","Diabetes Mellitus, Type 2",0,"LMF237 50/250 mg","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","20 Years","74 Years","171","May 2013","February 2014","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups","0","0","0","0","0","0","0","0","0"
"1302","NCT01811732","Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections","Skin and Subcutaneous Tissue Bacterial Infections",0,"Delafloxacin","Drug","Melinta Therapeutics, Inc.","Industry",0,0,"All","18 Years","N/A","660","April 2013","July 2014","area measurements of lesion erythema at primary infection site","0","0","0","0","0","0","0","0","0"
"1303","NCT01813812","A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034","Acute Gastritis",0,"DA-6034","Drug","Dong-A Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","75 Years","492","October 2010","August 2013","The number of erosions comparing the before and after the administration. For example, if the number of the erosion is 0, the score is 1 (normal).","0","0","0","0","0","0","0","0","0"
"1304","NCT01813890","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo","Hallux Valgus",0,"Tapentadol IR 50 mg","Drug","Janssen-Cilag International NV","Industry",0,0,"All","20 Years","80 Years","60","January 2013","January 2014","Sum of Pain Intensity Difference (SPID) Over 48 Hours","0.006","P-value adjusted for multiple treatment group comparisons using the Hochberg method.","ANCOVA","105.61","Mean Difference (Net)","95","2-Sided","32.0","179.2"
"1305","NCT01814137","A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","40","March 2013","March 2014","Change From Baseline in HbA1c (Glycosylated Haemoglobin)","0","0","0","0","0","0","0","0","0"
"1306","NCT01814800","Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)","Primary Immune Deficiency Disorder",0,"RI-002","Biological","ADMA Biologics, Inc.","Industry",0,0,"All","2 Years","75 Years","59","February 2014","December 2014","Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))","0","0","0","0","0","0","0","0","0"
"1307","NCT01814917","Long-term Extension Study of MCI-196","Chronic Kidney Disease",0,"colestilan","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","2 Years","18 Years","6","August 2013","December 2014","Proportion of responders (responders are defined as subjects demonstrating serum P levels ≤1.5 SD above the KDOQI 2008 age-related mean value)","0","0","0","0","0","0","0","0","0"
"1308","NCT01816139","Multicenter Study to Evaluate Safety and Efficacy of WC3011 in Postmenopausal Women","Vulvovaginal Atrophy",0,"WC3011","Drug","Warner Chilcott","Industry",0,0,"Female","35 Years","N/A","576","February 2013","November 2013","Change in Subject's Self-Assessment of Intensity of Vaginal Dryness","0","0","0","0","0","0","0","0","0"
"1309","NCT01816295","A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy","Hypogonadism",0,"Testosterone Solution","Drug","Eli Lilly and Company","Industry",0,0,"Male","18 Years","N/A","715","May 2013","October 2014","Number of Participants With Total Serum Testosterone Concentration Within Normal Range at Week 12","<0.001","0","Chi-squared","0","0","0","0","0","0"
"1310","NCT01817764","A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium/vilanterol","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","707","March 2013","October 2013","Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84","<0.001","0","ANCOVA","0.074","Mean Difference (Net)","95","2-Sided","0.038","0.110"
"1311","NCT01817790","Assessment of Fluticasone Propionate on Ocular Allergy Symptoms","Allergic Rhinitis",0,"Fluticasone propionate","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","N/A","626","December 2012","February 2013","Mean Change From Baseline in Reflective Total Ocular Symptom Score (rTOSS)","0.0024","p-value was not adjusted for multiple comparisons.","ANCOVA","-0.36","Least Square Mean Difference","95","2-Sided","-0.59","-0.13"
"1312","NCT01818336","Evaluation of Skin Testing Reagents for Penicillin Allergy","History of IgE Dependent Reaction to a Penicillin Product",0,"Penicillin skin test kit","Drug","AllerQuest LLC","Industry",0,0,"All","18 Years","N/A","481","December 2012","June 2013","Negative Predictive Value","0","0","0","0","0","0","0","0","0"
"1313","NCT01818596","Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment","HIV",0,"E/C/F/TAF","Drug","Gilead Sciences","Industry",1,0,"All","18 Years","N/A","252","March 27, 2013","July 31, 2014","Change From Baseline in the Estimated Glomerular Filtration Rate Calculated by the Cockcroft-Gault Formula (eGFR_CG) at Week 24","0","0","0","0","0","0","0","0","0"
"1314","NCT01818687","Safety and Tolerability Study of MCI-196","Chronic Kidney Disease",0,"colestilan","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","2 Years","18 Years","4","August 2013","December 2014","Percentage of subjects who, due to hyperphosphataemia, require rescue treatment and/or discontinuation of therapy with colestilan.","0","0","0","0","0","0","0","0","0"
"1315","NCT01819610","Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures","Pain",0,"SPRIX","Drug","Luitpold Pharmaceuticals","Industry",0,0,"All","12 Years","64 Years","60","February 2013","March 2014","Cmax","0","0","0","0","0","0","0","0","0"
"1316","NCT01821040","A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR","Polymyalgia Rheumatica",0,"Lodotra®","Drug","Mundipharma Research Limited","Industry",0,0,"All","50 Years","N/A","62","March 2013","April 2014","To show that treatment with Lodotra® is noninferior to treatment with prednisone IR with regards to the percentage of complete responders.","0","0","0","0","0","0","0","0","0"
"1317","NCT01821378","Lurasidone Low-Dose - High-Dose Study Study","Schizophrenia",0,"Lurasidone","Drug","Sunovion","Industry",0,0,"All","18 Years","75 Years","412","May 2013","June 2014","Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6 for Lurasidone 20 mg and 80-160 mg Versus Placebo.","0.255","0","Mixed Models Analysis","-3.1","Least Square Mean Difference","95","2-Sided","-8.4","2.2"
"1318","NCT01821391","Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses","Actinic Keratoses",0,"NDL-PDT","Drug","Galderma","Industry",0,0,"All","18 Years","N/A","131","July 2013","January 2014","lesion response","0","0","0","0","0","0","0","0","0"
"1319","NCT01821677","AP-05-002 A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema","Diabetic Macular Edema",0,"Low Dose Danazol","Drug","Ampio Pharmaceuticals. Inc.","Industry",0,0,"All","18 Years","N/A","355","February 2013","June 2014","Improvement in Best Corrected Visual Acuity","0","0","0","0","0","0","0","0","0"
"1320","NCT01822899","A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium bromide/Vilanterol","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","717","April 2013","October 2013","Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84","<0.001","0","ANCOVA","0.080","Mean Difference (Net)","95","2-Sided","0.046","0.113"
"1321","NCT01824238","A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)","Heterozygous Familial Hypercholesterolemia (HeFH)",0,"Anacetrapib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","80 Years","68","May 2013","May 2014","Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)","0","0","0","0","0","0","0","0","0"
"1322","NCT01824407","A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers","Diabetic Foot Ulcers",0,"Electrohydraulic-generated shock wave","Device","SANUWAVE, Inc.","Industry",0,0,"All","22 Years","N/A","90","March 2013","April 2014","Complete closure","0","0","0","0","0","0","0","0","0"
"1323","NCT01824667","Effect of B-GOS on GI Discomfort in Healthy Adults","Healthy",0,"B-GOS","Dietary Supplement","Clasado Limited","Industry",0,0,"All","18 Years","65 Years","400","February 2013","November 2013","To determine the effect of B-GOS on GI discomfort","0","0","0","0","0","0","0","0","0"
"1324","NCT01825200","Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age","Influenza",0,"Flublok","Biological","Protein Sciences Corporation","Industry",0,0,"All","50 Years","N/A","2640","March 2013","May 2013","Number of Participants With Common Hypersensitivity Reactions as Measure of Safety","0","0","0","0","0","0","0","0","0"
"1325","NCT01826630","A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema","Eczema",0,"CLn BodyWash","Other","Shari L Hand","Industry",0,0,"All","18 Years","N/A","4","July 2013","October 2014","Change in Amount of Skin Fauna","0","0","0","0","0","0","0","0","0"
"1326","NCT01827592","26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation","Chronic Idiopathic Constipation",0,"Elobixibat 10 mg","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","376","April 2013","March 2014","Overall Complete Spontaneous Bowel Movement (CSBM) Response","0","0","0","0","0","0","0","0","0"
"1327","NCT01827670","Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity","Dentine Hypersensitivity",0,"Stannous fluoride","Drug","GlaxoSmithKline","Industry",0,0,"All","18 Years","65 Years","119","February 2013","May 2013","Mean Change From Baseline in Schiff Sensitivity Score","<0.0001","0","ANCOVA","-1.29","Adjusted Mean","95","2-Sided","-1.53","-1.06"
"1328","NCT01829464","TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes","Diabetes",0,"Placebo","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","90","May 2013","February 2014","Change From Baseline in HbA1c at Week 24","0","0","0","0","0","0","0","0","0"
"1329","NCT01829477","Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"TAK-875","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","33","April 2013","February 2014","Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","0","0","0","0","0","0","0","0","0"
"1330","NCT01830140","A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","Glaucoma",0,"Bimatoprost 0.01%","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","466","July 2013","May 2014","Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye","0","0","0","0","0","0","0","0","0"
"1331","NCT01830985","A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis","Rheumatoid Arthritis",0,"VX-509","Drug","Vertex Pharmaceuticals Incorporated","Industry",0,0,"All","18 Years","65 Years","39","April 2013","July 2014","Long-term safety and tolerability of VX-509 treatment","0","0","0","0","0","0","0","0","0"
"1332","NCT01831791","A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia","Alopecia",0,"Dutasteride 0.5 mg","Drug","GlaxoSmithKline","Industry",0,0,"Male","20 Years","50 Years","120","April 2013","July 2014","Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)","0","0","0","0","0","0","0","0","0"
"1333","NCT01833065","Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation","Chronic Idiopathic Constipation",0,"Elobixibat 10 mg/day","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","314","April 2013","March 2014","Overall Complete Spontaneous Bowel Movement (CSBM) Response","0","0","0","0","0","0","0","0","0"
"1334","NCT01833533","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie","Industry",0,0,"All","18 Years","70 Years","305","March 2013","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses","0","0","0","90.2","Percentage of Participants","95","2-Sided","86.2","94.3"
"1335","NCT01834209","A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","Prostate Neoplasms",0,"Abiraterone acetate","Drug","Janssen Research & Development, LLC","Industry",0,0,"Male","18 Years","N/A","19","June 2013","October 2014","Number of participants affected by an adverse event","0","0","0","0","0","0","0","0","0"
"1336","NCT01834274","Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2",0,"Fasiglifam (TAK-875)","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","96","June 2013","March 2014","Change From Baseline in Glycosylated Hemoglobin (HbA1c)","0","0","0","0","0","0","0","0","0"
"1337","NCT01834885","A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","N/A","N/A","0","December 2013","September 2014","Area under the curve (AUC) 0-12 hours for FEV1 following 12 weeks of treatment","0","0","0","0","0","0","0","0","0"
"1338","NCT01835431","A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus","Diabetes",0,"insulin degludec/insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","1 Year","17 Years","362","October 2013","November 2014","Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)","0","0","0","0","0","0","0","0","0"
"1339","NCT01835535","Continued Safety and Performance of the TIVUS System","Hypertension, Resistant to Conventional Therapy",0,"TIVUS","Device","Cardiosonic","Industry",0,0,"All","18 Years","80 Years","80","August 2013","June 2014","Change in office Systolic Blood Pressure (SBP) from baseline to 6-month","0","0","0","0","0","0","0","0","0"
"1340","NCT01835548","NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder (ADHD)",0,"NT0102","Drug","Neos Therapeutics, Inc","Industry",0,0,"All","6 Years","12 Years","87","July 2013","July 2014","SKAMP","0","0","0","0","0","0","0","0","0"
"1341","NCT01837797","Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment","Major Depressive Disorder",0,"Placebo","Drug","H. Lundbeck A/S","Industry",0,0,"All","65 Years","N/A","129","April 2013","May 2014","Change From Randomisation in Depressive Symptoms During the Randomised Treatment","0","0","0","0","0","0","0","0","0"
"1342","NCT01838590","Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection","Hepatitis C Virus",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","103","March 2013","May 2014","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1343","NCT01838850","Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy","Essential Hypertension",0,"CS8635 20/5/12.5mg and placebo","Drug","Daiichi Sankyo Korea Co., Ltd.","Industry",0,0,"All","20 Years","75 Years","344","April 2013","August 2014","The changes of seated diastolic blood pressure of the Triple Combinations OM/AML/HCTZ 20/5/12.5mg vs.OM/HCTZ 20/12.5mg","0","0","0","0","0","0","0","0","0"
"1344","NCT01839175","Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","Neisseria Meningitidis",0,"Hexavalent vaccine","Biological","MCM Vaccines B.V.","Industry",0,0,"All","46 Days","76 Days","350","April 2013","July 2014","Proportion of subjects with an anti-hepatitis B concentration ≥10 IU/mL","0","0","0","0","0","0","0","0","0"
"1345","NCT01839188","Spanish Mixed HEXA/PENTA/HEXA Schedule","Neisseria Meningitidis",0,"PR5I (V419)","Biological","MCM Vaccines B.V.","Industry",0,0,"All","46 Days","76 Days","385","May 2013","March 2014","Proportion of subjects with an anti-hepatitis B titre ≥10 mIU/mL","0","0","0","0","0","0","0","0","0"
"1346","NCT01839331","AP-003-A A Efficacy and Safety Study of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee","Osteoarthritis of the Knee",0,"Low Dose Ampion","Drug","Ampio Pharmaceuticals. Inc.","Industry",0,0,"All","40 Years","85 Years","329","March 2013","August 2013","Improvement in knee pain","0","0","0","0","0","0","0","0","0"
"1347","NCT01839357","Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter","Atrial Fibrillation",0,"Rivaroxaban (Xarelto, BAY59-7939)","Drug","Bayer","Industry",0,0,"All","18 Years","N/A","60","August 2013","November 2014","The percentage of subjects with complete resolution of left atrial or left atrial appendage thrombus at the end of treatment","0","0","0","0","0","0","0","0","0"
"1348","NCT01840553","Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing","Colon Cleansing",0,"oral sodium phosphate tablets","Drug","Laboratoires Mayoly Spindler","Industry",0,0,"All","18 Years","75 Years","461","May 2013","March 2014","overall quality of bowel cleansing","0","0","0","0","0","0","0","0","0"
"1349","NCT01840605","A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis","Dermatitis",0,"Bepotastine besilate","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","7 Years","15 Years","303","March 2013","November 2013","Change From Baseline in Pruritus Score","0","0","0","0","0","0","0","0","0"
"1350","NCT01840943","A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy","Epithelial Ovarian Cancer",0,"CAELYX","Drug","Xian-Janssen Pharmaceutical Ltd.","Industry",0,0,"Female","18 Years","N/A","32","June 2013","May 2014","Number of Participants With Progression-free Survival Incidence at Week 24","0","0","0","0","0","0","0","0","0"
"1351","NCT01841684","Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)","Hyperlipoproteinemia Type II",0,"Anacetrapib","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","2","June 2013","June 2014","Percent change from Baseline in Low-density Lipoprotein-Cholesterol (LDL-C) using beta-quantification method","0","0","0","0","0","0","0","0","0"
"1352","NCT01841697","Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)","Type 2 Diabetes",0,"Omarigliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","642","June 2013","November 2014","Change From Baseline in A1C at Week 24","0","0","0","-0.03","Difference in least squares mean","95","2-Sided","-0.15","0.08"
"1353","NCT01842841","Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease","Gaucher Disease",0,"velaglucerase alfa","Drug","Shire","Industry",0,0,"All","2 Years","N/A","5","March 2013","October 2014","Number of Participants With Drug-related Adverse Events (AEs), Infusion-related AEs, and Serious AEs (SAEs)","0","0","0","0","0","0","0","0","0"
"1354","NCT01844115","Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder","Generalized Anxiety Disorder",0,"Placebo","Drug","Forest Laboratories","Industry",0,0,"All","18 Years","70 Years","415","April 2013","March 2014","Hamilton Rating Scale for Anxiety (HAM-A) total score","0","0","0","0","0","0","0","0","0"
"1355","NCT01844232","One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity","Multiple Sclerosis",0,"arbaclofen","Drug","Osmotica Pharmaceutical US LLC","Industry",0,0,"All","18 Years","70 Years","150","April 2013","December 2014","Assessment of Adverse Events","0","0","0","0","0","0","0","0","0"
"1356","NCT01844388","A Study to Compare a New Eye Drop Formulation With Refresh Contacts®","Contact Lens Lubrication",0,"carboxymethylcellulose based eye drop formula","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","365","April 2013","December 2013","Percentage of Participants With Contact Lens Distance Visual Acuity Change From Baseline","0","0","0","0","0","0","0","0","0"
"1357","NCT01844830","Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients","Anesthesia",0,"Tetracaine HCl 3% and Oxymetazoline HCl 0.05%","Drug","St. Renatus, LLC","Industry",0,0,"All","3 Years","17 Years","90","May 2013","July 2013","Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic (yes/no).","0","0","0","0","0","0","0","0","0"
"1358","NCT01844856","Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections","Complicated Intra-abdominal Infections",0,"Eravacycline","Drug","Tetraphase Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","541","August 2013","August 2014","Clinical Response of Eravacycline and Ertapenem Treatment Arms at the Test-of-cure (TOC) Visit in the Microbiological Intent-to-treat (Micro-ITT) Population","0","0","0","0","0","0","0","0","0"
"1359","NCT01844895","Methotrexate-Inadequate Response Autoinjector Device Sub Study","Rheumatoid Arthritis",0,"Abatacept","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","120","April 2013","July 2014","Pharmacokinetic (PK) Analysis: Adjusted Geometric Mean Observed Serum Trough Concentration at Steady State (Cminss) of Abatacept Using a Prefilled Syringe (Measured on Day 29) and Using an Autoinjector (Measured on Day 113)","0","0","0","0.91","geometric mean ratio","90","2-Sided","0.83","1.00"
"1360","NCT01845649","Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia","Vulvovaginal Atrophy",0,"Estradiol Vaginal Gel","Drug","Warner Chilcott","Industry",0,0,"Female","35 Years","N/A","550","April 2013","November 2013","Change in Intensity of Dyspareunia, Subject Self-Assessment","0","0","0","0","0","0","0","0","0"
"1361","NCT01846689","An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease","Anemia of Chronic Disease",0,"ESS (medical food/drug)","Drug","Targeted Medical Pharma","Industry",0,0,"All","18 Years","N/A","30","June 2013","August 2013","Hemoglogin/Hematocrit","0","0","0","0","0","0","0","0","0"
"1362","NCT01846793","Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)","Benign Prostatic Hyperplasia",0,"NX-1207","Drug","Nymox Corporation","Industry",0,0,"Male","45 Years","N/A","160","April 2013","October 2014","Safety","0","0","0","0","0","0","0","0","0"
"1363","NCT01848054","Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence","Opioid-Related Disorders",0,"Buprenorphine/naloxone sublingual tablets","Drug","Orexo AB","Industry",0,0,"All","18 Years","65 Years","313","June 2013","January 2014","Retention in Treatment in the Per Protocol Population","<0.05","0","t-test, 2 sided","0","0","0","0","0","0"
"1364","NCT01848106","A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI","Coronary Artery Disease",0,"pegnivacogin/anivamersen","Drug","Regado Biosciences, Inc.","Industry",0,0,"All","18 Years","N/A","3232","September 2013","August 2014","Ischemic composite","0","0","0","0","0","0","0","0","0"
"1365","NCT01848873","Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine","Essential Hypertension",0,"Amlodipine","Drug","Shenzhen Ausa Pharmed Co.,Ltd","Industry",0,0,"All","18 Years","75 Years","756","January 2013","August 2013","Combined effective rate of blood pressure and plasma homocysteine reduction","0","0","0","0","0","0","0","0","0"
"1366","NCT01849289","A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes","Diabetes",0,"Insulin Degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","833","June 2, 2013","May 15, 2014","Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)","0","0","0","0","0","0","0","0","0"
"1367","NCT01849497","Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen","Primary Hypercholesterolemia",0,"Evolocumab Pre-filled Syringe","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","149","April 2013","September 2013","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 2 and 4","0","0","0","-6.8","Treatment Difference","95","2-Sided","-16.3","2.0"
"1368","NCT01850615","Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","Diabetes",0,"Faster-acting insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","323","September 23, 2013","November 17, 2014","Change from baseline in HbA1c","0","0","0","0","0","0","0","0","0"
"1369","NCT01850823","Clinical Equivalence Study of Mometasone Nasal Spray","Seasonal Allergic Rhinitis",0,"placebo","Drug","Actavis Inc.","Industry",0,0,"All","12 Years","N/A","875","February 2013","December 2013","Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS) over Days 1 to 14.","0","0","0","0","0","0","0","0","0"
"1370","NCT01851330","Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)","Chronic Hepatitis C Virus",0,"LDV/SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","647","May 2013","December 2013","Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","<0.001","The p-value for the comparison of the LDV/SOF 8 week group against the adjusted historical null rate (60%) was based on a 2-sided 1-sample binomial test.","Binomial test","0","0","0","0","0","0"
"1371","NCT01852812","Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)","Perennial Allergic Rhinitis",0,"Montelukast Oral Granules (OG)","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","1 Year","15 Years","87","June 2013","December 2013","Percentage of Participants Who Experience at Least One Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"1372","NCT01853384","Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers","Venous Ulcer",0,"HP802-247","Biological","Healthpoint","Industry",0,0,"All","18 Years","N/A","252","November 2013","December 2014","Compare the Treatment Groups for the Number of Subjects With Complete Wound Closure Over the 12-Week Treatment Period From Baseline",".5348","Analysis adjusted for sites, with significance being at P < 0.05","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1373","NCT01853982","Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia","Ventilator-Associated Pneumonia (VAP)",0,"Ceftolozane/Tazobactam","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","N/A","4","July 2013","December 2013","Clinical Response at the End of Therapy Visit","0","0","0","0","0","0","0","0","0"
"1374","NCT01854528","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie","Industry",0,0,"All","18 Years","65 Years","148","June 2013","November 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment","<0.001","0","Stratum adjusted Mantel-Haenszel","34.26","Mean Difference (Final Values)","95","2-Sided","21.09","47.42"
"1375","NCT01854697","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267, ABT-333","Drug","AbbVie","Industry",0,0,"All","18 Years","65 Years","311","March 2013","November 2014","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses","0","0","0","14.7","Difference","95","2-Sided","1.3","28.2"
"1376","NCT01855919","A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain","Back Pain Lower Back Chronic",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","79 Years","458","May 2013","July 2014","Change From Baseline to Week 14 in Brief Pain Inventory (BPI) 24-Hour Average Pain Severity Item","0.0026","0","Mixed Models Analysis","-0.46","Mean Difference (Final Values)","95","2-Sided","-0.77","-0.16"
"1377","NCT01856413","A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant","Hepatitis B",0,"Zutectra","Drug","Biotest","Industry",0,0,"All","18 Years","75 Years","49","December 2012","September 2014","Trough levels of serum anti-HBs antibody concentrations","0","0","0","0","0","0","0","0","0"
"1378","NCT01856998","Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery","General Anesthesia",0,"Propofol","Drug","Fresenius Kabi","Industry",0,0,"All","18 Years","64 Years","71","May 2013","February 2014","Time to Loss of Eyelash Reflex (LOER)","0","0","0","0","0","0","0","0","0"
"1379","NCT01857063","Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)","Seasonal Allergic Rhinitis",0,"Montelukast","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","10 Years","15 Years","220","June 2013","September 2013","Change From Baseline in Total Nasal Symptom Score (TNSS) Averaged During 3 Hours of Exposure","0.913","Longitudinal Data Analysis (LDA) model with baseline TNSS as a covariate, sequence, treatment and period as fixed effects and participant as a random effect.","Longitudinal Data Analysis (LDA)","-0.01","Difference in Least Squares (LS) Means","95","2-Sided","-0.11","0.10"
"1380","NCT01857206","Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age","Influenza",0,"Mammalian cell based flu vaccine","Biological","Novartis Vaccines","Industry",0,0,"All","4 Years","17 Years","2055","May 2013","June 2014","Number Of Subjects Reporting Solicited Local and Systemic Adverse Events and Other Indicators Of Reactogenicity After Any Vaccination.","0","0","0","0","0","0","0","0","0"
"1381","NCT01857323","Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)","Asthma",0,"Albuterol Spiromax®","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","4 Years","N/A","317","May 2013","August 2013","Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count","0","0","0","0","0","0","0","0","0"
"1382","NCT01857622","Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment","Non-valvular Atrial Fibrillation",0,"DU-176b 15mg","Drug","Daiichi Sankyo Co., Ltd.","Industry",0,0,"All","20 Years","N/A","93","November 2011","January 2013","Incidence of Any Adjudicated Bleeding Events","0","0","0","3.8","Cox Proportional Hazard","95","2-Sided","-14.7","26.8"
"1383","NCT01860066","A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD","Chronic Obstructive Pulmonary Disease",0,"QVA149","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","N/A","N/A","0","December 2013","September 2014","Area under the curve (AUC) 0-12 hours for FEV1 following 12 weeks of treatment","0","0","0","0","0","0","0","0","0"
"1384","NCT01861522","The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"Bepotastine besilate","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","7 Years","15 Years","473","April 2013","December 2013","Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]","0","0","0","0","0","0","0","0","0"
"1385","NCT01863407","Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)","Postoperative Ileus",0,"DAM","Drug","Beijing Bozhiyin T&S Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","480","April 2013","November 2014","Time to achieve recovery of both upper and lower GI function as measured by a composite endpoint of time to the first bowel movement and time to tolerate first solid food. This endpoint is referred to as GI2.","0","0","0","0","0","0","0","0","0"
"1386","NCT01863667","A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)","Type 2 Diabetes Mellitus",0,"Omarigliptin","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","N/A","65","July 2013","April 2014","Change From Baseline in Hemoglobin A1C (A1C) at Week 54","0","0","0","0","0","0","0","0","0"
"1387","NCT01863680","Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel","Luteal Hormone Supplementation in In-vitro Fertilization",0,"COL-1620","Drug","Merck KGaA","Industry",0,0,"Female","20 Years","45 Years","178","July 2013","October 2014","Clinical Pregnancy Rate Per Embryo Transfer","0","0","0","0","0","0","0","0","0"
"1388","NCT01863810","Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain","Diabetic Neuropathy",0,"KW21052","Drug","KunWha Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","N/A","394","August 2013","October 2014","Numerical pain rating scale (NRS)","0","0","0","0","0","0","0","0","0"
"1389","NCT01866163","LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","Psoriasis Vulgaris",0,"LEO 90100","Drug","LEO Pharma","Industry",0,0,"All","18 Years","N/A","426","June 2013","October 2013","Treatment Success According to IGA","<0.001","0","Mantel Haenszel","30.27","Odds Ratio (OR)","95","2-Sided","9.72","94.30"
"1390","NCT01868009","DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"ELLIPTA","Device","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","287","May 2013","July 2013","Number of Participants With the Indicated Device Preference Based on the Size of the Numbers on the Dose Counter","<0.001","The response was analyzed and adjusted for study inhaler use sequence and preference question version. The method accounted for participants who indicated no preference.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1391","NCT01869491","Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study","Gastroesophageal Reflux Disease",0,"Compound Sodium Alginate Double Action Chewable Tablets","Drug","Reckitt Benckiser Healthcare (UK) Limited","Industry",0,0,"All","18 Years","65 Years","1107","June 2013","May 2014","Change from baseline in GERD dimension","0","0","0","0","0","0","0","0","0"
"1392","NCT01870362","Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis","Chronic Periodontitis",0,"Probiotic (Inersan)","Drug","CD Pharma India Pvt. Ltd.","Industry",0,0,"All","25 Years","60 Years","28","June 2013","July 2014","Improvement in periodontal indices","0","0","0","0","0","0","0","0","0"
"1393","NCT01870687","Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS","Premenstrual Syndrome",0,"20mg VAC BNO 1095 FCT","Drug","Bionorica SE","Industry",0,0,"Female","18 Years","45 Years","96","June 2013","October 2014","Maximum severity of cyclic breast pain","0","0","0","0","0","0","0","0","0"
"1394","NCT01870895","A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)","Diarrhea-predominant Irritable Bowel Syndrome",0,"YM060","Drug","Astellas Pharma Inc","Industry",0,0,"Female","20 Years","64 Years","577","February 2013","February 2014","Monthly responder rate of global assessment of relief of overall IBS symptoms at final point","0","0","0","0","0","0","0","0","0"
"1395","NCT01871402","A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)","Plaque Psoriasis",0,"000-0551 Lotion","Drug","Therapeutics, Inc.","Industry",0,0,"All","18 Years","N/A","221","May 2013","December 2013","Proportion of Subjects Rated a ""Treatment Success"" Based on the Investigator's Global Assessment (IGA)","<0.001","Treatment groups were compared with respect to the proportions of subjects with “treatment success” at Day 15 using the Cochran-Mantel-Haenszel (CMH) test stratified by analysis center.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1396","NCT01872234","MADIT ASIA Cardiac Resynchronization Trial","Congestive Heart Failure",0,"Two-lead CRT-P","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","N/A","1","February 2014","April 2014","Primary Endpoint","0","0","0","0","0","0","0","0","0"
"1397","NCT01872897","Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients","Gastroesophageal Reflux Disease",0,"Sodium Alginate Double Action Tablets","Drug","Reckitt Benckiser Healthcare (UK) Limited","Industry",0,0,"All","18 Years","65 Years","45","June 2013","December 2013","Percentage of time during the 4 hour post dosing period with pH below pH 4","0","0","0","0","0","0","0","0","0"
"1398","NCT01874145","Safety and Tolerability of Glatiramer Acetate","Relapsing-Remitting Multiple Sclerosis",0,"GA 20 mg/mL","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","N/A","209","June 2013","April 2014","Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period","0.0006","The overall significance level for this study was 5% using 2-tailed test.","Poisson regression model","0.501","Risk Ratio (RR)","95","2-Sided","0.338","0.743"
"1399","NCT01874470","Renal Denervation by Allegro System in Patients With Resistant Hypertension","Renal Denervation",0,"renal denervation","Device","Shanghai AngioCare Medical","Industry",0,0,"All","18 Years","65 Years","3","May 2013","May 2014","Change in office-based systolic blood pressure (SBP) from baseline to 6 months","0","0","0","0","0","0","0","0","0"
"1400","NCT01876368","Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","Hypertension",0,"LCZ696","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","376","September 2013","August 2014","Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)","<0.001","0","ANCOVA","-3.19","Mean Difference (Net)","95","2-Sided","-4.73","-1.65"
"1401","NCT01876420","The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study","Aortic Stenosis",0,"The CoreValve™ Evolut R TAV™ system","Device","Medtronic Cardiovascular","Industry",0,0,"All","N/A","N/A","60","October 2013","August 2014","All-cause mortality rate at 30 days","0","0","0","0","0","0","0","0","0"
"1402","NCT01879319","Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen","Primary Hypercholesterolemia",0,"Evolocumab AMD","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","164","July 2013","December 2013","Percentage of Participants With Full Administration of Evolocumab at Both Weeks 4 and 8","0","0","0","-2.4","Treatment Difference","95","2-Sided","-11.2","6.1"
"1403","NCT01879410","A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","700","June 2013","January 2014","Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Forced Expiratory Volume Over 1 Second (FEV1) at Day 84","<0.001","0","ANCOVA","0.101","Mean Difference (Final Values)","95","2-Sided","0.063","0.139"
"1404","NCT01880320","Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris","Acne Vulgaris",0,"CD0271 0.3% / CD1579 2.5%","Drug","Galderma R&D","Industry",0,0,"All","12 Years","N/A","503","July 2013","March 2014","Success Rate","0","0","0","0","0","0","0","0","0"
"1405","NCT01880697","Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above","Human Influenza",0,"TIVc","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","126","August 2013","September 2013","Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVc","0","0","0","0","0","0","0","0","0"
"1406","NCT01880736","A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes","Diabetes",0,"insulin degludec","Drug","Novo Nordisk A/S","Industry",0,0,"All","20 Years","N/A","458","June 2013","April 2014","Change From Baseline in HbA1c (%) Glycosylated Haemoglobin)","0","0","0","0","0","0","0","0","0"
"1407","NCT01881113","A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","Allergic Conjunctivitis",0,"AC-170 0.24%","Drug","Aciex Therapeutics, Inc.","Industry",0,0,"All","10 Years","N/A","101","June 2013","October 2013","Ocular itching at defined time points up to 2 weeks","0","0","0","0","0","0","0","0","0"
"1408","NCT01882647","A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)","Plaque Psoriasis",0,"000-0551 Lotion","Drug","Therapeutics, Inc.","Industry",0,0,"All","18 Years","N/A","222","June 2013","March 2014","The Percentage of Subjects Rated a ""Treatment Success"" Based on the Investigator's Global Assessment (IGA)","<0.001","Treatment groups were compared with respect to the proportions of subjects with “treatment success” at Day 15 using the Cochran-Mantel-Haenszel (CMH) test stratified by analysis center.","Cochran-Mantel-Haenszel","0","0","0","0","0","0"
"1409","NCT01882764","A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis","Ulcerative Colitis",0,"HMPL-004 tablet","Drug","Hutchison Medipharma Limited","Industry",0,0,"All","18 Years","N/A","1","June 2013","October 2014","The Efficacy of HMPL-004 in the maintenance of clinical remission","0","0","0","0","0","0","0","0","0"
"1410","NCT01885117","Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above","Human Influenza",0,"TIVf","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","125","August 2013","September 2013","Percentage of Subjects With Single Radial Hemolysis (SRH) Areas ≥25mm2, Against Each of Three Vaccine Strains After Receiving One Dose of TIVf","0","0","0","0","0","0","0","0","0"
"1411","NCT01885156","Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris","Tinea Cruris",0,"Naftin 1% Cream","Drug","Merz Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","17 Years","65","August 2013","November 2013","Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).","0","0","0","0","0","0","0","0","0"
"1412","NCT01886690","A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery","Bilateral LASIK Surgery",0,"carboxymethylcellulose sodium based new eye drop formulation","Drug","Allergan","Industry",0,0,"All","18 Years","60 Years","148","August 2013","August 2014","Ocular Surface Disease Index© (OSDI) Score Using a 5-Point Scale","0","0","0","0","0","0","0","0","0"
"1413","NCT01887678","Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee","Osteoarthritis, Knee",0,"Traumeel® / Zeel® Injectable Solution","Drug","Biologische Heilmittel Heel GmbH","Industry",0,0,"All","45 Years","80 Years","287","June 2013","January 2014","Change in Knee Pain as Measured by the WOMAC Osteoarthritis (OA) Index Pain Subscale (Section A, Items #1-5) Measured by 100 mm VAS","0.0383","0","ANCOVA","-6.37","Least Square","95","2-Sided","-12.40","-0.35"
"1414","NCT01888497","Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers","Healthy",0,"Gabapentin","Drug","Pfizer","Industry",0,0,"All","25 Years","55 Years","59","July 2013","December 2013","Standard Deviation of Lateral Position","0","0","0","0","0","0","0","0","0"
"1415","NCT01889251","A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion","Symptomatic Vitreomacular Adhesion",0,"Ocriplasmin","Drug","Alcon Research","Industry",0,0,"All","20 Years","N/A","251","July 2013","September 2014","Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA)","0","0","0","0","0","0","0","0","0"
"1416","NCT01890798","Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol","Muscular Dystrophies",0,"Drisapersen","Drug","GlaxoSmithKline","Industry",0,0,"Male","5 Years","N/A","0","January 2014","January 2014","Safety as assessed by the collection of adverse events (AEs)","0","0","0","0","0","0","0","0","0"
"1417","NCT01891864","Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","Chronic Stable Plaque Psoriasis",0,"GP2015 Etanercept","Drug","Sandoz","Industry",0,0,"All","18 Years","N/A","531","June 2013","June 2014","PASI 75 Response Rate at Week 12 - GP2015 Etanercept vs. Enbrel ® Etanercept","0","0","0","-2.3","Risk Difference (RD)","95","2-Sided","-9.85","5.3"
"1418","NCT01893177","Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)","Influenza",0,"Inflexal V","Biological","Crucell Holland BV","Industry",0,0,"All","18 Years","N/A","110","July 2013","August 2013","Percentage of subjects with seroconversion, seroprotection, and fold increase in geometric mean titer (GMT)","0","0","0","0","0","0","0","0","0"
"1419","NCT01893905","Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis","Knee Osteoarthritis",0,"CS+SG","Drug","Tedec-Meiji Farma, S.A.","Industry",0,0,"All","45 Years","N/A","193","June 2013","August 2014","Reduction of pain using VAS","0","0","0","0","0","0","0","0","0"
"1420","NCT01895218","Treatment of Women After Postpartum Haemorrhage","Postpartum Haemorrhage",0,"Iron isomaltoside 1000","Drug","Pharmacosmos A/S","Industry",0,0,"Female","18 Years","N/A","200","June 2013","December 2014","Physical fatigue","0","0","0","0","0","0","0","0","0"
"1421","NCT01895309","A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","Rheumatoid Arthritis",0,"Enbrel (etanercept)","Drug","Samsung Bioepis Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","596","June 2013","April 2014","American College of Rheumatology 20% Response Criteria (ACR20)","0","0","0","0","0","0","0","0","0"
"1422","NCT01895855","Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera","Cholera",0,"PXVX0200","Biological","PaxVax, Inc.","Industry",0,0,"All","18 Years","45 Years","210","September 2013","November 2014","Ten day cholera challenge","0","0","0","0","0","0","0","0","0"
"1423","NCT01896193","Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection","Hepatitis C",0,"SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","127","June 2013","April 2014","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1424","NCT01898286","Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®","Type 1 Diabetes",0,"DiaPep277®","Drug","Andromeda Biotech Ltd.","Industry",0,0,"All","18 Years","47 Years","38","October 2013","September 2014","Hypoglycemic Events","0","0","0","0","0","0","0","0","0"
"1425","NCT01900054","A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis",0,"Bepotastine besilate","Drug","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","7 Years","15 Years","58","June 2013","November 2013","Number of Patients With Adverse Events and Adverse Drug Reactions","0","0","0","0","0","0","0","0","0"
"1426","NCT01900444","Study of a Booster Dose of IMOJEV® Vaccine One Year After Primary Immunization in Healthy Children in South Korea","Japanese Encephalitis",0,"IMOJEV®: Live Attenuated Japanese Encephalitis Chimeric Virus","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","2 Years","4 Years","119","July 2013","April 2014","Summary of the Neutralizing antibody titers at baseline and following booster vaccination","0","0","0","0","0","0","0","0","0"
"1427","NCT01901185","Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept","Rheumatoid Arthritis",0,"Etanercept / Autoinjector A","Drug","Amgen","Industry",0,0,"All","18 Years","N/A","77","June 2013","December 2013","Percentage of Successful Self-injections to Total Non-missed Injections","0","0","0","0","0","0","0","0","0"
"1428","NCT01901302","Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","Opioid-Induced Constipation",0,"CB-5945","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","80 Years","61","July 2013","January 2014","Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12 Weeks","0","0","0","0","0","0","0","0","0"
"1429","NCT01901328","Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","Opioid-Induced Constipation",0,"CB-5945","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","80 Years","49","August 2013","February 2014","Overall Spontaneous Bowel Movement (SBM) Responder Rates at 12-weeks","0","0","0","0","0","0","0","0","0"
"1430","NCT01901341","The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation","Opioid-Induced Constipation",0,"CB-5945","Drug","Cubist Pharmaceuticals LLC","Industry",0,0,"All","18 Years","80 Years","44","July 2013","February 2014","Overall Spontaneous Bowel Movement (SBM) Responder Rates at the 12-weeks","0","0","0","0","0","0","0","0","0"
"1431","NCT01902134","Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride","Acute Pain",0,"Placebo","Drug","Menarini Group","Industry",0,0,"All","18 Years","80 Years","641","April 2013","February 2014","SPID8 (Sum of Pain Intensity Differences Over 8 Hours)","0","0","0","0","0","0","0","0","0"
"1432","NCT01903265","BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)","Primary Fibromyalgia",0,"TNX-102 SL 2.8mg","Drug","Tonix Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","205","September 2013","July 2014","Mean Change From Baseline in Weekly Average of Daily Pain Scores at Week 12","0","0","0","0","0","0","0","0","0"
"1433","NCT01904149","Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride","Acute Pain",0,"Placebo","Drug","Menarini Group","Industry",0,0,"Female","18 Years","75 Years","606","May 2013","May 2014","SPID8 (Sum of Pain Intensity Differences Over 8 Hours)","0","0","0","0","0","0","0","0","0"
"1434","NCT01905956","Safety and Efficacy of IQP- AK-102 in Reducing Body Weight","Weight Loss",0,"IQP-AK-102","Dietary Supplement","InQpharm Group","Industry",0,0,"All","18 Years","65 Years","119","July 2013","July 2014","Mean Change in Body Weight From Baseline to Week 12","0","0","0","0","0","0","0","0","0"
"1435","NCT01908140","Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)",0,"Aclidinium Bromide / Formoterol Fumarate","Drug","AstraZeneca","Industry",0,0,"All","40 Years","N/A","933","September 2013","August 2014","Peak Forced Expiratory Volume in One Second (FEV1) at Week 24","<0.001","0","MMRM","0.093","Mean Difference (Final Values)","95","2-Sided","0.063","0.123"
"1436","NCT01908829","A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)","Urinary Bladder Overactive",0,"Mirabegron","Drug","Astellas Pharma Europe Ltd.","Industry",0,0,"All","18 Years","N/A","3815","July 2013","November 2014","Change from Baseline in mean number of incontinence episodes per 24 hours","0","0","0","0","0","0","0","0","0"
"1437","NCT01908842","Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults","Opioid Dependence, on Agonist Therapy",0,"BNX sublingual tablets","Drug","Orexo AB","Industry",0,0,"All","18 Years","65 Years","759","August 2013","April 2014","Primary Endpoints of Retention in Treatment at Days 3 and 15","0","0","0","0","0","0","0","0","0"
"1438","NCT01908933","Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema","Emphysema",0,"AeriSeal Emphysematous Lung Sealant Syst","Device","Aeris Therapeutics","Industry",0,0,"All","40 Years","N/A","0","September 2013","November 2013","Volume change by CT","0","0","0","0","0","0","0","0","0"
"1439","NCT01910064","A Long Term Study of GK530G in Subjects With Acne Vulgaris","Acne Vulgaris",0,"GK530G","Drug","Galderma R&D","Industry",0,0,"All","12 Years","N/A","436","May 2013","August 2014","Local Tolerability (Erythema)","0","0","0","0","0","0","0","0","0"
"1440","NCT01910636","Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection","Hepatitis C",0,"Sofosbuvir","Drug","Gilead Sciences","Industry",0,0,"All","20 Years","N/A","153","February 2013","March 2014","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1441","NCT01911221","A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","Prevention of the Meningococcal Disease",0,"rMenB+OMV NZ","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","65 Years","13","August 2013","April 2014","Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule","0","0","0","0","0","0","0","0","0"
"1442","NCT01911442","Lurasidone Pediatric Autism Study","Autism",0,"Lurasidone 20 mg daily","Drug","Sunovion","Industry",0,0,"All","6 Years","17 Years","150","August 2013","November 2014","Change in Aberrant Behavior Checklist (ABC) Irritability Subscale Score at Week 6","0.5463","0","Mixed Models Analysis","-1.3","Mean Difference (Final Values)","95","2-Sided","-5.6","3.0"
"1443","NCT01911754","Japanese Pediatric H5N1 Vaccine Study","Influenza",0,"H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)","Biological","Nanotherapeutics, Inc.","Industry",0,0,"All","6 Months","17 Years","60","August 2013","November 2013","Co-Primary Evaluation of Immunogenicity by Single Radial Hemolysis (SRH) Assay: Number of participants with antibody response to vaccine strain (A/Indonesia/05/2005)","0","0","0","0","0","0","0","0","0"
"1444","NCT01911858","Askina Calgitrol Paste Burns","Third Degree Burns",0,"Askina Calgitrol Paste","Device","BBraun Medical SAS","Industry",0,0,"All","18 Years","N/A","0","April 2013","December 2013","The quantification of the amount of silver found in plasma during the treatment","0","0","0","0","0","0","0","0","0"
"1445","NCT01914432","Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia","Hyperlipidemia",0,"YH16410","Drug","Yuhan Corporation","Industry",0,0,"All","19 Years","N/A","210","November 2013","June 2014","Change in Diastolic Blood Pressure, Change in LDL Cholesterol","0","0","0","0","0","0","0","0","0"
"1446","NCT01914666","An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain","Back Pain Lower Back Chronic",0,"Duloxetine","Drug","Eli Lilly and Company","Industry",0,0,"All","20 Years","79 Years","151","September 2013","December 2014","Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's","0","0","0","0","0","0","0","0","0"
"1447","NCT01915459","Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity","Stroke",0,"Botulinum toxin type A(Botulax®)","Biological","Hugel","Industry",0,0,"All","20 Years","N/A","186","June 2013","May 2014","The change in MAS(Modified Ashworth Scale) grade","0","0","0","0","0","0","0","0","0"
"1448","NCT01915732","A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris","Acne Vulgaris",0,"Duac™Once Daily Gel","Drug","GlaxoSmithKline","Industry",0,0,"All","12 Years","45 Years","1018","April 2013","April 2014","Absolute Change in Total Lesion Count From Baseline to Week 12","0.002","0","ANCOVA","-4.5","Mean Difference (Final Values)","95","2-Sided","-7.4","-1.6"
"1449","NCT01915823","Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)","Seasonal Allergic Rhinitis",0,"azelastine hydrochloride and fluticasone propionate","Drug","Meda Pharmaceuticals","Industry",0,0,"All","4 Years","11 Years","348","July 2013","February 2014","Primary Efficacy","0","0","0","0","0","0","0","0","0"
"1450","NCT01916967","An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)","Urticaria",0,"Desloratadine","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","239","August 2013","February 2014","Change From Baseline in the Sum Score of Pruritus/Itch and Rash Assessed by Investigator at Week 2","<0.001","0","Constrained Longitudinal Data Analysis","-1.17","Difference in LS means","95","2-Sided","-1.69","-0.65"
"1451","NCT01916980","Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)","Eczema",0,"Desloratadine 5 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","94","August 2013","March 2014","Change From Baseline in Pruritus/Itch Score (Sum of Daytime and Nighttime Scores) Assessed by the Investigator at Week 2","<0.001","0","Longitudinal Data Analysis","0","0","0","0","0","0"
"1452","NCT01917357","A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject","Diphtheria",0,"Quinvaxem in Uniject","Biological","Crucell Holland BV","Industry",0,0,"All","42 Days","64 Days","400","September 2013","April 2014","Seroprotection Rate: Anti-PRP Antibodies","0","0","0","0","0","0","0","0","0"
"1453","NCT01918033","A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)","Perennial Allergic Rhinitis",0,"Desloratadine 5 mg","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","12 Years","N/A","608","August 2013","January 2014","Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2","0.661","0","Constrained Longitudinal Data Analysis","-0.09","Difference in Least Squares (LS) Means","95","2-Sided","-0.49","0.31"
"1454","NCT01918332","Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia","Hypertension,",0,"Valsartan 160mg","Drug","LG Life Sciences","Industry",0,0,"All","20 Years","80 Years","168","April 2012","March 2013","sitDBP Changes at Week 8 From Baseline","0","0","0","0","0","0","0","0","0"
"1455","NCT01922739","Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets","Low Back Pain",0,"Hydrocodone ER","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","18 Years","80 Years","182","July 2013","August 2014","Participants With Adverse Events","0","0","0","0","0","0","0","0","0"
"1456","NCT01923428","The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)","Constipation Predominant Irritable Bowel Syndrome",0,"AZD1722","Drug","Ardelyx","Industry",0,0,"All","18 Years","75 Years","371","August 2013","October 2014","Percent Complete Spontaneous Bowel Movement responders vs placebo","0","0","0","0","0","0","0","0","0"
"1457","NCT01926782","Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","Hypercholesterolemia",0,"Placebo (for alirocumab)","Drug","Regeneron Pharmaceuticals","Industry",0,0,"All","18 Years","N/A","803","September 2013","September 2014","Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis","<0.0001","Threshold for significance ≤ 0.025.","Mixed Models Analysis","-52.4","LS Mean Difference","97.5","2-Sided","-59.8","-45.0"
"1458","NCT01928628","Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients","Hypertension",0,"Lercanidipine 10mg","Drug","LG Life Sciences","Industry",0,0,"All","20 Years","75 Years","449","May 2012","April 2013","Change in mean sitDBP from week 0 to week 40","0","0","0","0","0","0","0","0","0"
"1459","NCT01929031","Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain","Pain, Postoperative",0,"ibuprofen + caffeine","Drug","Boehringer Ingelheim","Industry",0,0,"All","18 Years","55 Years","562","August 2013","March 2014","Time-weighted Sum of Pain Relief (PAR) and Pain Intensity Difference (PID) From 0 to 8 Hours (SPRID0-8h)","<0.0001","0","ANCOVA","41.738","Mean Difference (Final Values)","95","2-Sided","33.767","49.708"
"1460","NCT01929317","A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.","Parkinson Disease",0,"Ropinirole CR 2mg tablet","Drug","GlaxoSmithKline","Industry",0,0,"All","20 Years","N/A","81","August 2013","September 2014","Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at Week 12 in the CR High-dose Group","<0.001","0","t-test, 1 sided","-4.8","Mean change from Baseline","95","2-Sided","-6.3","-3.2"
"1461","NCT01931748","A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome","Menopausal Syndrome",0,"MELSMON","Drug","Unimed Pharmaceuticals","Industry",0,0,"Female","40 Years","N/A","104","April 2013","April 2014","Kupperman index score","0","0","0","0","0","0","0","0","0"
"1462","NCT01932970","Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide","Hyperparathyroidism, Secondary",0,"Etelcalcetide","Drug","Amgen","Industry",0,0,"All","18 Years","100 Years","158","August 2013","February 2014","Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period","0","0","0","0","0","0","0","0","0"
"1463","NCT01934036","Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women","Obesity",0,"Obex","Dietary Supplement","Catalysis SL","Industry",0,0,"Female","35 Years","60 Years","92","August 2013","February 2014","To evaluate the effect of OBEX on skinfolds","0","0","0","0","0","0","0","0","0"
"1464","NCT01934231","Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis","Sinusitis, Acute",0,"Amoxicillin-Potassium Clavulanate Combination","Drug","GlaxoSmithKline","Industry",0,0,"All","3 Months","15 Years","27","August 2013","November 2013","Number of Participants With a Clinical Outcome of ""Cure"" at Test of Cure (TOC: Day 15)","0","0","0","88.5","Rate of Cure","95","2-Sided","69.85","97.55"
"1465","NCT01934582","A Pharmacokinetic Substudy of the TDE-PH-304 Protocol","Pulmonary Arterial Hypertension",0,"UT-15C SR","Drug","United Therapeutics","Industry",0,0,"All","12 Years","75 Years","13","August 2013","November 2013","To Assess the Pharmacokinetics (Mean AM Dose) in Subjects During Twice Daily (BID) Dosing (up to 14 Days Prior to Transitioning to Three Times Daily [TID] Dosing Regimen at PK Visit 1) and up to 35 Days After Transitioning to TID Dosing (at PK Visit 2).","0","0","0","0","0","0","0","0","0"
"1466","NCT01936181","A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy","Rheumatoid Arthritis",0,"Remicade (infliximab)","Drug","Samsung Bioepis Co., Ltd.","Industry",0,0,"All","18 Years","75 Years","584","August 2013","September 2014","American College of Rheumatology 20% Response Criteria (ACR20)","0","0","0","0","0","0","0","0","0"
"1467","NCT01937156","A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting","Chemotherapy-induced Nausea and Vomiting",0,"SP-01 (Granisetron Transdermal Delivery System)","Drug","Solasia Pharma K.K.","Industry",0,0,"All","18 Years","N/A","313","August 2013","January 2014","Percentage of subjects achieving Complete Control (CC) of CINV from the first administration until 24 hour after the last administration of ME or HE multi-day chemotherapy","0","0","0","0","0","0","0","0","0"
"1468","NCT01942135","Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)","Metastatic Breast Cancer",0,"Palbociclib","Drug","Pfizer","Industry",0,0,"Female","18 Years","N/A","521","September 26, 2013","December 5, 2014","Progression-Free Survival (PFS) as Assessed by the Investigator","<0.000001","The overall Type-I error rate was persevered at 1-sided 0.025 level for the analysis of the primary endpoint PFS by the Haybittle-Peto efficacy boundary. The priori threshold for statistical significance at the interim analysis was 0.00135.","Stratified Log Rank Test (1-sided)","0.422","Hazard Ratio (HR)","95","2-Sided","0.318","0.560"
"1469","NCT01942161","A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia","Schizophrenia",0,"Aripiprazole Low (2 mg/day)","Drug","Otsuka Pharmaceutical Co., Ltd.","Industry",0,0,"All","13 Years","17 Years","106","August 2010","November 2014","Positive and Negative Syndrome Scale (PANSS) total sore","0","0","0","0","0","0","0","0","0"
"1470","NCT01942733","Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder","Sleep Disturbances",0,"Brexpiprazole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","44","September 2013","August 2014","Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters","0","0","0","0","0","0","0","0","0"
"1471","NCT01942785","Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy","Major Depressive Disorder",0,"Brexpiprazole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","65 Years","55","October 2013","July 2014","Change From Baseline to Week 6 in SIS Total Score","0","0","0","0","0","0","0","0","0"
"1472","NCT01943708","Novel Auto-continuous Positive Airway Pressure (CPAP) Validation","Sleep Apnea, Obstructive",0,"SPAP","Device","Fisher and Paykel Healthcare","Industry",0,0,"All","18 Years","N/A","74","September 2010","October 2013","AHI","0","0","0","0","0","0","0","0","0"
"1473","NCT01944969","Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder","Major Depressive Disorder",0,"Brexpiprazole","Drug","H. Lundbeck A/S","Industry",0,0,"All","18 Years","N/A","26","October 2013","May 2014","Safety","0","0","0","0","0","0","0","0","0"
"1474","NCT01945684","A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity","Spasticity",0,"Botulinum toxin type A","Drug","Daewoong Pharmaceutical Co. LTD.","Industry",0,0,"All","18 Years","N/A","197","September 2013","May 2014","The change in MAS(Modified Ashworth Scale)grade for Wrist flexor","0","0","0","0","0","0","0","0","0"
"1475","NCT01947062","Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma","Lung Cancer",0,"Intravenous Cisplatin & etoposide","Drug","Swami Rama Cancer Hospital and Research Institute","Industry",0,0,"All","18 Years","75 Years","60","October 2013","June 2014","Progression free survival","0","0","0","0","0","0","0","0","0"
"1476","NCT01947946","Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma","Asthma",0,"Benralizumab","Biological","AstraZeneca","Industry",0,0,"All","18 Years","75 Years","13","November 2013","July 2014","Asthma Exacerbations Over 48 Weeks Treatment","0","0","0","0","0","0","0","0","0"
"1477","NCT01948193","Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth","Diphtheria",0,"Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","6 Weeks","8 Weeks","177","February 2014","December 2014","Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial Oral Poliovirus Vaccine and Recombinant Hep B Monovalent Vaccine at Birth","0","0","0","0","0","0","0","0","0"
"1478","NCT01949142","OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement","Otitis Media With Effusion",0,"OTO-201","Drug","Otonomy, Inc.","Industry",0,0,"All","6 Months","17 Years","266","November 2013","May 2014","Percentage of Participants Who Were Treatment Failures","0","0","0","0","0","0","0","0","0"
"1479","NCT01949155","OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement","Otitis Media With Effusion",0,"OTO-201","Drug","Otonomy, Inc.","Industry",0,0,"All","6 Months","17 Years","266","November 2013","May 2014","Percentage of Participants Who Were Treatment Failures.","0","0","0","0","0","0","0","0","0"
"1480","NCT01952145","A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus","Diabetes",0,"insulin degludec/liraglutide","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","557","September 20, 2013","November 4, 2014","Change From Baseline in HbA1c (Glycosylated Haemoglobin)","< 0.001","0","ANCOVA","-0.59","Treatment contrast","95","2-Sided","-0.74","-0.45"
"1481","NCT01953328","Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events",0,"Atorvastatin","Drug","Amgen","Industry",0,0,"All","20 Years","85 Years","409","October 2013","June 2014","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12","<0.001","Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.","Repeated measures linear effects model","-73.97","LS Mean Treatment Difference","95","2-Sided","-78.54","-69.41"
"1482","NCT01956786","Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine","Essential Hypertension",0,"Amlodipine-FA tablet,low dose group","Drug","Shenzhen Ausa Pharmed Co.,Ltd","Industry",0,0,"All","18 Years","75 Years","540","September 2013","December 2013","Combined effective rate of blood pressure and plasma homocysteine reduction","0","0","0","0","0","0","0","0","0"
"1483","NCT01957163","Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"FF","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","619","October 2013","April 2014","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85","< 0.001","0","Mixed Model Repeated Measure","0.124","Least squared mean difference","95","2-Sided","0.093","0.154"
"1484","NCT01959230","Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.","Hyperemia",0,"Brimonidine Tartrate","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","60","November 2013","December 2013","Ocular Redness - Investigator","0","0","0","0","0","0","0","0","0"
"1485","NCT01959243","Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.","Hyperemia",0,"Brimonidine Tartrate","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","5 Years","N/A","507","February 2014","April 2014","Adverse Events","0","0","0","0","0","0","0","0","0"
"1486","NCT01959334","Evaluate the Immunogenicity of a Novel Glucagon Formulation","Drug-specific Antibodies",0,"Glucagon IN","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","70 Years","75","September 2013","January 2014","Immunogenicity data (titers)","0","0","0","0","0","0","0","0","0"
"1487","NCT01959828","Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery","Hypertension, Pulmonary",0,"IK-3001","Drug","Mallinckrodt","Industry",0,0,"All","N/A","80 Years","18","September 2013","March 2014","Change in mean pulmonary artery pressure (mPAP) in Adult subjects (with LVAD)","0","0","0","0","0","0","0","0","0"
"1488","NCT01959945","Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)","Influenza",0,"Flublok® Quadrivalent Influenza Virus Vaccine","Biological","Protein Sciences Corporation","Industry",0,0,"All","6 Years","17 Years","219","November 2013","June 2014","Number of Participants Reporting Solicited Injection Site and Systemic Events and Unsolicited Adverse Events Following Vaccination With Quadrivalent Vaccine.","0","0","0","0","0","0","0","0","0"
"1489","NCT01960010","A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye","Dry Eye Syndromes",0,"MIM-D3 Ophthalmic Solution","Drug","Mimetogen Pharmaceuticals USA, Inc.","Industry",0,0,"All","18 Years","N/A","403","October 2013","August 2014","Corneal Fluorescein Staining","0","0","0","0","0","0","0","0","0"
"1490","NCT01960517","Feasibility Assessment of ACS Catheter","Urological",0,"ACS Catheter","Device","Alternative Urological Catheter Systems Ltd.","Industry",0,0,"All","18 Years","N/A","0","January 2014","March 2014","Retention of the ACS catheter","0","0","0","0","0","0","0","0","0"
"1491","NCT01960647","FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease","Peripheral Artery Disease",0,"Percutaneous transluminal angioplasty with uncoated balloon","Device","Eurocor GmbH","Industry",0,0,"All","18 Years","N/A","280","May 2011","September 2014","Rate of clinically driven target lesion revascularization","0","0","0","0","0","0","0","0","0"
"1492","NCT01961349","Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy","Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy",0,"Intralipid","Drug","AstraZeneca","Industry",0,0,"All","20 Years","N/A","279","October 2013","March 2014","Achivement of Target Sedation","<0.001","0","ANOVA","0","0","0","0","0","0"
"1493","NCT01961947","Study of ASP7374, Cell-culture-derived Influenza Vaccine","Influenza",0,"ASP7374","Biological","Astellas Pharma Inc","Industry",0,0,"All","20 Years","64 Years","900","October 2013","November 2013","seroconversion rate of hemagglutination inhibition (HI) antibody titer","0","0","0","0","0","0","0","0","0"
"1494","NCT01961960","A Study to Evaluate Intramuscular ASP7374","Influenza",0,"ASP7374","Biological","Astellas Pharma Inc","Industry",0,0,"All","61 Years","N/A","55","October 2013","November 2013","hemagglutination inhibition (HI) antibody titer","0","0","0","0","0","0","0","0","0"
"1495","NCT01962974","A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)","Arthritis, Rheumatoid",0,"Golimumab 2 mg/kg IV","Biological","Janssen Biotech, Inc.","Industry",0,0,"All","18 Years","76 Years","7","October 2013","December 2014","Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Response at Week 24","0","0","0","0","0","0","0","0","0"
"1496","NCT01962987","A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis","Actinic Keratosis",0,"Diclofenac sodium","Drug","Actavis Inc.","Industry",0,0,"All","18 Years","75 Years","585","March 2013","September 2013","Bioequivalence in the Per-Protocol Population by evaluating the 90% CI of the difference between the proportion of patients in the test group and the proportion of patients in the reference group with 100% clearance of all AK","0","0","0","0","0","0","0","0","0"
"1497","NCT01964326","Actual Use Trial of Atorvastatin Calcium 10 mg","Hypercholesterolemia",0,"Atorvastatin calcium 10 mg","Drug","Pfizer","Industry",0,0,"All","18 Years","N/A","1311","October 2013","December 2014","Percentage of Participants Who Complied With the Direction to Check Their Low-density Lipoprotein Cholesterol (LDL-C) Level","0","0","0","0","0","0","0","0","0"
"1498","NCT01964716","13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.","Pneumococcal Vaccines",0,"13-valent pneumococcal conjugate vaccine","Biological","Pfizer","Industry",0,0,"All","42 Days","70 Days","500","January 2014","September 2014","Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series for Each Vaccine Group","0","0","0","-0.8","percent difference","97.5","2-Sided","-3.4","1.2"
"1499","NCT01964885","Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections","Common Cold",0,"IQP-AS-105","Dietary Supplement","InQpharm Group","Industry",0,0,"All","18 Years","70 Years","140","October 2013","April 2014","Difference in severity of common cold symptoms for cold episodes between the two arms","0","0","0","0","0","0","0","0","0"
"1500","NCT01966120","Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)","Actinic Keratosis",0,"BF-200 ALA gel","Drug","Biofrontera Bioscience GmbH","Industry",0,0,"All","18 Years","85 Years","87","October 2013","September 2014","Overall Patient Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT)","0","0","0","0","0","0","0","0","0"
"1501","NCT01967069","A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis","Psoriasis",0,"DFD01 Spray","Drug","Promius Pharma, LLC","Industry",0,0,"All","18 Years","N/A","277","November 2013","July 2014","Percentage of Participants With Treatment Success According to the Investigator's Global Assessment (IGA)","0","0","0","0","0","0","0","0","0"
"1502","NCT01967550","Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)","Osteoarthritis, Knee",0,"diclofenac diethylamine, DDEA 2.32% gel","Drug","Novartis","Industry",0,0,"All","50 Years","N/A","304","October 2013","May 2014","Measure: Pain On Movement (POM)","0","0","0","0","0","0","0","0","0"
"1503","NCT01967784","Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan","Influenza",0,"Quadrivalent Influenza Vaccine (split virion, inactivated)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","9 Years","17 Years","100","October 2013","April 2014","Geometric Mean Titers of Influenza Antibodies Before and Following Vaccination With a Quadrivalent Influenza Vaccine","0","0","0","0","0","0","0","0","0"
"1504","NCT01968005","Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain","Low Back Pain",0,"Etoreat®(Etodolac-Lidocaine Topical Patch)","Drug","MEDRx USA, Inc.","Industry",0,0,"All","14 Years","N/A","232","November 2013","May 2014","SPID (Summed pain intensity difference) from baseline over the pain assessments from Day 1 to Day 8","0","0","0","0","0","0","0","0","0"
"1505","NCT01969214","Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea","Diarrhoea",0,"IQP-MM-101","Device","InQpharm Group","Industry",0,0,"All","18 Years","65 Years","100","October 2013","April 2014","Time (in hours) between the 1st intake of IQP-MM-101 and first formed or hard stool followed by a non watery stool","0","0","0","0","0","0","0","0","0"
"1506","NCT01970033","Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes","Type 2 Diabetes",0,"Placebo","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","450","December 2012","January 2014","Change From Baseline in HbA1c (Hemoglobin A1C) at Week24","0","0","0","0","0","0","0","0","0"
"1507","NCT01970046","A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes","Type 2 Diabetes",0,"Placebo/Metformin","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","80 Years","360","April 2013","January 2014","Change From Baseline in HbA1c (Hemoglobin A1C) at Week24","0","0","0","0","0","0","0","0","0"
"1508","NCT01970059","A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension","Hypertension",0,"Extended-Release Carvedilol Sulfate","Drug","Jiangsu HengRui Medicine Co., Ltd.","Industry",0,0,"All","18 Years","70 Years","302","October 2013","October 2013","Mean Change From Baseline in Sitting Diastolic Blood Pressure (sDBP) at Week 8","0","0","0","0","0","0","0","0","0"
"1509","NCT01970475","Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis","Arthritis, Rheumatoid",0,"ABP 501","Biological","Amgen","Industry",0,0,"All","18 Years","80 Years","526","October 2013","November 2014","Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24","0","0","0","1.039","Risk Ratio (RR)","90","2-Sided","0.954","1.133"
"1510","NCT01970488","Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis","Psoriasis",0,"Adalimumab","Biological","Amgen","Industry",0,0,"All","18 Years","75 Years","350","October 2013","August 2014","Percent Improvement From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16","0","0","0","-2.18","Least Squares (LS) Mean Difference","95","2-Sided","-7.39","3.02"
"1511","NCT01973049","UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","202","December 2013","August 2014","Proportion of treated subjects in each of the naive arms with sustained virologic response (SVR12)","0","0","0","0","0","0","0","0","0"
"1512","NCT01973205","Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine","Acute Migraine",0,"Acetaminophen 250 mg and Aspirin 250 mg","Drug","Novartis","Industry",0,0,"All","18 Years","N/A","900","October 2013","July 2014","Number of Subjects Who Are Pain Free at the 2-hour Assessment","0","0","0","0","0","0","0","0","0"
"1513","NCT01973218","Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.","Meningococcal Disease",0,"Meningococcal B Recombinant vaccine rMenB+OMV NZ","Biological","Novartis Vaccines","Industry",0,0,"All","11 Years","17 Years","264","November 2013","April 2014","Percentage of Subjects With Serum Bactericidal Antibody (SBA) Titers ≥1:4 Against Neisseria Meningitidis Serogroup B by Vaccine Group.","0","0","0","0","0","0","0","0","0"
"1514","NCT01974141","A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","Acne Vulgaris",0,"Dapsone Gel","Drug","Allergan","Industry",0,0,"All","12 Years","N/A","2102","November 2013","October 2014","Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)","0","0","0","0","0","0","0","0","0"
"1515","NCT01974323","Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","Acne Vulgaris",0,"Dapsone Gel","Drug","Allergan","Industry",0,0,"All","12 Years","N/A","2238","November 2013","October 2014","Percentage of Patients With a Score of 0 (None) or 1 (Minimal) on the 5-point Global Acne Assessment Score (GAAS)","0","0","0","0","0","0","0","0","0"
"1516","NCT01975298","A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)","Relapsing Remitting Multiple Sclerosis",0,"Laquinimod","Drug","Teva Pharmaceutical Industries","Industry",0,0,"All","18 Years","55 Years","0","January 2014","March 2014","Brain Atrophyas observed by Magnetic Resonance Imaging (MRI)","0","0","0","0","0","0","0","0","0"
"1517","NCT01975675","Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection","Chronic HCV Infection",0,"LDV/SOF","Drug","Gilead Sciences","Industry",0,0,"All","20 Years","N/A","341","October 2013","June 2014","Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12), Treatment-naive, Noncirrhotic Participants","< 0.001","Treatment-naive noncirrhotic participants in the LDV/SOF (treatment naive) group were compared to the adjusted historical SVR null rate of 63% using a two-sided exact one-sample binomial test.","Binomial test","0","0","0","0","0","0"
"1518","NCT01977378","A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder","Major Depressive Disorder",0,"Sustained-Release Desvenlafaxine Hydrochloride","Drug","Jiangsu Hansoh Pharmaceutical Co., Ltd.","Industry",0,0,"All","18 Years","65 Years","300","October 2013","September 2014","Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17)","0","0","0","0","0","0","0","0","0"
"1519","NCT01979510","Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)","Low Back Pain",0,"MK-0663B","Drug","Merck Sharp & Dohme Corp.","Industry",0,0,"All","18 Years","75 Years","0","November 2013","May 2014","Number of Participants Experiencing an Adverse Event (AE)","0","0","0","0","0","0","0","0","0"
"1520","NCT01979939","UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects","Hepatitis C",0,"DCV/ASV/BMS-791325","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","416","December 2013","August 2014","Proportion of treated subjects in the naive cohort with sustained virologic response (SVR) 12","0","0","0","0","0","0","0","0","0"
"1521","NCT01982916","Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean","Allergic Rhinitis",0,"AGR tablet","Drug","Ahn-Gook Pharmaceuticals Co.,Ltd","Industry",0,0,"All","12 Years","N/A","330","December 2013","September 2014","Change of 4NTSS(4 Nasal Total Symptoms score) from baseline","0","0","0","0","0","0","0","0","0"
"1522","NCT01983735","Efficacy and Safety of TELMINUVO to Stage 2 Hypertension","Hypertension",0,"TELMINUVO Tab. (80/2.5mg)","Drug","Chong Kun Dang Pharmaceutical","Industry",0,0,"All","18 Years","N/A","200","January 2014","August 2014","Mean Sitting Systolic Blood Pressure (MSSBP)","0","0","0","0","0","0","0","0","0"
"1523","NCT01986335","Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial","Healthy",0,"DTP/HB/Hib Vaccine","Biological","PT Bio Farma","Industry",0,0,"All","6 Weeks","11 Weeks","600","August 2012","January 2013","Protectivity of DTP/HB/Hib (Bio Farma) vaccine","0","0","0","0","0","0","0","0","0"
"1524","NCT01986361","Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method","Acute Pharyngitis",0,"flurbiprofen","Drug","Reckitt Benckiser LLC","Industry",0,0,"All","18 Years","N/A","120","October 2013","May 2014","Time to Meaningful Pain Relief","0","0","0","0","0","0","0","0","0"
"1525","NCT01987011","Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers","Influenza",0,"MG1109","Biological","Green Cross Corporation","Industry",0,0,"All","18 Years","60 Years","420","August 2013","October 2013","Percentage of subjects achieving post-vaccination Hemagglutination Inhibition(HI) antibody titer ≥ 1:40","0","0","0","0","0","0","0","0","0"
"1526","NCT01989091","Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC","Dialysis Catheter Infections",0,"B-Lock","Device","Great Lakes Pharmaceuticals Inc.","Industry",0,0,"All","18 Years","85 Years","270","July 2012","October 2014","The number of adverse events (AEs), serious adverse events (SAEs) and device deficiencies (DDs) in the experimental and control populations","0","0","0","0","0","0","0","0","0"
"1527","NCT01989429","Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients","Plaque Psoriasis",0,"M518101","Drug","Maruho Europe Limited","Industry",0,0,"All","18 Years","N/A","788","October 2013","December 2014","Severity of psoriasis","0","0","0","0","0","0","0","0","0"
"1528","NCT01991821","European Phase III Study of APD421 in PONV","PONV",0,"APD421","Drug","Acacia Pharma Ltd","Industry",0,0,"All","18 Years","N/A","368","July 2013","January 2014","Complete Response (protection from PONV)","0","0","0","0","0","0","0","0","0"
"1529","NCT01991860","US Phase III Study of APD421 in PONV","PONV",0,"APD421","Drug","Acacia Pharma Ltd","Industry",0,0,"All","18 Years","N/A","364","August 2013","January 2014","Complete Response (protection from PONV)","0","0","0","0","0","0","0","0","0"
"1530","NCT01992094","Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older","Influenza",0,"QIVc","Biological","Novartis Vaccines","Industry",0,0,"All","18 Years","N/A","2680","November 2013","July 2014","1.Geometric Mean Titres (GMT) in Subjects After Receiving One Dose of Either QIVc, TIV1c or TIV2c","0","0","0","1.0","Ratios of GMT","95","2-Sided","0.9","1.1"
"1531","NCT01992107","Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old","Influenza",0,"QIVc","Biological","Novartis Vaccines","Industry",0,0,"All","4 Years","18 Years","2333","November 2013","August 2014","Geometric Mean Titre (GMT) in Subjects After Receiving One or Two Doses of Either QIVc, TIV1c or TIV2c","0","0","0","1.03","Ratios of GMT (Day 22/Day 50)","95","2-Sided","0.93","1.14"
"1532","NCT01993173","Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.","Diphtheria",0,"Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","4 Years","64 Years","1440","November 2013","February 2014","Percentage of participants with anti-diphtheria antibody concentrations ≥ 0.1 international unit (IU)/mL","0","0","0","0","0","0","0","0","0"
"1533","NCT01993212","A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%","Secondary Hypogonadism",0,"Androxal 12.5 mg or 25 mg","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","120","January 2014","September 2014","Comparison of the proportion of subjects meeting the composite endpoint for normal morning testosterone and semen concentration.","0","0","0","0","0","0","0","0","0"
"1534","NCT01993225","A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%","Secondary Hypogonadism",0,"Androxal 12.5 mg/25 mg","Drug","Repros Therapeutics Inc.","Industry",0,0,"Male","18 Years","60 Years","120","January 2014","August 2014","Comparison of the proportion of subjects who meet the composite endpoint of normal 24-hour average testosterone and sperm concentration.","0","0","0","0","0","0","0","0","0"
"1535","NCT01993875","Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation","Chronic Idiopathic Constipation",0,"Lubiprostone","Drug","Sucampo AG","Industry",0,0,"All","18 Years","N/A","164","October 2013","January 2014","Spontaneous Bowel Movement frequency rate","0","0","0","0","0","0","0","0","0"
"1536","NCT01993888","The EVARREST® Fibrin Sealant Patch Liver Study","Hemorrhage",0,"EVARREST® Fibrin Sealant Patch","Biological","Ethicon, Inc.","Industry",0,0,"All","18 Years","N/A","102","October 2013","July 2014","Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization","<.0001","0","Chi-squared","0","0","0","0","0","0"
"1537","NCT01996839","Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","Inflammation",0,"Loteprednol Etabonate Gel (BID)","Drug","Bausch & Lomb Incorporated","Industry",0,0,"All","18 Years","N/A","514","December 2013","May 2014","Resolution of AC Cells","0","0","0","0","0","0","0","0","0"
"1538","NCT01997268","The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)","Severe Hypertriglyceridemia",0,"Placebo","Drug","Sancilio and Company, Inc.","Industry",0,0,"All","18 Years","N/A","0",NA,"December 2014","Fasting Serum Triglycerides","0","0","0","0","0","0","0","0","0"
"1539","NCT01998165","A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised","Anesthesia",0,"Remifentanil","Drug","Janssen Pharmaceutical K.K.","Industry",0,0,"All","1 Year","15 Years","80","November 2013","November 2014","Number of participants with positive response to skin incision","0","0","0","0","0","0","0","0","0"
"1540","NCT01998477","A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications","Influenza",0,"TIVc","Biological","Novartis Vaccines","Industry",0,0,"All","3 Years","17 Years","430","October 2013","July 2014","Number of Subjects Reporting Solicited Adverse Events (AEs) Following Vaccination With Either TIVc or TIV by Overall Age Group","0","0","0","0","0","0","0","0","0"
"1541","NCT01999322","A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes","Diabetes",0,"Faster-acting insulin aspart","Drug","Novo Nordisk A/S","Industry",0,0,"All","18 Years","N/A","37","November 2013","May 2014","Number of microscopically confirmed episodes of infusion set occlusions","0","0","0","0","0","0","0","0","0"
"1542","NCT02003495","Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine","Meningitis",0,"MCV-ACYW135 Vaccine Group","Biological","Beijing Minhai Biotechnology Co., Ltd","Industry",0,0,"All","2 Months","6 Years","2195","October 2013","August 2014","Percentage of subjects exhibiting a >= 4fold increase in rSBA titers level from pre-vaccination to post-vaccination","0","0","0","0","0","0","0","0","0"
"1543","NCT02007434","Patient Experience Study of Deoxycholic Acid Injection","Moderate or Severe Submental Fullness",0,"Deoxycholic Acid Injection","Drug","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","65 Years","84","December 2013","June 2014","Change From Baseline in Pain Visual Analog Scale Scores","0.6803","0","ANCOVA","0.24","LS Mean Placebo-adjusted Difference","95","2-Sided","-0.93","1.41"
"1544","NCT02008942","Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients","Diabetes Mellitus, Type 2",0,"PL2200 Aspirin Capsules","Drug","PLx Pharma","Industry",0,0,"All","21 Years","79 Years","57","January 2014","April 2014","Time to 99% Inhibition of Serum Thromboxane","0","0","0","0","0","0","0","0","0"
"1545","NCT02009423","Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence","Gastro-Intestinal Stromal Tumour",0,"Masitinib","Drug","AB Science","Industry",0,0,"All","18 Years","N/A","330","January 2014","March 2014","Recurrence Free Survival (RFS)","0","0","0","0","0","0","0","0","0"
"1546","NCT02009865","Epanova® for Lowering Very High Triglycerides II (EVOLVE II)","Hypertriglyceridemia",0,"Epanova","Drug","AstraZeneca","Industry",0,0,"All","N/A","N/A","379","December 2013","December 2014","Percent Change in Triglyceride for All Subjects","0.017","0","Wilcoxon (Mann-Whitney)","-14.2","Median Difference (Final Values)","95","2-Sided","-26.2","-2.8"
"1547","NCT02010099","A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-H® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3","Bleeding Hemorrhoids",0,"PP110 Gel","Drug","Peritech Pharma Ltd.","Industry",0,0,"All","18 Years","70 Years","101","November 2013","May 2014","Bleeding / Spotting","0","0","0","0","0","0","0","0","0"
"1548","NCT02012218","Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy","Major Depressive Disorder (MDD)",0,"ADT","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","61","November 2013","October 2014","Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","<0.0001","P-values were calculated according to testing a null hypothesis of zero mean change.","Mixed Models Analysis","0","0","0","0","0","0"
"1549","NCT02013531","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms","Major Depressive Disorder",0,"Brexpiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","37","November 2013","May 2014","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score","<0.0001","0","Mixed Models Analysis","0","0","0","0","0","0"
"1550","NCT02013609","Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment","MDD",0,"Brexpiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","35 Years","48","November 2013","September 2014","Mean Change From Baseline to Week 12 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","<0.0001","0","Mixed Models Analysis","0","0","0","0","0","0"
"1551","NCT02013622","Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia","Schizophrenia",0,"Brexpiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","35 Years","49","November 2013","September 2014","Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score","<0.0001","0","Mixed Models Analysis","0","0","0","0","0","0"
"1552","NCT02014480","A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive",0,"Umeclidinium 62.5 mcg","Device","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","207","February 2013","June 2013","Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type","<0.001","Analysis was performed using an Analysis of Covariance (ANCOVA) model with covariates of treatment, period, mean Baseline, period Baseline, response type and treatment by response type interaction.","ANCOVA","0.108","Mean Difference (Final Values)","95","2-Sided","0.065","0.151"
"1553","NCT02015637","Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea","Gonorrhea",0,"Delafloxacin","Drug","Melinta Therapeutics, Inc.","Industry",0,0,"All","15 Years","N/A","460","January 2014","November 2014","Microbiological outcome of urogenital gonorrhea","0","0","0","0","0","0","0","0","0"
"1554","NCT02016716","A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis","Postmenopausal Osteoporosis",0,"Romosozumab 90 mg/mL","Drug","Amgen","Industry",0,0,"Female","55 Years","90 Years","294","December 3, 2013","September 8, 2014","The primary endpoint is the percent change from baseline in DXA BMD at the lumbar spine (noninferiority)","0","0","0","0","0","0","0","0","0"
"1555","NCT02023099","Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","Chronic Hepatitis C Infection",0,"ABT-450/r/ABT-267","Drug","AbbVie","Industry",0,0,"All","18 Years","75 Years","363","December 2013","October 2014","Percentage of Non-cirrhotic Treatment-Naïve Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment","0","0","0","0","0","0","0","0","0"
"1556","NCT02023268","Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome","Dry Eye Syndrome",0,"T2762","Device","Laboratoires Thea","Industry",0,0,"All","18 Years","N/A","105","December 2013","December 2014","Global Ocular Staining (With Oxford Scale - Ranges : 0-15)","0","0","0","0","0","0","0","0","0"
"1557","NCT02023879","Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","Hypercholesterolemia",0,"Alirocumab","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","233","December 2013","October 2014","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)","<0.0001","Threshold for significance at 0.05 level.","Mixed Models Analysis","-56.4","Least square (LS) mean difference","95","2-Sided","-62.9","-49.9"
"1558","NCT02024529","AP-004-A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee","Osteoarthritis of the Knee",0,"Ampion","Biological","Ampio Pharmaceuticals. Inc.","Industry",0,0,"All","35 Years","85 Years","538","December 2013","June 2014","Improvement on WOMAC A Pain SubScore","0","0","0","0","0","0","0","0","0"
"1559","NCT02024711","EYEFILL® C. -US Viscoelastic Clinical Investigation","Cataract",0,"EYEFILL® C.-US Viscoelastic","Device","Valeant Pharmaceuticals International, Inc.","Industry",0,0,"All","22 Years","N/A","284","December 2013","December 2014","Preservation of Endothelium","0","0","0","0","0","0","0","0","0"
"1560","NCT02031640","A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma","Asthma",0,"Beclomethasone dipropionate","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","532","December 2013","November 2014","Change from baseline in trough morning forced expiratory volume in 1 second (FEV1) over the 12-week treatment period","0","0","0","0","0","0","0","0","0"
"1561","NCT02032875","Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","116","March 2014","November 2014","Percentage of HCV Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"1562","NCT02032888","A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","238","February 2014","October 2014","Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)","0","0","0","0","0","0","0","0","0"
"1563","NCT02032901","Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV","Hepatitis C",0,"Daclatasvir","Drug","Bristol-Myers Squibb","Industry",0,0,"All","18 Years","N/A","173","January 2014","September 2014","Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND)","0","0","0","0","0","0","0","0","0"
"1564","NCT02035215","Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia","Hyperlipidemia, Familial Combined",0,"Atorvastatin 20mg","Drug","Kuhnil Pharmaceutical Co., Ltd.","Industry",0,0,"All","20 Years","80 Years","80","January 2014","October 2014","The mean percent change of Triglyceride(TG)","0","0","0","0","0","0","0","0","0"
"1565","NCT02037477","Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)","Healthy Volunteers",0,"Vonoprazan","Drug","Takeda","Industry",0,0,"Male","20 Years","45 Years","20","January 2014","March 2014","Intragastric pH Time Course Over 24 Hours","0","0","0","0","0","0","0","0","0"
"1566","NCT02040090","Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects","Rabies",0,"Active rabies vaccine (US-FDA approved)","Drug","Kamada, Ltd.","Industry",0,0,"All","18 Years","75 Years","118","April 2013","August 2014","Anti-rabies IgG concentration","0","0","0","0","0","0","0","0","0"
"1567","NCT02040779","A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","Persistent Asthma",0,"Beclomethasone dipropionate breath-actuated inhaler","Drug","Teva Branded Pharmaceutical Products, R&D Inc.","Industry",0,0,"All","12 Years","N/A","274","December 2013","December 2014","Change from Baseline in Trough Morning Forced Expiratory Volume in 1 Second (FEV1) over the 12-week Treatment Period","0","0","0","0","0","0","0","0","0"
"1568","NCT02041091","A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus","Lupus Erythematosus, Systemic",0,"Tabalumab Auto-Injector","Drug","Eli Lilly and Company","Industry",0,0,"All","18 Years","N/A","226","January 2014","October 2014","Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tabalumab After Loading Dose","0","0","0","0","0","0","0","0","0"
"1569","NCT02041754","Safety and Efficacy of IQP-AK-102 in Reducing Appetite","Weight Loss",0,"IQP-AK-102","Device","InQpharm Group","Industry",0,0,"All","18 Years","65 Years","40","January 2014","August 2014","Difference of VAS between two study arms measured from time '0 to '240 during baseline visit and the final visit","0","0","0","0","0","0","0","0","0"
"1570","NCT02044341","Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media","Acute Otitis Media",0,"AR01","Drug","Arbor Pharmaceuticals, Inc.","Industry",0,0,"All","2 Months","18 Years","304","December 2013","March 2014","Complete ear pain relief","0","0","0","0","0","0","0","0","0"
"1571","NCT02051348","Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion","HELICOBACTER INFECTION",0,"Pylopass","Biological","Atlantia Food Clinical Trials","Industry",0,0,"All","18 Years","75 Years","24","January 2014","December 2014","Efficacy of Pylopass to reduce H pylori load by urease breath test (UBT)","0","0","0","0","0","0","0","0","0"
"1572","NCT02052622","Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101","Subcutaneous Fat",0,"Examinations and surveys","Procedure","Kythera Biopharmaceuticals","Industry",0,0,"All","18 Years","N/A","201","February 2012","December 2013","Score on Clinician-reported submental fat rating scale (1-grade response)","0","0","0","0","0","0","0","0","0"
"1573","NCT02054702","Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia","Schizophrenia",0,"Brexpiprazole","Drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Industry",0,0,"All","18 Years","65 Years","97","February 2014","June 2014","Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score","<0.0001","0","Mixed Models Analysis","0","0","0","0","0","0"
"1574","NCT02059642","A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )","ADHD",0,"MG01CI (1400 mg)","Drug","Alcobra Ltd.","Industry",0,0,"All","18 Years","55 Years","300","March 2014","September 2014","Change in Total ADHD Symptom Score With Adult Prompts of the Conners Adult ADHD Rating Scale:O-SV in ADHD Adults From Baseline to 6 Weeks","0.1358","0","Mixed Models Analysis","-2.10","Least Square Mean Difference","95","2-Sided","-4.87","0.66"
"1575","NCT02060903","Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation","Head Lice Infestation",0,"Abametapir Lotion 0.74% w/w","Drug","Hatchtech Pty Ltd","Industry",0,0,"All","6 Months","N/A","379","February 2014","July 2014","Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.","0","0","0","0","0","0","0","0","0"
"1576","NCT02062060","P3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation","Head Lice Infestation",0,"Abametapir Lotion 0.74% w/w","Drug","Hatchtech Pty Ltd","Industry",0,0,"All","6 Months","N/A","325","February 2014","July 2014","Proportion of index subjects who are lice-free at all follow-up visits through to the Day 14 visit.","0","0","0","0","0","0","0","0","0"
"1577","NCT02064413","Essure (Model ESS310) Placement Rate Study","Contraception",0,"ESS310 (BAY1454032)","Device","Bayer","Industry",0,0,"Female","21 Years","44 Years","134","March 2014","October 2014","Rate of successful bilateral placement of the ESS310 insert at first attempt in subjects who undergo attempted ESS310 placement","0","0","0","0","0","0","0","0","0"
"1578","NCT02068417","Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT)","Erectile Dysfunction",0,"shock waves","Device","Storz Medical AG","Industry",0,0,"Male","18 Years","75 Years","40","October 2011","February 2014","Effects of erection problems on the sex life (International Index of Erectile Function (IIEF) Questionnaire)","0","0","0","0","0","0","0","0","0"
"1579","NCT02072330","Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","Grade I or II Essential Hypertension",0,"TAK-536CCB","Drug","Takeda","Industry",0,0,"All","20 Years","N/A","353","March 2013","December 2013","Change from Baseline in the office trough sitting diastolic blood pressure (DBP)","0","0","0","0","0","0","0","0","0"
"1580","NCT02072954","Bioequivalence Fasting Study in Patients","Schizophrenia",0,"Asenapine Sublingual Tablets 10 mg","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","65 Years","48","November 2013","February 2014","AUC 0-tau","0","0","0","0","0","0","0","0","0"
"1581","NCT02073006","A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation","Constipation",0,"Natural Fibre Supplement","Dietary Supplement","Atlantia Food Clinical Trials","Industry",0,0,"All","18 Years","80 Years","70","February 2014","July 2014","Number of bowel movements per week","0","0","0","0","0","0","0","0","0"
"1582","NCT02073188","Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose","Diabetes Mellitus",0,"iBGStar","Device","Sanofi","Industry",0,0,"All","14 Years","24 Years","186","June 2012","September 2014","Change in HbA1c levels from baseline","0","0","0","0","0","0","0","0","0"
"1583","NCT02073448","Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.","Acne Vulgaris",0,"GK530G","Drug","Galderma R&D","Industry",0,0,"All","12 Years","N/A","417","March 2014","October 2014","Percent Changes From Baseline in Total Lesion Counts","0","0","0","0","0","0","0","0","0"
"1584","NCT02073656","Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection","Hepatitis C Virus",0,"LDV/SOF","Drug","Gilead Sciences","Industry",0,0,"All","18 Years","N/A","335","February 2014","November 2014","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","0","0","0","0","0","0","0","0","0"
"1585","NCT02074007","Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)","Acute Otitis Media",0,"AR01","Drug","Arbor Pharmaceuticals, Inc.","Industry",0,0,"All","2 Months","18 Years","178","December 2013","June 2014","Complete ear pain relief","0","0","0","0","0","0","0","0","0"
"1586","NCT02076516","Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)","Coronary Artery Disease",0,"Drug-eluting stent: CORACTO®","Device","Alvimedica","Industry",0,0,"All","18 Years","N/A","100","October 2013","October 2014","In-stent late loss (LL) in patients implanted with a CORACTO® stent (per protocol analysis)","0","0","0","0","0","0","0","0","0"
"1587","NCT02079207","Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine","Pneumococcal Infections",0,"NBP606","Biological","SK Chemicals Co.,Ltd.","Industry",0,0,"All","50 Years","N/A","767","December 2013","October 2014","Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month(Day 28) After Vaccination 1","0","0","0","0","0","0","0","0","0"
"1588","NCT02082262","AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis","Conjunctivitis, Allergic",0,"AGN-229666","Drug","Allergan","Industry",0,0,"All","10 Years","N/A","140","March 2014","July 2014","Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale","0","0","0","0","0","0","0","0","0"
"1589","NCT02083783","TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Disorder With Hyperactivity",0,"TRI102","Drug","Tris Pharma, Inc.","Industry",0,0,"All","6 Years","12 Years","108","March 2014","October 2014","SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)","0","0","0","0","0","0","0","0","0"
"1590","NCT02084420","Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment","Peptic Ulcer",0,"Ilaprazole","Drug","Il-Yang Pharm. Co., Ltd.","Industry",0,0,"All","18 Years","74 Years","323","December 2012","January 2014","the rate of H.pylori eradication","0","0","0","0","0","0","0","0","0"
"1591","NCT02085135","A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)","Major Depressive Disorder",0,"ALKS 5461","Drug","Alkermes, Inc.","Industry",0,0,"All","18 Years","70 Years","66","February 2014","September 2014","Safety and tolerability: Number and percent of subjects experiencing a treatment emergent adverse event (TEAE)","0","0","0","0","0","0","0","0","0"
"1592","NCT02086929","Trazodone Once a Day in Major Depression Disorder","Major Depressive Disorder",0,"Trazodone","Drug","Aziende Chimiche Riunite Angelini Francesco S.p.A","Industry",0,0,"All","18 Years","75 Years","364","December 2012","April 2014","Hamilton Depression Rating Scale (HAMD) score","0","0","0","0","0","0","0","0","0"
"1593","NCT02087722","Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients","Sleep Initiation and Maintenance Disorders",0,"KI1001","Drug","Kuhnil Pharmaceutical Co., Ltd.","Industry",0,0,"All","55 Years","N/A","80","August 2013","January 2014","QOS in KMLSEQ","0","0","0","0","0","0","0","0","0"
"1594","NCT02088073","Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.","Hyperkalemia",0,"Zirconium silicate (acute phase)","Drug","ZS Pharma, Inc.","Industry",0,0,"All","18 Years","N/A","258","March 2014","August 2014","Maintenance of serum potassium level with once daily ZS for 28 days after establishment of normokalemia with ZS three times a day for first 48 hours.","0","0","0","0","0","0","0","0","0"
"1595","NCT02089347","Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old","Tetanus",0,"Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed","Biological","Sanofi Pasteur, a Sanofi Company","Industry",0,0,"All","11 Years","12 Years","534","March 2014","September 2014","Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT","0","0","0","1.42","Wilson score method","95","2-Sided","-0.31","4.61"
"1596","NCT02093260","Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)","Healthy",0,"Vaccine","Biological","PT Bio Farma","Industry",0,0,"All","6 Months","11 Years","405","May 2014","July 2014","To asses the immunogenicity of Flubio vaccine 28 days after 2 doses immunization in infants and children (6 months-8 years of age) and 1 dose immunization in children (9-11 years of age)","0","0","0","0","0","0","0","0","0"
"1597","NCT02093689","A Randomized, Placebo-controlled Study in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery","Intraocular Lens Replacement",0,"OMS302","Drug","Omeros Corporation","Industry",0,0,"Male","18 Years","N/A","14","February 2014","August 2014","Change in Pupil Diameter","0","0","0","0","0","0","0","0","0"
"1598","NCT02095314","Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine","Healthy",0,"Pentavalen","Biological","PT Bio Farma","Industry",0,0,"All","18 Months","24 Months","399","March 2014","June 2014","Geomoteric mean titer prior to booster administration of Pentabio vaccine","0","0","0","0","0","0","0","0","0"
"1599","NCT02095990","Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study","Facial Melasma",0,"Hydroquinone","Drug","Mesoestetic Pharma Group S.L.","Industry",0,0,"Female","18 Years","65 Years","17","March 2014","August 2014","To assess the ability of a new 4% Hydroquinone formulation (Melanoderm 4% Crema) to reduce melasma on the face.","0","0","0","0","0","0","0","0","0"
"1600","NCT02101359","Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery","Cataract",0,"T2380","Drug","Laboratoires Thea","Industry",0,0,"All","40 Years","88 Years","609","June 2011","January 2013","The Primary Efficacy Variable is Response Based on the Realisation of the Capsulorhexis Without Use of Any Additive Mydriatic Treatment.","0","0","0","0","0","0","0","0","0"
"1601","NCT02103322","Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions","Chronic Myeloid Leukemia",0,"Imatinib Mesylate Tablets, 400 mg","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"All","18 Years","55 Years","48","February 2014","March 2014","Cmax","0","0","0","0","0","0","0","0","0"
"1602","NCT02103439","An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients","Hepatitis",0,"Algeron","Drug","Biocad","Industry",0,0,"All","18 Years","70 Years","140","September 2013","July 2014","Early Virological Response","0.227","0","Fisher Exact","0","0","0","0","0","0"
"1603","NCT02104830","Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients","Chemotherapy-induced Neutropenia",0,"Empegfilrastim 6 mg","Biological","Biocad","Industry",0,0,"Female","18 Years","70 Years","135","September 2013","June 2014","Duration of Neutropenia CTCAE Grade 4","0","0","0","0","0","0","0","0","0"
"1604","NCT02106299","Safety and Efficacy Study of Regen Sling to Treatment SUI","Stress Urinary Incontinence",0,"Regen sling","Device","Medprin Regenerative Medical Technologies Co.,Ltd.","Industry",0,0,"Female","18 Years","75 Years","178","January 2014","December 2014","pressure test (subjective indicator)","0","0","0","0","0","0","0","0","0"
"1605","NCT02109562","Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","Schizophrenia",0,"RBP-7000 90mg","Drug","Indivior Inc.","Industry",0,0,"All","18 Years","55 Years","259","April 2014","November 2014","A change in Positive and Negative Syndrome Scale (PANSS) Total Score at week 8 or early discontinuation of 113 participants","0","0","0","0","0","0","0","0","0"
"1606","NCT02110238","Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA","Osteoarthritis",0,"Supartz","Device","Bioventus LLC","Industry",0,0,"All","40 Years","80 Years","421","March 2014","November 2014","WOMAC VAS (0:None -100:Extreme) Pain Subscale Score Change From Baseline","0","0","0","-3.30","Least square mean difference","95","2-Sided","-6.77","0.17"
"1607","NCT02110368","Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions","Primary Hypogonadism",0,"Testosterone Topical Gel, 1.62% Metered Pump","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"Male","18 Years","65 Years","32","March 2014","March 2014","AUC0-t","0","0","0","0","0","0","0","0","0"
"1608","NCT02118961","Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents","Diphtheria",0,"Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)","Biological","Mitsubishi Tanabe Pharma Corporation","Industry",0,0,"All","11 Years","12 Years","446","April 2014","August 2014","Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies","0","0","0","0","0","0","0","0","0"
"1609","NCT02119286","Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","Pulmonary Disease, Chronic Obstructive",0,"FF","Drug","GlaxoSmithKline","Industry",0,0,"All","40 Years","N/A","620","October 2013","April 2014","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) at Day 85","<0.001","0","Mixed Model Repeated Measure","0.122","Least squared mean difference","95","2-Sided","0.091","0.152"
"1610","NCT02120833","A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin","Eczema",0,"EpiCeram® Skin Barrier Emulsion","Device","Johnson & Johnson Consumer and Personal Products Worldwide","Industry",0,0,"All","2 Months","35 Months","51","March 2014","November 2014","Eczema Area and Severity Index (EASI) on Day 3 - Change From Baseline","<0.0001","The significance level threshold level was 0.05 (two-sided).","One-sample t-test","0","0","0","0","0","0"
"1611","NCT02120898","A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses","Actinic Keratosis",0,"Imiquimod","Drug","Actavis Inc.","Industry",0,0,"All","18 Years","N/A","600","October 2013","April 2014","Complete clearance rate (treatment success), defined as the proportion of subjects in each treatment group at End of Study Visit","0","0","0","0","0","0","0","0","0"
"1612","NCT02120924","A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea","Rosacea",0,"Azelaic acid","Drug","Actavis Inc.","Industry",0,0,"All","18 Years","N/A","1008","July 2013","September 2014","The primary endpoint is the percent change from baseline to Week 12 in the inflammatory (papules and pustules) lesion counts.","0","0","0","0","0","0","0","0","0"
"1613","NCT02121002","Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee","Osteoarthritis",0,"Diclofenac Sodium Topical Gel, 1%","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"All","35 Years","N/A","1176","April 2014","October 2014","WOMAC Pain Score","0","0","0","0","0","0","0","0","0"
"1614","NCT02125253","Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis",0,"Mometasone Furoate Nasal Spray, 50 mcg","Drug","Amneal Pharmaceuticals, LLC","Industry",0,0,"All","12 Years","N/A","811","January 2014","March 2014","Change from Baseline rTNSS","0","0","0","0","0","0","0","0","0"
"1615","NCT02131636","Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea","Erythema",0,"AGN-199201","Drug","Allergan","Industry",0,0,"All","18 Years","N/A","440","May 2014","November 2014","Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales","0","0","0","0","0","0","0","0","0"
"1616","NCT02132169","A Multi-Center Study Evaluating the Safety of AC-170 0.24%","Atopc Disease (Including Allergic Conjunctivitis)",0,"Drug: AC-170 0.24%","Drug","Aciex Therapeutics, Inc.","Industry",0,0,"All","2 Years","N/A","512","May 2014","October 2014","Tolerability of AC 170 0.24% compared to its vehicle","0","0","0","0","0","0","0","0","0"
"1617","NCT02137382","A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis","Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",0,"Creon®","Drug","Abbott","Industry",0,0,"All","12 Years","N/A","41","January 2014","August 2014","Coefficient of Fat Absorption (CFA)","0","0","0","0","0","0","0","0","0"
"1618","NCT02139124","The Efficacy and Safety of PRC-063 in Adult ADHD Patients","ADHD",0,"Placebo","Drug","Rhodes Pharmaceuticals, L.P.","Industry",0,0,"All","18 Years","N/A","360","April 2014","October 2014","Change from Baseline in Clinician-administered ADHD-5-Rating Scale","0","0","0","0","0","0","0","0","0"
"1619","NCT02139228","Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children","Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b",0,"Hib-CRM197","Biological","Novartis Vaccines","Industry",0,0,"All","5 Years","6 Years","426","November 2014","December 2014","Geometric Mean Anti-PRP (Polyribosyl Ribitol Phosphate) Concentrations at Day 1 (4 Years Post Booster Dose Administered in Study V37_07E1)","0","0","0","0.53","Vaccine Group Ratios","95","2-Sided","0.36","0.76"
"1620","NCT02145442","Effects of Obex in Overweight and Obese Patients","Overweight",0,"Obex","Dietary Supplement","Catalysis SL","Industry",0,0,"All","20 Years","60 Years","40","June 2014","July 2014","To evaluate the effect of Obex® on fasting glucose levels","0","0","0","0","0","0","0","0","0"
"1621","NCT02150499","A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects","Asthma",0,"levalbuterol tartrate HFA inhalation aerosol","Drug","Sunovion","Industry",0,0,"All","N/A","48 Months","18","July 2014","December 2014","The Overall Safety of Treatment With Levalbuterol Tartrate HFA Inhalation Aerosol as Measured by the Number of Subjects With Treatment-emergent Adverse Events.","0","0","0","0","0","0","0","0","0"
"1622","NCT02152579","Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci","Stable Angina",0,"Isosorbide-5-mononitrate","Drug","Laboratórios Baldacci S.A","Industry",0,0,"All","18 Years","80 Years","86","July 2014","September 2014","Absolute number of episodes of angina","0","0","0","0","0","0","0","0","0"
"1623","NCT02154308","Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults","Healthy",0,"IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL","Biological","Il-Yang Pharm. Co., Ltd.","Industry",0,0,"All","18 Years","N/A","787","November 2012","March 2013","Solicited local & general Adverse Event, Unsolicited Adverse Event","0","0","0","0","0","0","0","0","0"
"1624","NCT02155881","Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia","Seasonal Allergic Rhinitis",0,"Ciclesonide","Drug","AstraZeneca","Industry",0,0,"All","18 Years","N/A","80","August 2014","October 2014","Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS)","0.9716","0","ANCOVA","0.02","Mean Difference (Net)","95","2-Sided","-0.98","1.01"
"1625","NCT02157571","A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control","Acute Exacerbations of Chronic Bronchitis",0,"Prulifloxacin","Drug","Lee's Pharmaceutical Limited","Industry",0,0,"All","18 Years","70 Years","360","June 2013","June 2014","To evaluate the efficacy and safety of prulifloxacin film-coated tablet in the treatment of acute exacerbations of chronic bronchitis.","0","0","0","0","0","0","0","0","0"
"1626","NCT02161146","AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis","Conjunctivitis, Allergic",0,"AGN-229666","Drug","Allergan","Industry",0,0,"All","20 Years","N/A","240","June 2014","December 2014","Ocular Itching Score","0","0","0","0","0","0","0","0","0"
"1627","NCT02163824","Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation","Ocular Infections, Irritations and Inflammations",0,"KPI-121","Drug","Kala Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","N/A","380","May 2014","December 2014","Resolution of Anterior Chamber Cells","0","0","0","0","0","0","0","0","0"
"1628","NCT02164110","To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children","Prevention Harmful Effects",0,"Euvichol","Biological","EuBiologics Co.,Ltd","Industry",0,0,"All","1 Year","40 Years","3632","May 2014","September 2014","Efficacy","0","0","0","0","0","0","0","0","0"
"1629","NCT02168010","Analgecine for Treatment of Low Back Pain","Low Back Pain",0,"Analgecine","Drug","VanWorld Pharmaceutical (Rugao) Company Limited","Industry",0,0,"All","18 Years","70 Years","584","October 2013","July 2014","Change of Visual Analysis Scale on Pain","0","0","0","0","0","0","0","0","0"
"1630","NCT02174757","Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis","Chronic Periodontitis",0,"Inersan","Drug","CD Pharma India Pvt. Ltd.","Industry",0,0,"All","25 Years","60 Years","30","August 2014","November 2014","Improvement in periodontal clinical indices","0","0","0","0","0","0","0","0","0"
"1631","NCT02175797","Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System","Bradycardia",0,"MRI","Device","LivaNova","Industry",0,0,"All","18 Years","N/A","33","February 2014","August 2014","Measure the atrial and ventricular pacing thresholds in Volts before and after the MRI exam, using the programmer.","0","0","0","0","0","0","0","0","0"
"1632","NCT02176538","Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects","Atopic Dermatitis",0,"Product 0405","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","3 Months","17 Years","0","June 2012","May 2013","Statistically significant superiority of the test Product 0405 to the vehicle","0","0","0","0","0","0","0","0","0"
"1633","NCT02176551","Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects","Atopic Dermatitis",0,"Product 0405","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","3 Months","17 Years","0","June 2012","May 2013","Statistically significant superiority of the test Product 0405 to the vehicle","0","0","0","0","0","0","0","0","0"
"1634","NCT02176577","Study to Determine the Pharmacokinetics of Product 0405","Atopic Dermatitis",0,"Product 0405","Drug","Fougera Pharmaceuticals Inc.","Industry",0,0,"All","3 Months","17 Years","0","June 2012","May 2013","Phamacokinetic sampling","0","0","0","0","0","0","0","0","0"
"1635","NCT02177032","Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age","Rabies Infection",0,"Rabies vaccine","Biological","Novartis","Industry",0,0,"All","1 Year","N/A","885","June 2014","October 2014","Percentages of Subjects With RVNA Titer >= 0.5 and Vaccine Group Differences (""4-sites, 1-week"" to That of ""2-sites, TRC"" ID PEP Regimen of the PCEC Rabies Vaccine With or Without HRIG Administration)","0","0","0","-1","Protection Rate Differences","95","2-Sided","-2.4","0"
"1636","NCT02187757","Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels","Hyperlipidemia",0,"Study Dietary Supplement (Prelipid 500 mg capsules)","Dietary Supplement","PreEmptive Meds, Pvt. Ltd","Industry",0,0,"All","18 Years","65 Years","180","November 2013","November 2014","Efficacy of Dietary Supplement PreLipid 600 mg twice-daily in lowering LDL-C levels","0","0","0","0","0","0","0","0","0"
"1637","NCT02189005","Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels","Diabetes Mellitus",0,"Study dietary supplement (PreCrea 600 mg capsules)","Dietary Supplement","Joe Fenn","Industry",0,0,"All","18 Years","65 Years","210","November 2013","November 2014","Efficacy of Dietary Supplement PreCrea 600 mg twice-daily in lowering Hemoglobin A1c (Hb A1c) levels","0","0","0","0","0","0","0","0","0"
"1638","NCT02191540","Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients","Malignant Pleural Effusion",0,"Abnoba Viscum F 20mg","Drug","Abnoba Korea","Industry",0,0,"All","20 Years","80 Years","68","January 2011","January 2013","Efficacy","0","0","0","0","0","0","0","0","0"
"1639","NCT02192814","Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures","Epilepsy",0,"Lacosamide (200 mg/20 mL)","Drug","UCB Japan Co. Ltd.","Industry",0,0,"All","16 Years","N/A","9","June 2014","October 2014","The Total Number of Subjects Experiencing at Least One Adverse Event During the Study","0","0","0","0","0","0","0","0","0"
"1640","NCT02193165","The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis","Dental Plaque",0,"triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash","Drug","Colgate Palmolive","Industry",0,0,"All","21 Years","70 Years","120","July 2014","August 2014","Dental Plaque Scores","0.434","0","ANOVA","0","0","0","0","0","0"
"1641","NCT02193620","Study of PHN131 in Patients After Surgery","Analgesia Disorder",0,"PHN131 soft capsule with Nalbuphine HCl 60 mg/cap","Drug","PhytoHealth Corporation","Industry",0,0,"All","20 Years","N/A","120","April 2013","September 2014","the area under the curve of VAS pain intensity scores","0","0","0","0","0","0","0","0","0"
"1642","NCT02195986","A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis","Atrophic Vaginitis",0,"Estradiol Vaginal Cream, 0.01%","Drug","Mylan Inc.","Industry",0,0,"Female","40 Years","70 Years","366","June 2014","December 2014","Vaginal Cytology","0","0","0","0","0","0","0","0","0"
"1643","NCT02205840","A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.","Dry Eye Syndromes",0,"SI-614","Drug","Seikagaku Corporation","Industry",0,0,"All","18 Years","N/A","240","July 2014","November 2014","Corneal staining score","0","0","0","0","0","0","0","0","0"
"1644","NCT02210689","A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women","BACTERIAL VAGINOSIS",0,"clindamycin phosphate vaginal cream 2%","Drug","Actavis Inc.","Industry",0,0,"Female","18 Years","N/A","604","January 2014","October 2014","Both clinical and a bacteriological cure (Nugent score <4), evaluated at Visit 2 Test-of-cure (study day 22-30).","0","0","0","0","0","0","0","0","0"
"1645","NCT02214225","A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.","Influenza, Human",0,"Quadrivalent Influenza Vaccine (QIV)","Biological","Seqirus","Industry",0,0,"All","18 Years","N/A","3484","August 2014","November 2014","Postvaccination Geometric Mean Titer (GMT) (Statistical Analysis: GMT Ratios) in Subjects Aged ≥18 Years (Per Protocol Population).","0","0","0","0.92","GMT ratio (A/H1N1)","95","2-Sided","0.87","0.98"
"1646","NCT02215954","A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing","Colon Cleansing in Preparation for Colonoscopy or Colorectal Surgery",0,"FE 999169","Drug","Ferring Pharmaceuticals","Industry",0,0,"All","20 Years","80 Years","637","September 2014","December 2014","The efficacy rate based on the overall colon cleansing effect as assessed by the independent central judging committee using the Japanese colon cleansing scale","0","0","0","0","0","0","0","0","0"
"1647","NCT02216071","Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa","Acute Otitis Externa",0,"Ciprodex®","Drug","Exela Pharma Sciences, LLC.","Industry",0,0,"All","6 Months","N/A","500","July 2014","December 2014","Clinical Cure of AOE","0","0","0","0","0","0","0","0","0"
"1648","NCT02222896","Preoperative CHG Cloth","Surgical Skin Preparation",0,"Chlorhexidine Gluconate","Drug","Medline Industries","Industry",0,0,"All","16 Years","N/A","347","August 2014","November 2014","Count the number of bacteria on skin","0","0","0","0","0","0","0","0","0"
"1649","NCT02227212","Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM","Diabetes Mellitus Type 2",0,"Insulin glargine U300 (new formulation of insulin glargine) HOE901","Drug","Sanofi","Industry",0,0,"All","18 Years","N/A","40","August 2014","November 2014","Ease-of-use / ease of learning questionnaire","0","0","0","0","0","0","0","0","0"
"1650","NCT02229955","Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease","Dry Eye Syndromes",0,"Cyclosporine ophthalmic solution","Drug","Hanlim Pharm. Co., Ltd.","Industry",0,0,"All","21 Years","N/A","86","December 2013","April 2014","Corneal staining test","0","0","0","0","0","0","0","0","0"
"1651","NCT02230254","PE PREMIER CHINA CLINICAL TRIAL","Atherosclerosis",0,"Percutaneous coronary intervention PROMUS PREMIER","Device","Boston Scientific Corporation","Industry",0,0,"All","18 Years","75 Years","101","April 2014","July 2014","Technical success rate","0","0","0","0","0","0","0","0","0"
"1652","NCT02246920","Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients","Seasonal Allergic Rhinitis",0,"Fluticasone propionate","Drug","Teva Pharmaceuticals USA","Industry",0,0,"All","12 Years","N/A","1110","March 2014","July 2014","Change from baseline in average AM/PM reflective Total Nasal Symptom Score (rTNSS) over days 1 to 14.","0","0","0","0","0","0","0","0","0"
"1653","NCT02247765","Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion","Healthy",0,"Arterial line","Device","Medtronic - MITG","Industry",0,0,"All","18 Years","50 Years","18","November 2014","November 2014","SpO2 Accuracy During Motion Conditions - MaxA Sensor","0","0","0","0","0","0","0","0","0"
"1654","NCT02249767","Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel","Acne",0,"Tretinoin","Drug","Spear Pharmaceuticals","Industry",0,0,"All","12 Years","40 Years","574","November 2013","June 2014","percent Improvement of acne","0","0","0","0","0","0","0","0","0"
"1655","NCT02254525","A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain","Postoperative Pain",0,"Intravenous ibuprofen","Drug","Biomendi S.A.U.","Industry",0,0,"All","18 Years","80 Years","231","May 2012","June 2014","Evaluate the efficacy of intravenous ibuprofen for the management of postoperative pain in comparison to placebo","0","0","0","0","0","0","0","0","0"
"1656","NCT02263131","Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children","Healthy",0,"IL-YANG FLU Vaccine Prefilled Syringe INJ.","Biological","Il-Yang Pharm. Co., Ltd.","Industry",0,0,"All","6 Months","18 Years","416","October 2013","January 2014","Solicited Local & General Adverse Event, Unsolicited Adverse Event","0","0","0","0","0","0","0","0","0"
"1657","NCT02267746","A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris","Acne Vulgaris",0,"Tazarotene (Fabior™)","Drug","Actavis Inc.","Industry",0,0,"All","12 Years","40 Years","894","June 2014","September 2014","• Percent change in the inflammatory (papules and pustules) lesion counts","0","0","0","0","0","0","0","0","0"
"1658","NCT02271854","A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness","Muscle Soreness",0,"Diclofenac sodium gel 1%","Drug","Novartis","Industry",0,0,"All","18 Years","35 Years","102","October 2014","December 2014","Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.","0","0","0","0","0","0","0","0","0"
"1659","NCT02276274","Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects","Clinical Pharmacology",0,"SYR-322-MET","Drug","Takeda","Industry",0,0,"Male","20 Years","35 Years","12","June 2014","June 2014","AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z)","0","0","0","-0.0164","Least Squares Mean Difference","90","2-Sided","-0.0592","0.0264"
"1660","NCT02282670","A Study to Evaluate the Efficacy and Safety of DA-5204","Acute Gastritis",0,"DA-5204","Drug","Dong-A ST Co., Ltd.","Industry",0,0,"All","20 Years","75 Years","434","April 2014","November 2014","A percentage of subjects showed moderate or significant improvement of stomach erosions by the endoscopy.","0","0","0","0","0","0","0","0","0"
"1661","NCT02289352","Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea","Rosacea",0,"Brimonidine","Drug","Actavis Inc.","Industry",0,0,"All","18 Years","N/A","462","July 2014","December 2014","rosacea improvement or treatment success","0","0","0","0","0","0","0","0","0"
"1662","NCT02318875","Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders","Pain",0,"Kritech administration","Dietary Supplement","Vivatech","Industry",0,0,"All","18 Years","N/A","154","June 2012","June 2013","SMFA score","0","0","0","0","0","0","0","0","0"
"1663","NCT02324270","Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain","Ankle Sprain",0,"Diclofenac epolamine","Drug","Actavis Inc.","Industry",0,0,"All","18 Years","65 Years","658","May 2014","December 2014","Bioequivalence between test diclofenac epolamine patch and reference (Flector) patch in VAS score - changes from baseline","0","0","0","0","0","0","0","0","0"
"1664","NCT02328404","The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)","Polycystic Ovary Syndrome",0,"50,000 IU vitamin D3","Drug","Hayat Pharmaceutical Co. PLC","Industry",0,0,"Female","18 Years","49 Years","60","February 2014","September 2014","Ultrasound Examination of Number of Follicles and Ovarian Volume","0.001","0","Chi-squared","0","0","0","0","0","0"
"1665","NCT02332811","An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients","Renal Failure Chronic",0,"sevelamer carbonate 800mg","Drug","Genzyme, a Sanofi Company","Industry",0,0,"All","18 Years","N/A","96","October 2013","July 2014","The reduction in serum phosphorus from baseline to end of study with Sevelamer carbonate tablets 800 mg and Sevelamer carbonate Powder 2.4 g in chronic kidney disease (CKD) patients both on haemodialysis and not on dialysis","0","0","0","0","0","0","0","0","0"
"1666","NCT02344134","Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects","Influenza, Human",0,"NBP607","Biological","SK Chemicals Co.,Ltd.","Industry",0,0,"All","19 Years","N/A","1155","September 2013","November 2013","Geometric Mean Titers (GMTs) for Each of the Influenza Vaccine Antigen","0","0","0","0","0","0","0","0","0"
"1667","NCT02351531","Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy","Cow Milk Allergy",0,"Extensively Hydrolyzed formula","Dietary Supplement","United Pharmaceuticals","Industry",0,0,"All","1 Month","12 Months","32","November 2013","December 2014","Number of patients dropped out for intolerance","0","0","0","0","0","0","0","0","0"
"1668","NCT02352584","A Multicenter, Double-blind, Parallel Phase III Study","Influenza",0,"GC3110A(Quadrivalent)","Biological","Green Cross Corporation","Industry",0,0,"All","19 Years","N/A","1299","October 2014","December 2014","GMT rate of HI(Hemagglutination Inhibition) antibody for each strain","0","0","0","0","0","0","0","0","0"
"1669","NCT02361866","To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults","Bacterial Infections",0,"GC1107","Biological","Green Cross Corporation","Industry",0,0,"All","18 Years","N/A","376","May 2014","September 2014","seroprotection rate of diphtheria and tetanus","0","0","0","0","0","0","0","0","0"
"1670","NCT02376075","Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria","Arterial Hypertension",0,"Linagliptin","Drug","ikfe-CRO GmbH","Industry",0,0,"All","45 Years","80 Years","43","January 2013","September 2014","Albumin/Creatinine Ratio (UACR) in 24h urine change between Baseline and Visit 4","0","0","0","0","0","0","0","0","0"
"1671","NCT02379468","Efficacy & Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment","Diabetic Foot Ulcer",0,"Pedyphar Ointment","Drug","European Egyptian Pharmaceutical Industries","Industry",0,0,"All","18 Years","70 Years","80","April 2013","August 2014","Percentage of diabetic patients with successful healing of foot ulceration in treated with Pedyphar® ointment","0","0","0","0","0","0","0","0","0"
"1672","NCT02387294","Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents","Human Influenza",0,"ntervention: Vaccination with Fluval AB Novo.","Biological","Omninvest Vaccine Manufacturing, Researching and Trading Ltd.","Industry",0,0,"All","3 Years","18 Years","120","October 2014","December 2014","Immunogenicity of a single intramuscular injection of the study vaccine as measured by HAG test.","0","0","0","0","0","0","0","0","0"
"1673","NCT02393612","Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease","Peripheral Arterial Disease",0,"DP-R202","Drug","Alvogen Korea","Industry",0,0,"All","20 Years","N/A","151","October 2012","April 2014","Variation in lower limb pain (VAS)","0","0","0","0","0","0","0","0","0"
"1674","NCT02425423","Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula","Gastroesophageal Reflux",0,"New thickened formula","Dietary Supplement","United Pharmaceuticals","Industry",0,0,"All","N/A","5 Months","100","June 2013","March 2014","Number of episodes of regurgitation per day","0","0","0","0","0","0","0","0","0"
"1675","NCT02446990","Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure","Coronary Artery Disease",0,"Ivabradine","Drug","Servier","Industry",0,0,"All","55 Years","N/A","19102","September 2009","January 2014","Primary Composite Endpoint","0.1969","0","Regression, Cox","1.08","Cox Proportional Hazard","95","2-Sided","0.96","1.2"
"1676","NCT02461719","Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes","Dry Eye Syndromes",0,"CYPORIN N EYE DROPS 0.05%(TJCS eye drop)","Drug","Taejoon Pharm Co., Ltd.","Industry",0,0,"All","20 Years","N/A","158","January 2014","September 2014","Corneal staining test","0","0","0","0","0","0","0","0","0"
"1677","NCT02465203","3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study","Hepatitis C, Chronic",0,"Previous treatment in DEB025 study","Drug","Novartis Pharmaceuticals","Industry",0,0,"All","18 Years","70 Years","105","September 2012","January 2014","HCV RNA sequencing","0","0","0","0","0","0","0","0","0"
"1678","NCT02466490","Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension","Hypertension, Essential",0,"Fimasartan","Drug","Stendhal Americas, S.A.","Industry",0,0,"All","18 Years","70 Years","272","April 2013","February 2014","Blood Pressure Change From Baseline","0","0","0","0","0","0","0","0","0"
"1679","NCT02467842","Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607) in Adults and Elderly Subjects","Influenza",0,"NBP607-QIV(Quadrivalent)","Biological","SK Chemicals Co.,Ltd.","Industry",0,0,"All","19 Years","N/A","1503","September 2014","December 2014","Noninferiority of NBP607-QIV over NBP607-TIV on immunogenicity for each strain","0","0","0","0","0","0","0","0","0"
"1680","NCT02492412","Efficacy and Safety of HE10 for Dry Eye Syndrome","Dry Eye Syndrome",0,"HE 10","Drug","Huons Co.,Ltd.","Industry",0,0,"All","21 Years","N/A","101","May 2013","July 2014","Corneal staining Test to assess eye dryness","0","0","0","0","0","0","0","0","0"
"1681","NCT02586246","Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870","Active Rheumatoid Arthritis",0,"CDP870","Drug","Astellas Pharma Inc","Industry",0,0,"All","N/A","N/A","86","January 2011","May 2013","Percentage of subjects experiencing at least one adverse event or at least one serious adverse event during the study","0","0","0","0","0","0","0","0","0"
"1682","NCT02621177","Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents","Influenza, Human",0,"NBP607","Biological","SK Chemicals Co.,Ltd.","Industry",0,0,"All","6 Months","18 Years","385","November 2013","March 2014","CHMP criteria","0","0","0","0","0","0","0","0","0"
"1683","NCT02622958","Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)","Social Anxiety Disorder",0,"PH94B","Drug","Pherin Pharmaceuticals, Inc.","Industry",0,0,"All","18 Years","65 Years","23","March 2014","October 2014","Subjective units of distress","0","0","0","0","0","0","0","0","0"
"1684","NCT02629848","Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung",0,"Motesanib","Drug","Takeda","Industry",0,0,"All","18 Years","N/A","401","July 2012","September 2014","Progression Free Survival","0","0","0","0","0","0","0","0","0"
"1685","NCT02685137","Efficacy and Safety of Stannsoporfin in Neonates","Nutritional and Metabolic Diseases",0,"stannsoporfin","Drug","InfaCare Pharmaceuticals Corporation","Industry",0,0,"All","N/A","14 Days","185","April 2002","February 2013","need for phototherapy","0","0","0","0","0","0","0","0","0"
"1686","NCT02713139","Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.","Sexual Active Women",0,"Clotrimazole + Metronidazole","Drug","Ache Laboratorios Farmaceuticos S.A.","Industry",0,0,"Female","18 Years","45 Years","0","September 2013","March 2014","Ceasing of the symptoms of vaginal discharge after 3(three) days of the end of the treatment","0","0","0","0","0","0","0","0","0"
"1687","NCT02726269","Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","Helicobacter Pylori Gastritis",0,"CLA (Clarithro+Lanso+Amoxi)","Drug","Asofarma de México S.A de C.V.","Industry",0,0,"All","18 Years","65 Years","230","June 2012","March 2014","HP eradication rate calculated from negative 13C-urea breath tests.","0","0","0","0","0","0","0","0","0"
"1688","NCT02751034","Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold","Nasolabial Fold",0,"Neuramis® Deep Lidocaine","Device","Medy-Tox","Industry",0,0,"All","30 Years","70 Years","60","June 2013","August 2013","Change on the Wrinkle Severity Rating Scale as evaluated by photograph raters using photographs","0","0","0","0","0","0","0","0","0"
"1689","NCT02770625","Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease","Gaucher Disease, Type 1",0,"ISU302","Drug","ISU Abxis Co., Ltd.","Industry",0,0,"All","2 Years","N/A","8","September 2011","March 2013","the difference in hemoglobin concentration [g/dL]","0","0","0","0","0","0","0","0","0"
"1690","NCT02786745","Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris","Acne",0,"Dapsone gel","Drug","MedDerm Associates","Industry",0,0,"All","12 Years","N/A","17","November 2013","September 2014","Global Acne Assessment Score","0","0","0","0","0","0","0","0","0"
"1691","NCT02902861","Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)","Psoriasis Vulgaris",0,"Methotrexate","Drug","Prof. Kristian Reich","Industry",0,0,"All","18 Years","N/A","120","February 2013","September 2014","Difference in 75% reduction of Psoriasis Area Severity Index (PASI75) responder rate between treatment arms","0","0","0","0","0","0","0","0","0"
"1692","NCT02946541","A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin","Type 2 Diabetes Mellitus",0,"evogliptin 5mg","Drug","Dong-A ST Co., Ltd.","Industry",0,0,"All","18 Years","N/A","160","July 2013","October 2014","HbA1c","0","0","0","0","0","0","0","0","0"
"1693","NCT02949193","Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes","Type 2 Diabetes Mellitus",0,"evogliptin","Drug","Dong-A ST Co., Ltd.","Industry",0,0,"All","18 Years","N/A","222","May 2013","November 2014","HbA1c","0","0","0","0","0","0","0","0","0"
"1694","NCT03039816","Cellulose Powder Against Grass Pollen Allergic Rhinitis","Allergic Rhinitis",0,"Nasaleze","Device","Nasaleze International Ltd","Industry",0,0,"All","18 Years","40 Years","108","May 2013","June 2013","Symptoms of allergic rhinitis","0","0","0","0","0","0","0","0","0"
"1695","NCT03088670","Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.","Diabetes Mellitus, Type 2",0,"Gosogliptin","Drug","SatRx LLC","Industry",0,0,"All","18 Years","78 Years","299","April 23, 2013","March 30, 2014","Mean change of HbA1c","0","0","0","0","0","0","0","0","0"
"1696","NCT03116594","Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over","Herpes Zoster",0,"NBP608","Biological","SK Chemicals Co.,Ltd.","Industry",0,0,"All","50 Years","N/A","675","January 3, 2014","April 8, 2014","GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)","0","0","0","0","0","0","0","0","0"
